

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Mon, 21 Oct 2019 14:09:36 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Subject: NIH BMGF Steering Committee Meeting
Attachments: Moving Forward on the NIH-BMGF Collaboration, BMGF PUSH program timeline_for NIH.10212019.v10.xlsx

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Fri, 18 Oct 2019 17:07:49 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Mike McCune; Tucker, Jessica (NIH/OD) [E]; Emily Turner; Kedest Tesfagiorgis; Nina Russell; Adam Jiang (McKinsey Secondment); Timothy Attoye; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Hoots, W. Keith (NIH/NHLBI) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E]; Islam, Aminul (NIH/NHLBI) [C]; Shipp, Allan (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]
Subject: Moving Forward on the NIH-BMGF Collaboration
Attachments: APPENDIX C- NIH_BMGF Collaboration for SCD and HIV_Executive Committee Briefing 101519 (002).pptx, NIH-BMGF Collaboration Venn Diagram 101819.pptx

Dear Members of the NIH-BMGF Collaboration Steering Committee,

First, Mike and I wanted to let you know that the Executive Committee meeting this week to review the proposed Research Blueprint and Executive Summary went very well. The SC work products were very well received, and we wanted to express a huge thanks for all of your expertise and hard work to get us to this point. We will be convening as a team on **Monday, October 21st from 9:30 – 10:30 AM** to discuss how we will move forward. The specific agenda topics include:

- De-brief on October 15th Executive Committee Meeting (*slides from the meeting are attached—entitled “APPENDIX C”*)
- Plans for roll-out
- Discussion of Venn Diagram (*see attached file- NIH BMGF Collaboration Venn Diagram*)
- Moving Forward:
 - Refinement to Layers I and II and Development of Layer III of the Research Blueprint
 - Putting in place an NDA
 - FAQs (in addition to and/or refinements of those being developed by our respective comms teams)
 - Administrative and project management support needs

-
ACTION ITEM: One of the outcomes of Executive Committee engagement has been the development of a Venn Diagram intended to capture in a simple graphic the essence of this collaboration. We will need your input in the content of this graphic – and, in particular, which activities to include in the outermost circle in **Version C of the Venn diagram**. So please review the attached file entitled Collaboration Venn Diagram and send any comments via email and/or be prepared to discuss your input during our teleconference on Monday as we need to finalize the diagram by c.o.b. Monday.

Many thanks,
Mike and Amy

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thursday, September 26, 2019 5:44 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune (b)(6) Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily

Turner (b)(6) Kedest Tesfagiorgis
(b)(6) Nina Russell (b)(6); Adam
Jiang (McKinsey Secondment) (b)(6); Timothy Attoye
(b)(6); Perry, Mary (NIH/OD) [E] <perryma@mail.nih.gov>; Wilder,
Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>;
Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E]
<hootswk@nhlbi.nih.gov>
Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C]
<aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica
(NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Melody Earle (earlem2@nhlbi.nih.gov)
<earlem2@nhlbi.nih.gov>
Subject: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Please find attached the finalized set of documents/briefing materials that we have worked together to develop:

1. Executive Summary
2. Slide deck for Executive Committee briefing
3. Full slide deck reflecting in more detail the Steering Committee discussions

Documents 1 and 2 are intended for our use in briefing our respective leadership. (Please note that based on the votes from all the SC members, the 3 finalist names for the Collaboration were: Cooperate2Cures, Partner2Cures, and Path2Cures. These are listed in the slide deck)

Thanks to everyone for their input and time.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

Page 004 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 005 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 006 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 007 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 008 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 009 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 010 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 011 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 012 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 013 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 014 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 015 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 016 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 017 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 018 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 019 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 020 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 021 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 022 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 023 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 024 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 025 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 026 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 027 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 028 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 19 Sep 2019 22:07:44 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; Timothy Attoye
Subject: NIH-BMGF Steering Committee Meeting
Attachments: Meeting Materials for NIH-BMGF Collaboration SC Meeting September 20th at 9:30 AM EST (6:30 AM PT)

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 19 Sep 2019 22:05:01 +0000
To: Emily Turner;Kedest Tesfagiorgis;Nina Russell;Dieffenbach, Carl (NIH/NIAID) [E];Finzi, Diana (NIH/NIAID) [E];Read, Sarah (NIH/NIAID) [E];Tucker, Jessica (NIH/OD) [E];Hoots, W. Keith (NIH/NHLBI) [E];Perry, Mary (NIH/OD) [E];Wilder, Elizabeth (NIH/OD) [E]
Cc: Mike McCune;Adam Jiang (McKinsey Secondment);Timothy Attoye;Groesch, Mary (NIH/NHLBI) [E];Islam, Aminul (NIH/NHLBI) [C];Shipp, Allan (NIH/NHLBI) [E];Hostetler, Jessica (NIH/NHLBI) [E];Young, Cari (NIH/OD) [E];O'Reilly, Marina (NIH/OD) [E];Barasch, Kimberly (NIH/NIAID) [C];Earle, Melody (NIH/NHLBI) [E]
Subject: Meeting Materials for NIH-BMGF Collaboration SC Meeting September 20th at 9:30 AM EST (6:30 AM PT)
Attachments: NIH_BMGF Harmonized Research Plan Core Activities Full SC Meeting DRAFT Slides 091919.pptx

Dear Members of the NIH BMFG Steering Committee:

We look forward to our discussion tomorrow, Friday, September 20th at 9:30 am (ET). Please find the attached slides to guide our discussion. The focus of the discussion tomorrow will be on the Core Research Work Plans and Milestones as well as discussing the preparations for the upcoming Executive Committee meeting. We also wanted to save a few minutes to get everyone's views about potential names and acronyms for the collaboration. We've pasted in the agenda below for ease of reference.

Many thanks again,

Amy and Mike

NIH-BMGF Steering Committee Agenda September 20, 2019	
9:30- 9:35 AM	Welcome and Updates
9:35- 10:00 AM	Discussion of HIV and SCD Core Research Work Plans and Milestones
10:00- 10:15 AM	Review outline for Executive Summary and discuss deliverables for EC review
10:15- 10:25 AM	Discussion of NIH-BMGF Collaboration Name and Communication Plan
10:25- 10:30 AM	Next Steps and Action Items

Page 031 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 032 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 033 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 034 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 035 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 036 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 037 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 038 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 039 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 040 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 041 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 042 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 043 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 044 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 045 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 046 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 047 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 048 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 049 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 050 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 051 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 052 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 053 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 054 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 055 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 056 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 057 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 058 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 059 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Collins, Francis (NIH/OD) [E]
Sent: Sat, 9 Feb 2019 18:13:04 +0000
To: Dan Wattendorf;McCune, Mike
Cc: Fauci, Anthony (NIH/NIAID) [E];Gibbons, Gary (NIH/NHLBI) [E];Anderson, James (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie (NIH/OD) [E];Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E];Cook, Nakela (NIH/NHLBI) [E];Dieffenbach, Carl (NIH/NIAID) [E];Wilder, Elizabeth (NIH/OD) [E];Glass, Roger (NIH/FIC) [E];Eiss, Robert (NIH/FIC) [E];Finzi, Diana (NIH/NIAID) [E];Tisdale, John (NIH/NHLBI) [E];Read, Sarah (NIH/NIAID) [E];McManus, Ayanna (NIH/OD) [E];Wood, Gretchen (NIH/OD) [E];Schwetz, Tara (NIH/OD) [E]
Subject: Materials for NIH-BMGF meeting
Attachments: NIH-BMGF Meeting Feb 12 2019.pdf, NIH-BMGF New opportunities for SCD and HIV, 120418 Opportunities in HIV Cure Memo[1].docx

Hi Dan and Mike,

All of us are looking forward to the morning meeting on Tuesday, February 12, where we will discuss a possible scientific partnership on in vivo gene editing for sickle cell disease and HIV cure. With thanks to Amy Patterson, I attach a possible agenda, together with some background material on current NIH programs that are of relevance. I am also re-attaching Dan's note from last week, and the white paper from Mike on HIV cure, so that everyone on this e-mail will have all of the materials in one place. Please let me know if this agenda looks right to you.

This potential joint effort certainly fits the definition of high risk high reward research! To design a realistic path forward, with appropriate attention to intermediate milestones, we will need to employ a heavy dose of the kind of scientific vision and fearlessness that BMGF and NIH are famous for. Looking forward to it!

Best, Francis

P.S. to NIH colleagues -- if I have left off any addressees that should see these materials in advance of Tuesday, please forward.

Page 061 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 062 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 063 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 064 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 065 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 066 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 067 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 068 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 069 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 070 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 071 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 072 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 073 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 074 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 075 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 076 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 077 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 078 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 079 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 080 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 081 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 082 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 083 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 084 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 085 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 086 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 087 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 088 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 089 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 090 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 091 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 31 Oct 2019 16:00:41 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: Canceled: NIH-BMGF SC Meeting
Importance: High

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 31 Oct 2019 16:00:29 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: Canceled: NIH-BMGF SC Meeting
Importance: High

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 31 Oct 2019 16:00:11 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: Canceled: NIH-BMGF SC Meeting
Importance: High

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 31 Oct 2019 15:59:57 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: Canceled: NIH-BMGF SC Meeting
Importance: High

From: Earle, Melody (NIH/NHLBI) [E]
Sent: Thu, 31 Oct 2019 15:51:37 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Nina Russell; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Barasch, Kimberly (NIH/NIAID) [C]; Beckham, Shayla (NIH/NCI) [E]; Wilder, Elizabeth (NIH/OD) [E]; Perry, Mary (NIH/OD) [E]
Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Good morning,

The NIH-BMGF SC teleconferences that were scheduled yesterday will be canceled in order that we can poll everyone again to possibly get dates where we can have more participation. Would you kindly click on this Doodle Poll link to indicate your availability?

NIH-BMGF SC Meeting

Our apologies for the multiple polling and thank you in advance for working with us to find better times for the meetings.

Melody Earle
Program Specialist
Immediate Office of the Director
National Heart, Lung, and Blood Institute
31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Earlem2@mail.nih.gov



From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 30 Oct 2019 16:16:46 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: NIH-BMGF SC Meeting

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 30 Oct 2019 16:15:30 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: NIH-BMGF SC Meeting

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 30 Oct 2019 16:14:09 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; 'Emily Turner'; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; 'Timothy Attoye'
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: NIH-BMGF SC Meeting

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 30 Oct 2019 16:11:37 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Nina Russell; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: NIH-BMGF SC Meeting

From: Earle, Melody (NIH/NHLBI) [E]
Sent: Wed, 30 Oct 2019 16:08:31 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Nina Russell; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Barasch, Kimberly (NIH/NIAID) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: NIH-BMGF SC Standing Meeting Scheduling

Good afternoon,

Thank you for your responses to the polling request for the NIH-BMGF SC standing teleconferences. Mondays 11am – 12:30 pm ET work best for most of the members so I will send out calendar appointments for the upcoming meetings:

- Monday, Nov 4, 11am – 12:30 pm ET
- Monday, Nov 18, 11am – 12:30 pm ET
- Monday, Dec 2, 11am – 12:30 pm ET
- Monday, Dec 16, 11am – 12:30 pm ET

Best regards,

Melody Earle
Program Specialist
Immediate Office of the Director
National Heart, Lung, and Blood Institute
31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Earlem2@mail.nih.gov



From: Bryan Callahan
Sent: Fri, 25 Oct 2019 14:01:20 +0000
To: Kolberg, Rebecca (NIH/OD) [E]
Cc: Pelis, Kim (NIH/OD) [E]; George, Jill (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Eiss, Robert (NIH/FIC) [E]; Tucker, Jessica (NIH/OD) [E]; Collins, Francis (NIH/OD) [E]
Subject: RE: Trevor's Updated Speech Outline
Attachments: TrevorMundel_BMGF_GrandChallengesKeynote_DRAFT_20191025.pdf, Trevor Mundel GC Keynote-Outline1023v2.docx

Hi All,

Greetings from Addis Ababa. Please find attached updated draft slides from our designer to accompany the narrative flow of Trevor's remarks.

Trevor reviewed and approved the overall narrative flow yesterday.

Please let me know if you have any questions.

Thanks,
Bryan

From: Kolberg, Rebecca (NIH/OD) [E] <kolbergr@mail.nih.gov>
Sent: Friday, October 25, 2019 1:33 AM
To: Bryan Callahan (b)(6)
Cc: Pelis, Kim (NIH/OD) [E] <pelisk@od.nih.gov>; George, Jill (NIH/OD) [E] <georgejil@od.nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Eiss, Robert (NIH/FIC) [E] <eissr@mail.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
Subject: RE: Trevor's Updated Speech Outline

Hi Bryan,
Just responding to loop in a few more key people: Jill George, Rob Eiss, and Jessica Tucker.
Also, if you are sending Trevor's slides after 1:30 p.m. on Friday, please also cc Dr. Collins as back-up because he will be heading off to catch his flight.
Thanks!
Rebecca

*Rebecca Kolberg
Office of Communications and Public Liaison
Office of the Director, National Institutes of Health
Bldg 1/Rm 330
Bethesda, MD 20892
301-594-1275*

From: Myles, Renate (NIH/OD) [E]
Sent: Thursday, October 24, 2019 6:14 PM
To: Bryan Callahan (b)(6)
Cc: Kolberg, Rebecca (NIH/OD) [E] <kolbergr@mail.nih.gov>; Pelis, Kim (NIH/OD) [E] <pelisk@od.nih.gov>
Subject: Re: Trevor's Updated Speech Outline

Thanks, Bryan. I've shared the outline with Dr. Collins and his presentation team. I'm also looping his presentation team in here so you're in direct communication.

Best,
Renate

Renate Myles
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
301-435-3638

From: Bryan Callahan (b)(6)
Sent: Wednesday, October 23, 2019 11:30:58 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Subject: Trevor's Updated Speech Outline

Hi Renate,

Hope you are well, and thanks again for everything today. You and your team are a class act.

As promised, attached is an updated version of Trevor's opening keynote address. I will likely be able to share accompanying slides sometime Friday.

Please let me know if I can be of further help with Dr. Collins' remarks. We'll be happy to schedule time in Addis Ababa on Sunday to align speeches.

Thanks,
Bryan

Page 105 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 106 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 107 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 108 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 109 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 110 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 111 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 112 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 113 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 114 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 115 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 116 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 117 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 118 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 24 Oct 2019 22:23:32 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]; Earle, Melody (NIH/NHLBI) [E]; Mike McCune; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Nina Russell; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Barasch, Kimberly (NIH/NIAID) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Totally understand. We will try to make this work for everybody and understand when members cannot stay for the whole call or may need to miss a call – in which case we can catch up with you. Also, with the upcoming holidays etc., this will likely turn out to be 2 or at most 3 times per month with some significant decrease in frequency after January when the Executive Committee will meet to review the third and most detailed layer of the Blueprint describing specific research projects. At that juncture, we envision the SC serving in more of a strategic oversight and planning capacity.
Amy

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Sent: Thursday, October 24, 2019 1:08 PM
To: Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>; Mike McCune
(b)(6); Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Sengupta, Nivedita (NIH/NHLBI) [C] <nivedita.sengupta@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Emily Turner
(b)(6); Nina Russell (b)(6); Kedest Tesfagiorgis (b)(6); Adam Jiang (McKinsey Secondment)
(b)(6) Timothy Attoye <(b)(6)>
Cc: Squadere, Terrie (NIH/NHLBI) [E] <squaderet@mail.nih.gov>; Kellton, Karen (NIH/OD) [C] <karen.kellton@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Beckham, Shayla (NIH/OD) [E] <shayla.beckham@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

This is a huge time commitment for me and I will join as I can, once the day and times are set.

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>

Sent: Thursday, October 24, 2019 1:06 PM

To: Mike McCune (b)(6); Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Sengupta, Nivedita (NIH/NHLBI) [C] <nivedita.sengupta@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Emily Turner (b)(6); Nina Russell (b)(6); Kedest Tesfagiorgis (b)(6); Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye (b)(6)

Cc: Squadere, Terrie (NIH/NHLBI) [E] <squaderet@mail.nih.gov>; Kellton, Karen (NIH/OD) [C] <karen.kellton@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Beckham, Shayla (NIH/OD) [E] <shayla.beckham@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Good afternoon,

Below are additional options for the NIH/BMGF SC weekly standing meeting. Please respond with all the days and times that work for you. All times are in ET.

Mon	Available Yes/No
11:30 – 1:00	

3:30 – 5:00	
Tues	
11:30 – 1:00	
3:30 – 5:00	
Wed	
11:30 – 1:00	
Thurs	
11:30 – 1:00	
Fri	
9:00 – 10:30	
10:00 – 11:30	
11:30 – 1:00	

Thank you,

Melody

From: Earle, Melody (NIH/NHLBI) [E]
Sent: Wednesday, October 23, 2019 6:09 PM
To: Mike McCune (b)(6); Dieffenbach, Carl (NIH/NIAID) [E] <CDieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <DFINZI@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Perry, Mary (NIH/OD) [E] <perryyma@mail.nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Sengupta, Nivedita (NIH/NHLBI) [C] <nivedita.sengupta@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Emily Turner (b)(6); Nina Russell (b)(6) Kedest Tesfagiorgis (b)(6); Adam Jiang (McKinsey Secondment) (b)(6) imothy Attoye (b)(6)
Cc: Squadere, Terrie (NIH/NHLBI) [E] <squaderet@mail.nih.gov>; Kellton, Karen (NIH/OD) [C] <karen.kellton@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Beckham, Shayla (NIH/OD) [E] <Shayla.Beckham@nih.gov>
Subject: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Good afternoon,

We are trying to set up weekly standing meetings of the NIH-BMGF Steering Committee, and are proposing Wednesdays, 3:30 – 5:00 pm. Would you please indicate your availability to join these

meetings by teleconference? Please note that there will not be meetings during certain of the upcoming holiday weeks (e.g. Thanksgiving).

Thank you,

Melody Earle
Program Specialist
Immediate Office of the Director
National Heart, Lung, and Blood Institute
31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Earlem2@mail.nih.gov



From: Nina Russell
Sent: Thu, 24 Oct 2019 18:20:00 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]; Earle, Melody (NIH/NHLBI) [E]; Mike McCune; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Barasch, Kimberly (NIH/NIAID) [C]; Beckham, Shayla (NIH/NCI) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Ditto.

Also would appreciate if calls are not earlier than 8am PT, particularly if it becomes a standing time slot.

Thanks much,

Nina

Nina Russell, MD

Deputy Director, TB & HIV

V (b)(6)

F +1.206.494.7028

E (b)(6)

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Sent: Thursday, October 24, 2019 10:08 AM
To: Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>; Mike McCune (b)(6); Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Sengupta, Nivedita (NIH/NHLBI) [C] <nivedita.sengupta@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Emily Turner (b)(6); Nina Russell (b)(6); Kedest Tesfagiorgis (b)(6); Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye (b)(6)
Cc: Squadere, Terrie (NIH/NHLBI) [E] <squaderet@mail.nih.gov>; Kellton, Karen (NIH/OD) [C] <karen.kellton@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Beckham, Shayla (NIH/OD) [E] <shayla.beckham@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

This is a huge time commitment for me and I will join as I can, once the day and times are set.

Carl W. Dieffenbach, Ph.D.

Director

Division of AIDS, NIAID

5601 Fishers Lane, Room 8D34

Rockville, MD 20852-9831

he/him/his

Phone: (301) 496-9112

Fax: (240) 627-3466

Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>

Sent: Thursday, October 24, 2019 1:06 PM

To: Mike McCune (b)(6); Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Sengupta, Nivedita (NIH/NHLBI) [C] <nivedita.sengupta@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Emily Turner

(b)(6); Nina Russell (b)(6); Kedest

Tesfagiorgis (b)(6); Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6)

Cc: Squadere, Terrie (NIH/NHLBI) [E] <squaderet@mail.nih.gov>; Kellton, Karen (NIH/OD) [C] <karen.kellton@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Beckham, Shayla (NIH/OD) [E] <shayla.beckham@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Good afternoon,

Below are additional options for the NIH/BMGF SC weekly standing meeting. Please respond with all the days and times that work for you. All times are in ET.

Mon	Available Yes/No
11:30 – 1:00	
3:30 – 5:00	
Tues	
11:30 – 1:00	
3:30 – 5:00	
Wed	
11:30 – 1:00	
Thurs	
11:30 – 1:00	
Fri	
9:00 – 10:30	
10:00 – 11:30	
11:30 – 1:00	

Thank you,

Melody

From: Earle, Melody (NIH/NHLBI) [E]

Sent: Wednesday, October 23, 2019 6:09 PM

To: Mike McCune (b)(6); Dieffenbach, Carl (NIH/NIAID) [E] <CDieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <DFINZI@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Perry, Mary (NIH/OD) [E] <perry@mail.nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Sengupta, Nivedita (NIH/NHLBI) [C] <nivedita.sengupta@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Emily Turner

(b)(6); Nina Russell (b)(6); Kedest Tesfagiorgis (b)(6); Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6)

Cc: Squadere, Terrie (NIH/NHLBI) [E] <squaderet@mail.nih.gov>; Kellton, Karen (NIH/OD) [C] <karen.kellton@nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Beckham, Shayla (NIH/OD) [E] <Shayla.Beacham@nih.gov>

Subject: Please respond ASAP -- Scheduling NIH/BMGF Steering Committee Weekly Standing Meetings

Good afternoon,

We are trying to set up weekly standing meetings of the NIH-BMGF Steering Committee, and are proposing Wednesdays, 3:30 – 5:00 pm. Would you please indicate your availability to join these meetings by teleconference? Please note that there will not be meetings during certain of the upcoming holiday weeks (e.g. Thanksgiving).

Thank you,

Melody Earle
Program Specialist
Immediate Office of the Director
National Heart, Lung, and Blood Institute
31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Earlem2@mail.nih.gov



From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 24 Oct 2019 18:19:53 +0000
To: Timothy Attoye;Patterson, Amy (NIH/NHLBI) [E];Mike McCune;Adam Jiang (McKinsey Secondment)
Cc: Eiss, Robert (NIH/FIC) [E]
Subject: RE: Grand Challenges Roundtable Session_ The Case for an HIV Cure and How to Get There

Hi Tim,

Thanks so much for this information!

I'm looping in my colleague, Rob Eiss, who is staffing Dr. Collins for the Grand Challenges meeting. I don't think either Amy or I will be there in person. I have forwarded him the information you provided.

Many thanks,

Jessica

From: Timothy Attoye (b)(6)
Sent: Wednesday, October 23, 2019 6:46 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Mike McCune (b)(6) Adam Jiang (McKinsey Secondment) (b)(6) >
Subject: Grand Challenges Roundtable Session_ The Case for an HIV Cure and How to Get There

Dear NIH colleagues,

As discussed, kindly find some information on the roundtable session to use as you prepare briefing materials for Francis. We shared similar materials with Trevor's staffers for the event. Hope you find this helpful.

Please do not hesitate to reach out to me directly if there are any questions. We can also huddle on in Addis to fine tune any details knowing that some flexibility might be required with our principals.

Best,

Timothy Attoye MBBS, MPH, FWACP

Fellow

Global Health Program

Mobile (b)(6)

Email (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Show Respect. Offer Trust. Be Transparent. Create Energy.

From: Timothy Attoye
Sent: Wed, 23 Oct 2019 22:46:16 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E];Mike McCune;Adam Jiang (McKinsey Secondment)
Subject: Grand Challenges Roundtable Session_ The Case for an HIV Cure and How to Get There
Attachments: ROUNDTABLE SESSION_THE CASE FOR AN HIV CURE AND HOW TO GET THERE.docx

Dear NIH colleagues,

As discussed, kindly find some information on the roundtable session to use as you prepare briefing materials for Francis. We shared similar materials with Trevor's staffers for the event. Hope you find this helpful.

Please do not hesitate to reach out to me directly if there are any questions. We can also huddle on in Addis to fine tune any details knowing that some flexibility might be required with our principals.

Best,

Timothy Attoye MBBS, MPH, FWACP

Fellow

Global Health Program

Mobile (b)(6)

Email (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Show Respect. Offer Trust. Be Transparent. Create Energy.

Page 129 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 130 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 131 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 132 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 133 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 134 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 135 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 136 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 137 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Myles, Renate (NIH/OD) [E]
Sent: Tue, 22 Oct 2019 21:26:34 +0000
To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Trevor Mundel; moetim@who.int; Burklow, John (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Patterson, Amy (NIH/NHLBI) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Miner, Lucinda (NIH/NHLBI) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Rancourt, Anne (NIH/NIDA) [E]; Dan Wattendorf; Mike McCune; Bryan Callahan
Cc: McManus, Ayanna (NIH/OD) [E]; Anderson, James (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Shipp, Allan (NIH/NHLBI) [E]; Groesch, Mary (NIH/NHLBI) [E]; Johnson, Lenora (NIH/NHLBI) [E]; Cook, Nakela (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]; Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Dan Pawson; shongwes@who.int; caborej@who.int; dramehp@who.int
Subject: Final Materials for Telebriefing on NIH-Gates Foundation SCD HIV Cures Collaboration
Attachments: 1-RunOfShow_NIH_Gates_Cures_Collaboration_10.22.19.docx, 2-Telebriefing_Consolidated_TPs_NIH_Gates_Cures_Collaboration_10.22.19.docx, 3-Embargoed_Release_NIH_Gates_Cures_Collaboration_1130amET_10.23.19.docx, 4-Embargoed_Media_Advisory_Cures_Collaboration_1130amET_10.23.19.docx, 5-QA_NIH_Gates_SCD_HIV_Cures_Collaboration_10.22.19.docx, 6-Backgrounder_NIH_Gates_Cure_Collaboration_10.22.19.docx

Good evening:

Attached are the final materials for tomorrow's media telebriefing. They include:

- 1-Telebriefing Run of Show
- 2-Consolidated Telebriefing Talking Points
- 3-Embargoed Release
- 4-Embargoed Media Advisory
- 5-Internal QA
- 6-Backgrounder

Briefing books are being delivered to NIH speakers and will be provided to Dr. Mundel in the morning when he arrives at NIH.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

NIH . . . *Turning Discovery Into Health*

From: Myles, Renate (NIH/OD) [E]
Sent: Tuesday, October 22, 2019 11:07 AM
To: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>; Gibbons, Gary (NIH/NHLBI) [E] <gary.gibbons@nih.gov>; Trevor Mundel (b)(6); moetim@who.int; Burklow, John (NIH/OD) [E] (BurklowJ@OD.NIH.GOV) <BurklowJ@OD.NIH.GOV>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>; Miner, Lucinda (NIH/NHLBI) [E] <lucinda.miner@nih.gov>; Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Rancourt, Anne (NIH/NIAID) [E] <anne.rancourt@nih.gov>; Dan Wattendorf (b)(6); Mike McCune (b)(6); Bryan Callahan (b)(6)
Cc: McManus, Ayanna (NIH/OD) [E] <ayanna.mcmanus@nih.gov>; Anderson, James (NIH/OD) [E] <james.anderson2@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Johnson, Lenora (NIH/NHLBI) [E] <johnslen@mail.nih.gov>; Cook, Nakela (NIH/NHLBI) [E] <cookn2@nhlbi.nih.gov>; Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Dan Pawson <DPawson@globalhealthstrategies.com>; shongwes@who.int; caborej@who.int; dramehp@who.int
Subject: Media Telebriefing Details: NIH and BMGF SCD HIV Cures Collaboration

Good morning/afternoon:

This email confirms the telebriefing details to announce the NIH and Bill & Melinda Gates Foundation SCD HIV Cures Collaboration. Briefing books with final materials will be provided this afternoon and via email to Dr. Moeti.

DATE:	Wednesday, October 23, 2019
PURPOSE:	Media Telebriefing to Announce the NIH-Gates Foundation SCD HIV Cures Collaboration
PLACE:	NIH Campus, Bethesda, Maryland, Bldg. 1, Room 116
PREBRIEFING TIME:	11:00-11:30 a.m. ET This will provide an opportunity for speakers to connect before the call and work out any last minute issues.
SPEAKER CALL-IN:	(b)(4); (b)(6) (Speakers must use this phone number) Dr. Moeti: we will work with your team directly to put you into the call with speakers.
TELEBRIEFING TIME:	11:30 a.m.-12:30 p.m. ET
PARTICIPANT CALL-IN LISTEN ONLY LINE:	(b)(4); (b)(6) Participant Code: (b)(4); (b)(6) This number is for reporters and others from your organization that may want to listen in.
SPEAKERS AT THE TABLE:	Francis Collins Trevor Mundel Matshidiso Moeti, by phone Anthony Fauci, by phone

	Gary Gibbons John Burklow, Moderator Renate Myles, Coordinator
PARTICIPANTS:	Jessica Tucker Amy Patterson Keith Hoots Cindy Miner Carl Dieffenbach, by phone Diana Finzi Anne Rancourt Dan Wattendorf Mike Mccune, by phone Bryan Callahan

Best,
Renate

Renate Myles, MBA

Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

NIH . . . *Turning Discovery Into Health*

MEDIA TELEBRIEFING: NIH and Gates Foundation SCD HIV Cures Collaboration

Wednesday, October 23, 2019

All times Eastern

Location: NIH Campus, Bethesda, Maryland, Building 1, Room 116

Pre-Briefing Time: **11:00-11:30 a.m.:** will provide the opportunity for speakers to connect before the telebriefing and work out last minute issues.

Speaker Call-In: (b)(4); (b)(6) – no password required; speakers will remain on this line for telebriefing.

Call Dr. Moeti on (b)(4); (b)(6) (direct); (b)(4); (b)(6) (back up)

Telebriefing Time: **11:30 a.m.-12:30 p.m.**

Participant Call In: (b)(4); (b)(6); Participant Code (b)(4); (b)(6) (Listen only line for reporters)

Principal Participants:

- Francis Collins, NIH
- Trevor Mundel, BMGF
- Matshidiso (Tshidi) Moeti, WHO-AFRO, by phone
- Anthony Fauci, NIAID, by phone
- Gary Gibbons, NHLBI
- John Burklow, NIH, Moderator
- Renate Myles, NIH, Coordinator

Background Participants:

- Jessica Tucker, NIH
- Amy Patterson, NHLBI
- Keith Hoots, NHLBI
- Cindy Miner, NHLBI
- Carl Dieffenbach, NIAID, by phone
- Diana Finzi, NIAID
- Anne Rancourt, NIAID
- Dan Wattendorf, BMGF
- Mike McCune, BMGF, by phone
- Bryan Callahan, BMGF

11:00-11:30 a.m.: Speaker pre-brief session to allow discussion ahead of call with reporters.

11:30-11:35 a.m.: John Burklow welcomes everyone, establishes the rules of the call, introduces teleconference participants, hands to Francis Collins. (3 minutes)

Run of Show: Media Telebriefing for NIH-Gates SCD HIV Cures Collaboration

Last revised: 10.22.19

Page 1 of 2

11:35-11:38 a.m.:	Francis Collins makes announcement, describes importance of collaboration from NIH perspective, and outlines NIH's presence in Africa. Hands to Trevor Mundel. (3 minutes)
11:38-11:41 a.m.:	Trevor Mundel discusses why we must bring the best to medical science has to offer to bear on the greatest needs of those living in the world's poorest communities. Hands to Tshidi Moeti. (3 minutes)
11:41-11:46 a.m.:	Matshidiso (Tshidi) Moeti speaks to the burdens of SCD and HIV in the AFRO region and the importance of developing and scaling effective therapies. Hands to Anthony Fauci. (3 minutes)
11:46-11:49 a.m.:	Anthony Fauci explains the state of HIV science and possibilities of gene-based breakthroughs. Hands to Gary Gibbons. (3 minutes)
11:49-11:52 a.m.:	Gary Gibbons explains the state of SCD science and possibilities for gene-based breakthroughs. Hands to John Burklow. (3 minutes)
11:52 a.m.-12:25 a.m.:	QA with reporters. (Approx. 30 minutes)
12:25 p.m.:	John Burklow notes time for one more question.
12:30 p.m.:	John Burklow closes call and lets them know recording of call is available.

Consolidated Talking Points: Media Telebriefing on Cures Collaboration

Francis Collins, NIH Director:

- Good morning.
- I'm very pleased that Dr. Trevor Mundel and his colleagues from the Gates Foundation are able to join us here today on the NIH campus in Bethesda, Maryland, and that Dr. Tshidi (She-Dee) Moeti (Mowetee) of the World Health Organization is able to join us by phone from Congo-Brazzaville.
- We've come together to announce that the NIH and the Bill and Melinda Gates Foundation are planning to invest at least (b)(4) each over the next four years to accelerate the development of gene-based cures for sickle cell disease and HIV that are not only safe, effective, and durable, but also accessible to everyone around the world, including in low resource settings.
- That's important, because both diseases disproportionately affect the people of Africa or of African descent, even though sickle disease is inherited while HIV is acquired.
- Approximately 95% of the 38 million people living with HIV globally are in the developing world, with 67% in sub-Saharan Africa, half of whom are living untreated.
- And roughly 5 million babies will be born with sickle cell disease globally over the next 30 years, with about 75% of those births occurring in sub-Saharan Africa.
- Tragically, more than half of infants born with sickle cell disease in low-income countries will die before their fifth birthday.
- Those are devastating numbers!
- Making gene-based cures safe and effective is critically important, but if those who are most affected by these diseases can't access them, then we're not solving the problem.
- That's why this collaboration aims to build scalability and low-cost delivery into the design process from the start.
- I'm not going to lie – this is a very bold goal, but we have decided to go big.
- We are living in a time of unprecedented scientific opportunities in which biomedical technologies that allow us to modify genes have made dramatic leaps.
- For this collaboration, we identified sickle cell disease and HIV as two priorities because they are linked at several levels.
 - First, gene-based treatments for sickle cell disease already in development could serve as a proof of concept for similar (but more accessible) therapies.
 - Second, recent technological advances make sickle cell disease and HIV therapeutic "cure" strategies a feasible proposition, building on advances in gene editing that potentially allow precise targeting of specific genes in specific tissues of affected individuals.
 - Third, these conditions exact a devastating toll on lives and livelihoods throughout the world, but particularly so in developing countries.
- Thus, we will need to rely heavily on our government and research partners in Africa.

Talking Points: NIH-Gates Foundation SCD HIV Cures Collaboration

Last revised: 10.22.19

Page 1 of 6

- For NIH, this collaboration builds on more than three decades of NIH partnerships with African universities and national laboratories to foster innovation.
- The scope of our cooperation on the continent is robust, representing over 1,600 research and training partnerships in 37 nations.
- Under Tony Fauci's leadership of the research strategies implemented by the National Institute of Allergy and Infectious Diseases, the cooperation has yielded significant contributions to HIV prevention.
- Gary Gibbons and his team at the National Heart, Lung, and Blood Institute support a consortium of African institutes contributing to the clinical research infrastructure required to reduce the burden of sickle cell disease across the continent.
- NIH also invests in applying genomics to understand genetic and environmental factors in common diseases in Africa, through a cutting edge African-led program known as the Human Heredity and Health project or H3Africa.
- We also have a long and productive partnership with our colleagues at the Gates Foundation – in fact, for the past several years we have coordinated a series of 10 working groups to make sure our investments in global health are maximally creative and coordinated.
- We look forward to engaging our partners in the African scientific community and will be presenting early plans next week at the 2019 Grand Challenges meeting in Addis Ababa, Ethiopia.
- On so many fronts, the timing truly is ripe to launch this ambitious collaboration toward sickle cell disease and HIV cures. Yes, this is audacious. But if we don't put our best minds, resources, and vision together right now, we would not live up to our mandate to bring the best science to those who are suffering.
- Both Bill and Melinda Gates have set the right tone for this initiative by embracing the term "impatient optimists." My NIH colleagues and I surely share that temperament.

Trevor Mundel, President of Global Health, Bill & Melinda Gates Foundation

- Thank you. I'm very excited to be here.
- The Gates Foundation is making this commitment for a very simple reason: we believe that gene-based treatments offer a possible path to a cure to HIV and sickle cell disease that is affordable and accessible to everyone, but only if we all commit to developing it in the right way.
- Gene-based research has made tremendous progress in the last few years – moving from research labs to clinical use, and trials are underway for hundreds of cellular and gene-based therapies to fight diseases such as cancer and previously untreatable ones such as Huntington's disease.
- This is great news. But for the diseases that cause the greatest burdens of death and disability in the world – the diseases the foundation traditionally focuses on – the path to impact is murkier.
- With limited exceptions, like the sickle cell treatment Dr. Collins mentioned, this research does not touch on the major causes of mortality in low-income countries,

Talking Points: NIH-Gates Foundation SCD HIV Cures Collaboration

Last revised: 10.22.19

Page 2 of 6

especially infectious diseases. And all these treatments currently require complex medical settings to administer, which are neither affordable nor accessible in socially and economically marginalized countries around the world.

- To make that transition – to turn gene-based treatments from a miracle for some into a miracle for all – we need a dramatic re-thinking of the science. It's not possible to get public health impact unless we simplify complex cures to simple ones.
- And so, inspired by the potential of these tools, the NIH and the Gates Foundation are making a big bet. Through this investment, we aim to build upon the initial success of gene-based treatments and focus R&D on accessible therapies that can meet public health priorities.
- We are combining resources and expertise to accelerate progress and we aim to find safe and effective treatments that can be administered on a large scale and at low cost in communities and regions hardest hit by HIV and sickle cell disease.
- We have made tremendous progress in improving public health in low- and middle-income countries. But we don't have the tools to eliminate intractable diseases like HIV and SCD – and we will need new innovations to achieve our shared goals for sustainable development.
- We believe that it is possible to achieve these goals if we invest in science, but we need to think big and ensure innovation reaches all communities. The health and development challenges facing low- and middle-income countries demand the most innovative science available to overcome barriers related to income and access to healthcare.
- Through partnerships like this one, the Gates Foundation and the NIH are showing that we are willing to take bold steps to bring the best that medical science has to offer to bear on the greatest needs of those living in the world's poorest communities.
- We know that this investment will only be successful if we work together with scientists and investigators from across sub-Saharan Africa.
- As Dr. Collins said, HIV and SCD disproportionately affect sub-Saharan Africa. We are committed to elevating and strengthening scientific leadership from the countries whose populations stand most to benefit and who have the greatest interest and expertise in the issue.
- Next week, we'll announce this initiative in person at the Grand Challenges meeting in Ethiopia, which the foundation is co-hosting with the Ethiopian Ministry of Health and the African Union. I'm looking forward to discussing this initiative with the many African and other scientists who've helped guide us to this place, and whose leadership will be necessary for its ultimate success.
- This initiative couldn't be more in the spirit of Grand Challenges: knowing that in order to see transformational progress on the biggest problems in health and development, you sometimes have to take a chance.
- For HIV, sickle cell disease and the many other diseases affecting low-income communities that gene-based treatment might cure, now is that time. I'm very happy to be taking that chance with the people here today. Thank you.

Matshidiso Moeti, Director, World Health Organization Regional Office for Africa:

- Dr. Moeti's remarks will focus on the burden of HIV and sickle cell disease in Africa and the need for innovative tools. She may emphasize the need for complementary political leadership and investments in delivery to make sure that tools both new and existing are able to have their desired impact. She may also note the important precedent that this investment sets in designing innovative tools for use in low-income settings from their inception, rather than as modifications to tools designed for high-income settings.

Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases

- The science associated with HIV over the past few decades has been nothing short of breathtaking.
- These remarkable scientific advances have allowed us to now treat an individual with HIV and suppress the virus to below detectable levels resulting in permitting the person to have near normal life expectancy and return to normal daily activities.
- Furthermore, the person who receives ART and achieves and maintains a sustained undetectable viral load cannot transmit HIV to their sexual partner.
- Although this therapy is life-saving, this is not a cure, since these individuals must remain on ART indefinitely and such a situation is not sustainable in the long run for the following reasons.
- There are now approximately 38 million individuals living with HIV worldwide, 23.3 million of whom are currently receiving antiretroviral therapy (ART).
- The goal is to get the 14.6 million individuals with HIV who are not receiving ART on therapy.
- In addition, there are 1.7 million individuals newly infected each year. Thus, we have a scenario where we have millions of people who are currently receiving life-saving ART and there are millions more in the next ten years who will need ART.
- A major goal is to find a cure whereby life-long ART would not be required.
- There have been two major approaches toward achieving an HIV cure.
- The first approach is total eradication of HIV.
- Attempts at activating the virus to flush it out and eliminate it have failed.
- Stem cell transplantation has been successful in only two patients who needed stem cell transplantation for their underlying neoplastic disease.
- Other strategies that are being tested to eradicate HIV include altering effector cells, such as using CAR-T cells, and ex vivo gene editing followed by reinfusion of edited cells back into the patient.
- These approaches are logistically and financially highly problematic to implement on a large scale, particularly in regions of the world such as sub-Saharan Africa with the highest burden of disease.

- The purpose of the NIH/BMGF collaboration for HIV research is to develop “cures” that are feasible, affordable and scalable to individuals using an in vivo gene-based approach requiring no immunosuppressive conditioning, one that can be accomplished in a single or very few interventions.
- The most obvious gene-based editing approach would be to either modify the host cells in vivo, such as editing out CCR5 (an important co-receptor for HIV) or excising in vivo the HIV provirus from the cells that constitute the viral reservoir.
- While developing HIV “cures” are aspirational goals, they are goals that must be pursued.
- If we do successfully achieve a HIV cure, it will ultimately be important not only for millions of individuals with HIV, but also save hundreds of billions of dollars in health care costs.

Gary Gibbons, Director, National Heart, Lung, and Blood Institute

- I’m pleased to be able to join my colleagues here and across the globe to share news about this important collaboration.
- The National Heart, Lung, and Blood Institute and others at NIH have supported decades of basic research on sickle cell disease that have brought forward therapies that continue to improve the longevity and well-being of people living with the disease. To have a more global impact, several years ago NHLBI began building a research network in Sub-Saharan Africa to reduce sickle cell disease in Africa.
- Now we want to build on this legacy of support and new genetic breakthroughs that led us to launch a Cure Sickle Cell Disease Initiative in the U.S. to NOW work with our partners to safely bring these gene-based therapies to more communities severely burdened by the disease.
- Since sickle cell disease was discovered more than a century ago, the precise molecular and genetic underpinnings have been well characterized.
- The disease is caused by a genetic defect in Hb, the protein that carries oxygen in red blood cells.
- Over the past 10 years, researchers have been able to demonstrate successful gene-based inventions (such as gene editing and gene therapy) to correct this genetic defect in animal studies.
- Given the rapid pace of innovation in emerging technologies, we are now working to develop gene- and cell-based therapies that are safe and effective for all patients.
- Two principal approaches have shown great promise:
 - Reactivating a dormant fetal Hb gene
 - Replacing or repairing the faulty Hb gene
- Today’s announcement complements our domestic efforts to move the most promising gene-based curative therapies safely into clinical trials within 10 years.
- Just last year after we announced our Cure Sickle Cell Disease Initiative, researchers in our own intramural laboratory at NIH were able to demonstrate our progress

toward a cure by using a gene replacement therapy that enabled patients' bone marrow to produce normal red blood cells.

- We have many more promising therapies being moved into clinical trials.
- We will use our programs in Africa and work being done by other researchers globally to help improve the care and long-term survival for children and adults with sickle cell disease in other parts of the world.
- A person's health should not be limited by their geographic location, whether rural America or Sub-Saharan Africa; by harnessing the power of science we will be able to transcend borders to improve health for all.
- We look forward to working with our partners at the Bill & Melinda Gates Foundation, scientists in Africa and our other collaborators to provide hope and real cures for people all over the world.

EMBARGOED FOR RELEASE
11:30 a.m. ET, October 23, 2019

Contact:
NIH Office of Communications and Public Liaison
NIH News Media Branch
301-496-5787

NIH launches new collaboration to develop gene-based cures for sickle cell disease and HIV on global scale

Initial investment aims to advance accessible and scalable candidate interventions into clinical trials within 10 years


The National Institutes of Health plans to invest at least \$100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates Foundation will also invest \$100 million toward this goal. The intention is for these cures to be made globally available, including in low-resource settings.

This initiative follows a bold announcement made earlier this year by President Donald J. Trump during the State of the Union Address to end the HIV epidemic in the United States in the next 10 years. Ending the HIV Epidemic: A Plan for America aims to leverage the powerful data and tools now available to reduce new HIV diagnoses in the United States by 75 percent in five years and by 90 percent by 2030. The Trump Administration has also elevated the attention paid to sickle cell disease, identifying it as an intractable health challenge with the potential for dramatic advances in the coming years.

Dramatic advances in genetics over the last decade have made effective gene-based treatments a reality, including new treatments for blindness and certain types of leukemia. Yet these breakthroughs are largely inaccessible to most of the world by virtue of the complexity and cost of treatment requirements, which currently limit their administration to hospitals in wealthy countries. To make these treatments effective and available for SCD and HIV, which disproportionately affect populations living in Africa or of African descent, new investment is needed to focus research on the development of curative therapies that can be delivered safely, effectively and affordably in low-resource settings.

The collaboration between the NIH and the Gates Foundation sets out a bold goal of advancing safe, effective and durable gene-based cures to clinical trials in the United States and relevant countries in sub-Saharan Africa within the next seven to 10 years. The ultimate goal is to scale and implement these treatments globally in areas hardest hit by these diseases.

Page 1 of 4 Embargoed until 11:30 a.m. ET, Wednesday, October 23, 2019



The NIH and Bill & Melinda Gates Foundation collaboration will align aggressive, high-reward research efforts to accelerate progress on shared gene-based strategies (depicted in purple) to cure sickle cell disease and HIV that are available globally including in low-resource settings, while continuing to invest in other parallel research efforts on cures for these two diseases outside of the collaboration. Credit: NIH

“This unprecedented collaboration focuses from the get-go on access, scalability and affordability of advanced gene-based strategies for sickle cell disease and HIV to make sure everybody, everywhere has the opportunity to be cured, not just those in high-income countries,” said NIH Director Francis S. Collins, M.D., Ph.D. “We aim to go big or go home.”

The collaboration will align aggressive, high-reward research efforts to accelerate progress on shared gene-based strategies to cure SCD and HIV. Both organizations also will continue to invest in other parallel research efforts on cures for SCD and HIV outside of this collaboration.

“In recent years, gene-based treatments have been groundbreaking for rare genetic disorders and infectious diseases,” said Trevor Mundel, M.D., Ph.D., President, Global Health Program, Bill & Melinda Gates Foundation. “While these treatments are exciting, people in low- and middle-income countries do not have access to these breakthroughs. By working with the NIH and scientists across Africa, we aim to ensure these approaches will improve the lives of those most in need and bring the incredible promise of gene therapy to the world of public health.”

SCD and HIV are major burdens on health in low-resource communities around the world. Approximately 95% of the 38 million people living with HIV globally are in the developing world, with 67% in sub-Saharan Africa, half of whom are living untreated. Fifteen million babies will be born with SCD globally over the next 30 years, with about 75% of those births occurring in sub-Saharan Africa. An estimated 50-90% of infants born with SCD in low-income countries will die before their 5th birthday and SCD is identified as the underlying cause of about 1 in 12 newborn deaths in sub-Saharan Africa.

Collaboration Details

The collaboration will focus on two areas of coordination:

- **First**, identify potential candidate cures for SCD and HIV for pre-clinical and clinical evaluation, co-funded by the NIH and Gates Foundation
- **Second**, define long-term opportunities to work together and with African partners on advancing promising candidates to late-phase clinical trials, with funding to be determined as candidates progress

Though SCD, a genetically inherited disease, and HIV, an acquired infectious disease, present significantly different scientific challenges, gene-based treatments hold promise for both, and many of the technical challenges for gene-based cures are expected to be common to both diseases.

To achieve the goals of the collaboration, both projects will require new delivery systems that can get prospective therapies to the right places in the body and optimize treatments to target the cells involved in the respective diseases efficiently and specifically. For SCD, that would mean repairing or compensating for the mutations in hemoglobin that cause SCD in hematopoietic stem cells. For HIV, that would mean targeting the reservoir of proviral DNA that continues to lurk inside a small number of cells, even after many years of effective antiviral treatment.

Such treatments that happen entirely within the body, known as *in vivo* treatments, would be a major step forward from current treatments, which apply genetic therapies to cells taken outside the body (*ex vivo*) and then reinfused.

“We are losing too much of Africa’s future to sickle cell disease and HIV,” said Matshidiso Moeti, M.B., M.Sc., World Health Organization Regional Director for Africa. “Beating these diseases will take new thinking and long-term commitment. I’m very pleased to see the innovative collaboration announced today, which has a chance to help tackle two of Africa’s greatest public health challenges.”

SCD

The collaboration’s goal for SCD is to develop an easy-to-administer gene-based intervention to

either correct the SCD gene mutations or promote fetal hemoglobin gene expression to achieve normal hemoglobin function. The path to a cure will rely in part on the development of gene-based delivery systems capable of selectively targeting hematopoietic stem cells. This will result in the precise correction of gene mutations or addition of a gene to promote sufficient levels of normal hemoglobin expression and function.

“Our excitement around this partnership rests not only in its ability to leverage the expertise in two organizations to reduce childhood mortality rates in low resource countries, but to bring curative therapies for sickle cell disease and HIV to communities that have been severely burdened by these diseases for generations,” said Gary H. Gibbons, M.D., director, National Heart, Lung, and Blood Institute (NHLBI), part of the NIH. “A person’s health should not be limited by their geographic location, whether rural America or sub-Saharan Africa; harnessing the power of science is needed to transcend borders to improve health for all.”

In addition, more needs to be done to understand the burden of SCD in sub-Saharan Africa and to screen newborns for SCD in high-risk geographic areas. NHLBI has already begun to establish a clinical research infrastructure in sub-Saharan Africa. However, additional clinical research and capacity-building efforts are needed to deliver point-of-care screening, such as at the time of infant vaccinations, and to initiate a standard of care. These activities will be undertaken by NIH and Gates Foundation outside of the collaboration, but will support collaboration efforts.

HIV

Nearly 38 million people worldwide are living with HIV, with 770,000 deaths due to AIDS in 2018 alone. Like SCD, people in sub-Saharan Africa face a disproportionate risk of HIV. Antiretroviral therapy is highly effective and has made it possible for people with HIV to live long, healthy lives without transmitting the disease to sexual partners. However, treatment must be maintained for a lifetime. A low-cost, safe, effective and durable cure that also prevents reinfection upon sexual exposure has long been a goal to curb the HIV global pandemic.

A number of approaches will be considered to meet the goal of a scalable HIV cure. Both the Gates Foundation and National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, are already funding cure research, exploring gene-based treatments in concert with long-acting therapeutics, monoclonal antibodies and other immune-based targets. This collaboration will allow the partners to intensify and better coordinate ongoing research efforts on these strategies, accelerating studies into early phase clinical trials to safely test promising tools and interventions. A particularly appealing approach is to identify the location of the reservoir of infected cells that still harbor integrated HIV genomes after treatment and target those DNA sequences with gene editing technology.

“This collaboration is an ambitious step forward, harnessing the most cutting-edge scientific tools and NIH’s sizable global HIV research infrastructure to one day deliver a cure and end the global HIV pandemic.” said NIAID Director Anthony S. Fauci, M.D. “We are taking into account those with the greatest need at the foundation of this effort, to ensure that, if realized, this exceptional public health achievement will be made accessible to all.”

###

About the Bill & Melinda Gates Foundation: Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Sue Desmond-Hellmann and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency,

includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical and translational medical research, and is investigating the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health®

EMBARGOED FOR RELEASE
11:30 a.m. ET, October 23, 2019

Contact:
NIH Office of Communications and Public Liaison
NIH News Media Branch
301-496-5787

MEDIA ADVISORY

TELEBRIEFING: NIH launches new collaboration to develop gene-based cures for sickle cell disease and HIV on global scale

What: The National Institutes of Health plans to invest at least \$100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates Foundation will also invest \$100 million toward this goal. The intention is for these cures to be made globally available, including in low-resource settings. The collaboration sets out a bold goal of advancing safe, effective and durable gene-based cures to clinical trials in the United States and relevant countries in sub-Saharan Africa within the next seven to 10 years. Ultimately, the goal is to scale and implement these treatments globally in areas hardest hit by these diseases.

Who: Francis Collins, M.D., Ph.D., Director, NIH
Anthony Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases
Gary Gibbons, M.D., Director, National Heart, Lung, and Blood Institute
Trevor Mundel, M.D., Ph.D., President of Global Health, Bill & Melinda Gates Foundation
Matshidiso Rebecca Moeti, M.B., Director, World Health Organization Regional Office for Africa

When: Wednesday, October 23, 2019, at 11:30 a.m. ET

How: For call-in information, please provide your name, organization, and contact details to NIH News Media Branch or 301-496-5787.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <http://www.nih.gov>.

Page 154 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 155 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 156 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 157 of 977

Withheld pursuant to exemption


(b)(5)

of the Freedom of Information and Privacy Act

Backgrounder: National Institutes of Health and Bill & Melinda Gates Foundation Collaboration on Gene-Based Cures for SCD and HIV

Overview of NIH-Gates Foundation Cures Collaboration

- The U.S. National Institutes of Health (NIH) and Bill & Melinda Gates Foundation (BMGF) mutually committed to funding research that may lead to curative strategies for sickle cell disease (SCD) and HIV using gene-based treatments.
- Initially, each organization plans to invest at least \$100 million over the next four years. The collaboration will leverage the organizations' collective strengths in basic and translational science for gene-based technologies and efforts to combat diseases that have a major public health impact.
- The collaboration aims to produce gene-based candidate treatments for SCD and HIV that can be administered at scale via low-cost delivery systems and advance them toward clinical trials in the United States and in Africa for safety and effectiveness within the next seven to 10 years.
- The collaboration will focus on two areas of coordination with a focus on advancing the science on gene-based strategies that are common to both SCD and HIV:
 - **First**, identify potential cure candidates for SCD and HIV for pre-clinical and clinical evaluation, co-funded by the NIH and Gates Foundation
 - **Second**, define long-term opportunities to work together on advancing promising candidates to late-phase clinical trials, with funding and inclusion of other partners to be determined as candidates progress
- Both organizations also will continue to invest in parallel research on cures for SCD and HIV outside of this collaboration.



The NIH and Bill & Melinda Gates Foundation collaboration will align aggressive, high-reward research efforts to accelerate progress on shared gene-based strategies (depicted in green) to cure sickle cell disease and HIV that are available globally including in low-resource settings, while continuing to invest in other parallel research efforts on cures for these two diseases outside of the collaboration. Credit: NIH

The Potential of Gene-Based Treatments

- Gene therapy is a technique that uses genes to prevent or treat a disease. This can include replacing or inactivating a disease-causing gene or introducing a new or modified gene to help treat a disease.
- Gene editing is a technique that uses different technologies to modify DNA at a specific spot, allowing scientists to remove, add or replace the DNA where it was cut in order to correct a genetic defect.

- After dramatic changes in genetic science over the past decade, fueled by advances in gene delivery and expression technology and novel gene editing mechanisms, gene-based approaches are being used to successfully treat some genetic diseases and cancers. Between the U.S. Food and Drug Administration and the European Medicines Agency, six gene therapy products have been approved since 2016 and more than 800 cell- and gene-based therapies are currently in clinical development.
- Recently, NIH studies demonstrated the effectiveness of correcting defective genes outside the body and infusing them into the body of SCD patients to reverse the disease.
- These are tremendous breakthroughs, but they are time intensive and involve multiple complicated manufacturing and clinical steps. Thus, gene-based approaches are currently only available in high-resource settings and cannot be scaled up to help solve public health problems on a broad scale.
- This collaboration aims to change this treatment landscape by accelerating research on gene-based interventions for SCD and HIV.
- Though SCD, a heritable disease, and HIV, an acquired disease, present significantly different scientific challenges, gene-based treatments hold promise for both, and many of the technical challenges for developing scalable gene-based cures are expected to be common to both diseases.
- An effective gene-based intervention for SCD would correct the gene mutations that cause the disease or, alternatively, promote the production of normal red blood cells in sufficient quantity to ward off symptoms. For HIV, an effective gene-based treatment would safely modify selected cells to stop the virus from replicating, eliminate it from the body, and prevent re-infection.

Background on SCD and Current Therapeutic Approaches


- **Overview:**
 - SCD is a genetic condition that presents in infancy. Mutations in the gene for beta globin, a component of hemoglobin, cause red blood cells to become hard, sticky, and misshapen in the form of a C-shaped “sickle”. Sick cells die early, causing a constant shortage of red blood cells, and can clog blood flow, resulting in pain and other serious problems.
 - SCD affects millions of people and is particularly common across sub-Saharan Africa.
 - An estimated 300,000 children are born each year with SCD, about two-thirds of them in Africa. Between 50-90 percent of infants born with SCD in developing nations will die before their fifth birthday. Nigeria, Tanzania and the Democratic Republic of the Congo bear the majority of Africa's SCD burden.
 - Within the United States, SCD affects approximately 100,000 people, mostly within African American and Hispanic American communities.

Burden of Sickle Cell Disease	
COUNTRY	SICKLE CELL BIRTHS/YEAR
Nigeria	91,011
Dem. Rep. Congo	39,743
Tanzania	11,877
Uganda	10,877
Angola	9,017
Cameroon	7,172
Zambia	6,039
Ghana	5,815
Guinea	5,402
Niger	5,310
Sub-Saharan Africa Total	242,187
Worldwide Total	305,773

Source: NIH Fogarty International Center

- SCD occurs in approximately 1 out of every 365 black or African American births. Living with SCD typically requires frequent blood transfusions, hospitalizations and complication management.
- **Current Therapeutic Approaches:**
 - Treatments are available that can prevent complications, relieve symptoms and lengthen the lives of SCD patients.
 - For children, one of the most effective strategies for reducing mortality has been screening, caregiver education and pneumococcal prophylaxis. However, there remains a shortage of such programs in Africa and other resource-limited settings due to the high cost of screening, limited health system infrastructure, and lack of affordable treatment options.
 - In high-income settings, living with SCD typically requires frequent hospitalizations and complication management. Blood transfusions can be used to treat severe anemia or reduce the risk of stroke.
 - Currently, the only cure for SCD is through stem cell or bone marrow transplant, though some gene therapy approaches have cured several patients in the United States. Bone marrow transplantation infuses healthy stem cells into the body to replace diseased bone marrow. While these transplants are increasingly used to successfully cure SCD, they require a matched donor and can cause severe side effects.

Background on HIV and Current Therapeutic Approaches

- **Overview:**
 - Nearly 38 million people worldwide are living with HIV, with 770,000 AIDS-related deaths in 2018 alone.
- 

People estimated to be living with HIV
In millions

Total: 37.9 million

Source: UNAIDS | 2018 © DW

- Africa is the continent most severely affected by HIV and AIDS. Nearly 26 million people in sub-Saharan Africa are living with HIV, accounting for more than two-thirds of the people living with HIV worldwide.
 - In the United States, an estimated 1.1 million people are living with HIV, with nearly 39,000 people receiving a new HIV diagnosis in 2017.
 - In the United States, men who have sex with men are disproportionately impacted, accounting for two-thirds of all HIV diagnoses. Black/African-Americans and Latinx individuals are disproportionately affected.
- Source: DW

- **Current Therapeutic Approaches:**
 - Major strides have been made in treating people living with HIV in both high- and low-income settings around the world. HIV treatment consists of a combination of drugs, known as antiretroviral therapy (ART), that can be delivered in a single pill taken daily. ART has

transformed HIV from an almost uniformly fatal disease into a manageable chronic condition. Starting daily antiretroviral therapy as soon as possible after diagnosis and staying on treatment are essential for keeping HIV under control, benefiting individual health and preventing sexual transmission to others. ART is recommended for all people with HIV, regardless of how long they've had the virus.

- While robust research on multiple avenues toward an HIV cure has been ongoing for decades, only two people to date have been considered “cured” of HIV. Known as “the Berlin patient” and “the London patient,” these patients survived risky, high-cost procedures involving stem cell transplants from donors whose stem cells had a naturally-occurring HIV-resistant gene mutation. These cases have contributed to scientists’ understanding of how future gene-based treatments may be able to work safely and effectively in larger populations.

From: Timothy Attoye
Sent: Mon, 21 Oct 2019 17:18:23 +0000
To: Patterson, Amy (NIH/NHLBI) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Mike McCune; Tucker, Jessica (NIH/OD) [E]; Emily Turner; Kedest Tesfagiorgis; Nina Russell; Adam Jiang (McKinsey Secondment); Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Hoots, W. Keith (NIH/NHLBI) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]
Subject: RE: Moving Forward on the NIH-BMGF Collaboration

Hi Amy,

Many thanks for following up on this morning's call with these materials. They will be incredibly helpful in completing the briefing package for the panel discussion.

The plenary sessions by both our principals will come days before this panel and I believe these materials will also be very useful for those preparing both Francis' and Trevor's speeches.

Best,

Timothy Attoye MBBS, MPH, FWACP

M
E t (b)(4); (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Show Respect. Offer Trust. Be Transparent. Create Energy.

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Sent: Monday, October 21, 2019 10:05 AM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Mike McCune (b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6); Kedest Tesfagiorgis (b)(6); Nina Russell (b)(6); Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye (b)(6); Perry, Mary (NIH/OD) [E] <perryma@mail.nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>
Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>
Subject: RE: Moving Forward on the NIH-BMGF Collaboration

Dear SC Members,

Here is the latest version of the FAQs – please note they are still draft. This current version was sent last week by NIH comms to the BMGF comms team. I am also attaching the Executive Summary in case it is a useful source of verbiage for talking points (please note that it contains an outdated version of the Venn Diagram).

Amy

From: Patterson, Amy (NIH/NHLBI) [E]

Sent: Friday, October 18, 2019 1:08 PM

To: Dieffenbach, Carl (NIH/NIAID) [E] <CDieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <DFINZI@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune (b)(6) <(b)(6)>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6) <(b)(6)>; Kedest Tesfagiorgis (b)(6) <(b)(6)>; Nina Russell (b)(6) <(b)(6)>; Adam Jiang (McKinsey Secondment) (b)(6) <(b)(6)>; Timothy Attoye (b)(6) <(b)(6)>; Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>

Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Melody Earle (earlem2@nhlbi.nih.gov) <earlem2@nhlbi.nih.gov>

Subject: Moving Forward on the NIH-BMGF Collaboration

Dear Members of the NIH-BMGF Collaboration Steering Committee,

First, Mike and I wanted to let you know that the Executive Committee meeting this week to review the proposed Research Blueprint and Executive Summary went very well. The SC work products were very well received, and we wanted to express a huge thanks for all of your expertise and hard work to get us to this point. We will be convening as a team on **Monday, October 21st from 9:30 – 10:30 AM** to discuss how we will move forward. The specific agenda topics include:

- De-brief on October 15th Executive Committee Meeting (*slides from the meeting are attached—entitled “APPENDIX C”*)
- Plans for roll-out
- Discussion of Venn Diagram (*see attached file- NIH BMGF Collaboration Venn Diagram*)
- Moving Forward:
 - Refinement to Layers I and II and Development of Layer III of the Research Blueprint
 - Putting in place an NDA
 - FAQs (in addition to and/or refinements of those being developed by our respective comms teams)
 - Administrative and project management support needs

ACTION ITEM: One of the outcomes of Executive Committee engagement has been the development of a Venn Diagram intended to capture in a simple graphic the essence of this collaboration. We will need your input in the content of this graphic – and, in particular, which activities to include in the outermost

circle in **Version C of the Venn diagram**. So please review the attached file entitled Collaboration Venn Diagram and send any comments via email and/or be prepared to discuss your input during our teleconference on Monday as we need to finalize the diagram by c.o.b. Monday.

Many thanks,
Mike and Amy

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thursday, September 26, 2019 5:44 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune (b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6); Kedest Tesfagiorgis (b)(6); Nina Russell (b)(6); Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye (b)(6); Perry, Mary (NIH/OD) [E] <perryma@mail.nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>
Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Melody Earle (earlem2@nhlbi.nih.gov) <earlem2@nhlbi.nih.gov>
Subject: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Please find attached the finalized set of documents/briefing materials that we have worked together to develop:

1. Executive Summary
2. Slide deck for Executive Committee briefing
3. Full slide deck reflecting in more detail the Steering Committee discussions

Documents 1 and 2 are intended for our use in briefing our respective leadership. (Please note that based on the votes from all the SC members, the 3 finalist names for the Collaboration were: Cooperate2Cures, Partner2Cures, and Path2Cures. These are listed in the slide deck)

Thanks to everyone for their input and time.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Mon, 21 Oct 2019 17:04:37 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Mike McCune; Tucker, Jessica (NIH/OD) [E]; Emily Turner; Kedest Tesfagiorgis; Nina Russell; Adam Jiang (McKinsey Secondment); Timothy Attoye; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Hoots, W. Keith (NIH/NHLBI) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]
Subject: RE: Moving Forward on the NIH-BMGF Collaboration
Attachments: Draft SCD-HIV Tough QA 10-20.19.docx, APPENDIX B-Executive Summary NIH-BMGF Collaboration 101519.docx

Dear SC Members,

Here is the latest version of the FAQs – please note they are still draft. This current version was sent last week by NIH comms to the BMGF comms team. I am also attaching the Executive Summary in case it is a useful source of verbiage for talking points (please note that it contains an outdated version of the Venn Diagram).

Amy

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Friday, October 18, 2019 1:08 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <CDieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <DFINZI@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune (b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6); Kedest Tesfagiorgis (b)(6); Nina Russell (b)(6) Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye (b)(6); Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wilder@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>
Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Melody Earle (earlem2@nhlbi.nih.gov) <earlem2@nhlbi.nih.gov>
Subject: Moving Forward on the NIH-BMGF Collaboration

Dear Members of the NIH-BMGF Collaboration Steering Committee,

First, Mike and I wanted to let you know that the Executive Committee meeting this week to review the proposed Research Blueprint and Executive Summary went very well. The SC work products were very well received, and we wanted to express a huge thanks for all of your expertise and hard work to get us to this point. We will be convening as a team on **Monday, October 21st from 9:30 – 10:30 AM** to discuss how we will move forward. The specific agenda topics include:

- De-brief on October 15th Executive Committee Meeting (*slides from the meeting are attached—entitled “APPENDIX C”*)
- Plans for roll-out
- Discussion of Venn Diagram (*see attached file- NIH BMGF Collaboration Venn Diagram*)
- Moving Forward:
 - Refinement to Layers I and II and Development of Layer III of the Research Blueprint
 - Putting in place an NDA
 - FAQs (in addition to and/or refinements of those being developed by our respective comms teams)
 - Administrative and project management support needs

ACTION ITEM: One of the outcomes of Executive Committee engagement has been the development of a Venn Diagram intended to capture in a simple graphic the essence of this collaboration. We will need your input in the content of this graphic – and, in particular, which activities to include in the outermost circle in **Version C of the Venn diagram**. So please review the attached file entitled Collaboration Venn Diagram and send any comments via email and/or be prepared to discuss your input during our teleconference on Monday as we need to finalize the diagram by c.o.b. Monday.

Many thanks,
Mike and Amy

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thursday, September 26, 2019 5:44 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune (b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6); Kedest Tesfagiorgis (b)(6); Nina Russell (b)(6); Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye (b)(6); Perry, Mary (NIH/OD) [E] <perry@mail.nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wilder@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>
Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Melody Earle (earlem2@nhlbi.nih.gov) <earlem2@nhlbi.nih.gov>
Subject: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Please find attached the finalized set of documents/briefing materials that we have worked together to develop:

1. Executive Summary
2. Slide deck for Executive Committee briefing
3. Full slide deck reflecting in more detail the Steering Committee discussions

Documents 1 and 2 are intended for our use in briefing our respective leadership. (Please note that based on the votes from all the SC members, the 3 finalist names for the Collaboration were: Cooperate2Cures, Partner2Cures, and Path2Cures. These are listed in the slide deck)

Thanks to everyone for their input and time.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

Page 169 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 170 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 171 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 172 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 173 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 174 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 175 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 176 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 177 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 178 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Fri, 18 Oct 2019 17:07:49 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Mike McCune; Tucker, Jessica (NIH/OD) [E]; Emily Turner; Kedest Tesfagiorgis; Nina Russell; Adam Jiang (McKinsey Secondment); Timothy Attoye; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Hoots, W. Keith (NIH/NHLBI) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]
Subject: Moving Forward on the NIH-BMGF Collaboration
Attachments: APPENDIX C- NIH_BMGF Collaboration for SCD and HIV_Executive Committee Briefing 101519 (002).pptx, NIH-BMGF Collaboration Venn Diagram 101819.pptx

Dear Members of the NIH-BMGF Collaboration Steering Committee,

First, Mike and I wanted to let you know that the Executive Committee meeting this week to review the proposed Research Blueprint and Executive Summary went very well. The SC work products were very well received, and we wanted to express a huge thanks for all of your expertise and hard work to get us to this point. We will be convening as a team on **Monday, October 21st from 9:30 – 10:30 AM** to discuss how we will move forward. The specific agenda topics include:

- De-brief on October 15th Executive Committee Meeting (*slides from the meeting are attached—entitled “APPENDIX C”*)
- Plans for roll-out
- Discussion of Venn Diagram (*see attached file- NIH BMGF Collaboration Venn Diagram*)
- Moving Forward:
 - Refinement to Layers I and II and Development of Layer III of the Research Blueprint
 - Putting in place an NDA
 - FAQs (in addition to and/or refinements of those being developed by our respective comms teams)
 - Administrative and project management support needs

-
ACTION ITEM: One of the outcomes of Executive Committee engagement has been the development of a Venn Diagram intended to capture in a simple graphic the essence of this collaboration. We will need your input in the content of this graphic – and, in particular, which activities to include in the outermost circle in **Version C of the Venn diagram**. So please review the attached file entitled Collaboration Venn Diagram and send any comments via email and/or be prepared to discuss your input during our teleconference on Monday as we need to finalize the diagram by c.o.b. Monday.

Many thanks,
Mike and Amy

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thursday, September 26, 2019 5:44 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune (b)(6) Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily

Turner (b)(6) Kedest Tesfagiorgis
(b)(6) Nina Russel (b)(6) Adam
Jiang (McKinsey Secondment) (b)(6) Timothy Attoye
(b)(6); Perry, Mary (NIH/OD) [E] <perryma@mail.nih.gov>; Wilder,
Elizabeth (NIH/OD) [E] <wildere@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>;
Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E]
<hootswk@nhlbi.nih.gov>
Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C]
<aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica
(NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Melody Earle (earlem2@nhlbi.nih.gov)
<earlem2@nhlbi.nih.gov>
Subject: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Please find attached the finalized set of documents/briefing materials that we have worked together to develop:

1. Executive Summary
2. Slide deck for Executive Committee briefing
3. Full slide deck reflecting in more detail the Steering Committee discussions

Documents 1 and 2 are intended for our use in briefing our respective leadership. (Please note that based on the votes from all the SC members, the 3 finalist names for the Collaboration were: Cooperate2Cures, Partner2Cures, and Path2Cures. These are listed in the slide deck)

Thanks to everyone for their input and time.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

Page 181 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 182 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 183 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 184 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 185 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 186 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 187 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 188 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 189 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 190 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 191 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 192 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 193 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 194 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 195 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 196 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 197 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 198 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 17 Oct 2019 17:57:26 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Nina Russell; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Subject: NIH BMGF Steering Committee Meeting

From: Earle, Melody (NIH/NHLBI) [E]
Sent: Tue, 15 Oct 2019 20:53:05 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; Timothy Attoye
Cc: Squadere, Terrie (NIH/NHLBI) [E]; Kellton, Karen (NIH/OD) [C]; Barasch, Kimberly (NIH/NIAID) [C]; Beckham, Shayla (NIH/NCI) [E]
Subject: Please respond by COB 10/16/19 - Scheduling next NIH BMGF Steering Committee Meeting

Good afternoon,

Would you please click on this link [NIH-BMGF SC Meeting](#) to indicate your availability, by COB Wednesday, October 16, for a meeting on Friday or early next week?

Thank you,

Melody Earle
Program Specialist
Immediate Office of the Director
National Heart, Lung, and Blood Institute
31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Earlem2@mail.nih.gov



From: Mike McCune
Sent: Tue, 15 Oct 2019 19:47:20 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Re: Executive Committee Meeting Tomorrow - Grand Challenges side meeting

I'll see if the occasion arises. If not, it would be good to nudge him soon as we're hoping to finalize the program - and it would be GREAT to have him there.

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, October 15, 2019 12:42 PM

To: Mike McCune (b)(6)

Subject: Re: Executive Committee Meeting Tomorrow - Grand Challenges side meeting

Hmmm....he may not yet know the answer, but OK to ask, I think!

----- Original Message -----

From: Mike McCune (b)(6)

Date: Tue, Oct 15, 2019, 3:40 PM

To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>

Subject: Re: Executive Committee Meeting Tomorrow - Grand Challenges side meeting

Super! Should I ask him at the EC meeting. □

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, October 15, 2019 12:38 PM

To: Mike McCune (b)(6); Dieffenbach, Carl (NIH/NIAID) [E]
<cdieffenba@niaid.nih.gov>

Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Read, Sarah (NIH/NIAID) [E]
<reads@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; O'Reilly, Marina (NIH/OD)
[E] <oreillym@od.nih.gov>

Subject: Re: Executive Committee Meeting Tomorrow - Grand Challenges side meeting

Thanks, Mike. I have passed the info along to Francis.

----- Original Message -----

From: Mike McCune (b)(6)

Date: Tue, Oct 15, 2019, 9:14 AM

To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>, "Dieffenbach, Carl (NIH/NIAID)
[E]" <cdieffenba@niaid.nih.gov>

CC: "Patterson, Amy (NIH/NHLBI) [E]" <amy.patterson@nih.gov>, "Read, Sarah (NIH/NIAID)
[E]" <reads@niaid.nih.gov>, "Finzi, Diana (NIH/NIAID) [E]"
<dfinzi@niaid.nih.gov>, "O'Reilly, Marina (NIH/OD) [E]" <oreillym@od.nih.gov>

Subject: Re: Executive Committee Meeting Tomorrow - Grand Challenges side meeting

Hi Jessica,

The side meeting is scheduled from 11:30-12:30PM on Wednesday, October 30th in Conference Room 6 (see attached full agenda).

It would be great to have Francis there to talk briefly about the NIH collaboration during the opening section (he could use, for instance, some of the slides that we'll be presenting today at the EC meeting) and to then serve as a panelist for a discussion thereafter. Others who will be

participating include Thumbi Ndung'u from the Africa Health Research Institute in Durban (<https://www.ahri.org/scientist/thumbi-ndungu/>), Izukanji (Zuzu) Sikazwe from the Centre for Infectious Disease Research in Lusaka (<http://www.cidrz.org/about-us/leadership/dr-izukanji-zuzu-sikazwe/>), and Moses Supercharger, a community advocate from Uganda (<https://www.avac.org/fellow/moses-supercharger-nsubuga>).

Thanks for letting me know if this will be possible.

Mike

From: Mike McCune (b)(6) [mailto:mike.mccune@gatesfoundation.org]

Sent: Monday, October 14, 2019 4:20 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>

Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>

Subject: Re: Executive Committee Meeting Tomorrow

All good on all fronts, Jessica:

Francis can pass off the baton to Trevor and Tony.

I will make sure the Comms team here is represented on the call.

I'll get back to you with more info about the side meeting in Addis.

I'll also invite another SC member from our side to join in.

Thanks!

Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, October 14, 2019 3:57 PM

To: Mike McCune (b)(6) [mailto:mike.mccune@gatesfoundation.org]; Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>

Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>

Subject: Re: Executive Committee Meeting Tomorrow

All,

Sorry for the additional email.

Additionally, Francis noted he thinks it would be best if relevant Communications staff could attend the EC meeting tomorrow, so Mike, if anyone can BMGF could participate, that would be great.

Additionally, Francis may be able to attend the side meeting on Oct 30 re HIV Cures- what time is the side meeting, or has it been determined?

Finally, Francis noted it would be fine for Executive Committee members to bring along/have a Steering Committee member join them on the call/meeting.

Many thanks,

Jessica

----- Original Message -----

From: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>

Date: Mon, Oct 14, 2019, 6:28 PM

To: (b)(6) (b)(6), "Dieffenbach, Carl (NIH/NIAID) [E]" <cdieffenba@niaid.nih.gov>
CC: "Patterson, Amy (NIH/NHLBI) [E]" <amy.patterson@nih.gov>, "Read, Sarah (NIH/NIAID) [E]" <reads@niaid.nih.gov>, "Finzi, Diana (NIH/NIAID) [E]" <dfinzi@niaid.nih.gov>, "O'Reilly, Marina (NIH/OD) [E]" <oreillym@od.nih.gov>
Subject: Executive Committee Meeting Tomorrow

Mike and Carl,

I just heard from Francis, and he asked if he could open the meeting tomorrow and then hand it over to Trevor and Tony as the co-chairs of the EC- is this OK?

I think it will mostly be a matter of leading the group through discussion of the agenda (and, frankly, passing the baton to Amy and Mike to go through the work of the Steering Committee). Is this OK?

Thanks very much!

Jessica

From: Mike McCune
Sent: Tue, 15 Oct 2019 19:39:06 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Re: BMGF-NIH Exec Comm

Yup!

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, October 15, 2019 12:37 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Mike McCune <(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Fwd: BMGF-NIH Exec Comm

FYI

----- Original Message -----

From: "Collins, Francis (NIH/OD) [E]" <collinsf@od.nih.gov>
Date: Tue, Oct 15, 2019, 3:13 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" <afauci@niaid.nih.gov>,"Gibbons, Gary (NIH/NHLBI) [E]" <gary.gibbons@nih.gov>
CC: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
Subject: BMGF-NIH Exec Comm
Hi Tony and Gary,

Just to be clear, it's fine for members of the BMGF-NIH Steering Committee to join the discussion today at 4:15 PM EDT. In fact, it may be helpful for Tony and Trevor (the EC co-chairs) to call on Amy Patterson and Mike McCune to walk through the current proposed research plan and timelines.

I'm also encouraging the Comms folks from NIH (John/Renate) and BMGF to join, as we will be talking about the roll out plans.

Francis

From: Mike McCune
Sent: Tue, 15 Oct 2019 13:14:00 +0000
To: Tucker, Jessica (NIH/OD) [E]; Dieffenbach, Carl (NIH/NIAID) [E]
Cc: Patterson, Amy (NIH/NHLBI) [E]; Read, Sarah (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; O'Reilly, Marina (NIH/OD) [E]
Subject: Re: Executive Committee Meeting Tomorrow - Grand Challenges side meeting
Attachments: Grand Challenges Meeting Agenda.2019.pdf

Hi Jessica,
The side meeting is scheduled from 11:30-12:30PM on Wednesday, October 30th in Conference Room 6 (see attached full agenda).

It would be great to have Francis there to talk briefly about the NIH collaboration during the opening section (he could use, for instance, some of the slides that we'll be presenting today at the EC meeting) and to then serve as a panelist for a discussion thereafter. Others who will be participating include Thumbi Ndung'u from the Africa Health Research Institute in Durban (<https://www.ahri.org/scientist/thumbi-ndungu/>), Izukanji (Zuzu) Sikazwe from the Centre for Infectious Disease Research in Lusaka (<http://www.cidrz.org/about-us/leadership/dr-izukanji-zuzu-sikazwe/>), and Moses Supercharger, a community advocate from Uganda (<https://www.avac.org/fellow/moses-supercharger-nsubuga>).

Thanks for letting me know if this will be possible.

Mike

From: Mike McCune (b)(6)
Sent: Monday, October 14, 2019 4:20 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>
Subject: Re: Executive Committee Meeting Tomorrow

All good on all fronts, Jessica:
Francis can pass off the baton to Trevor and Tony.
I will make sure the Comms team here is represented on the call.
I'll get back to you with more info about the side meeting in Addis.
I'll also invite another SC member from our side to join in.
Thanks!

Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Monday, October 14, 2019 3:57 PM
To: Mike McCune (b)(6) Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Read, Sarah (NIH/NIAID) [E] <readsa@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; O'Reilly, Marina (NIH/OD)

[E] <oreillym@od.nih.gov>

Subject: Re: Executive Committee Meeting Tomorrow

All,

Sorry for the additional email.

Additionally, Francis noted he thinks it would be best if relevant Communications staff could attend the EC meeting tomorrow, so Mike, if anyone can BMGF could participate, that would be great.

Additionally, Francis may be able to attend the side meeting on Oct 30 re HIV Cures- what time is the side meeting, or has it been determined?

Finally, Francis noted it would be fine for Executive Committee members to bring along/have a Steering Committee member join them on the call/meeting.

Many thanks,

Jessica

----- Original Message -----

From: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>

Date: Mon, Oct 14, 2019, 6:28 PM

To: (b)(6) >,"Dieffenbach, Carl (NIH/NIAID) [E]" <cdieffenba@niaid.nih.gov>

CC: "Patterson, Amy (NIH/NHLBI) [E]" <amy.patterson@nih.gov>,"Read, Sarah (NIH/NIAID) [E]" <reads@niaid.nih.gov>,"Finzi, Diana (NIH/NIAID) [E]"

<dfinzi@niaid.nih.gov>,"O'Reilly, Marina (NIH/OD) [E]" <oreillym@od.nih.gov>

Subject: Executive Committee Meeting Tomorrow

Mike and Carl,

I just heard from Francis, and he asked if he could open the meeting tomorrow and then hand it over to Trevor and Tony as the co-chairs of the EC- is this OK?

I think it will mostly be a matter of leading the group through discussion of the agenda (and, frankly, passing the baton to Amy and Mike to go through the work of the Steering Committee).

Is this OK?

Thanks very much!

Jessica

2019 Grand Challenges Meeting
Addis Ababa, Ethiopia
United Nations Conference Centre & African Union
Sunday, October 27 - Wednesday, October 30, 2019

Sunday, October 27

pm	Registration Opens	UN
pm - 9:30 pm	Welcome Reception	UN

Monday, October 28

am	Registration Opens	UNCC F
am - 10:30 am	Opening Plenary: Innovation for Good, Innovation for Growth	Conf Room Conf Roo

Opening (MC)

Kedest Tesfagiorgis, Deputy Director, Global Partnerships and Grand Challenges, Discovery and Translational Sciences, Bill & Melinda Gates Foundation

Welcome Remarks

Amir Aman, Minister of Health, Federal Democratic Republic of Ethiopia

Keynote Remarks

Sarah Mbi Enow Anyang Agbor, Commissioner for Human Resources, Science and Technology, African Union

Keynote Remarks

Trevor Mundel, President, Global Health, Bill & Melinda Gates Foundation

Keynote Remarks

Francis Collins, Director, National Institutes of Health

Conversation and Q&A:

Going Faster Together: Scientific Priorities for Africa

Moderator: Tom Karinski, Director of Programs, The African Academy of Sciences

Panelists:

Felix Dakora, President, The African Academy of Sciences

Francis Collins, Director, National Institutes of Health

Ibrahim Mayaki, CEO, African Union Development Agency - New Partnership for Africa's Development (AUDA-NEPAD) (Invited)

Jennifer Blanke, Vice President, Agriculture, Human and Social Development, African Development Bank Group

Matshidiso Rebecca Moeti, Regional Director, World Health Organization Regional Office for Africa

Barbara Kerstiens, Head of Sector Public Health at Directorate-General for Research & Innovation, European Commission (Invited)

Spotlight Talk

Salim Abdool Karim, Director, Centre for the AIDS Programme of Research in South Africa (CAPRISA)

am - 11:00 am	Break
---------------	--------------

am - 1:30 pm	Scientific Track Sessions: African Innovation Research and Development Ecosystem Science in Africa: Priorities and opportunities Joint Session: Crop Production Analytics at Scale: Innovations in Ground Truthing & Pest and Disease Surveillance and Epidemiology Non-traditional data collection for better analytics DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations Market discovery Growth and Resilience: Optimizing Birth, Growth and Development Context and collaboration Improving Development Outcomes with Digital Tools Make better decisions with geospatial mapping and data Optimizing Drug Discovery and Translation Malaria Drug Accelerator (MalDA) as an integrated and collaborative platform in anti-malarial target discovery and hit development Scaling Innovation with a Gender Lens Communication innovation Vaccines and Global Health Technology Applying novel technologies to global health: Single-cell analytics and epigenetic platforms	Conf Roo Banquet Rc Caucus Room Delegates Lou Press Conf Roo Large Briefing Rc Conf Roo
pm - 2:30 pm	Lunch	Exhibition Area (Grou Banquet Rc Delegates Lou
pm - 5:00 pm	Scientific Track Sessions: African Innovation Research and Development Ecosystem The art of science advocacy: Increasing R&D investments Joint Session: Crop Productions Analytics at Scale: Innovations in Ground Truthing & Pest and Disease Surveillance and Epidemiology Marketplace of innovation in surveillance for pests and diseases and ground truth data DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations Value chain and industry mapping Joint Session: Gender Norms and Programmatic Impact & Scaling Innovation with a Gender Lens Transforming gender norms for girls' empowerment: Individual and community behavior change Growth and Resilience: Optimizing Birth, Growth and Development Neurodevelopment Improving Development Outcomes with Digital Tools Taking a customer-centric approach to digital financial services Leveraging Pathogen Genetic Sequencing in Africa The recent past: Lessons learned from implementing pathogen genetic sequencing in the field Joint Session: Optimizing Drug Discovery and Translation & Vaccines and Global Health Technology Modulating immunity through adjuvants and drugs	Conf Roo Banquet Rc Caucus Room Deleg Lou Conf Roo Press Conf Roo Conf Roo
pm - 5:30 pm	Break	

am	Registration Opens	UNCC F
am - 10:30 am	Plenary: Inclusive Innovation for Better Lives Opening Keynote Remarks <i>Representative, Government of the Federal Democratic Republic of Ethiopia (TBC)</i> Spotlight Talk <i>Moses Alobo, Program Manager, Grand Challenges Africa, The African Academy of Sciences</i> Spotlight Talk <i>Charles Rotimi, Director, Trans-NIH Center for Research on Genomics and Global Health</i> Keynote Remarks <i>Agnes Kalibata, President, Alliance for a Green Revolution in Africa</i> Conversation and Q&A: Women and Girls at the Center of Development <i>Moderator: Anita Zaidi, Director, Vaccine Development, Surveillance, and Enteric and Diarrheal Diseases, Bill & Melinda Gates Foundation</i> Panelists: <i>Representative, Government of the Federal Democratic Republic of Ethiopia (TBC)</i> <i>Diane Gasbumba, Minister of Health, Rwanda (Invited)</i> <i>Glenda Gray, President and CEO, South African Medical Research Council</i> <i>Senait Fisseha, Director of International Programs, Susan Thompson Buffett Foundation</i> <i>Emmanuela Gakidou, Senior Director, Institute for Health Metrics and Evaluation, University of Washington</i> Keynote Remarks <i>John Nkengasong, Director, Africa Centres for Disease Control and Prevention</i> Spotlight Talk <i>Zoleka Ngcete, Program Manager, Grand Challenges South Africa, South African Medical Research Council</i> Spotlight Talk <i>Patrice Matchaba, Group Head of Global Health and Corporate Responsibility, Novartis</i>	Conf Room Conf Roo
am - 11:00 am	Break	
am - 1:30 pm	Scientific Track Sessions: Joint Session: African Innovation Research and Development Ecosystem & Optimizing Drug Discovery and Translation Open database of African clinical trials capabilities and sites Crop Productions Analytics at Scale: Innovations in Ground Truthing Training data collection Joint Session: DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations & Scaling Innovation with a Gender Lens	Conf Roo Caucus Room Deleg Lou

		Improving Development Outcomes with Digital Tools	Press
		The AI you have vs. the AI you don't	
		Leveraging Pathogen Genetic Sequencing in Africa	Conf Roo
		The present: Current challenges and early capacity-building efforts	
pm - 2:30 pm	Lunch		Exhibition Area (Grou Banquet Rc Delegates Lou
pm - 5:00 pm	Scientific Track Sessions:		
	Joint Session: African Innovation Research and Development Ecosystem & Growth and Resilience: Optimizing Birth, Growth and Development		Conf Roo
	Maternal and neonatal health		
	DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations		Caucus Room
	Country considerations: Navigating the regulatory and policy landscape		
	Joint Session: Gender Norms and Programmatic Impact & Scaling Innovation with a Gender Lens		Deleg Lou
	Mobile technology, gender norms and social embeddedness: Why we can't just add technology and stir		
	Improving Development Outcomes with Digital Tools		Press
	Building open, secure and inclusive digital ecosystems		
	Optimizing Drug Discovery and Translation		Conf Roo
	Recent advances in Pv/Pc culture and target-based anti-malarial drug discovery case studies		
	Pest and Disease Surveillance and Epidemiology		Banquet Rc
	Building a global burden of crop loss		
	Vaccines and Global Health Technology		Conf Roo
	Designing protective immunity to malaria		
pm - 5:30 pm	Break		
pm - 6:30 pm	Roundtable Sessions:		
	Please see handout in your delegate packet for abstracts.		
	Frugal Science: Sharing and Scaling-up Tools for Mass Creativity (Foldscope, Octopi, Paperfuge)		Deleg Lou
	Gates Foundation Research and Development Strategy: Maternal, Neonatal and Child Health - Discovery and Tools		Conf Roo
	Gates Foundation Research and Development Strategy: Neglected Tropical Diseases and Malaria		Conf Roo
	Gates Foundation Research and Development Strategy: Translational Sciences for Global Health		Conf Roo
	What the Heck is HECT? Highly Efficient Clinical Trials in the African Context		Caucus Room
pm - 7:30 pm	Poster Session & Reception		Exhibition Area (Grou
pm	Shuttles to Off-Site Dinner		
pm - 10:00 pm	Dinner & Local Entertainment		Shera

am	Registration Opens	UNCC F
am - 11:00 am	Scientific Track Sessions: African Innovation Research and Development Ecosystem Planetary health	Conf Roo
	Joint Session: DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations & Scaling Innovation with a Gender Lens Public scaling strategies	Deleg Lou
	Growth and Resilience: Optimizing Birth, Growth and Development Pregnancy and preconception nutrition	Conf Roo
	Improving Development Outcomes with Digital Tools How can data and tech collaboration help improve your program?	Press
	Leveraging Pathogen Genetic Sequencing in Africa A path forward: Exploring data-sharing and a pathogen genetic sequencing governance body models	Conf Roo
am - 11:30 am	Break	
am - 12:30 pm	Roundtable Sessions: Please see handout in your delegate packet for abstracts.	
	Beyond Silos and Boundaries: Exploring Avenues for Collaboration Among Social Sciences, Humanities and Natural Sciences	Press
	The Case for an HIV Cure and How to Get There	Conf Roo
	Collaborative Efforts for Evidence Drive Health Decisions: Global, Regional and Ethiopian Caucus Room Perspectives	
	Genomics for Health in Africa	Conf Roo
	Opportunities and Challenges of Collaborative Research and Innovation in Africa: 50 Years Experience of the Armauer Hansen Research Institute	Conf Roo
	Supporting a Healthy Global Health Innovation Ecosystem: A Panel on Tending to Innovators, Investors and the Ecosystem to Achieve Lasting Global Health Impact	Deleg Lou
pm - 1:30 pm	Lunch	Exhibition Area (Grou
pm - 1:00 pm	<i>Transition to African Union</i>	
pm - 4:00 pm	Networking	African Ur
pm - 6:00 pm	Joint Plenary Session with Keystone Symposia: Where We Go Next: African Leadership for African Innovation	Nel Mandela I
	Welcome Remarks <i>Moussa Faki Mahamat, Chairperson, African Union Commission</i>	
	Keynote Remarks <i>Tedros Adhanom Ghebreyesus, Director-General, World Health Organization</i>	

Keynote Remarks

Abdoulaye Diouf Sarr, Minister of Health and Social Action, Republic of Senegal

Keynote Remarks

Representative, Government of Burkina Faso (TBC)

Spotlight Talk

Seget Kelemu, Director General & CEO, International Centre of Insect Physiology and Ecology

Conversation and Q&A: Gene Drive for Malaria Elimination

Moderator: Philip Welkhoff, Director, Malaria, Bill & Melinda Gates Foundation

Panelists:

Léonie Claudine Lougué, Minister of Health, Burkina Faso

Yaye Kène-Gassama Dia, Co-Chair, African Union High Level Panel on Emerging Technologies

Jerome Singh, Head of Ethics and Law, Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal

Abdoulaye Diabaté, Research Lead, Target Malaria

Spotlight Talk

Faith Osier, Research Lead, KEMRI-Wellcome Trust Research Programme, Kenya

Closing Conversation

Moderator: Trevor Mundel, President, Global Health, Bill & Melinda Gates Foundation

Panelists:

Tedros Adhanom Ghebreyesus, Director-General, World Health Organization

Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Republic of India

Balram Bhargava, Director General, Indian Council of Medical Research

Bonginkosi Emmanuel Nzimande, Minister of Higher Education, Science and Technology, Republic of South Africa (Invited)

George Gao, Director-General, Chinese Center for Disease Control and Prevention (Invited)

Closing (MC)

Kedest Tesfagiorgis, Deputy Director, Global Partnerships and Grand Challenges, Discovery and Translational Sciences, Bill & Melinda Gates Foundation

pm - 7:45 pm

Closing Reception

African Ur

Scientific Track

Appendices

Appendix	A African Innovation Research and Development Ecosystem
Appendix	B Crop Productions Analytics at Scale: Innovations in Ground Truthing
Appendix	C DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations
Appendix	D Gender Norms and Programmatic Impact
Appendix	E Growth and Resilience: Optimizing Birth, Growth and Development
Appendix	F Improving Development Outcomes with Digital Tools
Appendix	G Leveraging Pathogen Genetic Sequencing in Africa
Appendix	H Optimizing Drug Discovery and Translation
Appendix	I Pest and Disease Surveillance and Epidemiology
Appendix	J Scaling Innovation with a Gender Lens
Appendix	K Vaccines and Global Health Technology

Organizers: The African Academy of Sciences (AAS); Wellcome; African Union Development Agency - New Partnership for s Development (AUDA-NEPAD); National Institutes of Health, Bill & Melinda Gates Foundation; and German Federal ry of Education & Research (BMBF)

Abstract:

ck Abstract:

oss the African continent, a strong, integrated R&D ecosystem will be crucial to unlocking the solutions needed to meet sustainable elopment goal targets and tackle the continent’s biggest health and development challenges, ultimately improving the lives of more a billion people on the fastest growing continent. This track will look at the challenges and opportunities to further strengthen the can R&D ecosystem so innovative solutions are discovered, developed and delivered to those most in need. To ensure participants e the opportunity to engage in both this and other scientific tracks, the track will include sessions jointly organized with Optimizing g Discovery and Translation and Growth and Resilience: Optimizing Birth, Growth and Development.

sions Abstracts:

nce in Africa: Priorities and opportunities

opening session will welcome participants and provide an introduction to the state of science in Africa, including highlighting tific initiatives across the African continent and orienting participants to the goals for the track as a whole.

art of science advocacy: Increasing R&D investments

session will focus on arming scientists and scientific program managers with the tools to be champions for science and innovation he African continent. Session leaders will offer strategies to prepare researchers to advocate for increased R&D funding from their onal governments, and to better communicate about the value of research and innovation to the media and general public.

n database of African clinical trials capabilities and sites (joint session with Optimizing Drug Discovery and Translation)

session will focus on a new initiative aimed at developing an open database of African clinical trials capabilities and sites and related rts to strengthen clinical research and trial capabilities across the continent. This will be an opportunity for the database developer to e a progress update and for participants to provide feedback and offer examples of the types of information that clinical trial rsors and facilitators need in order to make site-related decisions. This session will offer perspectives from regulators both at the onal and ethics committee level and their early experiences feeding regulatory data into the database, and provide insights into highly ient clinical trial designs and best practices (<https://kiglobalhealth.org/>).

rel tools for optimizing birth outcomes (joint session with Growth and Resilience: Optimizing Birth, Growth and elopment)

joint session aims to build on preceding discussions related to shared priority areas of investigation regarding novel tools for mizing birth outcomes. The session will specifically focus on technological developments to enable antenatal and intrapartum risk ification, including ultrasound imaging, physiological sensing, and machine learning-based predictive algorithms. An additional goal is atalyze connections within the field to ensure applicability of tools to global clinical contexts, and support the development of nancy-related infrastructure and network building across Africa.

etary health

emerging field of planetary health seeks to understand how human impacts on the environment in turn affect human health and well- g and to develop effective solutions through integrated, systems approaches. This session, co-hosted by Wellcome’s Our Planet Our lth program and The African Academy of Sciences, will explore how planetary health can support Africa in realizing its enormous ntial, protect the African development agenda from the growing risks of environmental change, provide immediate relief for lenges confronting African nations—such as air pollution, changing infectious disease profiles, and growing population exposure to eme weather events and drought—and improve public health. Discussion will center on topics related to cities, food systems, climate ge, and the interactions among them, and on institutional development to promote African planetary health science.

Monday, October 28

Nelson Torto, *The African Academy of Sciences*

Welcome and opening remarks

Aggrey Ambali, *African Union Development Agency - New Partnership for Africa's Development (AUDA-NEPAD)*

Welcome remarks

Quick fire talks: Promising scientific innovation in Africa

Moderator: Juliette Muthen, *The African Academy of Sciences*

Iruka Okeke, *University of Ibadan, Nigeria*

Siana Nkya, *Mubimbili University of Health and Allied Sciences and Mubimbili National Hospital, Tanzania*

Paul Ogongo, *Africa Health Research Institute in Durban*

Breakout session: Building a vibrant innovation ecosystem in Africa: What's next

Moses Alogo, *The African Academy of Sciences*

Tom Kariuki, *The African Academy of Sciences*

Closing discussion

pm - 2:30 pm	Lunch	Exhibition Area (Group 1) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	African Innovation Research and Development Ecosystem	Conf Room
--------------	--	------------------

The art of science advocacy: Increasing R&D investments

Session Chairs: *Gretchen Sorensen, Sorensen Group; Traci Siegel, GMMB*

Aggrey Ambali, *African Union Development Agency - New Partnership for Africa's Development (AUDA-NEPAD)*

Welcome and setting the stage: The value of message strategy

Clare Wenham, *London School of Economics and Political Science*

Building a case for investment in health sciences research and research capacity in Africa

Presentation and discussion

Rules of the road: Message strategy considerations

Jerome Singh, *University of KwaZulu-Natal, South Africa*

Case stories: Communications, outreach and advocacy

Interactive session with participants

Developing strategic responses to science advocacy and communications scenarios

Tuesday, October 29

am - 1:30 pm	Joint Session: African Innovation Research and Development Ecosystem & Optimizing Drug Discovery and Translation	Conf Room
--------------	---	------------------

Open database of African clinical trials capabilities and sites

Session Chairs: *Jennifer Maroa, The African Academy of Sciences; Thy Pham, Bill & Melinda Gates Foundation*

Beno Yakubu, National Agency for Food and Drug Administration and Control (NAFDAC), African Vaccine Regulatory Forum (AVAREF) Technical Committee; Diadie Maiga, World Health Organization Regional Office for Africa and African Vaccine Regulatory Forum (AVAREF)

Aggregated African countries clinical trials regulatory and ethics requirements – a pilot of early adopters

Thea Norman, Bill & Melinda Gates Foundation

Highly efficient clinical trials

pm - 2:30 pm	Lunch	Exhibition Area (Group) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	Joint Session: Growth and Resilience: Optimizing Birth, Growth and Development & African Innovation Research and Development Ecosystem	Conf Room
--------------	---	------------------

Novel tools for optimizing birth outcomes

Session Chairs: *Moses Aloba, African Academy of Sciences; Bryan Ranger and Hilary Gammill, Bill & Melinda Gates Foundation*

Session Lead: *Charles Mgone, Hubert Kairuki Memorial University*

Joy Lawn, London School of Hygiene and Tropical Medicine

Global considerations for MNH innovation

Shravya Shetty, Google

Machine learning-based methods for automated interpretation of obstetric ultrasound images

Jeff Stringer, University of North Carolina at Chapel Hill

The LABOR Study: An intrapartum cohort study to improve maternal and fetal outcomes

Steve Xu, Northwestern University and Sibel Inc.

Advanced, bio-integrated sensors for maternal, fetal, and neonatal health

Pius Okong, St. Francis Hospital Nsambya, Uganda

Pathways forward for MNH innovation

Wednesday, October 30

am - 11:00 am	African Innovation Research and Development Ecosystem	Conf Room
---------------	--	------------------

Planetary health

Session Chairs: *Judy Omumbo, African Academy of Sciences; José Siri, Wellcome Trust*

Judy Omumbo, The African Academy of Sciences

Welcome and opening remarks

Tolullah Oni, University of Cambridge

Introduction to planetary health

Nelson Sewankambo, Makerere University College of Health Sciences

Planetary health and sustainable development in Africa

Ernest Afiesimama, World Meteorological Association; Chikoko Hastings, C40 Cities Africa Regional Office;

Sam Oti, International Development Research Centre

Three perspectives on planetary health in Africa: Climate, cities and food

Q&A Discussion

dix [B]- Crop Productions Analytics at Scale: Innovations in Ground Truthing: Abstract & Agenda

Organizer: Bill & Melinda Gates Foundation

Abstract:

ck Abstract:

paucity of ground data to train and calibrate machine learning and AI models remains one of the biggest barriers preventing the e widespread application of satellite-based data and analytics in agriculture in emerging markets. This gap is particularly pronounced smallholder landscapes, where the scale, remoteness, complexity, and heterogeneity of farming practices intensify data and analytical irements. Unlocking the ability to generate accurate, near real-time, high-resolution insights on agricultural performance (e.g., water soil conditions; timing and progress of growing season; crops planted; cropping area; yields; biotic and abiotic stress crop yields, age, production) at field to national scales could significantly enhance market function and national policies by improving strategic operational decisions for a wide range of market, government and non-governmental actors working in agriculture.

; track will bring together technology experts, scientists, modelers, data collection practitioners and users from both public and ate sector in interactive sessions that will a) explore the current state of play in ground truthing and b) identify the major, highest act priorities for short-term donor-funded support.

sion Abstracts:

1-traditional data collection for better analytics (joint session with Pest and Disease Surveillance and Epidemiology)
; introductory session will bring together crop and data scientists to discuss enabling factors to achieving impact. Participants will e the opportunity to learn from each other in a marketplace setting on a variety of topics from IP, regulations of chemical inputs, tosanitary and biotechnology, financing, and engaging with governments.

marketplace of innovation in surveillance for pests and diseases and ground truth data (joint session with Pest and Disease veillance and Epidemiology)
; session will be an interactive expo, highlighting innovations and approaches to on-the-ground surveillance for pests and diseases ground truthing for crop analytics. Participants will explore the state of play in ground truthing and surveillance. This session offers vorking opportunities for organizations involved in measurement and sampling (crowd-sourcing, field sensors, UAVs), diagnostics, . sharing, workflow processing (data integration, QA/QC), modeling, and end user model usage/business process integration.

ubling satellite-based crop production analytics at scale: Innovations in ground truthing and training data collection
; session will focus on sharing use case, lessons learned, methodologies, and approaches to predicting crop production, crop type crop area and innovations around ground truth and training data collection.

Monday, October 28

am - 1:30 pm	Joint Session: Crop Productions Analytics at Scale: Innovations in Ground Truthing & Pest and Disease Surveillance and Epidemiology Non-traditional data collection for better analytics Session Chairs: <i>Stewart Collis and Christine Owen, Bill & Melinda Gates Foundation</i> Welcome and introductions, goals of the session Sector use cases - highlighting the data gaps Group discussion and request/offer activity at tables Table readouts Session close	Banquet R
pm - 2:30 pm	Lunch	Exhibition Area (Grou

pm - 5:00 pm	Joint Session: Crop Production Analytics at Scale: Innovations in Ground Truthing & Pest and Disease Surveillance and Epidemiology Marketplace of innovation in surveillance for pests and diseases and ground truth data Session Chairs: <i>Stewart Collis and Christine Owen, Bill & Melinda Gates Foundation</i>	Banquet Room
	Welcome and introductions, goals of the session, instructions for marketplace	
	Round 1: 4 rotations x 10 min Each participant has the chance to visit 4 stations per round.	
	Shift marketplace stations and new innovator introductions	
	Round 2: 4 rotations x 10 min	
	Shift marketplace stations and new innovator introductions	
	Round 3: 4 rotations x 10 minutes	
	Session Close	

Tuesday, October 29

am - 1:30 pm	Crop Production Analytics at Scale: Innovations in Ground Truthing Enabling satellite-based crop production analytics at scale: Innovations in ground truthing and training data collection Session Chair: <i>Stewart Collis, Bill & Melinda Gates Foundation</i>	Caucus Room
	Welcome and introductions, goals of the session	
	Crop analytics use cases	
	Ground truthing: Current state	
	Group working session – innovation ideation	
	Break	
	Group wrap up and readout	
	Session close	

dix [C]- DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations: Abstract and a

Organizers: Grand Challenges Canada; U.S. Agency for International Development

Abstract:

ck Abstract:

igating the complexity of scaling global health products and services requires in-depth understanding of the various conditions that d enable or prevent innovations from reaching their intended impact. While there may be a clinical or public health need for a icular product or service, this does not always align with market demand or health system realities, resulting in promising innovations reaching their full potential. Understanding the nuanced and dynamic issues facing global health innovations are critical for donors, stors, innovators, intermediaries, and development practitioners working to meet the needs of vulnerable maternal and newborn ulations in hard-to-reach geographies.

; track will address the challenges and opportunities in scaling maternal and newborn health products or services through expert kers and interactive workshops. Sessions will focus on determing market receptivity and influencers that help or hinder adoption of vation; understanding and navigating complex health systems and key stakeholdersin in maternal and newborn health; identifying and aging the necessary funding and resources to scale; navigating nascent or non-existent regulatory landscapes; and understanding erent pathways to scale. This interactive series of practical sessions will feature investors, donors, non-government organizations, thcare providers, corporations, government officials, local distributors, and innovators providing tools, resources, advice, and orking opportunities for participants to accelerate their work and improve maternal and newborn health.

sion Abstracts:

cket discovery

v big is the market or uptake for a particular innovation? How accepting is the market of new entrants? How fast growing is the ket? How are products or services distributed in this market? This session will provide tools, frameworks, case studies, resources, and l expert advice to help participants better understanding market conditions for maternal and newborn health innovative product and ices, test hypotheses for bringing a new innovation to a market, and map key stakeholders and influences that will accelerate or slow ket adoption.

ue chain and industry mapping

value chain is the full range of organizational activities needed to create a product or service that provide value for its customers. The erent types and needs of maternal and newborn global heath customers and the complexity of healthcare environments in low-resource ngs often lead to fragmented or protracted adoption of innovations. In this session, participants will hear directly from a variety of eholders on the challenges and opportunities in bringing maternal and newborn health innovations to patients, including health essional societies, manufacturers, distributors, and healthcare providers.

draising and financial management (joint session with Scaling Innovation with a Gender Lens)

lstanding the fundraising strategy, the types of resources available, and how to best mobilize and operationalize financial resources help accelerate an innovations path to scale. Often, entrepreneurs with a breakthrough technology or service struggle with the financial agement and business operations of turning their innovation into a viable business or organization. This session will provide tools and practices for effective and efficient fundraising and financial management. Participants will better understand what funders look for in vestee company, how to strengthen funding applications, and when is the right time to approach a funder, while providing the ortunity to meet various types of funders and business expert to help strengthen their innovations financial capacity.

entry considerations: Navigating the regulatory and policy landscape

rel innovations or new applications of existing tools and services often must navigate unknown or ambiguous regulatory, policy, and stration requirements at a global and local level for widespread adoption. From evidence studies to clinical guidelines to country stration, to scopes of practice and health profession training, the process can be expensive and frustrating. This session with demystify regulatory process from a variety of perspectives: multi-lateral governing bodies, regional regulatory authorities, health professional ds, and local ministries and health systems. Participants will gain valuable insights and understanding of the regulatory landscape ific to maternal and newborn health innovations.

lic scaling strategies (joint session with Scaling Innovation with a Gender Lens)

pathway to scale is unique for each innovation and often a non-linear process. Utilizing examples of different maternal and newborn vations that achieved significant growth and impact, we will review the lessons learned, successes, and failures on their scaling journey

Monday, October 28

am - 1:30 pm	DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations Market discovery Session Chairs: <i>Cara Barnes and Christina Tamer, VentureWell; Brinnon Mandel, VLA Global Health; Wilfred Njagi, Villgro Kenya</i> <i>Amy Lin, Center for Innovation and Impact, U.S. Agency for International Development</i> Introduction to customer discovery and hypothesis testing Panel: Innovator experience testing assumptions <i>Darash Desai, PharmaChk</i> <i>Anne Pringle, Lucky Iron Fish</i> <i>Tigistu Adamu, College of Surgeons of East, Central and Southern Africa, St. Paul Medical College</i> PESTEL framework and case study discussion Buyer influences framework and case study discussion Facilitated discussion <i>Sintayehu Silas, Pharmaceuticals Fund and Supply Agency</i>	Caucus Room
pm - 2:30 pm	Lunch	Exhibition Area (Group) Banquet Room Delegates Lounge
pm - 5:00 pm	DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations Value chain and industry mapping Session Chairs: <i>Cara Barnes, VentureWell; Eunice Mutindi, Duke University; Matthew Grollneck, Open Capital Advisors; Brinnon Mandel, VLA Global Health</i> Introduction to value chain framework Panel: Upstream value chain <i>Edward Bitarakwate, Elizabeth Glaser Pediatric AIDS Foundation</i> TBC Panel: Downstream value chain <i>Adam Lewis, Gadian Health Systems</i> <i>Cathy Mwangi, mHealth Kenya</i> <i>Tigistu Adamu, College of Surgeons of East, Central and Southern Africa, St. Paul Medical College</i> Case study discussion	Caucus Room

Tuesday, October 29

am - 1:30 pm	Joint Session: DevelopmentXChange: Accelerating Adoption of Maternal and Newborn	Delegates Lounge
--------------	---	-------------------------

Introduction to types of funding (grants, debt, equity)

Breakout groups by type of funding

Moderators: *Donna Brezinski, Little Sparrows Technologies; Beth Kolko, Shift Labs*

Introduction to financial management

Breakout groups by level of financial knowledge

Wrap up

pm - 2:30 pm	Lunch	Exhibition Area (Group 1) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations	Caucus Room
	Country considerations: Navigating the regulatory and policy landscape Session Chairs: <i>Mark Marino, VentureWell; Patricia Otero, Duke University; Robert Beyer and Wilfred Njagi, Villgro Kenya</i>	

Welcome and introduction

Regulatory and policy pop quiz

Panel Discussion: Regulatory and policy frameworks - product and service policies, guidelines, rules , and regulations

Workagegnehu Degefe Kabtibyimer, Ethiopian Food and Drug Administration

Fred Siyoi, Pharmacy and Poisons Board, Kenya

Simon Kipchirchir, Standards and Quality Assurance Policy and Regulation, Ministry of Health, Kenya

Innovator spotlight: Lessons learned from navigating the regulatory and policy landscape

Regulatory final exam

Wrap up

Wednesday, October 30

am - 11:00 am	Joint Session: DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations & Scaling Innovation with a Gender Lens	Delegates Lounge
	Public scaling strategies Session Chairs: <i>Mark Marino, VentureWell; Sarah Dunn Phillips, Duke University; Matthew Grollneck, Open Capital Advisors; Alden Zecha, We Scale Impact</i>	

Welcome and introduction

Panel: Government partnership

Patricia Garcia, Former Minister of Health, Peru

Scaling strategy: Organic growth innovator talk

Suparna Kalghati, Bempu

Scaling strategy: Distribution partner innovator talk

Maria Oden, Rice University

Scaling strategy: Licensing innovator talk

Data Santorino, Mbarara University

Scaling strategy: Teach/train and innovator talk

Catherine Kirk, Partners in Health Rwanda

Q&A

Abstract

k Abstract:

track will feature evidence and lessons learned from several grantees of the Women and Girls at the Center of Development (WGCD) d Challenge in two sessions. Each session will draw from research findings related to a key aspect of WGCD programming, and ge other Grand Challenge researchers and initiatives in the biomedical field.

ally, there are 1.8 billion young people aged 10-24 - roughly a quarter of the world's population. Young people throughout the world, ularly adolescent girls and young women, face significant challenges that prevent them from meeting their full potential. Rigid norms xpectations related to gender and age, which typically become firmer and more influential during adolescence, can profoundly and ively affect both girls and boys, and can particularly constrain girls' aspirations and opportunities. These norms can contribute to er-based discrimination in the form of physical or emotional violence; child, early and forced marriage; sexual abuse and exploitation; tions on reproductive control; and exclusion from education, employment and decision-making, among others. Evidence suggests gender-related factors create significant barriers to accessing and practicing healthy behaviors. Gender-intentional programming aims end social structures, policies and social norms in two ways: by fostering critical examination of inequalities and gender roles, norms dynamics, while simultaneously strengthening positive norms that support gender equality and an enabling environment.

lists from two Bill & Melinda Gates Foundation initiatives - the Women and Girls at the Center of Development Learning Agenda CD) and the Stanford Lancet Series - and from the Bill & Melinda Gates Foundation's Discovery and Translational Sciences team in al Health will discuss findings, lessons learned and challenges in developing and implementing gender-intentional youth programming v- and middle-income countries. Increased recognition of how gender norms impact development outcomes can encourage greater tments in interventions that address gender norms with the potential to achieve gender equality and sustained health behaviors across fe course.

ion Abstracts:

Transforming gender norms for girls' empowerment: Individual and community behavior change (joint session with Scaling Innovation with a Gender Lens)

gender norms that influence health, education and economic development can have profound negative impacts for girls' aspirations opportunities. Norms can contribute to gender-based violence, child, early and forced marriage, limitations on reproductive control exclusion from education, employment, and access to healthcare services. Evidence also suggests that gender-related factors create ificant barriers to accessing and practicing healthy behaviors. Gender-intentional programming aims to upend social structures, policies ocial norms in two ways: by fostering critical examination of inequalities and gender roles, norms and dynamics; and simultaneously gthening positive norms that support gender equality and an enabling environment. Panelists will discuss findings, lessons learned and nges in developing and implementing gender-intentional programming. Increased recognition of how gender norms impact opment outcomes can encourage greater investments in interventions that address gender norms with the potential to achieve gender ity and sustained health behaviors across the life course.

Mobile technology, gender norms and social embeddedness: Why we can't just add technology and stir (joint session with Scaling Innovation with a Gender Lens)

panel draws on research findings from the Women and Girls at the Center of Development research initiative supported by the Bill & ida Gates Foundation and engages other Grand Challenge researchers and initiatives in the bio-medical field. The panel recognizes ast potential presented by digital technologies and platforms to address economic development, health and gender equality concerns, : also interrogates how these technologies are deployed, examines who has access to them and asks salient questions about the socially dded nature of technology. It seeks to inform and refine policy and programs: How does digital technology work to improve en's lives, health and wellbeing? What unintended consequences might arise from their use? How can women and girls maximize their s to and control over mobile technology? And how can we maximize the benefits and minimize any costs from the use of mobile ology?

Monday, October 28

Ben Cislighi, Centre for Gender, Health and Violence, London School of Hygiene and Tropical Medicine
 Gender inequality, social norms and health: Evidence from the Stanford Lancet series
Rebekah Neal, Bill & Melinda Gates Foundation
 Gender considerations in clinical trials
Serkadis Admansu, CARE Ethiopia
 Developing a measurement framework for social norms: Lessons from Abdiboru
Bonginkosi Ndlangamandla, Swaziland Action Group Against Abuse (SWAGAA)
 Building capacity for norm change with community groups and government institutions
Anderson Kumpoloto, CARE Umodzi
 Evidence on the effectiveness and scalability of gender norm transformation
Perna Kumar, International Center for Research on Women
 Skills-building and other drivers of effective gender norm change

Tuesday, October 29

pm - 5:00 pm

Joint Session: Gender Norms and Programmatic Impact & Scaling Innovation with a Gender Lens

**Deleg
Lou**

Mobile technology, gender norms and social embeddedness: Why we can't just add technology and stir

Session Chair: *Sarah Gammage, International Center for Research on Women*

Fran Baker, Arm

Partnerships for digital innovation for WASH in urban settings

Wendy Chamberlin, BOMA Project

Gender, technology and women's financial inclusion in northern Kenya

Laiah Idelson, Youth Tech Health

Technology and girls' empowerment programs: Promises and pitfalls

Richard Matikanya, Triggerise

Mobile solutions for public health

Philip Roessler, William and Mary College, Research on Poverty Alleviation (REPOA)

Barriers to women's use of digital financial services

Simone Schaner, University of Southern California

Strengthening women's financial control through personal bank accounts

Abstract:

Lead: Hilary Gammill

k Abstract:

track will bring together diverse expertise to strengthen global collaborations in maternal, neonatal, and child health and discuss the of knowledge informing optimization of birth, growth, and development in low- and middle-income countries (LMICs). Focusing on and novel opportunities for prevention and intervention, topics will emphasize maximization of resilience for both mothers and ring. To this end, sessions will focus on sharing ideas and delineating the burden of disease; developing novel tools for optimizing outcomes with potential to address research priorities in Africa; understanding the impact of the vaginal microbiome and host une response on birth outcomes and HIV acquisition; discussing nutrition during preconception, pregnancy, and lactation; and essing neurodevelopmental outcomes.

ion Abstracts:

text and collaboration

goal of Grand Challenges is to solve global, interdisciplinary challenges. Novel application of existing science and technology, as well llaboration across fields, is required to advance maternal, newborn, and child health. Our objective is to encourage innovative ideas ur changing global context by harnessing your emerging insights and natural curiosity. Thus, in this interactive session we will engage cipants in activities to reframe problems, explore alternative perspectives, and spark new partnerships—to look in new places with people and generate tangible contributions to the field. This session will challenge participants to create a collaborative ethos and : creatively across disciplines to develop innovative solutions in global health for mothers and children.

rodevelopment

goal of this session is to explore the relationships linking brain energetics and metabolism, stress, and neurodevelopmental outcomes. ging together world experts in the neuromasurement (MRI) of brain structure, function, metabolism, and oxidative stress, as well as rts in child development and the implications of fetal and infant stress, we will seek a new understanding of early brain development, he potential use of MRI to enable novel approaches for neurodevelopmental assessments and neurocognitively-optimized ventions in global contexts. Such approaches have broad implications for early detection of neurodevelopmental abnormalities and iation of interventions. To optimize growth, resilience, and neurodevelopment in the field of maternal, newborn, and child health, l, interdisciplinary approaches like this are essential.

inal microbiome and immunological determinants of birth outcomes and HIV acquisition (joint session with Vaccines and al Health Technology)

is session we plan to explore both microbiome and immunological factors that associate with birth outcomes and HIV acquisition. hese factors the same for both adverse birth outcomes and HIV acquisition? For which birth outcomes (preterm birth, small for tional age, preeclampsia) is there the strongest evidence of association? To what degree do microbial and immunological factors co- iate vs. associate independently with adverse birth outcomes and HIV?

el tools for optimizing birth (joint session with African Innovation Research and Development Ecosystem)

joint session aims to build on preceding discussions related to shared priority areas of investigation regarding novel tools for nizing birth outcomes. The session will specifically focus on technological developments to enable antenatal and intrapartum risk fication, including ultrasound imaging, physiological sensing, and machine learning-based predictive algorithms. An additional goal is talyze connections within the field to ensure applicability of tools to global clinical contexts, and support the development of nancy-related infrastructure and network building across Africa.

nancy and preconception nutrition

session will provide an overview of the importance of nutrition during the preconception and pregnancy periods for improving birth omes and maternal health. Ongoing trials testing novel interventions including nutrients such as choline and selenium, and food ucts such as fortified balanced protein energy supplements will be presented and discussed. The combined role of infection and tion in impacting outcomes of stillbirth, SGA and preterm birth will be described.

Hilary Gammill and Anisha Gururaj, Bill & Melinda Gates Foundation

Introduction to track and session

Nicholas Kassebaum, Institute for Health Metrics and Evaluation

Global context for maternal, newborn, and child health

Yemane Berhane, Addis Continental Institute of Public Health

Maternal, newborn, and child health in Africa

Nicholas Kassebaum and Yemane Berhane, facilitated by Anisha Gururaj

Context Q&A

Anisha Gururaj and the Maternal, Newborn and Child Health Discovery and Tools team, Bill & Melinda Gates Foundation

Collaboration workshop

Multiple speakers

Lightning round chalk-talks

Anisha Gururaj

Discussion & wrap-up

pm - 2:30 pm	Lunch	Exhibition Area (Group) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	Growth and Resilience: Optimizing Birth, Growth and Development	Conference Room
--------------	--	------------------------

Neurodevelopment

Session Chair: *Sean Deoni, Bill & Melinda Gates Foundation*

Christopher Kuzawa, Northwestern University

Balancing energy demands: Physical growth, brain development, and potential impact on cognitive development

Peter Basser, National Institutes of Health

Measuring metabolism and energy balance in vivo

Catherine Lebel, University of Calgary

Cerebral metabolism, brain development, and cognitive outcomes

Moriah Thomason, New York University School of Medicine

Fetal stress and impacts of pre- and post-natal brain development

Steven Williams, King's College London

Great, but what can we image at low field?

Vesna Kutlesic, National Institutes of Health

Global neurodevelopment research priorities: The National Institute of Child Health and Human Development strategic plan

Tuesday, October 29th

am - 1:30 pm	Joint Session: Growth and Resilience: Optimizing Birth, Growth and Development & Vaccines and Global Health Technology	Banquet Room
--------------	---	---------------------

Vaginal microbiome and immunological determinants of birth outcomes & HIV acquisition

Session Chairs: *Chris Damman and Karen Makar, Bill & Melinda Gates Foundation*

Session Lead: *Jacques Ravel, University of Maryland School of Medicine*

Sharon Hillier, University of Pittsburgh/Magee-Womens Research Institute

Microbiome and HIV risk in pregnant and breastfeeding women

Adam Burgener, University of Manitoba
 Vaginal microbiome proteomics
Georgia Tomaras, Duke University
 Vaginal mucus

pm - 2:30 pm	Lunch	Exhibition Area (Group 1) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	Joint Session: Growth and Resilience: Optimizing Birth, Growth and Development & African Innovation Research and Development Ecosystem	Conf Room
--------------	---	------------------

Novel tools for optimizing birth outcomes
 Session Chairs: *Moses Aloba, The African Academy of Sciences; Bryan Ranger and Hilary Gammill, Bill & Melinda Gates Foundation*
 Session Lead: *Charles Mgone, Hubert Kairuki Memorial University*

Joy Lawn, London School of Hygiene and Tropical Medicine
 Global considerations for maternal and newborn health innovation
Sbravya Shetty, Google
 Machine learning-based methods for automated interpretation of obstetric ultrasound images
Jeff Stringer, University of North Carolina at Chapel Hill
 The LABOR Study: an intrapartum cohort study to improve maternal and fetal outcomes
Steve Xu, Northwestern University and Sibel Inc.
 Advanced, bio-integrated sensors for maternal, fetal, and neonatal health
Pius Okong, St. Francis Hospital Nsambya, Uganda
 Pathways forward for maternal and newborn health innovation

Wednesday, October 30

am - 11:00 am	Growth and Resilience: Optimizing Birth, Growth and Development	Conf Room
---------------	--	------------------

Pregnancy and preconception nutrition
 Session Chair: *Parul Christian, Bill & Melinda Gates Foundation*

Gernand Alison, Pennsylvania State University
 Nutrition in pregnancy and preconception - an overview
Nita Bhandari, SAS
 The WINGS study, India
James Tielsch, George Washington University
 The MINT trial, Nepal
Patrick Kolsteren
 The MISAME-3 trial, Burkina Faso
Yasir Shafiq, VITAL Trust
 VITAL study, Pakistan
CC Anne Lee, Brigham Women's Hospital
 ENAT trial, Ethiopia

Q&A Discussion

dix [F]- Improving Development Outcomes with Digital Tools: Abstract & Agenda

Organizers: U.S. Agency for International Development; Arm

Abstract:

ck Abstract:

hnology is changing the way we address global health and development problems around the world. Mobile phones, the internet, and s such as artificial intelligence make it cheaper and easier to meet the needs of communities around the world. As technology solutions iferate, new questions arise around ensuring solutions are inclusive, secure, and interoperable bolstered by a strong enabling ronment. How should innovators, donors, and development practitioners work with governments and the private sector to build asive digital societies? This track will touch on all aspects of digital development from building the overall ecosystem to how itioners can apply these tools in their work and issues around data protection and privacy.

us for an exciting and interactive series of learning workshops focused on providing practical expertise, lessons learned, advice, and urces to help you effectively apply digital tools in your work.

sion Abstracts:

ke better decisions with geospatial mapping and data

lication of geospatial technology allows us to see relationships between people and their environments in ways that are not possible g traditional assessments. A geographic approach provides valuable insight into the people most vulnerable to changing social, ionic and environmental factors and how they may be adapting to new conditions. This session introduces participants to the graphic approach to development and highlights technology and analytic approaches most likely to help the many partners working to ince international development.

ing a customer-centric approach to digital financial services

ess to finance remains among the most common and most intractable of development challenges, undermining the ability of the poor ove out of poverty and enterprises to flourish. The remarkable proliferation of mobile phone networks across the developing world, pled with a subtle but radical rethink of the business model behind payment systems and financial services, presents a powerful ortunity to advance financial inclusion and build new market systems that enable efficient, affordable financial transactions. Despite global trend, promising innovations are often chasing challenges while missing opportunities to address the specific needs of women low-income customers. This session will explore key challenges faced by women and low-income customers, and examine hands-on hods and approaches to developing customer-centric solutions.

: AI you have vs. the AI you don't

idst surging interest in machine learning (ML) and artificial intelligence (AI) technologies, the development community has an edible opportunity. These tools, which allow computers to make data-derived predictions and automate decisions, increasingly ence our daily lives and also have the potential to improve the efficiency and effectiveness of development work. Yet they rely on ider digital ecosystems to create an environment for inclusive, relevant, fair, and ultimately beneficial application. In this session, we bring together development practitioners, technology innovators, and industry thought leaders to learn about the system level factors are essential for further integrating ML and AI in health and development work. This session will showcase real-world examples and ge participants in discussion to identify critical barriers and action-oriented solutions that will strengthen digital ecosystems for better

lding open, secure and inclusive digital ecosystems

ing digital tools to address health and development problems allows us to save resources, improve products, and reach more eficiaries. At a macro level, digital technology has the potential to transform countries and societies. This session will explore how we think beyond our individual projects and work in partnership to support the development of strong digital ecosystems across the lic and private sectors. It will also highlight the Principles for Digital Development, a set of guidelines that are intended to help itioners succeed in applying digital technologies to development programs. These principles lay the foundation for best practices in eloping and deploying new digital tools. This session will focus on the specific topics and questions that need to be asked when ying any of this tech toward lasting change in underserved communities.

w can data and tech collaboration improve your programs?

funders and ecosystem supporters, this discussion and feedback session turns the tables on you. We would like to hear about your lenges and pain points such as lack of visibility into the innovation landscape, ways you can continue to support your innovation folio, and how you can explore an innovation's impact after your investment has concluded.

am - 1:30 pm	<p>Improving Development Outcomes with Digital Tools</p> <p>Make better decisions with geospatial mapping and data</p> <p>Session Chairs: <i>USAID; Arm</i></p> <p><i>Alma Golden, Executive Director, U.S. Global Development Lab</i></p> <p>Keynote opening</p> <p><i>Michael Crino, U.S. Agency for International Development GeoCenter</i></p> <p>Introduction to the geographic approach to development</p> <p>Strategy session: Geo-focusing exercise for strategic planning</p> <p>Using data, learn how to identify development challenges and key social, economic, health and environmental data available to inform the strategic planning of government ministries and development organizations.</p> <p><i>Michael Crino, U.S. Agency for International Development GeoCenter</i></p> <p>Panel: Most promising geospatial technology and approaches for advancing health and development</p> <p>Industry leaders will provide insights into how evolution in the geospatial industry is most enhancing their work and where the technology is falling short of expectations.</p> <p><i>Peter Richards, U.S. Agency for International Development Bureau for Food Security</i></p> <p><i>Rhiannan Price, Sustainable Development Practice, Maxar Technologies</i></p> <p><i>Lyndon Estes, Clark University Graduate School of Geography</i></p>	Press
pm - 2:30 pm	Lunch	<p>Exhibition Area (Group)</p> <p>Banquet Room</p> <p>Delegates Lounge</p>
pm - 5:00 pm	<p>Improving Development Outcomes with Digital Tools</p> <p>Taking a customer-centric approach to digital financial services</p> <p>Session Chairs: <i>USAID; ARM</i></p> <p><i>Mark Henderson, U.S. Agency for International Development Ethiopia</i></p> <p>Introduction to digital financial services</p> <p>Workshop: The importance of understanding the ecosystem and the customers</p> <p>Participants will learn how to use a mini market assessment and user profile to better design customer-centric digital financial solutions.</p> <p><i>Talia Dweck, DAI</i></p> <p>Lightening talk: HiveOnline</p> <p><i>Sofie Blakstad, HiveOnline</i></p> <p>Panel and Q&A with actors across the digital financial services ecosystem</p> <p>This panel will bring together various actors across the digital financial services ecosystem to discuss their approaches to developing customer-centric solutions. Participants will be given ample time to ask questions.</p> <p><i>Sofie Blakstad, HiveOnline</i></p>	Press

Tuesday, October 29

am - 1:30 pm **Improving Development Outcomes with Digital Tools** **Press**
The AI you have vs. the AI you don't
Session Chairs: *USAID; ARM*

Amy Paul, U.S. Agency for International Development
Introduction to artificial intelligence and machine learning

Lightning talks and dialogue

Development and industry leaders provide insights on the use of machine learning and AI in international development through honest conversation about how system-level factors shape how, and for whom, AI tools work in practice.

Davis Musinguzi, The Medical Concierge Group

Hya Umaran, Plan International

Sambir Vasdev, International Research & Exchanges Board

Leila Toplic, NetHope

Problem solving discussion groups: System-level barriers and recommended actions

Panelists will facilitate tabletop discussions to allow participants to interact with each other, share experiences, and ask questions.

pm - 2:30 pm **Lunch** **Exhibition Area (Group)**
Banquet Room
Delegates Lounge

pm - 5:00 pm **Improving Development Outcomes with Digital Tools** **Press**
Building open, secure and inclusive digital ecosystems
Session Chairs: *USAID; ARM*

Introduction to session

Participants will hear the objectives and desired outcomes of the session. We will aim to refine our ideas around what challenges we can best address through technology partnerships and by adhering to digital principles in our work.

Blair Palmer, Innovation Specialist, UNICEF; Kate Kallot, Director of AI Ecosystems, ARM

Digital principles 101

Participants will review the digital principles adopted by 180+ organizations. UNICEF will discuss how they have applied these principles in practice in the field and with partners, and how technology can be made accessible, scaled and used responsibly.

Blair Palmer, UNICEF

Tech trends, realities, and opportunities

Participants will be presented with the latest technology trends including cloud computing, artificial intelligence, and 5G networks. We will realistically address both the opportunities and implications for social impact, as well as the potential pitfalls in the deployment of these technologies.

Lightning talks

These talks begin a broader conversation on using digital tools and emerging technologies in developing countries.

Blair Palmer, UNICEF

Alexandra Grigore, Simprints

Cliff Schmidt, Amplio

Ciira wa Maina, Data Science Africa

Breakout session and partner fair

Moderator: *Fran Baker, Arm*

Participants will first recap discussion by answering prompts related to the digital principles. We will seek to explore rationale and examples of best practices of the application of the digital principles. We will then break out into a Partner Fair, a mini expo with partners where participants can have Q&A with speakers and informal conversations.

Steven Sadi, UNICEF

Alexandra Grigore, Simprints

Cliff Schmidt, Amplio

Ciira wa Maina, Data Science Africa

Oyinkuro Benafa, Arm Education (University Kits)

John Goodenough, Arm Research

Wednesday, October 30

am - 11:00 am

Improving Development Outcomes with Digital Tools

Press

How can data and tech collaboration improve your programs?

Session Chairs: *Global Innovation Exchange; USAID*

Introduction to data and tech collaboration to improve your programs

Moderator: *Alexis Bonnell, U.S. Agency for International Development*

From funders and ecosystem supporters, during this discussion and feedback session turns the tables on you to hear about your challenges and pain points in navigating a noisy innovation landscape.

Global innovation exchange (GIE) live demo

See the latest GIE functionalities so you can see how your programs and innovations can use it.

Sweta Govani, Results for Development

Group discussion for funders and ecosystem supporters

For funders and ecosystem supporters, this discussion turns the tables on you to hear about your challenges and feedback on new functionalities (e.g. tracking your portfolio's progress).

Alexis Bonnell, U.S. Agency for International Development

dix [G]- Leveraging Pathogen Genetic Sequencing in Africa: Abstract & Agenda

Organizers: Bill & Melinda Gates Foundation

Abstract:

Abstract:

The genome sequencing of pathogens has enormous potential for improving public health in Africa, whether by mitigating the impact of zoonotic diseases such as Ebola or Lassa viruses, or helping to control endemic diseases such as malaria or tuberculosis. Several lines of effort have expanded the current scope of technology and software available, the potential challenges of using pathogen genetic sequencing (PGS) in a low- and middle-income (LMIC) setting, and the viable use cases that have been identified by Africa Centres for Disease Control and Prevention. Several groups will report interim results of recently-funded projects underway in Africa and South Asia. Potential partnerships that can be leveraged to better implement this technology in the field will then be discussed. Many challenges remain before PGS can be fully deployed in Africa, not least of which is designing a rational platform for genetic sequence data sharing. We will discuss some of these challenges as well as potential technological and policy solutions. In addition, we will present some potential software solutions, as well as an example from a recent outbreak, to demonstrate key principles and design features that should be incorporated into any future work. Finally, we will share progress on a PGS-related governance body.

Session Abstracts:

Recent past: Lessons learned from implementing pathogen genetic sequencing in the field

This first session will focus on current implementation of PGS in the field, with a particular emphasis on use cases in Africa and other LMIC settings. These will include lessons learned regarding appropriate epidemiologically-based sampling methods, PGS applied to the current response in the Democratic Republic of the Congo, PGS applied to mapping the burden of cholera, PGS applied to antimicrobial resistance mapping in Nigeria, and experiences optimizing low-cost sequencing techniques to identify pathogens present in “mystery” meningitis cases.

Present: Current challenges and early capacity-building efforts

This session will take a systems-level approach to pathogen genetic sequencing, focused on the future of using PGS in Sub-Saharan Africa and other LMIC settings. We will highlight examples of end-to-end systems developed to generate actionable, real-time information and operational strategies to build up workforce sequencing and data-sharing capacity. The session will also present institutional strategies and ongoing efforts to develop laboratory networks in LMICs and incorporate new data generated from them in several African research and surveillance centers.

Path forward: Exploring data-sharing and a pathogen genetic sequencing governance body models

In this session we will explore an early prototype of data-sharing architecture for the international sequencing community, highlighting key design features and future development milestones. Participants will have the opportunity to see the early design up-close in an interactive demo, which will be followed by feedback, a Q&A session, and a brainstorming session to generate ideas for future API development. In addition to the demo, we will be sharing an update on the Public Health Alliance for Genomic Epidemiology (P.H.A.G.E.), with the goal of making it a policy-framing and technical standards-setting organization to enable responsible pathogen genomic data sharing across the global health community.

Monday, October 28

pm - 5:00 pm	Leveraging Pathogen Genetic Sequencing in Africa	Conf Room
	The recent past: Lessons learned from implementing pathogen genetic sequencing in the field	
	Session Chair(s): TBD	
	<i>Jean-Jacques Muyembe-Tamfum, Institut National de Recherche Biomédicale</i>	
	Leveraging PGS in Democratic Republic of the Congo Ebola outbreak	
	<i>Iruka N. Okeke, University of Ibadan</i>	
	Antimicrobial resistance mapping in Nigeria	
	<i>Senjuti Saha, Child Health Research Foundation</i>	
	CZI-partnered pathogen discovery efforts	
	<i>Justin Lessler, Johns Hopkins University</i>	

am - 1:30 pm

Leveraging Pathogen Genetic Sequencing in Africa

Conf Roo

The present: Current challenges and early capacity-building efforts

John Nkengasong, Africa Centres for Disease Control and Prevention

The new African public health order

Philip Onyebujoh, Africa Centres for Disease Control and Prevention

The Pathogen Genomic Institute and its role in strengthening surveillance and cross-border information sharing in the African region

Nicholas J. Loman, University of Birmingham

ARTIC network training courses as a mechanism to encourage data-sharing and capacity-building

Cristina Tato, Chan Zuckerberg Biohub

CZB's experience building up sequencing capacity in LMIC-based laboratories

Nicola Mulder, H3Africa

The future of H3 Africa: Human capital challenges

Noelle Huskins and Xin Jin, BGI-Shenzhen

Talk Title TBD

Alan Christoffels, South African National Bioinformatics Institute

Africa genomics archive: data-sharing challenges

am - 11:00 am

Leveraging Pathogen Genetic Sequencing in Africa

Conf Roo

A path forward: Exploring data-sharing and a pathogen genetic sequencing governance body models

Bronwyn MacInnes, Broad Institute

Software demonstration of pathogen genetic sequencing data-sharing architecture and Q&A session

David Aanensen, Sanger Institute

Demo: Toward a flexible and interoperable community of modules for data sharing and analysis

Duncan MacCannell, Office of Advanced Molecular Detection, Center for Disease Control and Prevention

Progress to date and next steps to stand up a pathogen genetic sequencing secretariat

dix [H]- Optimizing Drug Discovery and Translation: Abstract & Agenda

Organizer: Bill & Melinda Gates Foundation

Abstract:

Abstract:

track highlights some of the innovations, advances and challenges in drug discovery and translational research in global health, with a particular focus on malaria. Recent optimization of phenotypic screening hits have resulted in novel and powerful compounds that are entering in clinical development for achieving radical cure of malaria. However, limitation of accessible chemical matters and advancement of genetic tools have elevated the target-based drug discovery approach to a more prominent role. Advances in our understanding of the biology of malaria enable new approaches to target discovery. Ways in which to enhance collaboration across disciplines will also be presented.

Session Abstracts:

Malaria Drug Accelerator (MalDA) as an integrated and collaborative platform in anti-malarial target discovery and hit development

MalDA is a fourteen-member consortium dedicated to develop better therapies for malaria eradication and elimination. Chemogenetic characterization through in vitro evolution of phenotypically active compounds combined with whole-genome analysis are routinely applied to MalDA to identify antimalarial drug targets and drug-resistance genes. In this session, case studies using this approach in discovering two novel targets against *P. falciparum*, including PfNCR-1 and PfAcCS, will be presented. A number of innovative platforms for target validation, including metabolomics, RNA-seq, CRISPR/Cas9-mediated gene editing, gene essentiality through TetR-aptamer conditional knockdown (cKD) will also be highlighted.

Modulating immunity through adjuvants and drugs (joint session with Vaccines and Global Health Technology)

In this session, we will explore novel technologies to screen for modulators of the innate and adaptive immune system. Approaches to vaccine modulation will be explored, including breakthrough tactics and their application, with a focus on the potential for transition of vaccines and drugs into global health.

An open database of African clinical trials capabilities and sites (joint session with African Innovation Research and Development system)

This session will focus on a new initiative aimed at developing an open database of African clinical trials capabilities and sites and related efforts to strengthen clinical research and trial capabilities across the continent. This will be an opportunity for the database developer to present a progress update and for participants to provide feedback and offer examples of the types of information that clinical trial sponsors and facilitators need in order to make site-related decisions. This session will offer perspectives from regulators both at the national and regional committee level and their early experiences feeding regulatory data into the database, and provide insights into highly efficient clinical trial designs and best practices (<https://kiglobalhealth.org/>).

Recent advances in Pv/Pc culture and target-based anti-malarial drug discovery case studies

New drugs are needed that target the dormant hypnozoite stage of vivax malaria that can persist in liver for years before activating to cause relapsing malaria. Over the past decade, novel systems for long term maintenance of primary hepatocyte physiology in vitro have been developed for both Pv and Pc. The application of these systems to develop the first high content imaging assay to discover anti-hypnozoite drugs will be presented. In this session, three types of target-based anti-malarial drug discovery projects, i.e. aaRS, pentathamide metabolites, Plasmodium kinases, will also be presented. The opportunities and challenges related to such approaches to accelerate novel antimalarial drug discovery will be discussed.

Monday, October 28

9 am - 1:30 pm	Optimizing Drug Discovery and Translation Malaria Drug Accelerator (MalDA) as an integrated and collaborative platform in anti-malarial target discovery and hit development Session Chair: <i>Elizabeth Winzeler, University of California San Diego</i> <i>Eva Istvan, Washington University in St. Louis</i> Discovery of PfNCR-1 as a druggable target required for parasite membrane homeostasis	Conf Room
----------------	--	-----------

Jacquin Niles, MIT

TetR Aptamer-based conditional knockdown in Plasmodium

Manuel Llinás, Pennsylvania State University

Metabolomics and transcriptomics in anti-malarial target discovery

Jake Baum, Imperial College London

Identifying and defining antimalarial drug action from cell-based imaging using machine learning

pm - 2:30 pm	Lunch	Exhibition Area (Group)
		Banquet Room
		Delegates Lounge

pm - 5:00 pm	Joint Session: Optimizing Drug Discovery and Translation & Vaccines and Global Health Technology	Conf Room
--------------	---	------------------

Modulating immunity through adjuvants and drugs

Robert Wallis, Aurum Institute

Improving TB outcomes by host-directed therapy

Matthew Albert, Insitro

A path towards precision adjuvant selection

Robbert van der Most, GSK

Differential innate immune responses in various populations

David Russell, Cornell University

Using the host: Novel routes to host-dependent therapeutics

Lisa Wagar, Stanford University

Tonsil organoid culture system for vaccine and adjuvant screening

Tuesday, October 29

am - 1:30 pm	Joint Session: Optimizing Drug Discovery and Translation & African Innovation Research and Development Ecosystem	Conf Room
--------------	---	------------------

Open database of African clinical trials capabilities and sites

Session Chairs: *Jennifer Maroa, The African Academy of Sciences; Thy Pham, Bill & Melinda Gates Foundation*

Jennifer Maroa, The African Academy of Sciences

The African clinical trials community: An update

Peter Ward, Max Peterson and Matthew Wintle, Interactive Pharma Solutions

Introducing the African clinical trials community concept, interactive workshop, and findings

Beno Yakubu, NAFDAC and Chair of the AVAREF Technical Committee; Diadie Maiga, WHO AFRO and AVAREF Secretariat

Aggregated African countries clinical trials regulatory and ethics requirements – a pilot of early adopters

Thea Norman, Bill & Melinda Gates Foundation

Highly efficient clinical trials

pm - 2:30 pm	Lunch	Exhibition Area (Group)
		Banquet Room
		Delegates Lounge

Lauren Arendse, University of Cape Town

Pf kinase programm, including PI4K

Beatriz Baragana, University of Dundee, Dundee Discovery Unit

KRS and ProRS, target-based and phenotypic drug discovery

Koen Dechering, TropiQ Health Sciences

Pantothenamides form antimetabolites that block acetylCoA synthesis in human malaria parasites

Steven Maher, University of Georgia

Discovery and development of antirelapse compounds in a globally-collaborative, medium throughput P. vivax liver stage platform

Erika Flannery, Novartis (NTD)

Developing in vitro and in vivo assays for Pv and Pc

dix [I]- Pest and Disease Surveillance and Epidemiology: Abstract & Agenda

Organizer: Bill & Melinda Gates Foundation

Abstract:

ck Abstract:

ances in satellite imagery, machine learning, and the digitization of agriculture present new opportunities to better understand the true
len of pest and diseases, how they impact crop productivity, and the nature of the threat over different geographies and time scales.
; track will bring together the leading experts in pest and disease surveillance and epidemiology and innovators working on enabling
nologies for interactive sessions to network, share lessons learned, identify gaps and explore new tools, technologies, approaches and
egies to collecting on-the-ground data on pest and diseases at scale.

sion Abstracts:

a-traditional data collection for better analytics (joint session with Crop Productions Analytics at Scale: Innovations in Groun
thing track)

; introductory session will bring together crop and data scientists to discuss enabling factors to achieving impact. Participants will have
opportunity to learn from each other in a marketplace setting on a variety of topics from IP, regulations of chemical inputs, phytosanitari
biotechnology, financing, and engaging with governments.

arketplace of innovation in surveillance for pests and diseases and ground truth data (joint session with Crop Productions
lytics at Scale: Innovations in Ground Truthing track)

; session will be an interactive expo, highlighting innovations and approaches to on-the-ground surveillance for pests & diseases and
ind truthing for crop analytics. Participants will explore the state of play in ground-truthing and surveillance. This session offers
working opportunities for organizations involved in measurement and sampling (crowd-sourcing, field sensors, UAVs), diagnostics, data
ing, workflow processing (data integration, QA/QC), modeling, and end user model usage/business process integration.

lding a global burden of crop loss

; session will focus on sharing lessons learned, methodologies, and approaches to creating formal measures of global burden of disease i
ian health, animal health, and crop health.

Monday, October 28

am - 1:30 pm	Joint Session: Pest and Disease Surveillance and Epidemiology & Crop Productions Analytics at Scale: Innovations in Ground Truthing Non-traditional data collection for better analytics Session Chairs: <i>Stewart Collis and Christina Owen, Bill & Melinda Gates Foundation</i> Welcome and introductions, goals of the session Sector use cases - highlighting the data gaps Group discussion and request/offer activity at tables Table readouts Session close	Banquet Room
pm - 2:30 pm	Lunch	Exhibition Area (Group) Banquet Room Delegates Lounge
pm - 5:00 pm	Joint Session: Pest and Disease Surveillance and Epidemiology & Crop Productions	Banquet Room

Welcome and introductions, goals of the session, instructions for marketplace

Round 1: 4 rotations x 10 min

Each participant has the chance to visit 4 stations per round.

Shift marketplace stations and new innovator introductions

Round 2: 4 rotations x 10 min

Shift marketplace stations and new innovator introductions

Round 3: 4 rotations x 10 minutes

Session Close

Tuesday, October 29

pm - 5:00 pm

Pest and Disease Surveillance and Epidemiology

Banquet Room

Building a global burden of crop loss

Sessions Chair: *Christina Owen, Bill & Melinda Gates Foundation*

Christine Owen, Bill & Melinda Gates Foundation

Welcome and introductions, goals of the session

David Pigott, Institute for Health Metrics and Evaluation

Global burden of disease - lessons learned from human health

Jonathan Rushton, University of Liverpool

Global burden of animal disease - efforts in animal health

Brie Finegold, CABI

Global burden of crop disease - potential approaches in crops

Discussion

Session close

dix [J]- Scaling Innovation with a Gender Lens: Abstract & Agenda

Organizer: Grand Challenges Canada

Abstract:

on Abstracts:

municating innovation

s casual participatory session, Grand Challenges Canada innovators will each have the chance to share their interventions in a nic way, and enlist the support of the network to accomplish goals during the annual meeting. This is a session to meet other rators, Grand Challenges Canada staff, and establish relationships.

sforming gender norms for girls' empowerment: Individual and community behavior change (joint session with Gender ns and Programmatic Impact)

gender norms that influence health, education and economic development can have profound negative impacts for girls' aspirations pportunities. Norms can contribute to gender-based violence, child, early and forced marriage, limitations on reproductive control xclusion from education, employment, and access to healthcare services. Evidence also suggests that gender-related factors create icant barriers to accessing and practicing healthy behaviors. Gender-intentional programming aims to upend social structures, es and social norms in two ways: by fostering critical examination of inequalities and gender roles, norms and dynamics; and taneously strengthening positive norms that support gender equality and an enabling environment. Panelists will discuss findings, is learned and challenges in developing and implementing gender-intentional programming. Increased recognition of how gender s impact development outcomes can encourage greater investments in interventions that address gender norms with the potential to ve gender equality and sustained health behaviors across the life course.

lraising and financial management (joint session with DevelopmentXChange: Accelerating Adoption of Maternal and born Global Health Innovations)

rstanding the fundraising strategy, the types of resources available, and how to best mobilize and operationalize financial resources elp accelerate an innovations path to scale. Often, entrepreneurs with a breakthrough technology or service struggle with the cial management and business operations of turning their innovation into a viable business or organization. This session will provide and best practices for effective and efficient fundraising and financial management. Participants will better understand what funders for in an investee company, how to strengthen funding applications, and when is the right time to approach a funder, while providing pportunity to meet various types of funders and business expert to help strengthen their innovations financial capacity.

ile technology, gender norms and social embeddedness: Why we can't just add technology and stir (joint session with ler Norms and Programmatic Impact)

panel draws on research findings from the Women and Girls at the Center of Development research initiative supported by the Bill linda Gates Foundation and engages other Grand Challenge researchers and initiatives in the bio-medical field. The panel recognizes ast potential presented by digital technologies and platforms to address economic development, health and gender equality concerns, also interrogates how these technologies are deployed, examines who has access to them and asks salient questions about the socially dded nature of technology. It seeks to inform and refine policy and programs: How does digital technology work to improve en's lives, health and wellbeing? What are unintended consequences might arise from their use? How can women and girls maximize access to and control over mobile technology? And how can we maximize the benefits and minimize any costs from the use of le technology?

ic scaling strategies

athway to scale is unique for each innovation and often a non-linear process. Utilizing examples of different maternal and newborn rations that achieved significant growth and impact, we will review the lessons learned, successes, and failures on their scaling journey a particular focus on government adoption. This session will detail best practices in stakeholder engagement, government uptake, and gic partnerships, featuring perspectives from government, NGOs, hospitals, healthcare providers, suppliers, and patients.

Monday, October 28

am - 1:30 pm	Scaling Innovation with a Gender Lens Communicating innovation Session Chairs: <i>Natasha Cassinath and Maximillian Seunik, Grand Challenges Canada</i>	Large Briefing Rc
--------------	--	--------------------------

pm - 2:30 pm	Lunch	Exhibition Area (Group) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	Joint Session: Scaling Innovation with a Gender Lens & Gender Norms and Programmatic Impact Transforming gender norms for girls' empowerment: Individual and community behavior change Session Chair: <i>Chisina Kapungu, ICRW</i> <i>Ben Cislighi, Centre for Gender, Health and Violence, London School of Hygiene and Tropical Medicine</i> Gender inequality, social norms and health: Evidence from the Stanford Lancet series <i>Rebekah Neal, Bill & Melinda Gates Foundation</i> Gender considerations in clinical trials <i>Serkadis Admansu, CARE Ethiopia</i> Developing a measurement framework for social norms: Lessons from Abdiboru <i>Bonginkosi Ndlangamandla, SWAGAA</i> Building capacity for norm change with community groups and government institutions <i>Anderson Kumpoloto, CARE Umodzi</i> Evidence on the effectiveness and scalability of gender norm transformation <i>Prerna Kumar, International Center for Research on Women</i> Skills-building and other drivers of effective gender norm change	Delegates Lounge
--------------	---	-------------------------

Tuesday, October 29

am - 1:30 pm	Joint Session: Scaling Innovation with a Gender Lens & DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations Fundraising and financial management Session Chairs: <i>Christina Tamer, VentureWell; Lisa Bourget, Duke University; Robert Beyer, Villgro Kenya; Alden Zeche, We Scale Impact</i>	Delegates Lounge
--------------	--	-------------------------

Introduction to types of funding (grants, debt, equity)

Breakout groups by type of funding

Introduction to financial management

Breakout groups by level of financial knowledge

Wrap up

pm - 2:30 pm	Lunch	Exhibition Area (Group) Banquet Room Delegates Lounge
--------------	--------------	--

pm - 5:00 pm	Joint Session: Scaling Innovation with a Gender Lens & Gender Norms and Programmatic Impact Mobile technology, gender norms and social embeddedness: Why we can't just add technology and stir Session Chair: <i>Sarah Gammage, ICRW</i>	Delegates Lounge
--------------	---	-------------------------

Wendy Chamberlin, BOMA Project

Gender, technology and women's financial inclusion in northern Kenya

Laiah Idelson, Youth Tech Health

Technology and girls' empowerment programs: Promises and pitfalls

Richard Matikanya, Triggerise

Mobile solutions for public health

Philip Roessler, William and Mary College, REPOA

Barriers to women's use of digital financial services

Simone Schaner, University of Southern California

Strengthening women's financial control through personal bank accounts

Wednesday, October 30

am - 11:00 am

Joint Session: Scaling Innovation with a Gender Lens & DevelopmentXChange: Accelerating Adoption of Maternal and Newborn Global Health Innovations

**Deleg
Lou**

Public scaling strategies

Session Chairs: *Mark Marino, VentureWell; Sarah Dunn Phillips, Duke University; Matthew Grollnek, Open Capital Advisors; Alden Zecha, We Scale Impact*

Welcome and introduction

Dignitary speaker panel

Scaling strategy: Organic growth innovator talk

Scaling strategy: Distribution partner and innovator talk

Scaling strategy: Licensing and innovator talk

Scaling strategy: Teach/train and innovator talk

Q&A

dix [K]- Vaccines and Global Health Technology: Abstract & Agenda

Organizer: Bill & Melinda Gates Foundation

Abstract:

Abstract:

This track will highlight innovations transforming human immunobiology and new insights into disease biology and vaccinology, then demonstrate how the combination of these innovations and insights can be applied to develop tools and interventions against infectious diseases.

Session Abstracts:

Applying novel technologies to global health: Single cell analytics and epigenetic platforms

Recent advances in single cell analytics and measurement of epigenetic changes associated with immune mechanisms have the potential to identify novel pathways and increase our understanding of host/pathogen interactions. The speakers in this session will discuss how transformative technologies can be applied to enable insights into disease pathology and identify prophylactic and therapeutic targets for infectious disease.

Modulating immunity through adjuvants and drugs (joint session with Optimizing Drug Discovery and Translation)

In this session, we will explore novel technologies to screen for modulators of the innate and adaptive immune system. Approaches to immune modulation will be explored, including breakthrough tactics and their application, with a focus on the potential for transition of adjuvants and drugs into global health.

Perinatal microbiome and immunological determinants of birth outcomes and HIV acquisition (joint session with Growth and Development: Optimizing Birth, Growth and Development)

In this session we plan to explore both microbiome and immunological factors that associate with birth outcomes and HIV acquisition. Are these factors the same for both adverse birth outcomes and HIV acquisition? For which birth outcomes (preterm birth, stillbirth, low gestational age, preeclampsia) is there the strongest evidence of association? To what degree do microbial and immunological factors co-associate vs. associate independently with adverse birth outcomes and HIV?

Designing protective immunity to malaria

Malaria vaccine candidates have been tested in controlled human malaria infection models and in malaria-endemic regions with differing levels of efficacy. Insights gained from these studies into putative immune mechanisms of protection can be used to inform the rational design of effective new vaccines and novel tools to end malaria. The potential of monoclonal antibodies directed against Plasmodium antigens as tool for malaria prevention will also be explored.

Monday, October 28

9 am - 1:30 pm	Vaccines and Global Health Technology Applying novel technologies to global health: Single cell analytics and epigenetic platforms Session Chair: <i>Karen Makar, Bill & Melinda Gates Foundation</i> <i>Munyaradzi Musvosvi, South African Tuberculosis Vaccine Institute, University of Cape Town</i> TCR sequencing for TB antigen discovery <i>Alex Shalek, MIT, Ragon Institute, Broad Institute, Harvard Medical School, Massachusetts General Hospital</i> Developing experimental and computational tools to define the impact of TB on lung homeostasis at single cell resolution <i>Ido Amit, Howard Hughes Medical Institute International Scholar, Weizmann Institute</i> The power of ONE: Immunology in the age of single cell genomics <i>Musa Mhlamba, University of Cape Town</i> Epigenetic mechanisms of trained innate immunity <i>Bali Pulendran, Stanford University</i> Single-cell technologies for understanding epigenetic imprinting of innate immunity to vaccination	Conf Room
----------------	--	-----------

pm - 5:00 pm	Joint Session: Vaccines and Global Health Technology & Optimizing Drug Discovery and Translation Modulating immunity through adjuvants and drugs Session Chairs: <i>Anastasia Older Aguilar, Gang Liu, and Harry Kleanthous, Bill & Melinda Gates Foundation</i> <i>Robert Wallis, Aurum Institute</i> Improving TB outcomes by host-directed therapy <i>Matthew Albert, Insitro</i> A path towards precision adjuvant selection <i>Robbert van der Most, GSK</i> Differential innate immune responses in various populations <i>David Russell, Cornell University</i> Using the host: Novel routes to host-dependent therapeutics <i>Lisa Wagar, Stanford University</i> Tonsil organoid culture system for vaccine and adjuvant screening	Conf Roo
--------------	--	----------

Tuesday, October 29

am - 1:30 pm	Joint Session: Vaccines and Global Health Technology & Growth and Resilience: Optimizing Birth, Growth and Development Vaginal microbiome and immunological determinants of birth outcomes and HIV acquisition Session Chairs: <i>Chris Damman and Karen Makar, Bill & Melinda Gates Foundation</i> Session Lead: <i>Jacques Ravel, University of Maryland School of Medicine</i> <i>Sharon Hillier, University of Pittsburgh Magee-Womens Research Institute</i> Microbiome and HIV risk in pregnant and breastfeeding women <i>Doug Kwon, Harvard University</i> Vaginal microbiome and HIV <i>ZaZa Ndblovu, Harvard University and University of KwaZulu-Natal</i> HIV-specific T cell responses in lymph nodes and blood during hyperacute HIV infection <i>Adam Burgener, University of Manitoba</i> Vaginal microbiome proteomics <i>Georgia Tomaras, Duke University</i> <i>Vaginal mucus</i>	Banquet Rc
pm - 2:30 pm	Lunch	Exhibition Area (Grou Banquet Rc Delegates Lou
pm - 5:00 pm	Vaccines and Global Health Technology Designing protective immunity to malaria Session Chair: <i>Holger Kanzler, Bill & Melinda Gates Foundation</i> <i>Katie Ewer, Oxford University</i> Immunogenicity and correlates of protection with R21 <i>Peter Crompton, National Institutes of Health</i> The potential impact of immune 'dysregulation' on malaria vaccine efficacy in endemic areas <i>Hedda Wardemann, DKFZ</i>	Conf Roo

From: Tucker, Jessica (NIH/OD) [E]
Sent: Fri, 11 Oct 2019 20:39:47 +0000
To: Mike McCune
Cc: Patterson, Amy (NIH/NHLBI) [E];Groesch, Mary (NIH/NHLBI) [E];Dieffenbach, Carl (NIH/NIAID) [E];O'Reilly, Marina (NIH/OD) [E]
Subject: Materials for 10/15 EC Meeting
Attachments: APPENDIX A-NIH BMGF EC Meeting_draft agenda_101519.docx, APPENDIX B- Executive Summary NIH-BMGF Collaboration 101519.docx, APPENDIX C- NIH_BMGF Collaboration for SCD and HIV_ Executive Committee Briefing 101519.pptx, APPENDIX D- NIH BMGF SCD HIV Cures _Roster_101119.docx, APPENDIX E-MOU NIH_BMGF Collaborative Efforts on In Vivo Gene Editing for SCD and HIV signed 06252019.pdf

Hi Mike,

Please find attached the documents for the meeting on 10/15. I think you indicated you would get them to the right people at BMGF (thanks!), but please let me know if I should transmit them directly to peoples' scheduling POCs. As you can see, we made the adjustment that we discussed on the phone, re: identifying HIV reservoir biomarkers as a component that is within the scope of the collaboration.

Please note the Monday, 10/14 is a Federal holiday- I may be checking e-mail a bit, but I won't be as accessible as usual.

We look forward to the discussion on Tuesday, and have a great weekend.

Best,

Jessica

Page 246 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 247 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 248 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 249 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 250 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 251 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 252 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 253 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 254 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 255 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 256 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 257 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 258 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 259 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 260 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 261 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 262 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 263 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 264 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 265 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 266 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 267 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Memorandum of Understanding

between

National Institutes of Health

and

Bill and Melinda Gates Foundation

for

Collaborative Efforts on *In Vivo* Gene Editing for Sickle Cell Disease and Human Immunodeficiency Virus

This Memorandum of Understanding (MOU) is between the National Institutes of Health (NIH), part of the U.S. Department of Health & Human Services, and the Bill and Melinda Gates Foundation (BMGF). NIH and BMGF are referred to herein individually as a Party and collectively as the Parties.

1. DESCRIPTION OF EACH PARTY AND ITS INTEREST

The NIH mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Under Section 402 of the Public Health Service Act, 42 U.S.C. § 282, the Director of NIH is responsible for the overall direction of the NIH and coordinates and oversees the operation of the national research institutes, national centers, and administrative entities within the NIH. The NIH is composed of various institutes, centers, and offices with unique research missions and capabilities that may contribute to the development of *in vivo* gene editing approaches for Sickle Cell Disease (SCD) and Human Immunodeficiency Virus (HIV) infection. Key NIH entities include:

- The National Institute of Allergy and Infectious Diseases (NIAID), which supports a global research portfolio on HIV/Acquired Immune Deficiency Syndrome (AIDS), its related co-infections, and co-morbidities;
- The National Heart, Lung, and Blood Institute (NHLBI), which provides global leadership in research, training, and education to prevent and treat heart, lung, blood, and sleep disorders; and
- The Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) within the Office of the NIH Director, which identifies emerging scientific opportunities, rising public health challenges, and scientific knowledge gaps that merit further research.

The HIV Frontiers Program at BMGF has as its vision to accelerate the decline of the global burden and incidence of HIV infection by ensuring development and use of impactful prevention and treatment interventions.

The Parties expect this non-binding agreement will help provide a structure for potential collaborative activities.

The Parties hereby agree as follows:

2. SCOPE AND PURPOSE OF COLLABORATION

The Parties agree that their mutual intention under this MOU is to collaborate to support studies to advance the development of *in vivo* gene editing and other relevant approaches to cure HIV infection and SCD.

For SCD, the ultimate goal is the availability in seven to ten years of a sustainable clinical trial platform that will provide the foundation for infant screening across high-risk geographic areas as well as for clinical trials evaluating an *in vivo* gene editing-based cure that would be readily available, scalable, and sustainable in low resource countries. The ultimate goal for HIV is the availability in seven to ten years of an affordable, one shot, *in vivo* gene editing product that results in reduction of virus to undetectable levels with no need for continuation of drug therapy, and with successful management of any recurrences.

3. ROLES AND PROPOSED CONTRIBUTIONS OF THE PARTIES

Subject to conclusion of an appropriate final binding agreement and the availability of resources, among other considerations, NIH is interested in supporting this collaborative effort, including providing anticipated financial support for the operational cost of the collaborative effort, and technical input to the development of such approaches. NIH may support research projects, in accordance with its mission and applicable laws, regulations, and policies, to further the goals of this collaborative effort.

Subject to conclusion of an appropriate final binding agreement and the availability of resources, among other considerations, BMGF is interested in supporting this collaborative effort, including providing anticipated financial support for the operational cost of the collaborative effort, and technical input to the development of such approaches. BMGF may support research projects, in accordance with its mission and applicable laws, regulations, and policies, to further the goals of this collaborative effort.

The intention of the collaboration between the Parties is to share costs in approximately a 1:1 ratio.

Additionally, the Parties have a shared intention to establish mechanisms to collaborate in this effort, which may include a Steering Committee and an Executive Committee, as described in Section 4 below.

4. ESTABLISHMENT OF STEERING AND EXECUTIVE COMMITTEES

Subject to final agreements, the Parties may establish a Steering Committee to guide implementation of the collaboration, allow for information sharing on progress of the collaborative efforts, and discuss which projects fit within the joint research plan for the collaboration. The Steering Committee will not provide recommendations regarding funding

decisions to either NIH or BMGF. The Steering Committee will convene as needed, but at least bimonthly to share information and assess progress on the research plan. The Steering Committee will be composed of representatives from NIH OD, NIAID, DPCPSI, NHLBI, and BMGF with appropriate content expertise and decision-making authority. The Steering Committee may form Working Groups and subcommittees made up of NIH and BMGF representatives as needed.

Subject to final agreements, the Parties will also establish an Executive Committee to assess overarching progress on the collaborative effort, consider any gaps that may exist, and discuss setting or adjusting priorities for the collaborative effort. The Executive Committee will not provide recommendations regarding funding decisions to either NIH or BMGF. The Executive Committee, if established, will convene as needed but no less than two (2) times per year and will be informed by input from the Steering Committee. The Executive Committee will be composed of NIH and BMGF leadership.

5. LIMITATIONS

This MOU is intended as an expression of mutual goodwill and of shared interest. Any statements of intent made under this MOU shall be subject to the Parties entering into a final, binding agreement related to the collaborative effort, the availability of sufficient resources to support the collaborative effort, and applicable laws, regulations, internal rules, policies, administrative procedures and practices, among other considerations.

This MOU imposes no funding obligations on the Parties. Nothing in this MOU authorizes or is intended to obligate the Parties to expend, exchange, or reimburse funds, services, or supplies, or transfer or receive anything of value, or to enter into any contract, assistance agreement, interagency agreement, or other financial obligation. Any financial arrangements between the Parties shall be subject to a separate agreement. This MOU is not intended to create any contractual rights between the Parties. This MOU in no way restricts the Parties from participating in any activity with other public or private agencies, organizations, or individuals.

6. PROPRIETARY INFORMATION AND CONFIDENTIALITY

It is acknowledged that each Party may possess confidential information, which may be required to be shared for the performance of joint work under this MOU. Any such information shall only be shared between the Parties under a separate confidential disclosure agreement, specifically covering such information. Each Party retains its intellectual property rights over its pre-existing information and know-how, including information related to the subject of the research projects covered by this MOU but not directly arising from the work conducted jointly under this MOU. Such information and know-how may be disclosed and used by the other Parties, subject to the above obligations of confidentiality and only for the purposes of the work to be carried out under this MOU.

No Party claims by virtue of this MOU any legal right, title, interest, or license in the other Party's intellectual property, including patent, copyright, trademark, or trade secret, of the other Party or in any intellectual property that might result from the other Parties' activities.

7. LIABILITY

Each Party shall be solely responsible for the manner in which it carries out its part of the collaborative activities under this MOU, except that the NIH, as an agency of the U.S. Government, may be liable only to the extent as provided under the Federal Tort Claims Act (28 U.S.C. Chapter 171). Thus, no Party shall be responsible for any loss, accident, damage or injury suffered or caused by any other Party, or any other Party's staff, grantees, or contractors, in connection with, or as a result of, the collaboration under this MOU.

8. USE OF THE PARTIES' NAMES

Each Party may refer to this MOU and the relationship with the other Party in communications, provided that such Party provides the other Party with an opportunity to review the drafts of communications at least seven (7) days prior to public availability or dissemination. Except as explicitly provided for in this MOU, no Party shall, in any written communication, statement or material of a promotional nature, use any other Party's name, acronym and/or logo without the prior written consent of that other Party.

9. RELATIONSHIP BETWEEN THE PARTIES

For the purposes of this MOU, each Party is an independent entity and not the joint venturer, agent or employee of any other Party. No Party shall have authority to make any statements, representations, or commitments of any kind, or to take any action which shall be binding on any other Party, except as may be authorized in writing by the other Party.

10. DURATION AND TERMINATION

This MOU becomes effective on the date of its last signature and shall continue for a period of 4 years, unless modified or terminated. Either Party may terminate its participation in this MOU at any time. Notwithstanding the foregoing, it is agreed that any termination of participation in this MOU by any Party shall be without prejudice to: (i) the orderly completion of any ongoing collaborative activity; and (ii) any other rights and obligations of the Parties accrued prior to the date of termination of this MOU.

11. AMENDMENTS

The Parties may revise, extend or modify this MOU by written amendment, provided such revisions and/or modifications are mutually agreed upon, and that any such amendment is signed by each Party hereto.

12. ENTIRE AGREEMENT

This MOU constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior and/or contemporaneous agreements or understandings, written or oral, with respect to the subject matter of this MOU.

13. SEVERABILITY

Any terms of this MOU found to be inconsistent with applicable laws, regulations, and/or policies of any of the Parties shall be invalid, but all the other terms shall remain in effect.

14. CONTACT INFORMATION OF THE PARTIES

NIH:

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health
U.S. Department of Health and Human Services
1 Center Drive
Bethesda, MD 20892

Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
U.S. Department of Health and Human Services
31 Center Dr.
Bethesda, MD 20892

Gary H. Gibbons, M.D.
Director
National Heart, Lung, and Blood Institute
National Institutes of Health
U.S. Department of Health and Human Services
31 Center Dr.
Bethesda, MD 20892

James M. Anderson, M.D., Ph.D.
Director
Division of Program Coordination, Planning, and Strategic Initiatives
National Institutes of Health
U.S. Department of Health and Human Services
1 Center Drive
Bethesda, MD 20892

BMGF:

Trevor Mundel, MD, PhD
President, Global Health Program
Bill & Melinda Gates Foundation
500 5th Avenue North
Seattle, WA 98109

Daniel J. Wattendorf, MD
Director, Global Health Program
Bill & Melinda Gates Foundation
500 5th Avenue North
Seattle, WA 98109


Joseph Mike McCune, MD, PhD
Senior Advisor, Global Health Program
Bill & Melinda Gates Foundation
500 5th Avenue North
Seattle, WA 98109

SIGNATURES

In witness whereof each Party has caused this MOU to be executed by its duly authorized representative, as of the dates set forth below.



(Signature)




(Date)

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health



(Signature)



(Date)

Bill Gates
Co-Chair
Bill & Melinda Gates Foundation

From: Mike McCune
Sent: Wed, 9 Oct 2019 21:53:20 +0000
To: Tucker, Jessica (NIH/OD) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: Re: Touch Base? - another thought

Hi Jessica, Carl, and Mary,

Thanks for the time on the phone. That was fun and I like the way the description of the collaboration is heading.

One thing, on reflection, I thought should raise...

The reason we previously "grayed out" the SCD boxes before is because - in fact - the budgeted "new" \$100M from the foundation does not have anything earmarked towards those activities. There are, indeed, activities elsewhere at the foundation under separate budget that are focused on activities like "LMIC-adaptable detection devices" but, these, like many of the other activities in the HIV-specific and SCD-specific boxes, should probably not be considered as ones "paid for" by the new "collaboration" money. I hope that makes sense.

I think if we just color the "HIV biomarker" box purple and move it as we discussed, we'll be good to go!

Thanks,

M

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Wednesday, October 9, 2019 11:42 AM

To: Mike McCune (b)(6); Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>

Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>

Subject: RE: Touch Base?

Hi Mike,

We look forward to the discussion at 4 PM ET this afternoon.

To help guide our discussion and to reflect feedback we received from NIH Executive Committee members, we have proposed some revisions for consideration/for discussion to both the Executive Summary and the slide deck. Most notable changes are in yellow on the Executive Summary. For the slides (b)(5)

(b)(5)

Thanks so much for taking time to talk through this with us, and we will speak with you soon.

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, October 8, 2019 5:25 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Re: Touch Base?

Sure, I'm also good at 4 or 4:30 EDT tomorrow, if one of those times is better.

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Sent: Tuesday, October 8, 2019 2:19 PM
To: Mike McCune (b)(6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: RE: Touch Base?

Alternatively, if you have time tomorrow afternoon after 2:30 EDT, that would work a bit better.

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dieffenbach, Carl (NIH/NIAID) [E]
Sent: Tuesday, October 8, 2019 5:07 PM
To: Mike McCune (b)(6)
Cc: Kimberly (NIH/NIAID) Barasch [C] (kimberly.barasch@nih.gov) <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Touch Base?

Hi Mike,

Do you have time for a 30 min call some time on Friday review nearer final versions of the slides and concepts for our cures collaboration? We want to completely nail down the pivotal role of gene-based cures as we move forward.

Kim can help with scheduling.

Best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tucker, Jessica (NIH/OD) [E]
Sent: Wed, 9 Oct 2019 18:42:05 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Groesch, Mary (NIH/NHLBI) [E]; Patterson, Amy (NIH/NHLBI) [E]; O'Reilly, Marina (NIH/OD) [E]
Subject: RE: Touch Base?
Attachments: Executive Summary NIH-BMGF Collaboration REVISED
10092019_clean_v4.docx, NIH_BMGF Collaboration for SCD and HIV_Executive Committee Briefing
REVISED SLIDES 100919_v2.pptx

Hi Mike,

We look forward to the discussion at 4 PM ET this afternoon.

To help guide our discussion and to reflect feedback we received from NIH Executive Committee members, we have proposed some revisions for consideration/for discussion to both the Executive Summary and the slide deck. Most notable changes are in yellow on the Executive Summary. For the slides, (b)(5)

(b)(5)

Thanks so much for taking time to talk through this with us, and we will speak with you soon.

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, October 8, 2019 5:25 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Re: Touch Base?

Sure, I'm also good at 4 or 4:30 EDT tomorrow, if one of those times is better.

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Sent: Tuesday, October 8, 2019 2:19 PM
To: Mike McCune (b)(6)

Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: RE: Touch Base?

Alternatively, if you have time tomorrow afternoon after 2:30 EDT, that would work a bit better.

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dieffenbach, Carl (NIH/NIAID) [E]
Sent: Tuesday, October 8, 2019 5:07 PM
To: Mike McCune (NIH/NIAID) [E]
Cc: Kimberly (NIH/NIAID) Barasch [C] (kimberly.barasch@nih.gov) <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Touch Base?

Hi Mike,

Do you have time for a 30 min call some time on Friday review nearer final versions of the slides and concepts for our cures collaboration? We want to completely nail down the pivotal role of gene-based cures as we move forward.

Kim can help with scheduling.

Best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Page 280 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 281 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 282 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 283 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 284 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 285 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 286 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 287 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 288 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 289 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 290 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 291 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 292 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 293 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 294 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 295 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 296 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 297 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 298 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 299 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: McManus, Ayanna (NIH/OD) [E]
Sent: Wed, 9 Oct 2019 16:52:47 +0000
To: christa.bowles(b)(6) Gary.Feldman(b)(6).org; fabi.prechte(b)(6)
on.org; marcelle.sisson(b)(6) Simon, Dina (NIH/OD) [C]; Hardesty, Rebecca (NIH/OD)
[E]; Hughes, Karen (NIH/OD) [E]; Dimishkov, Roxanne (NIH/NHLBI) [C]; Conrad, Patricia (NIH/NIAID)
[E]; Shuler, Tonia (NIH/NIAID) [C]
Cc: Tucker, Jessica (NIH/OD) [E]
Subject: CONFIRMATION; NIH-BMGF Executive Committee Meeting

Dear all,

Many thanks for your flexibility! This note confirms the meeting as follows:

DATE:	Tuesday, October 15, 2019
TIME:	4:15 p.m. – 5:15 p.m. EDT/ 1:15 p.m – 2:15 p.m. PDT
PLACE:	Bldg. 1, Room 116
COORDINATES:	Dial: (b)(4); (b)(6) Code: (b)(4); (b)(6)
PURPOSE:	NIH-BMGF Executive Committee Meeting
NIH PARTICIPANTS:	Francis Collins Lawrence Tabak James Anderson Anthony Fauci Gary Gibbons Jessica Tucker Carrie Wolinetz
BMGF PARTICIPANTS:	Trevor Mundel Dan Wattendorf Mike McCune Toni Hoover Emilio Emini

Thank you,
Ayanna

From: McManus, Ayanna (NIH/OD) [E]
Sent: Thursday, October 3, 2019 10:39 AM
To: christa.bowles(b)(6) Gary.Feldman(b)(6)
fabi.prechte(b)(6); marcelle.sisson(b)(6) Simon, Dina (NIH/OD) [C]
<dina.simon@nih.gov>; Hardesty, Rebecca (NIH/OD) [C] <rebecca.hardesty@nih.gov>; Hughes, Karen

(NIH/OD) [E] <karen.hughes@nih.gov>; Dimishkov, Roxanne (NIH/NHLBI) [C] <roxanne.dimishkov@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Shuler, Tonia (NIH/NIAID) [C] <tonia.shuler@nih.gov>

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Subject: MEETING REQUEST: NIH-BMGF Executive Committee Meeting

Good morning,

Director Collins would like to convene the full NIH-BMGF Executive Committee in the near future. Please provide your principal's availability [here](#). Since there's eagerness to meet, as always, your flexibility is greatly appreciated.

Sincere apologies for the limited scheduling option.

Thank you,
Ayanna

Ayanna L. McManus

Immediate Office of the Director
National Institutes of Health
Bethesda, MD 20892
Voice: 301-496-2433
Fax: 301-402-2700
Email: amcmanus@od.nih.gov

Confidentiality Statement: This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use, disclosure, or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and delete from your mailbox or any other storage devices.



Follow @NIHDirector on Twitter 

Celebration of Science at NIH: *watch how medical research saves lives and improves health*

From: McManus, Ayanna (NIH/OD) [E]
Sent: Wed, 9 Oct 2019 16:36:50 +0000
To: Dan Wattendorf; Mike McCune; trevor.munde(b)(6); Tucker, Jessica (NIH/OD) [E]
Cc: Gary Feldman; christa.bowles(b)(6); fabi.prechte(b)(6); marcelle.sissor(b)(6); (b)(6); Dimishkov, Roxanne (NIH/NHLBI) [C]; Conrad, Patricia (NIH/NIAID) [E]; Hardesty, Rebecca (NIH/OD) [E]; Hughes, Karen (NIH/OD) [E]
Subject: NIH-BMGF Executive Committee Meeting

From: Tucker, Jessica (NIH/OD) [E]
Sent: Wed, 9 Oct 2019 02:12:37 +0000
To: Mike McCune
Cc: Patterson, Amy (NIH/NHLBI) [E]
Subject: RE: Grand Challenges meeting - side meeting

Mike,

Thanks. I am checking with Rob Eiss re his thoughts on the side meeting.

I think/hope Amy should be in the loop re scheduling for the EC- Amy, if you need any info from me, please let me know, but I know Gary's schedulers have been providing his availability to FC's schedulers. They are likely the best source of the latest information.

Talk soon,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, October 8, 2019 10:06 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Grand Challenges meeting - side meeting

Hi Jessica,

I see from the scrolls on our side that the following individuals from NIH are attending GC:

Frances Collins
Peter Crompton
Bob Seder
Karen Tountas
Stacy Wallick
Charles Rotimi
Robert Eiss
Yingda Xie

Are any of these individuals, other than Frances, in the orbit of the collaboration?

Do you think Frances would like to attend and participate in the side meeting (which will take place, I believe, on Wed(30)? That would be fab!

Re, the 15th: yes! That's great. Amy and I have talked about her dialing in (or attending on your side) so that both of us could be in attendance to present the work of the SC. Can you keep her in the loop of the scheduling so that can happen?

Also, I heard indirectly (via Dan W) that it was difficult to confirm my availability on that day. If that ever happens in the future, please don't hesitate to text or call me at (b)(6) Gary Feldman (at (b)(6)) is also always able to find me.

Cheers,

M

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, October 8, 2019 6:00 PM

To: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Grand Challenges meeting - side meeting

Hi Mike,

Thanks so much for your message and for sharing the information about what looks to be a very interesting side meeting in Addis. It looks very exciting, and, like you said, potentially another good opportunity to discuss the partnership.

Unfortunately, I do not know of anyone else from NIH who is attending. I won't be there. Let me check around a bit more and confirm that information.

In the meantime, please let us know if there is anything else we can do to assist. It looks like we may be touching base tomorrow with Carl, which is great. And additionally, I think/hope the Executive Committee meeting is getting confirmed for Oct 15. Thank you so much for finding a way to make that work!

Looking forward to talking soon.

Best,

Jessica

From: Mike McCune (b)(6)

Sent: Monday, October 7, 2019 6:06 PM

To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Subject: Grand Challenges meeting - side meeting

Hi Amy and Jessica,

I'm writing to pick your brains about potential NIH participants in a side meeting that we are planning at the Grand Challenges meeting in Addis.

As you know, Frances and Trevor will make an announcement about the collaboration on Day 1 of the meeting. On Day 3 (Oct 30), there will be a side meeting to discuss the work of the "Sunnylands" working groups focused on developing a TPP for HIV cure in sub-Saharan Africa and a public-private partnership (called HCAAP) to facilitate entry of such interventions if and when they arise. We're just in the process of planning this meeting now and a tentative outline is attached. You'll note that it is being led by well-respected clinical investigators and community advocates from sub-Saharan Africa. We imagine that it will also be another forum in which the NIH-BMGF collaboration can be discussed.

The question is: might there be someone from NIH - preferably from the steering committee or close to it - who will be at Addis, perhaps accompanying Frances, who could participate in this meeting? Amy, I know that we have already figured out that you would not be able to attend. Jessica, will you be there? Any other thoughts?

Thanks for letting me know! Please also let me know if you have any thoughts about the current outline of the meeting.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Dieffenbach, Carl (NIH/NIAID) [E]
Sent: Tue, 8 Oct 2019 21:27:07 +0000
To: Mike McCune
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Tucker, Jessica (NIH/OD) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: RE: Touch Base?

Thanks Mike,

If we can lock in 4:00EST tomorrow that will be great. Kim can send out call in information in the morning.

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mike McCune (b)(6)
Sent: Tuesday, October 8, 2019 5:25 PM
To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Re: Touch Base?

Sure, I'm also good at 4 or 4:30 EDT tomorrow, if one of those times is better.

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Sent: Tuesday, October 8, 2019 2:19 PM
To: Mike McCune (b)(6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: RE: Touch Base?

Alternatively, if you have time tomorrow afternoon after 2:30 EDT, that would work a bit better.

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dieffenbach, Carl (NIH/NIAID) [E]
Sent: Tuesday, October 8, 2019 5:07 PM
To: Mike McCune <(b)(6)>
Cc: Kimberly (NIH/NIAID) Barasch [C] (kimberly.barasch@nih.gov) <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Touch Base?

Hi Mike,

Do you have time for a 30 min call some time on Friday review nearer final versions of the slides and concepts for our cures collaboration? We want to completely nail down the pivotal role of gene-based cures as we move forward.

Kim can help with scheduling.

Best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director

Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mike McCune
Sent: Tue, 8 Oct 2019 21:21:37 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Tucker, Jessica (NIH/OD) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: Re: Touch Base?

Hi Carl,
It'd be great to touch bases.
Friday, I'd be good anytime between 6 - 9 am, 11-11:30, and after 3 pm PT.
Might one of those times work for you?
M

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>
Sent: Tuesday, October 8, 2019 2:06 PM
To: Mike McCune (b)(6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Subject: Touch Base?

Hi Mike,

Do you have time for a 30 min call some time on Friday review nearer final versions of the slides and concepts for our cures collaboration? We want to completely nail down the pivotal role of gene-based cures as we move forward.

Kim can help with scheduling.

Best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
Rockville, MD 20852-9831
he/him/his
Phone: (301) 496-9112
Fax: (240) 627-3466
Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and

Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dan Wattendorf
Sent: Tue, 8 Oct 2019 14:18:09 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: McManus, Ayanna (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]
Subject: Re: SCD HIV Executive Committee meeting

Hi all,

Not sure how I missed this. I am on it. We will resolve this today.

Dan

Get [Outlook for iOS](#)

From: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
Sent: Tuesday, October 8, 2019 4:38:20 AM
To: Dan Wattendorf (b)(6)
Cc: McManus, Ayanna (NIH/OD) [E] <ayanna.mcmanus@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Wolinetz, Carrie (NIH/OD) [E] <carrie.wolinetz@nih.gov>
Subject: SCD HIV Executive Committee meeting

Hey Dan,

Ayanna and Jessica are trying to schedule an Exec Comm meeting for the BMGF-NIH collaboration on SCD and HIV. This needs to happen before the Grand Challenges meeting, so that we're all on the same page before this becomes public.

We're having a really tough time getting on schedules for BMGF members. To remind you, they are

Trevor Mundel (Co-Chair)

Dan Wattendorf

Mike McCune

Toni Hoover

Emilio Emini

Bill Gates (as available)

Additionally, in case it is useful, the preferred time right now for the Executive Committee meeting, based on most participants' availability, is 4:15- 5:15 PM ET on 10/15. I highlighted in yellow above the individuals who are able to participate at that time. As I understand, Mike McCune has not provided his availability, and you and Emilio are said to not be available at any of the times offered on Oct 15 or 18.

Can you help? I'd judge that you, Trevor, and Mike are most crucial – if you three could somehow make it for this date on 10/15, we could go ahead.

Thanks, Francis

From: Mike McCune
Sent: Mon, 7 Oct 2019 22:06:08 +0000
To: Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E]
Subject: Grand Challenges meeting - side meeting
Attachments: HCAAP.Grand Challenges discussion slides.20191001.v02.pptx

Hi Amy and Jessica,

I'm writing to pick your brains about potential NIH participants in a side meeting that we are planning at the Grand Challenges meeting in Addis.

As you know, Frances and Trevor will make an announcement about the collaboration on Day 1 of the meeting. On Day 3 (Oct 30), there will be a side meeting to discuss the work of the "Sunnylands" working groups focused on developing a TPP for HIV cure in sub-Saharan Africa and a public-private partnership (called HCAAP) to facilitate entry of such interventions if and when they arise. We're just in the process of planning this meeting now and a tentative outline is attached. You'll note that it is being led by well-respected clinical investigators and community advocates from sub-Saharan Africa. We imagine that it will also be another forum in which the NIH-BMGF collaboration can be discussed.

The question is: might there be someone from NIH - preferably from the steering committee or close to it - who will be at Addis, perhaps accompanying Frances, who could participate in this meeting? Amy, I know that we have already figured out that you would not be able to attend. Jessica, will you be there? Any other thoughts?

Thanks for letting me know! Please also let me know if you have any thoughts about the current outline of the meeting.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers
Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 314 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 315 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 316 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 317 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 318 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 319 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 320 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 321 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 322 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 323 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 324 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 325 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 326 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 327 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 328 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 329 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 330 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 331 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 332 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 333 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 334 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Marcelle Sisson
Sent: Thu, 3 Oct 2019 18:42:06 +0000
To: McManus, Ayanna (NIH/OD) [E];Christa Bowles;Gary Feldman;Fabi Prechtel;Simon, Dina (NIH/OD) [C];Hardesty, Rebecca (NIH/OD) [E];Hughes, Karen (NIH/OD) [E];Dimishkov, Roxanne (NIH/NHLBI) [C];Conrad, Patricia (NIH/NIAID) [E];Shuler, Tonia (NIH/NIAID) [C]
Cc: Tucker, Jessica (NIH/OD) [E]
Subject: RE: MEETING REQUEST: NIH-BMGF Executive Committee Meeting

Hi Ayanna,

Thank you for sending along this poll. Unfortunately, Emilio will be attending a conference overseas during these dates, and will be unable to join.

Thank you,
Marcelle

Marcelle Sisson

Senior Program Assistant
Global Health – TB and HIV

V (b)(6)

E (b)(6)

Bill & Melinda Gates Foundation
www.gatesfoundation.org

From: McManus, Ayanna (NIH/OD) [E] <ayanna.mcmanus@nih.gov>
Sent: Thursday, October 3, 2019 7:39 AM
To: Christa Bowles (b)(6); Gary Feldman (b)(6); Fabi Prechtel (b)(6); Marcelle Sisson (b)(6); Simon, Dina (NIH/OD) [C] <dina.simon@nih.gov>; Hardesty, Rebecca (NIH/OD) [C] <rebecca.hardesty@nih.gov>; Hughes, Karen (NIH/OD) [E] <karen.hughes@nih.gov>; Dimishkov, Roxanne (NIH/NHLBI) [C] <roxanne.dimishkov@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Shuler, Tonia (NIH/NIAID) [C] <tonia.shuler@nih.gov>
Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: MEETING REQUEST: NIH-BMGF Executive Committee Meeting

Good morning,

Director Collins would like to convene the full NIH-BMGF Executive Committee in the near future. Please provide your principal's availability [here](#). Since there's eagerness to meet, as always, your flexibility is greatly appreciated.

Sincere apologies for the limited scheduling option.

Thank you,
Ayanna

Ayanna L. McManus

Immediate Office of the Director

National Institutes of Health

Bethesda, MD 20892


Voice: 301-496-2433

Fax: 301-402-2700

Email: amcmanus@od.nih.gov

Confidentiality Statement: This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use, disclosure, or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and delete from your mailbox or any other storage devices.



Follow @NIHDirector on Twitter 

Celebration of Science at NIH: *watch how medical research saves lives and improves health*

From: Mike McCune
Sent: Thu, 26 Sep 2019 23:49:21 +0000
To: Patterson, Amy (NIH/NHLBI) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Tucker, Jessica (NIH/OD) [E]; Emily Turner; Kedest Tesfagiorgis; Nina Russell; Adam Jiang (McKinsey Secondment); Timothy Attoye; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Hoots, W. Keith (NIH/NHLBI) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]
Subject: Re: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents

This is great, all!

I'd like to chime in with Amy to thank everyone for working through all of this so thoughtfully and completely, and in such a timely manner.

I am very excited about the way we are moving forward.

Best,

Mike

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Thursday, September 26, 2019 2:44 PM

To: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>; Mike McCune

(b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6); Kedest Tesfagiorgis

(b)(6); Nina Russell (b)(6) Adam Jiang (McKinsey Secondment) (b)(6); Timothy Attoye

(b)(6); Perry, Mary (NIH/OD) [E] <perry@nih.gov>; Wilder, Elizabeth (NIH/OD) [E] <wilder@od.nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Hoots, W. Keith (NIH/NHLBI) [E] <hootswk@nhlbi.nih.gov>

Cc: Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Islam, Aminul (NIH/NHLBI) [C] <aminul.islam@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Hostetler, Jessica (NIH/NHLBI) [E] <jessica.hostetler@nih.gov>; Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>

Subject: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Please find attached the finalized set of documents/briefing materials that we have worked together to develop:

1. Executive Summary
2. Slide deck for Executive Committee briefing
3. Full slide deck reflecting in more detail the Steering Committee discussions

Documents 1 and 2 are intended for our use in briefing our respective leadership. (Please note that based on the votes from all the SC members, the 3 finalist names for the Collaboration were: Cooperate2Cures, Partner2Cures, and Path2Cures. These are listed in the slide deck)

Thanks to everyone for their input and time.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 26 Sep 2019 21:44:01 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Mike McCune; Tucker, Jessica (NIH/OD) [E]; Emily Turner; Kedest Tesfagiorgis; Nina Russell; Adam Jiang (McKinsey Secondment); Timothy Attoye; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Hoots, W. Keith (NIH/NHLBI) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]
Subject: Final Executive Summary and Slides for NIH-BMGF Collaboration: Briefing Documents
Attachments: Executive Summary NIH-BMGF Collaboration FINAL 09262019.docx, NIH_BMGF Collaboration for SCD and HIV_Executive Committee Briefing FINAL SLIDES 092619.pptx, NIH_BMGF Harmonized Research Plan Core Activities SC Meeting POST REVIEW FINAL Slides 092619.pptx

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Please find attached the finalized set of documents/briefing materials that we have worked together to develop:

1. Executive Summary
2. Slide deck for Executive Committee briefing
3. Full slide deck reflecting in more detail the Steering Committee discussions

Documents 1 and 2 are intended for our use in briefing our respective leadership. (Please note that based on the votes from all the SC members, the 3 finalist names for the Collaboration were: Cooperate2Cures, Partner2Cures, and Path2Cures. These are listed in the slide deck)

Thanks to everyone for their input and time.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

Page 340 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 341 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 342 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 343 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 344 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 345 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 346 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 347 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 348 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 349 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 350 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 351 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 352 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 353 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 354 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 355 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 356 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 357 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 358 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 359 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 360 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 361 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 362 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 363 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 364 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 365 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 366 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 367 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 368 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 369 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 370 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 371 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 372 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 373 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 374 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 375 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 376 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 377 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 378 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 379 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 380 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 381 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 382 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 383 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 384 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 26 Sep 2019 02:29:07 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E];Mike McCune;Finzi, Diana (NIH/NIAID) [E];Hoots, W. Keith (NIH/NHLBI) [E];Read, Sarah (NIH/NIAID) [E];Wilder, Elizabeth (NIH/OD) [E];Perry, Mary (NIH/OD) [E];Tucker, Jessica (NIH/OD) [E];O'Reilly, Marina (NIH/OD) [E];Adam Jiang (McKinsey Secondment);Emily Turner;Timothy Attoye;Nina Russell;Kedest Tesfagiorgis;Young, Cari (NIH/OD) [E]
Cc: Groesch, Mary (NIH/NHLBI) [E];Islam, Aminul (NIH/NHLBI) [E];Sengupta, Nivedita (NIH/NHLBI) [C];Shipp, Allan (NIH/NHLBI) [E];Hostetler, Jessica (NIH/NHLBI) [E];Earle, Melody (NIH/NHLBI) [E]
Subject: PLEASE REVIEW Exec Summary and Slides for NIH BMGF Collaboration
Attachments: NIH_BMGF Harmonized Research Plan Core Activities SC Meeting POST REVIEW Slides 092519.pptx, NIH_BMGF Collaboration for SCD and HIV_Executive Committee Briefing DRAFT SLIDES 092519.pptx, Exec Summary NIH-BMGF Collaboration REVISED DRAFT 09252019.docx

Dear Members of the NIH-BMGF Collaboration Steering Committee,

Thanks for a very productive discussion today. Please find attached for your review and the following documents:

- Revised slides reflecting today's NIH-BMGF Collaboration SC Meeting
- Revised Executive Summary
- Draft slides for Executive Committee briefing

Please note that there are a couple of new phrases (highlighted in yellow) in the Executive Summary – this is from our legal counsel to keep us in good standing from a legal point of view.

We tried to capture all of your comments but kindly review these materials to see if we hit the mark and, if at all possible, please provide any comments by noon on Thursday, September 26. Also, please send to me your top 3 choices for the name for the collaboration (candidate names are listed on slide #25 in the POST- SC REVIEW deck).

Our goal is to provide you with the Executive Summary and Executive Committee briefing slide deck tomorrow afternoon (after finalization based on any additional comments from the group) so that you can use them in briefings of your respective leadership channels and for use as background materials for the Executive Committee. Our plan will be to brief up our channels this week and early next in order to have everyone prepared for the Executive Committee meeting (yet to be scheduled).

Thanks again to each of you for all of your input and efforts.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48

Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

Page 387 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 388 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 389 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 390 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 391 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 392 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 393 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 394 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 395 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 396 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 397 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 398 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 399 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 400 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 401 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 402 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 403 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 404 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 405 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 406 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 407 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 408 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 409 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 410 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 411 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 412 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 413 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 414 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 415 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 416 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 417 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 418 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 419 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 420 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 421 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 422 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 423 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 424 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 425 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 426 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 427 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 428 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 429 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 430 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 431 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Dimishkov, Roxanne (NIH/NHLBI) [C] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 25 Sep 2019 17:20:06 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; Timothy Attoye
Subject: NIH BMGF SC Meeting
Attachments: NIH_BMGF Harmonized Research Plan Core Activities SC Meeting Slides 092519.MM.AJ.eds.pptx, Exec Summary NIH-BMGF Collaboration DRAFT 09252019.docx

Please note that a revised executive summary and slide deck are attached. We look forward to this afternoon's discussion.

Page 433 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 434 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 435 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 436 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 437 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 438 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 439 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 440 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 441 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 442 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 443 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 444 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 445 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 446 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 447 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 448 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 449 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 450 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 451 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 452 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 453 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 454 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 455 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 456 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 457 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 458 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 459 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 460 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 461 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 462 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 463 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 464 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 465 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 466 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 467 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 24 Sep 2019 17:02:02 +0000
To: Mike McCune; Gary Feldman
Cc: Patterson, Amy (NIH/NHLBI) [E]; O'Reilly, Marina (NIH/OD) [E]
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Thanks, Mike, for the confirmation (b)(5)

Many thanks, and I look forward to speaking with you further tomorrow.

Best,

Jessica

From: Mike McCune (b)(6) >
Sent: Tuesday, September 24, 2019 12:59 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>
Subject: Re: NIH-BMGF Executive Committee Meeting - early October

Thanks for your note, Jessica, and understood!

(b)(5)

Cheers,

Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, September 24, 2019 9:34 AM
To: Mike McCune (b)(6); Gary Feldman (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Hi Mike,

Many thanks for your note, and I appreciate your patience as we try to figure out the best way for the EC to provide feedback on relevant products.

Since Francis will be attending Grand Challenges, he would like to be part of any EC discussion. Of course, as noted on the last SC call, SC members are keeping the EC members briefed and up to date on

work products, to hopefully ensure their timely review, when the time comes. We are working on other contingency plans, including piggy backing on other existing meetings, to try to facilitate these discussions.

I think we will discuss the process for reviewing the Communications materials a bit more tomorrow.

Just to confirm- is (b)(5) Colleen indicated that prior to the 1st SC meeting in the summer, but I wanted to confirm.

Again, I apologize for the scheduling difficulties, and thanks for your patience.

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Monday, September 23, 2019 8:59 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman (b)(6) g>
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>
Subject: Re: NIH-BMGF Executive Committee Meeting - early October

Thanks, Jessica.

I think it will be important to garner EC approval of the collaboration plan and the Addis announcement by the 1st or 2nd week of October (the Comms Teams can confirm this timing).

I wonder: do you think it would be possible to hold a meeting of the EC without Francis (and Bill) - asking them to chime in via review of written documents (or recommendations) sent their way?

Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Monday, September 23, 2019 7:26 AM
To: Gary Feldman (b)(6)
Cc: Mike McCune (b)(6) Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Gary and Mike,

I just wanted to follow up on my message below. I apologize for the lack of progress in scheduling a meeting. Francis is still hoping to squeeze in an EC meeting prior to Grand Challenges, but schedules are very difficult this time of year. We may want/need to push out to the week of Oct 14, or even early the week of Oct 21, though that is a little close for comfort. I will certainly keep you posted as soon as I hear anything, and thank you for your patience and understanding.

(b)(5)

Thanks,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tuesday, September 17, 2019 7:11 AM
To: Gary Feldman (b)(6) >
Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; McManus, Ayanna (NIH/OD) [E] <Ayanna.McManus@nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Gary,

Thanks for providing the Pacific Time availabilities of some of the BMGF participants for the Executive Committee call we are planning for either the week of Sept 30 or early the week of Oct 7. I also appreciate the contact information for the other scheduling POCs for Trevor, Toni, and Emilio.

I am looping in others from NIH who are assisting with this effort, and we will be in touch as we have further information or questions.

Best,

Jessica

From: Gary Feldman (b)(6)
Sent: Monday, September 16, 2019 8:09 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Hi Jessica, hope all is well. I can provide availability for Mike and Dan below, but for our other calendars best bet is to reach out to their assistants as I have no visibility and they could tell you all the things not showing:

Trevor contact (b)(6)
Toni contact (b)(6)
Emilio contact (b)(6)

For Dan and Mike both free times in Pacific Time are:

9/30: 8:00 a.m. - 11 a.m., 3:00 - 5:00 p.m.
10/2: 8:00 a.m. - 11 a.m., 2:00 - 3:00 p.m.
10/7: 8:00 a.m. - 11 a.m., 1:00 - 2:00 p.m., 3:00 - 5:00 p.m.
10/9: 8:00 a.m. - 11 a.m., 1:00 - 3:00 p.m.

Thanks,
Gary Feldman
Senior Program Assistant to:

Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates *foundation*
Seattle Office
Tel (b)(6)
Email (b)(6)
Web www.gatesfoundation.org

From: Mike McCune (b)(6) >
Sent: Saturday, September 14, 2019 3:46 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman (b)(6) >
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>
Subject: Re: NIH-BMGF Executive Committee Meeting - early October

Thanks, Jessica.
I believe that Gary will be back to you about this next week.
Please let me know if there is anything I can do.
Mike


From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Friday, September 13, 2019 1:49 PM
To: Mike McCune (b)(6) >; Gary Feldman (b)(6) >
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E]

<oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Thanks for the e-mail, Mike, and good to hear you on the phone this morning.

As Amy noted, I am trying to help pull the Executive Committee together from the NIH end. We hope to find 60 minutes for the Executive Committee members to talk the week of Sept 30 (avoiding Rosh Hashanah) or early the week of Oct 7. Once you have pockets of availability for your members, please let me know, and I will do the same. Hopefully, we can find something that works.

Also, for full awareness, we are planning to include the following individuals, per the EC roster circulated at the first steering committee meeting. Note that Francis does plan to participate. (I just struck through Bill's name for completion, since it sounds like he will not be participating this time.) There may be some staff on the call to support each member.



I will loop back when I have more information. Any questions, please let Amy or me know.
Thanks!

Jessica


From: Mike McCune <(b)(6)>
Sent: Thursday, September 12, 2019 8:12 PM
To: Gary Feldman <(b)(6)>
Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: NIH-BMGF Executive Committee Meeting - early October

Hi Gary,

As part of the NIH collaboration, we need to plan for an Executive Committee meeting (by phone) during the first week or so of October. Jessica (copied) here is coordinating scheduling on the NIH side. Can you please work with her to coordinate scheduling on ours?

I believe that the meeting should probably be scheduled upfront for an hour, though the agenda may at the end take less time than that.

The BMGF members are:



Thanks! And please let me know if you have any questions.

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Mike McCune
Sent: Tue, 24 Sep 2019 16:59:19 +0000
To: Tucker, Jessica (NIH/OD) [E]; Gary Feldman
Cc: Patterson, Amy (NIH/NHLBI) [E]; O'Reilly, Marina (NIH/OD) [E]
Subject: Re: NIH-BMGF Executive Committee Meeting - early October
Attachments: NIH BMGF SCD HIV Cures _Committee.Roster_DRAFT_092319.docx

Thanks for your note, Jessica, and understood!

(b)(5)

Cheers,

Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, September 24, 2019 9:34 AM

To: Mike McCune (b)(6); Gary Feldman

(b)(6)

Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>

Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Hi Mike,

Many thanks for your note, and I appreciate your patience as we try to figure out the best way for the EC to provide feedback on relevant products.

Since Francis will be attending Grand Challenges, he would like to be part of any EC discussion. Of course, as noted on the last SC call, SC members are keeping the EC members briefed and up to date on work products, to hopefully ensure their timely review, when the time comes. We are working on other contingency plans, including piggy backing on other existing meetings, to try to facilitate these discussions.

I think we will discuss the process for reviewing the Communications materials a bit more tomorrow.

(b)(5)

Colleen indicated that prior

to the 1st SC meeting in the summer, but I wanted to confirm.

Again, I apologize for the scheduling difficulties, and thanks for your patience.

Best,

Jessica

From: Mike McCune (b)(6)

Sent: Monday, September 23, 2019 8:59 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman

(b)(6)

Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>

Subject: Re: NIH-BMGF Executive Committee Meeting - early October

Thanks, Jessica.

I think it will be important to garner EC approval of the collaboration plan and the Addis announcement by the 1st or 2nd week of October (the Comms Teams can confirm this timing).

I wonder: do you think it would be possible to hold a meeting of the EC without Francis (and Bill) - asking them to chime in via review of written documents (or recommendations) sent their way?

Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, September 23, 2019 7:26 AM

To: Gary Feldman (b)(6)

Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>

Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Gary and Mike,

I just wanted to follow up on my message below. I apologize for the lack of progress in scheduling a meeting. Francis is still hoping to squeeze in an EC meeting prior to Grand Challenges, but schedules are very difficult this time of year. We may want/need to push out to the week of Oct 14, or even early the week of Oct 21, though that is a little close for comfort. I will certainly keep you posted as soon as I hear anything, and thank you for your patience and understanding.

(b)(5)

which Colleen had conveyed previously. (b)(5) I've attached the updated roster, reflecting this information.

Thanks,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Tuesday, September 17, 2019 7:11 AM

To: Gary Feldman (b)(6)

Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; McManus, Ayanna (NIH/OD) [E] <Ayanna.McManus@nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Gary,

Thanks for providing the Pacific Time availabilities of some of the BMGF participants for the Executive Committee call we are planning for either the week of Sept 30 or early the week of Oct 7. I also appreciate the contact information for the other scheduling POCs for Trevor, Toni, and Emilio.

I am looping in others from NIH who are assisting with this effort, and we will be in touch as we have further information or questions.

Best,

Jessica

From: Gary Feldman (b)(6)
Sent: Monday, September 16, 2019 8:09 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Hi Jessica, hope all is well. I can provide availability for Mike and Dan below, but for our other calendars best bet is to reach out to their assistants as I have no visibility and they could tell you all the things not showing:

Trevor contact (b)(6)
Toni contact (b)(6)
Emilio contact (b)(6)

For Dan and Mike both free times in Pacific Time are:
9/30: 8:00 a.m. - 11 a.m., 3:00 - 5:00 p.m.
10/2: 8:00 a.m. - 11 a.m., 2:00 - 3:00 p.m.
10/7: 8:00 a.m. - 11 a.m., 1:00 - 2:00 p.m., 3:00 - 5:00 p.m.
10/9: 8:00 a.m. - 11 a.m., 1:00 - 3:00 p.m.

Thanks,
Gary Feldman
Senior Program Assistant to:
Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates *foundation*
Seattle Office
Tel (b)(6)
Email (b)(6)
Web www.gatesfoundation.org

From: Mike McCune <(b)(6)>
Sent: Saturday, September 14, 2019 3:46 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman <(b)(6)>
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>
Subject: Re: NIH-BMGF Executive Committee Meeting - early October

Thanks, Jessica.
I believe that Gary will be back to you about this next week.
Please let me know if there is anything I can do.
Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Friday, September 13, 2019 1:49 PM
To: Mike McCune <(b)(6)>; Gary Feldman <(b)(6)>
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Thanks for the e-mail, Mike, and good to hear you on the phone this morning.

As Amy noted, I am trying to help pull the Executive Committee together from the NIH end. We hope to find 60 minutes for the Executive Committee members to talk the week of Sept 30 (avoiding Rosh Hashanah) or early the week of Oct 7. Once you have pockets of availability for your members, please let me know, and I will do the same. Hopefully, we can find something that works.

Also, for full awareness, we are planning to include the following individuals, per the EC roster circulated at the first steering committee meeting. Note that Francis does plan to participate. (I just struck through Bill's name for completion, since it sounds like he will not be participating this time.) There may be some staff on the call to support each member.

(b)(5)

(b)(5)

I will loop back when I have more information. Any questions, please let Amy or me know.
Thanks!

Jessica

From: Mike McCune (b)(6)
Sent: Thursday, September 12, 2019 8:12 PM
To: Gary Feldman (b)(6)
Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: NIH-BMGF Executive Committee Meeting - early October

Hi Gary,

As part of the NIH collaboration, we need to plan for an Executive Committee meeting (by phone) during the first week or so of October. Jessica (copied) here is coordinating scheduling on the NIH side. Can you please work with her to coordinate scheduling on ours?

I believe that the meeting should probably be scheduled upfront for an hour, though the agenda may at the end take less time than that.

The BMGF members are:

(b)(5)

Thanks! And please let me know if you have any questions.

Mike

Joseph (Mike) McCune, MD, PhD
Head, HIV Frontiers
Global Health Innovative Technology Solutions
V +1 (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + 1 (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 480 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Mon, 23 Sep 2019 14:26:11 +0000
To: Gary Feldman
Cc: Mike McCune;Patterson, Amy (NIH/NHLBI) [E];O'Reilly, Marina (NIH/OD) [E]
Subject: RE: NIH-BMGF Executive Committee Meeting - early October
Attachments: NIH BMGF SCD HIV Cures _Roster_DRAFT_092319.docx

Gary and Mike,

I just wanted to follow up on my message below. I apologize for the lack of progress in scheduling a meeting. Francis is still hoping to squeeze in an EC meeting prior to Grand Challenges, but schedules are very difficult this time of year. We may want/need to push out to the week of Oct 14, or even early the week of Oct 21, though that is a little close for comfort. I will certainly keep you posted as soon as I hear anything, and thank you for your patience and understanding.

Additionally, (b)(5) [REDACTED]
which Colleen had conveyed previously. Tony Fauci has agreed to serve as the NIH Co-Chair. I've attached the updated roster, reflecting this information.

Thanks,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tuesday, September 17, 2019 7:11 AM
To: Gary Feldman (b)(6) [REDACTED]
Cc: Mike McCune (b)(6) [REDACTED]; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <OReillyM@OD.NIH.GOV>; McManus, Ayanna (NIH/OD) [E] <Ayanna.McManus@nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Gary,

Thanks for providing the Pacific Time availabilities of some of the BMGF participants for the Executive Committee call we are planning for either the week of Sept 30 or early the week of Oct 7. I also appreciate the contact information for the other scheduling POCs for Trevor, Toni, and Emilio.

I am looping in others from NIH who are assisting with this effort, and we will be in touch as we have further information or questions.

Best,

Jessica

From: Gary Feldman (b)(6)
Sent: Monday, September 16, 2019 8:09 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Hi Jessica, hope all is well. I can provide availability for Mike and Dan below, but for our other calendars best bet is to reach out to their assistants as I have no visibility and they could tell you all the things not showing:

Trevor contact (b)(6)
Toni contact (b)(6)
Emilio contact (b)(6)

For Dan and Mike both free times in Pacific Time are:
9/30: 8:00 a.m. - 11 a.m., 3:00 - 5:00 p.m.
10/2: 8:00 a.m. - 11 a.m., 2:00 - 3:00 p.m.
10/7: 8:00 a.m. - 11 a.m., 1:00 - 2:00 p.m., 3:00 - 5:00 p.m.
10/9: 8:00 a.m. - 11 a.m., 1:00 - 3:00 p.m.

Thanks,
Gary Feldman
Senior Program Assistant to:
Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates *foundation*
Seattle Office
Tel (b)(6)
Email (b)(6)g
Web www.gatesfoundation.org

From: Mike McCune (b)(6)
Sent: Saturday, September 14, 2019 3:46 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>
Subject: Re: NIH-BMGF Executive Committee Meeting - early October

Thanks, Jessica.
I believe that Gary will be back to you about this next week.
Please let me know if there is anything I can do.
Mike

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Friday, September 13, 2019 1:49 PM
To: Mike McCune (b)(6); Gary Feldman (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Young, Cari (NIH/OD) [E] <caroline.young@nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>
Subject: RE: NIH-BMGF Executive Committee Meeting - early October

Thanks for the e-mail, Mike, and good to hear you on the phone this morning.

As Amy noted, I am trying to help pull the Executive Committee together from the NIH end. We hope to find 60 minutes for the Executive Committee members to talk the week of Sept 30 (avoiding Rosh Hashanah) or early the week of Oct 7. Once you have pockets of availability for your members, please let me know, and I will do the same. Hopefully, we can find something that works.

Also, for full awareness, we are planning to include the following individuals, per the EC roster circulated at the first steering committee meeting. Note that Francis does plan to participate. (I just struck through Bill's name for completion, since it sounds like he will not be participating this time.) There may be some staff on the call to support each member.

(b)(5)

I will loop back when I have more information. Any questions, please let Amy or me know.
Thanks!

Jessica

From: Mike McCune (b)(6)
Sent: Thursday, September 12, 2019 8:12 PM
To: Gary Feldman (b)(6)

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>


Subject: NIH-BMGF Executive Committee Meeting - early October

Hi Gary,

As part of the NIH collaboration, we need to plan for an Executive Committee meeting (by phone) during the first week or so of October. Jessica (copied) here is coordinating scheduling on the NIH side. Can you please work with her to coordinate scheduling on ours?

I believe that the meeting should probably be scheduled upfront for an hour, though the agenda may at the end take less time than that.

The BMGF members are:



Thanks! And please let me know if you have any questions.

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 485 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 19 Sep 2019 22:05:01 +0000
To: Emily Turner;Kedest Tesfagiorgis;Nina Russell;Dieffenbach, Carl (NIH/NIAID) [E];Finzi, Diana (NIH/NIAID) [E];Read, Sarah (NIH/NIAID) [E];Tucker, Jessica (NIH/OD) [E];Hoots, W. Keith (NIH/NHLBI) [E];Perry, Mary (NIH/OD) [E];Wilder, Elizabeth (NIH/OD) [E]
Cc: Mike McCune;Adam Jiang (McKinsey Secondment);Timothy Attoye;Groesch, Mary (NIH/NHLBI) [E];Islam, Aminul (NIH/NHLBI) [E];Shipp, Allan (NIH/NHLBI) [E];Hostetler, Jessica (NIH/NHLBI) [E];Young, Cari (NIH/OD) [E];O'Reilly, Marina (NIH/OD) [E];Barasch, Kimberly (NIH/NIAID) [C];Earle, Melody (NIH/NHLBI) [E]
Subject: Meeting Materials for NIH-BMGF Collaboration SC Meeting September 20th at 9:30 AM EST (6:30 AM PT)
Attachments: NIH_BMGF Harmonized Research Plan Core Activities Full SC Meeting DRAFT Slides 091919.pptx

Dear Members of the NIH BMFG Steering Committee:

We look forward to our discussion tomorrow, Friday, September 20th at 9:30 am (ET). Please find the attached slides to guide our discussion. The focus of the discussion tomorrow will be on the Core Research Work Plans and Milestones as well as discussing the preparations for the upcoming Executive Committee meeting. We also wanted to save a few minutes to get everyone's views about potential names and acronyms for the collaboration. We've pasted in the agenda below for ease of reference.

Many thanks again,

Amy and Mike

NIH-BMGF Steering Committee Agenda September 20, 2019	
9:30- 9:35 AM	Welcome and Updates
9:35- 10:00 AM	Discussion of HIV and SCD Core Research Work Plans and Milestones
10:00- 10:15 AM	Review outline for Executive Summary and discuss deliverables for EC review
10:15- 10:25 AM	Discussion of NIH-BMGF Collaboration Name and Communication Plan
10:25- 10:30 AM	Next Steps and Action Items

Page 487 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 488 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 489 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 490 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 491 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 492 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 493 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 494 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 495 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 496 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 497 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 498 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 499 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 500 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 501 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 502 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 503 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 504 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 505 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 506 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 507 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 508 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 509 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 510 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 511 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 512 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 513 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 514 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 515 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Myles, Renate (NIH/OD) [E]
Sent: Tue, 17 Sep 2019 16:03:23 +0000
To: Colleen Silcox;Mike McCune;Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E];Kedest Tesfagiorgis;Jeff Chertack;Bahati Ngongo;Kitty Harding;Emily Turner;Rancourt, Anne (NIH/NIDA) [E];Fine, Amanda (NIH/OD) [E];Shipp, Allan (NIH/NHLBI) [E];Dan Pawson;Finzi, Diana (NIH/NIAID) [E];Groesch, Mary (NIH/NHLBI) [E]
Cc: Anna Casparius;Donna Lewis;Bryan Callahan
Subject: RE: [Today] NIH/BMGF comms plan discussion

Hi Colleen:

The following NIH communication staff will participate in a weekly call:

Renate Myles
Amanda Fine
Anne Rancourt
Lucinda (Cindy) Miner

All are copied on this email. Below are standing dates/times that we can be available every week. I assumed 30 minute calls, but let me know if you think more will be needed:

Tuesdays:
3:30-4:00

Fridays:
3:00-3:30
3:30-4:00

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

NIH . . . *Turning Discovery Into Health*

From: Colleen Silcox (b)(6)
Sent: Friday, September 13, 2019 4:19 PM
To: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Kedest Tesfagiorgis (b)(6)

Jeff Chertack (b)(6); Bahati Ngongo
(b)(6); Kitty Harding (b)(6); Emily
Turner (b)(6); Rancourt, Anne (NIH/NIAID) [E]
<anne.rancourt@nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Shipp, Allan
(NIH/NHLBI) [E] <allan.shipp@nih.gov>; Dan Pawson <DPawson@globalhealthstrategies.com>; Finzi,
Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>
Cc: Anna Casparius (b)(6) Donna Lewis
(b)(6); Bryan Callahan (b)(6)
Subject: RE: [Today] NIH/BMGF comms plan discussion

Dear Colleagues,

Thank you again for a very productive kickoff call. We're looking forward to working with you on this exciting announcement.

I am writing to introduce you to **Anna** and **Donna**, who will be assisting in scheduling a weekly check-in call in the lead up to the official announcement on October 26/27.

We would be grateful if you would confirm the names of individual participants from NIH, NIAID, and NHLBI and provide us with your best available times for a check-in call.

Bryan, Jeff, and Kitty will participate on behalf of the foundation, and the foundation team will circulate a detailed draft agenda 48 hours in advance of our next call to ensure that USG participants have an opportunity to review/edit/update the document.

In the meantime, please feel free to reach out to Bryan if you have any needs, questions or concerns.

Have a wonderful weekend.

Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Colleen Silcox
Sent: Friday, September 13, 2019 6:42 AM
To: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Myles, Renate
(NIH/OD) [E] <mylesr@mail.nih.gov>; Bryan Callahan (b)(6) Kedest
Tesfagiorgis (b)(6); Jeff Chertack
(b)(6)>
Cc: Bahati Ngongo (b)(6); Kitty Harding
(b)(6); Emily Turner (b)(6); Adrienne
Burns (b)(6); Rancourt, Anne (NIH/NIAID) [E]
<anne.rancourt@nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Shipp, Allan
(NIH/NHLBI) [E] <allan.shipp@nih.gov>; Dan Pawson <DPawson@globalhealthstrategies.com>; Finzi,
Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>;

Edna Garrett (b)(6) >
Subject: [Today] NIH/BMGF comms plan discussion

Dear all,

We are looking forward to the call this morning to discuss the announcement of the NIH and BMGF SCD/HIV collaboration. We know this will be the first of many discussions between now and October.

As we only have 30 minutes for this initial call, we'll suggest that Bryan Callahan from BMGF and Renate Myles from NIH, help facilitate an efficient and productive discussion.

Updated agenda below, with outlines attached for reference.

Many thanks,
Colleen

AGENDA:

- Introductions
- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story – **DRAFT** talking points:
 - Our ultimate goal is to develop safe, effective, and affordable cures for sickle cell disease and for HIV disease. These cures will be accessible to everyone in need around the world.
 - We aim for the HIV and SCD curative interventions to be easy to administer and to not require hospitalization or advanced technology. Ideally neither intervention would require more than a one-time treatment regimen.
 - We believe that such interventions can be developed if we learn how to target and modify specific cells in the body that are key to restoring more normal cellular function in those with sickle cell disease or with HIV disease.
- Communications point of contact and working group to provide input on announcement
- Materials needed and development process
- Media outreach

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

-----Original Appointment-----

From: Mike McCune (b)(6)

Sent: Wednesday, September 11, 2019 10:47 AM

To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Bryan Callahan; Kedest Tesfagiorgis; Jeff Chertack

Cc: Bahati Ngongo; Kitty Harding; Emily Turner; Adrienne Burns; Colleen Silcox; Rancourt, Anne (NIH/NIAID) [E]; Fine, Amanda (NIH/OD) [E]; Shipp, Allan (NIH/NHLBI) [E]; Dan Pawson; Finzi, Diana (NIH/NIAID) [E]; Groesch, Mary (NIH/NHLBI) [E]; Edna Garrett

Subject: NIH/BMGF comms plan discussion

When: Friday, September 13, 2019 1:00 PM-1:30 PM (UTC-05:00) Eastern Time (US & Canada).

Where: Skype for Business Call

AGENDA:

- Introductions
- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story (3-4 bullets – Assigned to Mike McCune EOD Thursday)
- Communications point of contact and working group to provide input on announcement
- Materials needed and development process
- Media outreach

Join Skype for Business Call via this link

Trouble Joining? [Try Skype Web App](#)

Join by phone

(b)(4); (b)(6)	North America	English (United States)
	North America	English (United States)

[Find a local number](#)

Conference ID: (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

From: Dimishkov, Roxanne (NIH/NHLBI) [C] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Mon, 16 Sep 2019 18:00:52 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; Timothy Attoye
Subject: NIH-BMGF Steering Committee Meeting

From: Gary Feldman
Sent: Fri, 13 Sep 2019 21:00:56 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Automatic reply: NIH-BMGF Executive Committee Meeting - early October

Please note I am out of the office today. In my absence, for any urgent scheduling matters please contact Alli via (b)(6) or I will respond as soon as I am able.

Thank you, Gary

From: Dimishkov, Roxanne (NIH/NHLBI) [C]
Sent: Fri, 13 Sep 2019 20:06:38 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Kellton, Karen (NIH/OD) [C]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; Nina Russell; Kedest Tesfagiorgis; Adam Jiang (McKinsey Secondment); Timothy Attoye
Cc: Kellton, Karen (NIH/OD) [C]; Squadere, Terrie (NIH/NHLBI) [E]; Earle, Melody (NIH/NHLBI) [E]; Gary Feldman
Subject: NIH BMGF SC Meeting

Good afternoon,

I hope that this message finds you well. Dr. Patterson would like to convene the subject meeting next Friday, September 20, if possible. Could you please reply with your availability at the following times:


9:00-10:00 a.m.
10:00-11:00 a.m.
11:00 a.m.-12:00 p.m.
12:00-2:00 p.m.

While we hope for everyone's participation, if necessary, Dr. Patterson can touch base offline with those who are not able to make it in order to get their feedback on the materials. Thank you for your attention. We look forward to your replies.

Best regards,

Roxanne Dimishkov

Executive Assistant to the Director



31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Email: roxanne.dimishkov@nih.gov

From: Myles, Renate (NIH/OD) [E]
Sent: Fri, 13 Sep 2019 16:59:19 +0000
To: Colleen Silcox;Mike McCune;Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E];Bryan Callahan;Kedest Tesfagiorgis;Jeff Chertack
Cc: Bahati Ngongo;Kitty Harding;Emily Turner;Adrianne Burns;Rancourt, Anne (NIH/NIDA) [E];Fine, Amanda (NIH/OD) [E];Shipp, Allan (NIH/NHLBI) [E];Dan Pawson;Finzi, Diana (NIH/NIAID) [E];Groesch, Mary (NIH/NHLBI) [E];Edna Garrett
Subject: RE: [Today] NIH/BMGF comms plan discussion

Hi Colleen:

Sounds good. We'll talk to you shortly.

Best,
Renate

From: Colleen Silcox (b)(6)
Sent: Friday, September 13, 2019 9:42 AM
To: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Bryan Callahan (b)(6); Kedest Tesfagiorgis (b)(6); Jeff Chertack (b)(6)
Cc: Bahati Ngongo (b)(6); Kitty Harding (b)(6); Emily Turner (b)(6); Adrianne Burns (b)(6); Rancourt, Anne (NIH/NIAID) [E] <anne.rancourt@nih.gov>; Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>; Dan Pawson <DPawson@globalhealthstrategies.com>; Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Edna Garrett (b)(6)
Subject: [Today] NIH/BMGF comms plan discussion

Dear all,

We are looking forward to the call this morning to discuss the announcement of the NIH and BMGF SCD/HIV collaboration. We know this will be the first of many discussions between now and October.

As we only have 30 minutes for this initial call, we'll suggest that Bryan Callahan from BMGF and Renate Myles from NIH, help facilitate an efficient and productive discussion.

Updated agenda below, with outlines attached for reference.

Many thanks,
Colleen

AGENDA:

- Introductions

- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story – **DRAFT** talking points:
 - Our ultimate goal is to develop safe, effective, and affordable cures for sickle cell disease and for HIV disease. These cures will be accessible to everyone in need around the world.
 - We aim for the HIV and SCD curative interventions to be easy to administer and to not require hospitalization or advanced technology. Ideally neither intervention would require more than a one-time treatment regimen.
 - We believe that such interventions can be developed if we learn how to target and modify specific cells in the body that are key to restoring more normal cellular function in those with sickle cell disease or with HIV disease.
- Communications point of contact and working group to provide input on announcement
- Materials needed and development process
- Media outreach

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

-----Original Appointment-----

From: Mike McCune (b)(6)

Sent: Wednesday, September 11, 2019 10:47 AM

To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Bryan Callahan; Kedest Tesfagiorgis; Jeff Chertack

Cc: Bahati Ngongo; Kitty Harding; Emily Turner; Adrienne Burns; Colleen Silcox; Rancourt, Anne (NIH/NIAID) [E]; Fine, Amanda (NIH/OD) [E]; Shipp, Allan (NIH/NHLBI) [E]; Dan Pawson; Finzi, Diana (NIH/NIAID) [E]; Groesch, Mary (NIH/NHLBI) [E]; Edna Garrett

Subject: NIH/BMGF comms plan discussion

When: Friday, September 13, 2019 1:00 PM-1:30 PM (UTC-05:00) Eastern Time (US & Canada).

Where: Skype for Business Call

AGENDA:

- Introductions
- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story (3-4 bullets – Assigned to Mike McCune EOD Thursday)

- Communications point of contact and working group to provide input on announcement
- Materials needed and development process
- Media outreach

Join Skype for Business Call via this link

Trouble Joining? [Try Skype Web App](#)

Join by phone

(b)(4); (b)(6)	(North America)	English (United States)
	(North America)	English (United States)

[Find a local number](#)

Conference ID

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

From: Colleen Silcox
Sent: Fri, 13 Sep 2019 13:42:15 +0000
To: Mike McCune;Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E];Myles, Renate (NIH/OD) [E];Bryan Callahan;Kedest Tesfagiorgis;Jeff Chertack
Cc: Bahati Ngongo;Kitty Harding;Emily Turner;Adrianne Burns;Rancourt, Anne (NIH/NIDA) [E];Fine, Amanda (NIH/OD) [E];Shipp, Allan (NIH/NHLBI) [E];Dan Pawson;Finzi, Diana (NIH/NIAID) [E];Groesch, Mary (NIH/NHLBI) [E];Edna Garrett
Subject: [Today] NIH/BMGF comms plan discussion
Attachments: 072419 Outline of HIV-SCD Announcement Strategy.docx, Brainstorming_NIH_BMGF_HIV_SC_Project 9.12.19.docx

Dear all,

We are looking forward to the call this morning to discuss the announcement of the NIH and BMGF SCD/HIV collaboration. We know this will be the first of many discussions between now and October.

As we only have 30 minutes for this initial call, we'll suggest that Bryan Callahan from BMGF and Renate Myles from NIH, help facilitate an efficient and productive discussion.

Updated agenda below, with outlines attached for reference.

Many thanks,
Colleen

AGENDA:

- Introductions
- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story – **DRAFT** talking points:
 - Our ultimate goal is to develop safe, effective, and affordable cures for sickle cell disease and for HIV disease. These cures will be accessible to everyone in need around the world.
 - We aim for the HIV and SCD curative interventions to be easy to administer and to not require hospitalization or advanced technology. Ideally neither intervention would require more than a one-time treatment regimen.
 - We believe that such interventions can be developed if we learn how to target and modify specific cells in the body that are key to restoring more normal cellular function in those with sickle cell disease or with HIV disease.
- Communications point of contact and working group to provide input on announcement
- Materials needed and development process
- Media outreach

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

v + (b)(6)

M (b)(6)
E (b)(6)
Bill & Melinda Gates Foundation
www.gatesfoundation.org
Senior Program Assistant: Gary Feldman
V + (b)(6)
E (b)(6)

-----Original Appointment-----

From: Mike McCune (b)(6)
Sent: Wednesday, September 11, 2019 10:47 AM
To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Bryan Callahan; Kedest Tesfagiorgis; Jeff Chertack
Cc: Bahati Ngongo; Kitty Harding; Emily Turner; Adrienne Burns; Colleen Silcox; Rancourt, Anne (NIH/NIAID) [E]; Fine, Amanda (NIH/OD) [E]; Shipp, Allan (NIH/NHLBI) [E]; Dan Pawson; Finzi, Diana (NIH/NIAID) [E]; Groesch, Mary (NIH/NHLBI) [E]; Edna Garrett
Subject: NIH/BMGF comms plan discussion
When: Friday, September 13, 2019 1:00 PM-1:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Skype for Business Call

AGENDA:

- Introductions
- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story (3-4 bullets – Assigned to Mike McCune EOD Thursday)
- Communications point of contact and working group to provide input on announcement
- Materials needed and development process
- Media outreach

Join Skype for Business Call via this link

Trouble Joining? [Try Skype Web App](#)

Join by phone

(b)(4); (b)(6)	(North America)	English (United States)
	(North America)	English (United States)

[Find a local number](#)

Conference ID: (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

Proposed Communications Approach for Announcing Collaborative Efforts on *In Vivo* Gene Editing for Sickle Cell Disease and Human Immunodeficiency Virus

Overview: NIH/NIAID/NHLBI and BMGF recently signed an MOU to facilitate the 1:1 co-funding of the development of *in vivo* treatments for sickle cell disease (SCD) and human immunodeficiency virus (HIV). The goal of the partnership is to produce – within a timeframe of 7-10 years – candidate *in vivo* constructs and the clinical trial infrastructure required to test these constructs in human populations. This document lays out a proposed approach designed to maximize the impact of this announcement among key stakeholders.

Key Stakeholders: Federal Executive Branch (especially White House, DHHS leadership, and State Department/USAID); Federal Legislative Branch (especially committees with oversight of DHHS and State Department); African Heads of State and Ministers of Health; global health advocates in the U.S., Europe, and sub-Saharan Africa; advocate affinity groups, especially communities advocating for people living with HIV and people living with SCD; scientific research community, especially leading researchers on gene therapy.

Key Considerations:

- NIH/NIAID/NHLBI have a strategic interest in informing the scientific research community, via a series of meetings over the next several months, that they have signed an MOU with BMGF that will direct unprecedented funding to the development of *in vivo* therapies for SCD and HIV. Doing so will help both institutions secure the interest of leading researchers and research labs, ensuring that the best-available talent and resources are secured.
- While BMGF understands that NIH/NIAID/NHLBI are concerned about the delay in announcing the full details of the MOU, we believe that we can “tease” the announcement so that top-tier reporters will hold on their coverage until the Grand Challenges meeting in Addis at the end of October. Holding will allow us to leverage foundation assets – including Bill Gates’ voice in press materials and the active support of the foundation’s media relations, advocacy, and government relations teams – and thereby secure strong media coverage in the United States and Africa that features the voices of Dr. Fauci, Dr. Gibbons, and Dr. Collins prominently.

Strategy:

- To achieve each goal, we propose a “teaser” strategy as follows:
 - NIH/NIAID/NHLBI should be empowered to speak about the MOU with researchers at closed events and conferences over the next 90 days.
 - Messaging can be developed that speaks to the “unprecedented level of funding” for *in vivo* gene therapy research and the timeframe for bringing testable constructs forward in 7-10 years.
 - We would, however, withhold information on the \$200 million combined commitment of the partners until Grand Challenges in Addis Ababa, Ethiopia, on October 27-30.
 - BMGF would also work with NIH/NIAID/NHLBI to pitch the story of the partnership under embargo to elite health and medicine reporters, preparing press materials and scheduling embargoed interviews with Dr. Fauci, Dr. Collins, Dr. Gibbons, and senior leadership from Gates.
 - Reporters would agree to hold the publication of the story on the full details of the partnership until Grand Challenges in October, ensuring that Dr. Fauci,

Dr. Collins, and Dr. Gibbons are widely quoted in the announcement coverage.

- The final Grand Challenges press release would include quotes from Dr. Fauci, Dr. Collins, Dr. Gibbons, and Bill Gates and a supporting quote from either an African country, WHO AFRO, or the African Academy of Sciences.
- BMGF would work with NIAID/NHLBI to secure a video of Dr. Fauci and Dr. Gibbons (if not planning to be at GC in person) that would be played at the announcement in Addis Ababa and serve as B-roll for broadcast media.
- We would also conduct outreach to African American media given the disproportionate impact of HIV and SCD on this population and the elevated interest that the story is likely to generate among African American health reporters.
- The effect of this advance outreach will be to engage elite reporters in developing in-depth coverage of the announcement, thereby magnifying its impact on the public and policy makers.
- Advocacy activities in alignment with the announcement
 - Beyond pitching the story to media, BMGF will work with NIH/NIAID/NHLBI to ensure that global health advocates and SCD and HIV patient advocacy groups in the United States receive the release and briefings on the commitments as part of the announcement process.
 - This will help to drive further word-of-mouth coverage on social media channels, reaching key populations.
 - We would work with AVAC and African health advocates to ensure that HIV advocates and SCD patient advocates across the U.S. and sub-Saharan Africa are fully briefed on, and engaged with, the announcement.
 - We would collaborate on supporting Hill briefings and Executive Branch briefings in collaboration with BMGF's Government Relations team with a focus on key appropriators, Foreign Relations Committee heads, and the Congressional Black Caucus.

Next Steps:

- Draft communications plan for approval by partners
- Work with the GC team to identify the best plenary session at GC to make the announcement and any related media session.
- Develop key messages and tough Q&A for NIH/NIAID/NHLBI staff to use in discussing the partnership prior to the main announcement in October.
- Develop media pitch list for American and African health reporters
- Schedule embargoed interviews for Dr. Fauci, Dr. Collins, Dr. Gibbons, African research partners (TBD), and foundation leaders
- Develop video for Dr. Fauci and Dr. Gibbons's remote participation in the Addis Ababa event and as B-roll for video coverage
- Develop press release, op-ed for date of announcement

Page 531 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 532 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 533 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 534 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Fri, 13 Sep 2019 13:34:01 +0000
To: Mike McCune
Subject: Accepted: NIH/BMGF comms plan discussion

From: Myles, Renate (NIH/OD) [E]
Sent: Fri, 13 Sep 2019 11:02:09 +0000
To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]; Bryan Callahan; Kedest Tesfagiorgis; Jeff Chertack
Cc: Bahati Ngongo; Kitty Harding; Emily Turner; Adrienne Burns; Colleen Silcox; Rancourt, Anne (NIH/NIDA) [E]; Fine, Amanda (NIH/OD) [E]; Shipp, Allan (NIH/NHLBI) [E]; Dan Pawson; Finzi, Diana (NIH/NIAID) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: RE: NIH/BMGF comms plan discussion
Attachments: Brainstorming_NIH_BMGF_HIV_SC_Project 9.12.19.docx

Good morning:

NIH would like to add the attached document for discussion as well.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

-----Original Appointment-----

From: Mike McCune (b)(6)
Sent: Wednesday, September 11, 2019 1:47 PM
To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Bryan Callahan; Kedest Tesfagiorgis; Jeff Chertack
Cc: Bahati Ngongo; Kitty Harding; Emily Turner; Adrienne Burns; Colleen Silcox; Rancourt, Anne (NIH/NIAID) [E]; Fine, Amanda (NIH/OD) [E]; Shipp, Allan (NIH/NHLBI) [E]; Dan Pawson; Finzi, Diana (NIH/NIAID) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: NIH/BMGF comms plan discussion
When: Friday, September 13, 2019 1:00 PM-1:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Skype for Business Call

AGENDA:

- Introductions
- Reflections on draft communications approach (review foundation 2-pager)
- Who, What, Where, When, Why -
 - Partners involved in the announcement (specifics)
 - Timing of the announcement
 - How do we ensure appropriate inclusion of Tony Fauci of NIAID and Gary Gibbons of NHLBI?
 - Messaging – What is the story (3-4 bullets – Assigned to Mike McCune EOD Thursday)
- Communications point of contact and working group to provide input on announcement

- Materials needed and development process
- Media outreach

Join Skype for Business Call via this link

Trouble Joining? [Try Skype Web App](#)

Join by phone

(b)(4); (b)(6)

(North America)

English (United States)

(North America)

English (United States)

[Find a local number](#)

Conference ID: (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

Page 538 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 539 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 540 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 541 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Myles, Renate (NIH/OD) [E]
Sent: Fri, 13 Sep 2019 03:04:28 +0000
To: Colleen Silcox; Gary Feldman
Cc: Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Next Steps for Communication Planning
Attachments: Brainstorming_NIH_BMGF_HIV_SC_Project 9.12.19.docx

Hi Colleen:

We put some thoughts together on messaging and possible tactics, building on some of BMGF initial thoughts that Jessica shared with us, for tomorrow's. This hasn't been shared with our senior leadership; it's just to start the conversation. Look forward to our discussion tomorrow.

Best,
Renate

From: Colleen Silcox (b)(6)
Sent: Tuesday, September 10, 2019 3:23 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Gary Feldman (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: RE: Next Steps for Communication Planning

Hi Renate,

That's wonderful, thanks for confirming.

We are establishing a small core communications working group that will include Mike McCune and Emily Turner, who are both representatives of the joint Steering Committee, but from our side the call will be led by the communications team to address exactly the topics you list below.

Would you like us to send the invite? I'll ask our communications folks to send out a note in advance of the call.

All the best,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Sent: Tuesday, September 10, 2019 11:05 AM
To: Gary Feldman (b)(6)>; Colleen Silcox (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E]

<jessica.tucker@nih.gov>

Subject: RE: Next Steps for Communication Planning

Hi Gary and Colleen:

It's looking like 1:00 p.m. ET on Friday works better for most folks on our team. Just so I'm clear, this call is with communication staff from each of our organizations to discuss options for announcing the partnership and plans in October, correct? Or are you planning on having program staff join the call? I just want to make sure who needs to join on our end.

Thanks,
Renate

Renate Myles, MBA

Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

NIH . . . *Turning Discovery Into Health*

From: Gary Feldman (b)(6)

Sent: Monday, September 09, 2019 8:17 PM

To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Cc: Colleen Silcox <Colleen.Silcox@gatesfoundation.org>

Subject: RE: Next Steps for Communication Planning

Hello all,

For our team, 3:00 p.m. Pacific Time aligns everyone on Sept. 11 but I realize that is late for you on the East Coast but would be our first choice. Other option could be 10 a.m. Pacific time on Sept. 13 as an alternate choice.

Looking into next week 11 a.m. Pacific on Sept. 17 also works as a last preference.

We will await your availability and thanks in advance.

Gary

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates foundation

Seattle Office

Tel (b)(6)

Email (b)(6)
Web www.gatesfoundation.org

From: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Sent: Sunday, September 8, 2019 7:02 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox (b)(6)>
Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Hi Colleen:

I manage media relations for the NIH Office of the Director and have had the opportunity to connect internally with those involved in this exciting project. We'd love to set up a call this week to discuss the rollout. We've put together some thoughts about the rollout as well and look forward to talking through options with you and your team. If you can share dates/times that you are available this week, I'm happy to coordinate with the communication team on SCD and HIV as well as Dr. Patterson to get something on the calendar.

All the best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, September 4, 2019 12:46 PM
To: Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Dear Colleen,

My apologies for the delay in my response- I was out of the office some of last week unexpectedly, and I am still running a little behind.

I'm looping in Renate Myles from our Communications team- she or someone from her team will likely be your main point of contact. I'm also ccing Amy Patterson from NIH/NHLBI, who is co-chairing this effort with Mike. We have also been having some discussions internally about the rollout, and I think Renate or someone from her team will be in touch soon.

Many thanks for your patience, and we look forward to working with you on this effort!

Best,

Jessica

From: Colleen Silcox (b)(6)
Sent: Wednesday, August 28, 2019 11:36 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: Next Steps for Communication Planning

Hi Jessica,

Hope you are doing well.

Our communications team is ready to kick off joint planning for the October announcement at Grand Challenges.

Who would be the best points of contact to lead communications from the NIH side? Would be great to get representation across HIV and SCD to facilitate coordination and decision making across both areas leading up to October.

We will consider as well how to best engage the Steering and Advisory Committees through this process.

Appreciate your insight.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V + (b)(6)

M +

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Page 546 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 547 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 548 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 549 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 12 Sep 2019 22:36:02 +0000
To: Emily Turner;Kedest Tesfagiorgis;Nina Russell;Dieffenbach, Carl (NIH/NIAID) [E];Finzi, Diana (NIH/NIAID) [E];Read, Sarah (NIH/NIAID) [E];Tucker, Jessica (NIH/OD) [E];Hoots, W. Keith (NIH/NHLBI) [E];Perry, Mary (NIH/OD) [E];Wilder, Elizabeth (NIH/OD) [E]
Cc: Mike McCune;Adam Jiang (McKinsey Secondment);Timothy Attoye;Groesch, Mary (NIH/NHLBI) [E];Islam, Aminul (NIH/NHLBI) [E];Shipp, Allan (NIH/NHLBI) [E];Hostetler, Jessica (NIH/NHLBI) [E];Young, Cari (NIH/OD) [E];O'Reilly, Marina (NIH/OD) [E];Barasch, Kimberly (NIH/NIAID) [C];Earle, Melody (NIH/NHLBI) [E]
Subject: Meeting Materials for NIH-BMGF Collaboration SC Meeting September 13 at 9:30 AM EST (6:30 AM PT)
Attachments: NIH_BMGF Harmonized Research Plan Core Activities SC Meeting FINAL 091319.pptx, BMGF PUSH program timeline_for NIH.09102019.v09.xlsx

Dear Members of the NIH BMFG Steering Committee:

We look forward to our discussion tomorrow at 9:30 am (ET). Please find the attached slides to guide our discussion, as well as a draft template for the research blueprint. The focus of the discussion tomorrow will be on reaching agreement on the Core Research Work Plans and Milestones. We will also touch briefly on the communication plans and non-disclosure agreement, but these will be topics that we explore in more depth next week. We've pasted in the agenda below for ease of reference.

Many thanks again,

Amy and Mike

9:30 - 9:35 AM	Welcome and Introductions
9:35 - 10:45 AM	Discussion of Core Research Work Plans and Milestones
10:45 - 10:50 AM	Discussion of Public Announcement and Communications Plan
10:50 - 10:55 AM	Discussion of NDA/CDA Development
10:55 - 11:00 AM	Next Steps and Action Items

Page 551 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 552 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 553 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 554 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 555 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 556 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 557 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 558 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 559 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 560 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 561 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 562 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 563 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 564 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 565 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 566 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 567 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 568 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 569 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 570 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 571 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 572 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 573 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 574 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 575 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 576 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 577 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 578 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 579 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 580 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 581 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 582 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 583 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 12 Sep 2019 18:44:48 +0000
To: Mike McCune
Subject: Accepted: FW: NIH/BMGF comms plan discussion

From: Myles, Renate (NIH/OD) [E] on behalf of "Mike McCune"
(b)(6)
Sent: Wed, 11 Sep 2019 18:48:54 +0000
To: Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Rancourt, Anne (NIH/NIDA) [E]; Miner, Lucinda (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: FW: NIH/BMGF comms plan discussion

-----Original Appointment-----

From: Mike McCune (b)(6)
Sent: Wednesday, September 11, 2019 1:47 PM
To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Bryan Callahan; Kedest Tesfagiorgis; Jeff Chertack
Cc: Bahati Ngongo; Kitty Harding; Emily Turner; Adrienne Burns
Subject: NIH/BMGF comms plan discussion
When: Friday, September 13, 2019 1:00 PM-1:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Skype for Business Call

Agenda to be sent out on Thursday

Join Skype for Business Call via this link

Trouble Joining? [Try Skype Web App](#)

Join by phone

(b)(4); (b)(6)	(North America)	English (United States)
	(North America)	English (United States)

[Find a local number](#)

Conference ID (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 11 Sep 2019 16:09:24 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; Timothy Attoye
Subject: NIH BMGF SC Meeting

From: Myles, Renate (NIH/OD) [E]
Sent: Tue, 10 Sep 2019 19:36:41 +0000
To: Colleen Silcox; Gary Feldman
Cc: Patterson, Amy (NIH/NHLBI) [E]; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Next Steps for Communication Planning

Sure, that would be great, and I can forward to my colleagues at NHLBI and NIAID.

From: Colleen Silcox (b)(6)
Sent: Tuesday, September 10, 2019 3:23 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Gary Feldman (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: RE: Next Steps for Communication Planning

Hi Renate,

That's wonderful, thanks for confirming.

We are establishing a small core communications working group that will include Mike McCune and Emily Turner, who are both representatives of the joint Steering Committee, but from our side the call will be led by the communications team to address exactly the topics you list below.

Would you like us to send the invite? I'll ask our communications folks to send out a note in advance of the call.

All the best,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Sent: Tuesday, September 10, 2019 11:05 AM
To: Gary Feldman (b)(6); Colleen Silcox (b)(6)
Cc: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: RE: Next Steps for Communication Planning

Hi Gary and Colleen:

It's looking like 1:00 p.m. ET on Friday works better for most folks on our team. Just so I'm clear, this call is with communication staff from each of our organizations to discuss options for announcing the partnership and plans in October, correct? Or are you planning on having program staff join the call? I just want to make sure who needs to join on our end.

Thanks,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

NIH . . . *Turning Discovery Into Health*

From: Gary Feldman (b)(6)
Sent: Monday, September 09, 2019 8:17 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Cc: Colleen Silcox (b)(6)
Subject: RE: Next Steps for Communication Planning

Hello all,

For our team, 3:00 p.m. Pacific Time aligns everyone on Sept. 11 but I realize that is late for you on the East Coast but would be our first choice. Other option could be 10 a.m. Pacific time on Sept. 13 as an alternate choice.

Looking into next week 11 a.m. Pacific on Sept. 17 also works as a last preference.

We will await your availability and thanks in advance.

Gary

Gary Feldman
Senior Program Assistant to:
Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates foundation
Seattle Office
Tel (b)(6)
Email (b)(6)
Web www.gatesfoundation.org

From: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Sent: Sunday, September 8, 2019 7:02 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: RE: Next Steps for Communication Planning

Hi Colleen:

I manage media relations for the NIH Office of the Director and have had the opportunity to connect internally with those involved in this exciting project. We'd love to set up a call this week to discuss the rollout. We've put together some thoughts about the rollout as well and look forward to talking through options with you and your team. If you can share dates/times that you are available this week, I'm happy to coordinate with the communication team on SCD and HIV as well as Dr. Patterson to get something on the calendar.

All the best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Wednesday, September 4, 2019 12:46 PM

To: Colleen Silcox (b)(6)

Cc: Mike McCune (b)(6); Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Next Steps for Communication Planning

Dear Colleen,

My apologies for the delay in my response- I was out of the office some of last week unexpectedly, and I am still running a little behind.

I'm looping in Renate Myles from our Communications team- she or someone from her team will likely be your main point of contact. I'm also ccing Amy Patterson from NIH/NHLBI, who is co-chairing this effort with Mike. We have also been having some discussions internally about the rollout, and I think Renate or someone from her team will be in touch soon.

Many thanks for your patience, and we look forward to working with you on this effort!

Best,

Jessica

From: Colleen Silcox (b)(6)

Sent: Wednesday, August 28, 2019 11:36 AM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: Next Steps for Communication Planning

Hi Jessica,

Hope you are doing well.

Our communications team is ready to kick off joint planning for the October announcement at Grand Challenges.

Who would be the best points of contact to lead communications from the NIH side? Would be great to get representation across HIV and SCD to facilitate coordination and decision making across both areas leading up to October.

We will consider as well how to best engage the Steering and Advisory Committees through this process.

Appreciate your insight.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Collins, Francis (NIH/OD) [E]
Sent: Tue, 10 Sep 2019 10:49:56 +0000
To: Dan Wattendorf
Cc: McManus, Ayanna (NIH/OD) [E]; Wood, Gretchen (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Eiss, Robert (NIH/FIC) [E]
Subject: RE: Checking in

Let's talk on Friday. Looping in Ayanna and Gretchen to get it on the calendar.

FC

From: Dan Wattendorf (b)(6)
Sent: Monday, September 9, 2019 8:46 PM
To: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
Subject: Re: Checking in

Anytime. No rush. I just want to make sure you have ground truth on everything on our side.

Get [Outlook for iOS](#)

From: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
Sent: Monday, September 9, 2019 5:45:28 PM
To: Dan Wattendorf (b)(6)
Subject: RE: Checking in

It would be good to catch up, but I am utterly swamped this week. Would you have time Friday afternoon around 2 PM EST? I'll be on a train to NYC.

FC

From: Dan Wattendorf (b)(6)
Sent: Monday, September 9, 2019 12:57 PM
To: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
Subject: Checking in

Hi Francis,

Let me know if you would like to discuss any of the SCD-HIV options and the Grand Challenges meeting.

Dan

Get [Outlook for iOS](#)

From: Myles, Renate (NIH/OD) [E]
Sent: Tue, 10 Sep 2019 00:20:54 +0000
To: Gary Feldman;Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E]
Cc: Colleen Silcox
Subject: Re: Next Steps for Communication Planning

Thanks, Gary. I'll check on our end and will get back to you.

Renate Myles

Deputy Director for Public Affairs

Chief, News Media Branch

Office of Communications and Public Liaison

National Institutes of Health

301-435-3638

From: Gary Feldman <(b)(6)>

Sent: Monday, September 9, 2019 8:16:53 PM

To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Cc: Colleen Silcox <(b)(6)>

Subject: RE: Next Steps for Communication Planning

Hello all,

For our team, 3:00 p.m. Pacific Time aligns everyone on Sept. 11 but I realize that is late for you on the East Coast but would be our first choice. Other option could be 10 a.m. Pacific time on Sept. 13 as an alternate choice.

Looking into next week 11 a.m. Pacific on Sept. 17 also works as a last preference.

We will await your availability and thanks in advance.

Gary

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director

Mike McCune, Senior Advisor

Colleen Silcox, Senior Program Manager

Innovative Technology Solutions (ITS)

Global Health (GH)

Bill & Melinda Gates *foundation*

Seattle Office

Tel (b)(6)

Email (b)(6)

Web www.gatesfoundation.org

From: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Sent: Sunday, September 8, 2019 7:02 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox <(b)(6)>

Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Hi Colleen:

I manage media relations for the NIH Office of the Director and have had the opportunity to connect internally with those involved in this exciting project. We'd love to set up a call this week to discuss the rollout. We've put together some thoughts about the rollout as well and look forward to talking through options with you and your team. If you can share dates/times that you are available this week, I'm happy to coordinate with the communication team on SCD and HIV as well as Dr. Patterson to get something on the calendar.

All the best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, September 4, 2019 12:46 PM
To: Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Dear Colleen,

My apologies for the delay in my response- I was out of the office some of last week unexpectedly, and I am still running a little behind.

I'm looping in Renate Myles from our Communications team- she or someone from her team will likely be your main point of contact. I'm also ccing Amy Patterson from NIH/NHLBI, who is co-chairing this effort with Mike. We have also been having some discussions internally about the rollout, and I think Renate or someone from her team will be in touch soon.

Many thanks for your patience, and we look forward to working with you on this effort!

Best,

Jessica

From: Colleen Silcox (b)(6)
Sent: Wednesday, August 28, 2019 11:36 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: Next Steps for Communication Planning

Hi Jessica,

Hope you are doing well.

Our communications team is ready to kick off joint planning for the October announcement at Grand Challenges.

Who would be the best points of contact to lead communications from the NIH side? Would be great to get representation across HIV and SCD to facilitate coordination and decision making across both areas leading up to October.

We will consider as well how to best engage the Steering and Advisory Committees through this process.

Appreciate your insight.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V + (b)(6)

M + (b)(6)

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Myles, Renate (NIH/OD) [E]
Sent: Mon, 9 Sep 2019 21:52:52 +0000
To: Colleen Silcox;Tucker, Jessica (NIH/OD) [E]
Cc: Mike McCune;Patterson, Amy (NIH/NHLBI) [E]
Subject: RE: Next Steps for Communication Planning

Terrific. We'll look for your email.

From: Colleen Silcox (b)(6)
Sent: Monday, September 09, 2019 5:42 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Dear Renate,

Great to be in contact with you, and look forward to hearing your thoughts on the communications rollout.

We'll come back to you very soon with a few options for an initial call this week.

Many thanks,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v + (b)(6)

From: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>
Sent: Sunday, September 8, 2019 7:02 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Hi Colleen:

I manage media relations for the NIH Office of the Director and have had the opportunity to connect internally with those involved in this exciting project. We'd love to set up a call this week to discuss the rollout. We've put together some thoughts about the rollout as well and look forward to talking through options with you and your team. If you can share dates/times that your available this week, I'm happy to coordinate with the communication team on SCD and HIV as well as Dr. Patterson to get something on the calendar.

All the best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Chief, News Media Branch
Office of Communications and Public Liaison
National Institutes of Health
Tel: 301-435-3638

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, September 4, 2019 12:46 PM
To: Colleen Silcox <(b)(6)>
Cc: Mike McCune <(b)(6)>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Dear Colleen,

My apologies for the delay in my response- I was out of the office some of last week unexpectedly, and I am still running a little behind.

I'm looping in Renate Myles from our Communications team- she or someone from her team will likely be your main point of contact. I'm also ccing Amy Patterson from NIH/NHLBI, who is co-chairing this effort with Mike. We have also been having some discussions internally about the roll out, and I think Renate or someone from her team will be in touch soon.

Many thanks for your patience, and we look forward to working with you on this effort!

Best,

Jessica

From: Colleen Silcox <(b)(6)>
Sent: Wednesday, August 28, 2019 11:36 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune <(b)(6)>
Subject: Next Steps for Communication Planning

Hi Jessica,

Hope you are doing well.

Our communications team is ready to kick off joint planning for the October announcement at Grand Challenges.

Who would be the best points of contact to lead communications from the NIH side? Would be great to get representation across HIV and SCD to facilitate coordination and decision making across both areas leading up to October.

We will consider as well how to best engage the Steering and Advisory Committees through this process.

Appreciate your insight.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V (b)(6)

M (b)(6)

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Mon, 9 Sep 2019 16:39:48 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: NIH BMGF SC Meeting

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Mon, 9 Sep 2019 16:35:54 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Emily Turner; 'Nina Russell'; 'Kedest Tesfagiorgis'; 'Adam Jiang (McKinsey Secondment)'; Timothy Attoye
Subject: NIH BMGF SC Meeting

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Fri, 6 Sep 2019 17:08:03 +0000
To: Colleen Silcox;Tucker, Jessica (NIH/OD) [E];Mike McCune
Cc: Gary Feldman;Alli Steiner
Subject: RE: Update for Steering Committee Meeting

Thanks for sending this contact information.
Amy

From: Colleen Silcox <(b)(6)>
Sent: Tuesday, July 30, 2019 11:35 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Mike McCune <(b)(6)>
Cc: Gary Feldman <(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Alli Steiner <(b)(6)>
Subject: RE: Update for Steering Committee Meeting

Jessica,

Many thanks for the comprehensive update.

As I know Gary is working onsite with the current convening, I've added Alli from our team who may be able to assist getting an invite out to our foundation participants with the call-in information you've provided below and the meeting materials

Also appreciate the confirmation regarding observers at the meeting, we will let Timothy Attoye and Adam Jiang know they can attend in this capacity.

For reference, contact information is:

- Emily Turner <(b)(6)> - attending in person
- Nina Russell <(b)(6)> - dialing in
- Kedest Tesfagiorgis <(b)(6)> - TBD membership not confirm, would be dialing in
- Adam Jiang (McKinsey Secondment) <(b)(6)> - observer attendee
- Timothy Attoye <(b)(6)> - observer attendee

Many thanks,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v + <(b)(6)>

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 30, 2019 6:40 AM
To: Mike McCune <(b)(6)>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Friday, July 26, 2019 7:03 AM
To: Mike McCune <(b)(6)>
Cc: Colleen Silcox <(b)(6)>
Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6)
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when (b)(6) t and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V + (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Fri, 6 Sep 2019 13:53:32 +0000
To: 'Mike McCune'; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: NIH BMGF SC

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Fri, 6 Sep 2019 13:27:17 +0000
To: Mike McCune; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Young, Cari (NIH/OD) [E]; Islam, Aminul (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]; Sengupta, Nivedita (NIH/NHLBI) [C]; Groesch, Mary (NIH/NHLBI) [E]; Hostetler, Jessica (NIH/NHLBI) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: NIH BMGF SC

From: Colleen Silcox
Sent: Wed, 4 Sep 2019 16:49:49 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Mike McCune; Myles, Renate (NIH/OD) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: RE: Next Steps for Communication Planning

Dear Jessica,

No worries. Appreciate the follow up now that you're back in the office.

Renate, great to meet you. Our communications team is looking forward to starting a working group around the announcement activities – we look forward to hearing from you on who we should work with from NIH to represent the HIV and SCD collaboration announcement. Let us know what would make the most sense from your perspective.

All the best,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

V + (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, September 4, 2019 9:46 AM
To: Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: RE: Next Steps for Communication Planning

Dear Colleen,

My apologies for the delay in my response- I was out of the office some of last week unexpectedly, and I am still running a little behind.

I'm looping in Renate Myles from our Communications team- she or someone from her team will likely be your main point of contact. I'm also ccing Amy Patterson from NIH/NHLBI, who is co-chairing this effort with Mike. We have also been having some discussions internally about the roll out, and I think Renate or someone from her team will be in touch soon.

Many thanks for your patience, and we look forward to working with you on this effort!

Best,

Jessica

From: Colleen Silcox <(b)(6)>
Sent: Wednesday, August 28, 2019 11:36 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: Next Steps for Communication Planning

Hi Jessica,

Hope you are doing well.

Our communications team is ready to kick off joint planning for the October announcement at Grand Challenges.

Who would be the best points of contact to lead communications from the NIH side? Would be great to get representation across HIV and SCD to facilitate coordination and decision making across both areas leading up to October.

We will consider as well how to best engage the Steering and Advisory Committees through this process.

Appreciate your insight.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V + (b)(6)

M + (b)(6)

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

From: Colleen Silcox
Sent: Tue, 3 Sep 2019 19:41:35 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Mike McCune
Subject: RE: Next Steps for Communication Planning

Hi Jessica,

I hope you enjoyed the long weekend! Checking in on the below in case you may have any insight for us as we establish the communications working group.

All the best,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

V + (b)(6)

From: Colleen Silcox
Sent: Wednesday, August 28, 2019 8:36 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6) (b)(6)
Subject: Next Steps for Communication Planning

Hi Jessica,

Hope you are doing well.

Our communications team is ready to kick off joint planning for the October announcement at Grand Challenges.

Who would be the best points of contact to lead communications from the NIH side? Would be great to get representation across HIV and SCD to facilitate coordination and decision making across both areas leading up to October.

We will consider as well how to best engage the Steering and Advisory Committees through this process.

Appreciate your insight.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager & Interim Deputy Director Strategy, Planning & Management
Innovative Technology Solutions, Global Health

V + (b)(6)

M -

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Mike McCune
Sent: Tue, 3 Sep 2019 02:04:12 +0000
To: Patterson, Amy (NIH/NHLBI) [E]
Cc: Tucker, Jessica (NIH/OD) [E]; Adam Jiang (McKinsey Secondment); Timothy Attoye
Subject: Re: Follow up

That's great, Amy. Thanks!

Should we plan to share information beforehand about activities/grants/etc related to the collaboration? If you have a template that you would like to use, please send it along. We can otherwise suggest something as a straw dog.

All my best,

Mike

Get [Outlook for iOS](#)

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Monday, September 2, 2019 5:52 PM

To: Mike McCune

Cc: Tucker, Jessica (NIH/OD) [E]; Adam Jiang (McKinsey Secondment); Timothy Attoye

Subject: Re: Follow up

Hi Mike,

Wishing you safe travels! Our office should be in touch tomorrow or a Wednesday to poll for a few dates. We'd like to get several meetings on the books in September and October.

Amy

Sent from my iPhone

On Sep 2, 2019, at 8:31 PM, Mike McCune (b)(6) wrote:

Hi Amy and Jessica,

Here's hoping that you each had a restful and fun long weekend!

I wonder: what are your thoughts about planning for another meeting of the Steering Committee in the near future?

I am doing some invigorating travel this week (to (b)(6) on Tues, to (b)(6) on Wed, back from (b)(6) on Fri) but will be in touch by email (at least) throughout.

Cheers,

Mike

From: Mike McCune (b)(6)

Sent: Wednesday, August 28, 2019 8:41 AM

To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6)

Subject: Re: Follow up

Very good, Amy - thanks for the update!

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Wednesday, August 28, 2019 8:14 AM

To: Mike McCune (b)(6)

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6)

Subject: RE: Follow up

Hi Mike,

We are still having some internal discussions that will be very helpful in refining the template for your input along with some ideas about goals/deliverables. Will send a soon as we can.

Amy

From: Mike McCune (b)(6)

Sent: Saturday, August 24, 2019 2:11 PM

To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6) >

Subject: Re: Follow up

Very good. Thanks, Amy. Have a great weekend.

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Saturday, August 24, 2019 10:45 AM

To: Mike McCune <(b)(6)>

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Adam Jiang (McKinsey Secondment)

<(b)(6)>; Timothy Atttoy <(b)(6)>

Subject: Re: Follow up

Hi Mike,

Our NIH team is touching base on Monday morning. We have a proposed format for capturing the grants etc (layered excel spreadsheet that uses the table your team provided as the top layer) that we will be discussing and possibly refining a bit. We can send that to you after we revise - hopefully by Tuesday.

Amy

Sent from my iPhone

On Aug 23, 2019, at 9:58 PM, Mike McCune <(b)(6)> wrote:

Hi Amy and Jessica,

I'm writing about several things:

- **Timing of our next call:** I received a note (that I cannot retrieve now) indicating that a time was being planned for next week. Do you know where that stand now?
- **Description of projects funded or planned:** I have received the note below (and attachments) from Carl. As a next step, I think we talked about itemizing, to the extent possible, specific grants that have been made and general ideas about grants that are planned. If that's right, I

wonder: have you settled upon a format for doing so? If not, we could suggest one that would allow the viewer to move from the attached "high level" program timeline to more granular detail. We've also figured out ways to "sanitize" the grants that we are contemplating (but have not executed) in such a manner as to maintain confidentiality while also conveying the intended direction. If you would like us to do so, we could send that along as a template for your review.

Let me know what you think.

Mike

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>

Sent: Wednesday, August 21, 2019 1:22 PM

To: Mike McCune (b)(6)

Cc: Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>

Subject: Follow up

Hi Mike,

Based upon the slides that your team sketched out, we have taken a run at putting on paper the research that that will help to get us to the end goal. In order to help keep our conversation going, I felt it would be useful to share now so that we could discuss.

Hope the Seattle meeting is going well.

Best regards,

Carl

Carl W. Dieffenbach, Ph.D.

Director

Division of AIDS, NIAID

5601 Fishers Lane, Room 8D34

Rockville, MD 20852-9831

he/him/his

Phone: (301) 496-9112

Fax: (240) 627-3466

Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<NIH BMGF.20190803_HIV high-level timeline 82019.pptx>

<workplan on cure V6 82119 .pptx>

From: Mike McCune
Sent: Sat, 24 Aug 2019 01:58:19 +0000
To: Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E]
Cc: Adam Jiang (McKinsey Secondment);Timothy Attoye
Subject: Fw: Follow up
Attachments: NIH BMGF.20190803_HIV high-level timeline 82019.pptx, workplan on cure V6 82119 .pptx

Hi Amy and Jessica,

I'm writing about several things:

- **Timing of our next call:** I received a note (that I cannot retrieve now) indicating that a time was being planned for next week. Do you know where that stand now?
- **Description of projects funded or planned:** I have received the note below (and attachments) from Carl. As a next step, I think we talked about itemizing, to the extent possible, specific grants that have been made and general ideas about grants that are planned. If that's right, I wonder: have you settled upon a format for doing so? If not, we could suggest one that would allow the viewer to move from the attached "high level" program timeline to more granular detail. We've also figured out ways to "sanitize" the grants that we are contemplating (but have not executed) in such a manner as to maintain confidentiality while also conveying the intended direction. If you would like us to do so, we could send that along as a template for your review. Let me know what you think.

Mike

From: Dieffenbach, Carl (NIH/NIAID) [E] <cdieffenba@niaid.nih.gov>

Sent: Wednesday, August 21, 2019 1:22 PM

To: Mike McCune (b)(6)

Cc: Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Read, Sarah (NIH/NIAID) [E] <reads@niaid.nih.gov>

Subject: Follow up

Hi Mike,

Based upon the slides that your team sketched out, we have taken a run at putting on paper the research that that will help to get us to the end goal. In order to help keep our conversation going, I felt it would be useful to share now so that we could discuss.

Hope the Seattle meeting is going well.

Best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34

Rockville, MD 20852-9831

he/him/his

Phone: (301) 496-9112

Fax: (240) 627-3466

Email: cdieffenba@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Page 617 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 618 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 619 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 620 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 621 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 622 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 623 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 624 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 625 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 626 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 627 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 628 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 629 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Tue, 20 Aug 2019 17:41:09 +0000
To: Patterson, Amy (NIH/NHLBI) [E]
Cc: Tucker, Jessica (NIH/OD) [E]; Adam Jiang (McKinsey Secondment); Timothy Attoye; Emily Turner; Gary Feldman; Earle, Melody (NIH/NHLBI) [E]; Groesch, Mary (NIH/NHLBI) [E]
Subject: Re: SC meeting call

Very good. Thanks, Amy. Looking forward to it!

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Tuesday, August 20, 2019 10:19 AM

To: Mike McCune (b)(6)

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6); Emily

Turner (b)(6); Gary Feldman (b)(6)

Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>; Groesch, Mary (NIH/NHLBI) [E]

<mary.groesch@nih.gov>

Subject: Re: SC meeting call

Hi Mike,

Hope things are going well. I think we will need to meet next week or so as we are still pulling info together. I have cc'd Melody to help us set some times up.

Amy

Sent from my iPhone

On Aug 20, 2019, at 8:42 AM, Mike McCune (b)(6) > wrote:

Hi Amy and Jessica,

I hope you each had fun and relaxing trips.

I'm writing because I think we made tentative plans to get in touch by phone this week and also to have a meeting of the entire group either next week or the first week of September.

I would be free tomorrow and Thurs, but not Friday; next week is open; during the week of 9/2, Tues and Wed are good.

Should we try to get something on everyone's calendars? I am copying Gary Feldman, who can help with schedules on our end.

Thanks,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates foundation

www.gatesfoundation.org

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Mon, 12 Aug 2019 21:08:10 +0000
To: Mike McCune
Cc: Tucker, Jessica (NIH/OD) [E]; O'Reilly, Marina (NIH/OD) [E]; Groesch, Mary (NIH/NHLBI) [E]; Shipp, Allan (NIH/NHLBI) [E]
Subject: Re: Timing of NIH-BMGF communications team meeting

Sure just let me know!

Sent from my iPhone

On Aug 12, 2019, at 12:28 PM, Mike McCune (b)(6) wrote:

Hi Amy,

Good to hear from you.

Let me see if I can make that work. Might you be free from 2:30-3:30?

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Monday, August 12, 2019 11:31 AM

To: Mike McCune (b)(6)

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>

Subject: Re: Timing of NIH-BMGF communications team meeting

Hi Mike,

I apologize for just seeing this message now. If it still works with your schedule, I can come by to see you at 2:00 pm tomorrow. Please let me know if that works for you.

Thank so much,

Amy

Sent from my iPhone

On Aug 9, 2019, at 7:53 PM, Mike McCune (b)(6) wrote:

Hi Amy,

Yes, this sounds good. I will be talking to our Comms team on Monday and will let them know. On another point: would you like to visit Timothy, Adam, and me at the foundation sometime on Tuesday when you're in Seattle? I have free time that day before 9, between 2-3, and after 5. If those times don't work, I could try to move things around between 11-1. Might one of those intervals work for you? Let me know and I can see what works for Timothy and Adam. We'd love to meet up and show you around.

Bon weekend!

Mike

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Friday, August 9, 2019 9:22 AM

To: Mike McCune (b)(6) g>

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; O'Reilly, Marina (NIH/OD) [E] <oreillym@od.nih.gov>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>; Shipp, Allan (NIH/NHLBI) [E] <allan.shipp@nih.gov>

Subject: Timing of NIH-BMGF communications team meeting

Hi Mike,

Great discussion yesterday! We agreed that it would be best to get our collective communications teams going on the public announcement sooner rather than later. On the NIH side, we'll have to coordinate and brief three teams of our comms folks. We checked in folks' vacation schedules, and it seems that getting together will be challenging in mid August. So we would propose that we bring our comms teams together in late August, early September. Does this seem reasonable to you?

Amy

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Fri, 9 Aug 2019 13:18:39 +0000
To: Mike McCune
Cc: Tucker, Jessica (NIH/OD) [E]; Gary Feldman; Adam Jiang; Groesch, Mary (NIH/NHLBI) [E]
Subject: Re: workplan - next steps

No worries. We can do it another time!!

Sent from my iPhone

On Aug 9, 2019, at 8:56 AM, Mike McCune (b)(6) wrote:

Very good, Amy, and greetings, Mary.

We are trying to round up the troops here and, at short notice on our "home week," I am not sure if and when we'll get a quorum - but stay tuned!

If we cannot swing it this time, there will be another, I'm sure.

Mike

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Thursday, August 8, 2019 7:10 PM

To: Mike McCune (b)(6)

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Gary Feldman

(b)(6) [E] <[REDACTED]>; Adam Jiang <Adam_Jiang@mckinsey.com>; Groesch, Mary (NIH/NHLBI) [E] <mary.groesch@nih.gov>

Subject: Re: workplan - next steps

Hi Mike, I will actually be available Tuesday afternoon rather than morning— I hope that can work out and really appreciate you looking into it.

My colleague is Mary Groesch. And I have cc'd her on this email.

Amy

Sent from my iPhone

On Aug 8, 2019, at 7:43 PM, Mike McCune (b)(6) wrote:

Thanks very much, Amy and Jessica, for the time on the phone today!

I am trying to schedule a time for you to meet with people at the foundation next Tuesday morning, Amy. I hope we can pull that off.

I am also asking my colleague, Gary Feldman, to plan for a call on 8/21 at either 1 pm PT (preferred) or 8 am PT (possible for some but not all).

Thanks!

Mike

PS - Amy, I don't think I have the email address for Mary Groesch (sp?) Can you please send that along?

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Sent: Thursday, August 8, 2019 2:08 PM
To: Mike McCune (b)(6)
Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: workplan

Amy P. Patterson, M.D.

Chief Science Advisor and

Director of Scientific Research Programs, Policy, and Strategic Initiatives

National Heart, Lung, and Blood Institute

National Institutes of Health

Bldg. 31, Room 5A48

Bethesda, MD 20892

(301) 496-5166

amy.patterson@nih.gov

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 8 Aug 2019 14:13:12 +0000
To: Mike McCune;Tucker, Jessica (NIH/OD) [E]
Cc: Adam Jiang;Timothy Attoye
Subject: RE: Presentations - CGT4HIVCure 2019

thank you, Mike! Very helpful

From: Mike McCune (b)(6)
Sent: Thursday, August 8, 2019 12:38 AM
To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye (b)(6)
Subject: Re: Presentations - CGT4HIVCure 2019

Dear Amy and Jessica,

To share with your team: attached is a more detailed list of authors and talk titles as well as abstracts (for most) of the presentations at the upcoming CGT4HIV meeting in Seattle: <https://www.cgt4hivcure2019.org>.

If anyone is interested in attending, please let me know and I will look into registration waivers.

Best,

Mike

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Wed, 7 Aug 2019 21:38:05 +0000
To: Mike McCune
Cc: Tucker, Jessica (NIH/OD) [E];Adam Jiang;Timothy Attoye;Emily Turner;Kedest Tesfagiorgis;Nina Russell
Subject: Re: HIV Frontiers investment allocation approach

Thanks, Mike, much appreciated

Sent from my iPhone

On Aug 7, 2019, at 5:14 PM, Mike McCune (b)(6) wrote:

Hi Amy and Jessica,

Thanks again for the productive discussion on Monday.

(b)(5)

Please let me know if you have any questions! Otherwise, looking forward to connecting again on Thursday afternoon.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

<BMGF Frontiers.Investment Allocation Approach.080719.docx>

From: Mike McCune
Sent: Wed, 7 Aug 2019 21:14:25 +0000
To: Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E]
Cc: Adam Jiang;Timothy Attoye;Emily Turner;Kedest Tesfagiorgis;Nina Russell
Subject: Re: HIV Frontiers investment allocation approach
Attachments: BMGF Frontiers.Investment Allocation Approach.080719.docx

Hi Amy and Jessica,

Thanks again for the productive discussion on Monday.

(b)(5)

Please let me know if you have any questions! Otherwise, looking forward to connecting again on Thursday afternoon.

Best,
Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers
Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates foundation

www.gatesfoundation.org

Page 640 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Tue, 6 Aug 2019 03:32:33 +0000
To: Patterson, Amy (NIH/NHLBI) [E]
Cc: Tucker, Jessica (NIH/OD) [E]; Adam Jiang (McKinsey Secondment); Timothy Attoye; Dan Wattendorf
Subject: Re: NIH BMGF collaboration - call to discuss work plan

Great, Amy. My thanks, too!

Get [Outlook for iOS](#)

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Sent: Monday, August 5, 2019 7:38:34 PM

To: Mike McCune (b)(6)

Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Adam Jiang (McKinsey Secondment)

(b)(6); Timothy Attoye (b)(6); Dan Wattendorf (b)(6)

Subject: Re: NIH BMGF collaboration - call to discuss work plan

Hi Mike,

That sounds fine to me unless others have topics to discuss. Thanks for a productive call today.
Amy

Sent from my iPhone

On Aug 5, 2019, at 8:35 PM, Mike McCune (b)(6) wrote:

Hi all,

I am canceling the call that we reserved for tomorrow, looking forward to talking Thurs.
Please let me know if you think we should keep it.

Mike

Get [Outlook for iOS](#)

From: Mike McCune
Sent: Tue, 6 Aug 2019 00:35:05 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E];Adam Jiang (McKinsey Secondment);Timothy Attoye;Dan Wattendorf
Subject: Canceled: NIH BMGF collaboration - call to discuss work plan
Importance: High

From: Mike McCune
Sent: Tue, 6 Aug 2019 00:35:05 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E];Adam Jiang (McKinsey Secondment);Timothy Attoye;Dan Wattendorf
Subject: Canceled: NIH BMGF collaboration - call to discuss work plan
Importance: High

From: Mike McCune
Sent: Mon, 5 Aug 2019 17:11:05 +0000
To: Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E];Adam Jiang;Timothy Attoye;Kedest Tesfagiorgis;Nina Russell;Emily Turner;Dan Wattendorf
Subject: NIH BMGF SC - discussion of scientific plan/timelines - draft 1

Join online meeting

Join by Phone

(b)(4); (b)(6)	(North America)	English (United States)
	(North America)	English (United States)

[Find a local number](#)

Conference ID: (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

From: Mike McCune
Sent: Mon, 5 Aug 2019 02:15:28 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E]
Cc: Adam Jiang;Timothy Attoye;Dan Wattendorf
Subject: Re: NIH BMGF Steering Committee
Attachments: NIH BMGF.20190803_HIV SCD high-level timeline_v02.pptx, NIH BMGF.20190805_HIV SCD cure timeline_v04.xlsx

Hi Jessica and Amy,

With great assistance from Adam and Timothy, attached are some DRAFT ideas about how to coalesce the working plans that we each have ongoing.

We can walk you through this during our call tomorrow at 9 am PT but by way of overview now.

I am also copying Dan so that he is aware and can chime in.

(b)(5)

Looking forward to talking tomorrow.

Cheers,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*
www.gatesfoundation.org

From: Mike McCune

Sent: Saturday, August 3, 2019 9:46 AM

To: Jessica Tucker <jessica.tucker@nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Cc: Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye (b)(6)

Subject: Re: NIH BMGF Steering Committee

Hi Jessica and Amy,

Several things here:

- Re, "Frontiers NIH slide deck" shown at the SC meeting Thurs - I attach here a version updated with the appropriate BMGF "confidentiality" etc tags and good to pass around to members of the SC (and EC, as you think best). It would be best to not distribute further prior to the formal announcement in October at the Grand Challenges meeting.
 - On a related point, I wonder if we should put an NDA in place in the SC so that we can speak freely about matters that would otherwise be deemed confidential.
 - Re, the CGT4HIV meeting in Seattle on Aug 22 and 23 of this month, see <https://www.cgt4hivcure2019.org>. I've attached the current agenda. You might pass this out to members of the SC, noting especially the session on in vivo applications on Aug 23. If anyone wants to attend, I am sure that we can obtain a waiver on the registration fee.
- I look forward to talking more on Monday, re: the draft for the scientific plans.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*
www.gatesfoundation.org

Page 647 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 648 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Sat, 3 Aug 2019 17:53:41 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Re: NIH BMGF Steering Committee

No worries! Bon weekend.

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

v (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Saturday, August 3, 2019 10:22 AM
To: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>
Cc: Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye (b)(6)
Subject: Re: NIH BMGF Steering Committee

Sorry, was on my phone. Looks like I attached it twice!

----- Original Message -----

From: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
Date: Sat, Aug 3, 2019, 1:21 PM
To: Mike McCune (b)(6); "Patterson, Amy (NIH/NHLBI) [E]"
<amy.patterson@nih.gov>
CC: Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye
(b)(6)
Subject: Re: NIH BMGF Steering Committee

Thanks, Mike, Per our discussion yesterday, here is the other version of the one pager. I distributed another version as Appendix C during the discussion on Thursday.

Thanks,

Jessica

----- Original Message -----

From: Mike McCune (b)(6)
Date: Sat, Aug 3, 2019, 12:58 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>; "Patterson, Amy (NIH/NHLBI) [E]"
<amy.patterson@nih.gov>
CC: Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye

(b)(6)

Subject: Re: NIH BMGF Steering Committee

Hi Jessica and Amy,

Several things here:

- Re, "Frontiers NIH slide deck" shown at the SC meeting Thurs - I attach here a version updated with the appropriate BMGF "confidentiality" etc tags and good to pass around to members of the SC (and EC, as you think best). It would be best to not distribute further prior to the formal announcement in October at the Grand Challenges meeting.
 - On a related point, I wonder if we should put an NDA in place in the SC so that we can speak freely about matters that would otherwise be deemed confidential.
 - Re, the CGT4HIV meeting in Seattle on Aug 22 and 23 of this month, see <https://www.cgt4hivcure2019.org>. I've attached the current agenda. You might pass this out to members of the SC, noting especially the session on in vivo applications on Aug 23. If anyone wants to attend, I am sure that we can obtain a waiver on the registration fee.
- I look forward to talking more on Monday, re: the draft for the scientific plans.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Mike McCune
Sent: Sat, 3 Aug 2019 17:53:23 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E]
Cc: Adam Jiang;Timothy Attoye
Subject: Re: NIH BMGF Steering Committee

Very good. Thanks, Jessica!

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6) rg

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Saturday, August 3, 2019 10:21 AM
To: Mike McCune (b)(6); Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>
Cc: Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye (b)(6)
Subject: Re: NIH BMGF Steering Committee

Thanks, Mike, Per our discussion yesterday, here is the other version of the one pager. I distributed another version as Appendix C during the discussion on Thursday.

Thanks,

Jessica

----- Original Message -----

From: Mike McCune (b)(6)
Date: Sat, Aug 3, 2019, 12:58 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>,"Patterson, Amy (NIH/NHLBI) [E]" <amy.patterson@nih.gov>
CC: Adam Jiang <Adam_Jiang@mckinsey.com>,Timothy Attoye (b)(6)
Subject: Re: NIH BMGF Steering Committee
Hi Jessica and Amy,
Several things here:

(b)(5)

- On a related point, I wonder if we should put an NDA in place in the SC so that we can speak freely about matters that would otherwise be deemed confidential.
 - Re, the CGT4HIV meeting in Seattle on Aug 22 and 23 of this month, see <https://www.cgt4hivcure2019.org>. I've attached the current agenda. You might pass this out to members of the SC, noting especially the session on in vivo applications on Aug 23. If anyone wants to attend, I am sure that we can obtain a waiver on the registration fee.
- I look forward to talking more on Monday, re: the draft for the scientific plans.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E]
Sent: Sat, 3 Aug 2019 17:21:38 +0000
To: Mike McCune;Patterson, Amy (NIH/NHLBI) [E]
Cc: Adam Jiang;Timothy Attoye
Subject: Re: NIH BMGF Steering Committee
Attachments: SCD-HIV Collab BMGF-NIH_032019.docx, SCD-HIV Collab BMGF-NIH_032019.docx

Thanks, Mike, Per our discussion yesterday, here is the other version of the one pager. I distributed another version as Appendix C during the discussion on Thursday.

Thanks,
Jessica

----- Original Message -----

From: Mike McCune <(b)(6)>
Date: Sat, Aug 3, 2019, 12:58 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>, "Patterson, Amy (NIH/NHLBI) [E]" <amy.patterson@nih.gov>
CC: Adam Jiang <Adam_Jiang@mckinsey.com>, Timothy Attoye <(b)(6)>
Subject: Re: NIH BMGF Steering Committee

Hi Jessica and Amy,

Several things here:

- Re, "Frontiers NIH slide deck" shown at the SC meeting Thurs - I attach here a version updated with the appropriate BMGF "confidentiality" etc tags and good to pass around to members of the SC (and EC, as you think best). It would be best to not distribute further prior to the formal announcement in October at the Grand Challenges meeting.
 - On a related point, I wonder if we should put an NDA in place in the SC so that we can speak freely about matters that would otherwise be deemed confidential.
 - Re, the CGT4HIV meeting in Seattle on Aug 22 and 23 of this month, see <https://www.cgt4hivcure2019.org>. I've attached the current agenda. You might pass this out to members of the SC, noting especially the session on in vivo applications on Aug 23. If anyone wants to attend, I am sure that we can obtain a waiver on the registration fee.
- I look forward to talking more on Monday, re: the draft for the scientific plans.

Best,
Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers
Global Health Innovative Technology Solutions

V (b)(5) .
E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)
E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 655 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 656 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Sat, 3 Aug 2019 16:46:10 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E]
Cc: Adam Jiang;Timothy Attoye
Subject: Re: NIH BMGF Steering Committee
Attachments: CGT4HIVCure 2019_Final Agenda.pdf, Frontiers.NIH slide deck.080319.pptx

Hi Jessica and Amy,
Several things here:

- Re, "Frontiers NIH slide deck" shown at the SC meeting Thurs - I attach here a version updated with the appropriate BMGF "confidentiality" etc tags and good to pass around to members of the SC (and EC, as you think best). It would be best to not distribute further prior to the formal announcement in October at the Grand Challenges meeting.
 - On a related point, I wonder if we should put an NDA in place in the SC so that we can speak freely about matters that would otherwise be deemed confidential.
 - Re, the CGT4HIV meeting in Seattle on Aug 22 and 23 of this month, see <https://www.cgt4hivcure2019.org>. I've attached the current agenda. You might pass this out to members of the SC, noting especially the session on in vivo applications on Aug 23. If anyone wants to attend, I am sure that we can obtain a waiver on the registration fee.
- I look forward to talking more on Monday, re: the draft for the scientific plans.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

5th Conference on Cell & Gene Therapy for HIV Cure 2019 August 22-23, 2019 | Seattle, WA

Marriott Residence Inn Seattle, Downtown/Convention Center | Ballroom, 2nd Floor

Thursday, August 22, 2019	DAY 1 AGENDA
7:15 – 8:00	Registration and Breakfast
SESSION 1	Opening Remarks & HIV Cure Overview
8:00 – 8:20	Conference Welcome: Keith R. Jerome and Hans-Peter Kiem
8:20 – 8:40	Rowena Johnston
SESSION 2	HSC Transplantation & Gene Editing
8:40 – 9:10	PLENARY: Monique Nijhuis
9:10 – 9:30	Paula Cannon
9:30 – 9:50	John A. Zaia
9:50 – 10:05	Tricia Burdo
10:05 – 10:15	Sandra Dross (oral abstract)
10:15 – 10:40	BREAK
SESSION 3	Keynote
10:40 – 10:45	Keynote Introduction: Keith R. Jerome
10:45 – 11:45	Keynote Speaker: Robert F. Siliciano
11:45 – 1:00	LUNCH
SESSION 4	HIV Latency & Reservoirs
1:00 – 1:20	Pamela Skinner
1:20 – 1:30	Hadia Abdelaal (oral abstract)
1:30 – 1:40	Michael Farzan (oral abstract)
1:40 – 2:00	Laurie Sylla
SESSION 5	CAR T Cells & Other T Cell Therapies for HIV
2:00 – 2:20	Catherine Bollard
2:20 – 2:40	James Riley
2:40 – 2:55	Christopher Peterson
2:55 – 3:05	Kim Anthony-Gonda (oral abstract)
3:05 – 3:15	Mayra Carrillo (oral abstract)
3:15 – 3:25	Eytan Herzog (oral abstract)
3:25 – 3:50	BREAK
SESSION 6	Lessons from Cell & Gene Therapy for Other Conditions
3:50 – 4:10	Aude Chapuis
4:10 – 4:30	Keith R. Jerome
4:30 – 4:45	Holly Peay
4:45 – 5:00	Olivier Humbert
Evening Activities	
5:00 – 6:20	Poster Session: serving hors d'oeuvres, beer and wine
6:30 – 7:00	Shuttle to MOHAI dock and board the Argosy Cruise ship
7:00 – 10:00	Lakes dinner cruise and reception

Friday, August 23, 2019	DAY 2 AGENDA
7:30 – 8:00	Registration and Breakfast
	Workshop on In Vivo Gene Therapy <i>Sponsored by Bill & Melinda Gates Foundation</i>
SESSION 7	In Vivo Gene Therapy Overview
8:00 – 8:15	Workshop Overview: Mike McCune and Hans-Peter Kiem
8:15 – 8:45	PLENARY: David Baker
SESSION 8	Viral Delivery Vectors
8:45 – 9:05	Hildegard Büning
9:05 – 9:25	Guangping Gao
9:25 – 9:40	Koki Morizono
9:40 – 10:00	Priti Kumar
10:00 – 10:20	André Lieber
10:20 – 10:45	BREAK
10:45 – 11:00	Jing Wen
11:00 – 11:20	Els Verhoeyen
11:20 – 11:30	Hsu-Yu Chen (oral abstract)
SESSION 9	Non-Viral Delivery Vectors
11:30 – 11:50	Daniel Anderson
11:50 – 12:10	Drew Weissman
12:10 – 1:20	LUNCH
1:20 – 1:40	Chris Jewell
1:40 – 2:00	Leah Sabin
2:00 – 2:20	Ross Wilson
2:20 – 2:30	Sarah D. Slack for Kim Woodrow (oral abstract)
SESSION 10	In Vivo Gene Therapy Panel Discussion
2:30 – 3:00	Moderated by Romas Gelezianas, Manuel Venegas, Mike McCune
3:00 – 3:05	Closing Remarks: Keith R. Jerome and Hans-Peter Kiem

Page 660 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 661 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 662 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 663 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 664 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 665 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 666 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 667 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 668 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 669 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 670 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 671 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 672 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 673 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Fri, 2 Aug 2019 18:14:27 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E];Adam Jiang (McKinsey Secondment);Timothy Attoye
Subject: NIH BMGF collaboration - call to discuss work plan

Join online meeting

Join by Phone

(b)(4); (b)(6)	(North America)	English (United States)
	(North America)	English (United States)

[Find a local number](#)

Conference ID: (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

From: Mike McCune
Sent: Fri, 2 Aug 2019 18:13:46 +0000
To: Patterson, Amy (NIH/NHLBI) [E];Tucker, Jessica (NIH/OD) [E];Adam Jiang;Timothy Attoye
Subject: NIH BMGF collaboration - call to discuss work plan

Join online meeting

Join by Phone

(b)(4); (b)(6)	(North America)	English (United States)
	(North America)	English (United States)

[Find a local number](#)

Conference ID (b)(4); (b)(6)

[Forgot your dial-in PIN?](#) | [Help](#)

Use Conference ID to join by Phone or VTC. See Help link for more information.

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 1 Aug 2019 21:12:50 +0000
To: Colleen Silcox; Gary Feldman; Adam Jiang; Timothy Attoye; Emily Turner; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Hoots, W. Keith (NIH/NHLBI) [E]; Perry, Mary (NIH/OD) [E]; Wilder, Elizabeth (NIH/OD) [E]
Cc: Tucker, Jessica (NIH/OD) [E]; Mike McCune
Subject: Quick Follow up to Today's Steering Committee Meeting
Attachments: Draft Concepts & Ideas for Project Name.docx

Dear Colleagues,

Thank you for an informative and productive kick-off meeting of the NIH-BMGF Steering Committee for Curing SCD & HIV. It was great to have us all in one room to bounce ideas off one another. We will be sending out a meeting summary shortly and suggested next steps. In the meantime, we wanted to keep the momentum and to jumpstart the discussion about the project name while things are still fresh in our minds. We took a few minutes this afternoon to identify some key concepts that might be considered in contemplating names, and then took a stab at developing some strawman names and acronyms (Attached). See what you think (you may/may not like any of them, but at least it will stimulate your thoughts/dialogue!). And please send in your own suggestions. We will be happy to collate suggestions and send out the master list of possible names.

Looking forward to working with all of you.

Regards,
Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
[\(301\) 496-5166](tel:3014965166)
amy.patterson@nih.gov

Page 677 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Thu, 1 Aug 2019 20:01:50 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E]
Subject: Re: quick follow up

Agreed! Go for it.
Let me know if there is anything you'd like me to do.
Thanks for the meeting today.
I look forward to many more!
Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers
Global Health Innovative Technology Solutions

V (b)(6) 7

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Thursday, August 1, 2019 3:27 PM
To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Mike McCune
(b)(6)
Subject: RE: quick follow up

Sounds good- nice ideas!

From: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Sent: Thursday, August 1, 2019 3:26 PM
To: Mike McCune (b)(6) brg>; Tucker, Jessica (NIH/OD) [E]
<jessica.tucker@nih.gov>
Subject: quick follow up

Dear Mike and Jessica,

We were brainstorming some possible names/acronyms for the NIH-BMGF Collaboration that could be sent out to the Steering Committee to jumpstart an email dialogue in follow up to today's discussion. (They may hate the candidate names, but at least it will get their creative juices flowing!) Might be good to just get a quick note out to the group either today or tomorrow to keep up the momentum and to thank them for their time and insights; the email

could include the name prompt and indicate we will be following up with another email summarizing the meeting and next steps. What do you think?

Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
[\(301\) 496-5166](tel:3014965166)
amy.patterson@nih.gov

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 1 Aug 2019 19:25:58 +0000
To: Mike McCune;Tucker, Jessica (NIH/OD) [E]
Subject: quick follow up
Attachments: Document1 - Compatibility Mode.docx

Dear Mike and Jessica,

We were brainstorming some possible names/acronyms for the NIH-BMGF Collaboration that could be sent out to the Steering Committee to jumpstart an email dialogue in follow up to today's discussion. (They may hate the candidate names, but at least it will get their creative juices flowing!) Might be good to just get a quick note out to the group either today or tomorrow to keep up the momentum and to thank them for their time and insights; the email could include the name prompt and indicate we will be following up with another email summarizing the meeting and next steps. What do you think?

Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
[\(301\) 496-5166](tel:3014965166)
amy.patterson@nih.gov

Page 681 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 1 Aug 2019 19:07:22 +0000
To: Emily Turner;Tucker, Jessica (NIH/OD) [E]
Subject: RE: SC follow-up and planning

Dear Emily,

We totally understand the need to jet in order to catch your flight. We will definitely be following up and appreciate your willingness to meet.

Amy

Amy P. Patterson, M.D.
Chief Science Advisor and
Director of Scientific Research Programs, Policy, and Strategic Initiatives
National Heart, Lung, and Blood Institute
National Institutes of Health

Bldg. 31, Room 5A48
Bethesda, MD 20892
(301) 496-5166
amy.patterson@nih.gov

From: Emily Turner (b)(6)
Sent: Thursday, August 01, 2019 1:45 PM
To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: SC follow-up and planning

Dear Amy and Jessica,

A quick note from the plane to say thank you for your very adept management of the first Steering Committee meeting. I was glad to see so many opportunities to harmonize early- and late-stage work. My apologies for leaving so abruptly for the airport – if there are any immediate questions or comments, I'm happy to clarify via email or a phone call early next week. My office line is below, and my mobile is

(b)(6)

If it is helpful for planning purposes, I will be in DC with a flexible schedule Aug 20th-23rd and would be happy to dedicate time to a deeper in-person dive on some of the key working group questions.

Best,
Emily

Emily Turner, PhD MScPH
Program Officer
Global Health, Innovative Technology Solutions
Bill & Melinda Gates Foundation

V (b)(6)

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

From: Earle, Melody (NIH/NHLBI) [E] on behalf of Patterson, Amy (NIH/NHLBI) [E]
Sent: Thu, 1 Aug 2019 18:08:43 +0000
To: Mike McCune;Tucker, Jessica (NIH/OD) [E]
Subject: NIH-BMGF Collaboration

From: Earle, Melody (NIH/NHLBI) [E]
Sent: Thu, 1 Aug 2019 18:08:33 +0000
To: Mike McCune
Cc: Gary Feldman; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Request for a phone call tomorrow

Confirming 1:30 pm ET/10:30 am PT. I will send a calendar invitation shortly with the teleconference number. Thank you.

From: Mike McCune (b)(6)
Sent: Thursday, August 1, 2019 1:39 PM
To: Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>
Cc: Gary Feldman (b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Request for a phone call tomorrow

Hi Melody,

Would 1:30 pm ET = 10:30 am PT work?

Thanks,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org


From: Earle, Melody (NIH/NHLBI) [E] <earlem2@nhlbi.nih.gov>
Sent: Thursday, August 1, 2019 1:12 PM
To: Gary Feldman <(b)(6)>; Tucker, Jessica (NIH/OD) [E]
<jessica.tucker@nih.gov>
Cc: Mike McCune <(b)(6)>; Tucker, Jessica (NIH/OD) [E]
<jessica.tucker@nih.gov>
Subject: Request for a phone call tomorrow

Dear Gary and Jessica,

Amy Patterson is requesting a call with Mike tomorrow. Amy has flexibility from 12Noon ET and later. Would you please let me know if you can find 30 minutes for this call?

Thank you,

Melody Earle
Immediate Office of the Director
National Heart, Lung and Blood Institute
31 Center Drive, Bldg. 31, Room 5A48
Bethesda, MD 20892-2486
Ph: 301-496-5166
Fax: 301-402-0818
Earlem2@mail.nih.gov



From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 1 Aug 2019 16:05:48 +0000
To: Nina Russell
Cc: Mike McCune; Emily Turner
Subject: Re: Just checking

No problem! I just wanted to ensure there were no technical difficulties. Enjoy your vacation!

----- Original Message -----

From: Nina Russell <(b)(6)>
Date: Thu, Aug 1, 2019, 11:37 AM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
CC: Mike McCune <(b)(6)> Emily Turner
(b)(6)
Subject: Re: Just checking

Apologies - was hoping to call in from my vacation but have been in transit and not able to make it work. I will get a de-brief from Mike.

Thanks

Nina

Sent from my iPhone

On Aug 1, 2019, at 10:28 AM, Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov> wrote:

To see if you are trying to call in/having any difficulties.

Just in case, the call in info is

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Jessica Tucker, Ph.D.

Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy

Office of Science Policy

National Institutes of Health

301-451-4431

<image001.png>

OSP Blog: [Under the Poliscope](#)

Twitter: @CWolinetzNIH

From: Emily Turner
Sent: Thu, 1 Aug 2019 13:51:22 +0000
To: Mike McCune;Tucker, Jessica (NIH/OD) [E]
Cc: Colleen Silcox;Gary Feldman;Patterson, Amy (NIH/NHLBI) [E];Adam Jiang;Timothy Attoye
Subject: RE: Materials for Steering Committee Meeting
Attachments: 20190801_BMGF-SCD-Approach_FirstLook.pptx

Hello Jessica,

Please see the attached for the sickle cell slide deck.

Thank you,
Emily

From: Mike McCune (b)(6)
Sent: Thursday, August 1, 2019 9:15 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6); Gary Feldman (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye (b)(6); Emily Turner (b)(6)
Subject: Re: Materials for Steering Committee Meeting

Hi Jessica,

Here is the slide deck that I will be showing.

See you soon!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)
E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Wednesday, July 31, 2019 10:47 PM

To: Mike McCune (b)(6); Emily Turner

(b)(6)

Cc: Colleen Silcox (b)(6); Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: Materials for Steering Committee Meeting

Thanks for the discussion earlier today, Mike and Emily,

Apologies for the delay, but please find materials for the meeting tomorrow, attached.

Since I have not been in direct contact with those dialing in from BMGF, I won't pass this along to them directly, but please do share with them.

As you know, the dial-in for those calling in remotely from the West Coast is as follows:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

I will have folders with copies for everyone in the room.

I look forward to the discussion tomorrow!

Best,

Jessica

From: Mike McCune (b)(6)

Sent: Tuesday, July 30, 2019 3:47 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner

(b)(6)

Cc: Colleen Silcox (b)(6); Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

My 3:30 meeting Wed afternoon is by phone, so meeting somewhere on the NIH campus would be fine.

I am also copying my colleague, Emily Turner, in hopes that she can join in person or by phone.

Just let us know the place (and, if need be, dial-in numbers).

Looking forward to it!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 12:05 PM

To: Mike McCune <(b)(6)>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: RE: Update for Steering Committee Meeting

Thanks, Mike,

No problem- I know you are at HIV reservoirs today (me too!). Amy is available at 2 PM tomorrow- should we try to meet then? Let me look into a good location- where is your 3:30 meeting?

Thanks,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, July 30, 2019 12:01 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6); Gary Feldman (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

Apologies for not getting back in touch more quickly.

We'll get materials to you for the SC meeting as soon as possible.

It would also be great to meet with you and Amy beforehand. I am in meetings until tomorrow at noon. Might we try to meet sometime between 12:30-3:30 (when I have another meeting scheduled)?

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 6:40 AM

To: Mike McCune <(b)(6)>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Friday, July 26, 2019 7:03 AM
To: Mike McCune (b)(6)
Cc: Colleen Silcox
Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune <(b)(6)>
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6)
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

INNOVATIVE TECHNOLOGY SOLUTIONS



PRIORITY APPROACHES FOR SICKLE CELL DISEASE

EMILY TURNER | DAN WATTENDORF



ACCELERATING GENE THERAPY FOR GLOBAL HEALTH

Build a roadmap for scalable cures for sickle cell disease Emerging cures for sickle cell disease will not be accessible to the vast majority of people with sickle cell

Commercial markets are nearly exclusively focused on gene therapy modalities that are prohibitively expensive, and require clinical expertise and infrastructure that is unlikely to be available in LMICs.

BMGF provides a unique viewpoint and ability to incubate and accelerate efforts that will bend the development curve towards scalable solutions for sickle cell disease and then HIV

BMGF has an active portfolio of investments to enable scalable, low-cost gene therapy for global health

POTENTIAL PRIORITY APPROACHES FOR SICKLE CELL DISEASE

Establish accurate data on the global burden of sickle cell disease
A top priority for the foundation is reducing the global number of deaths of children under 5

We know sickle cell contributes to a high burden of morbidity and mortality in children, disproportionately affecting populations in key low-income countries (Nigeria, DRC, and India)

As the global infectious disease burden drops, we hypothesize that sickle cell will continue to contribute to childhood mortality

Substantial data gaps exist in our estimation of the true burden of sickle cell disease (and other hemoglobinopathies), particularly at sub-national scales

Facilitating rapid collection, annotation and integration of sickle cell data with global health databases is essential in order to prioritize and deliver Screen & Treat interventions for sickle cell disease



POTENTIAL INTERVENTION STRATEGIES

Deliver low-cost, effective interventions BMGF is exploring methods of case detection and prevalence mapping to enable potential intervention strategies Screening plus low-cost interventions (education, prophylaxis against pneumococcal infections, hydroxyurea) can reduce childhood morbidity and mortality

Patient encounters during routine immunization visits provide an opportunity to perform point-of-care screening, introduce the intervention and monitor recipients

Early analysis suggests that delivering point-of-care screening and an interventions package that synchronizes with the GAVI vaccination schedule would be highly cost-effective in sub-Saharan Africa at a maximum cost of \$124/DALY, including delivery costs

Health care system improvements, education, diagnostic product development and continuous therapeutic intervention packages are not areas of active investment



TOOLS AVAILABLE FOR DIAGNOSIS

Evaluate scalable point-of-care screening tools Current screening rates are as low as 1% and limited by high laboratory costs, technical laboratory requirements, and the fact that many children are born outside of hospitals

To reach the poorest children, centralized newborn screening programs will likely need to be complimented by point-of-care tools compatible with L0 or L1 labs

BMGF could leverage its capacity around diagnostics product development, vaccine campaigns, digital health and community health workers to evaluate point-of-care diagnostics opportunities

BMGF has ongoing programs to develop non-invasive diagnostic approaches appropriate for sickle cell, malaria, anemia and other disorders of the blood

OVERVIEW OF EMERGING POC TOOLS FOR SICKLE CELL DISEASE

Product	Description	Price	Sensitivity	Specificity	Result interpretation	Time to result	Power req	Regulatory considerations	Additional applications
HemotypeSC	Lateral flow monoclonal	\$1-2 / test	99.5% ¹	99.9% ¹	Human eye	10 minutes	None	CE Mark, Registration in Nigeria and Kenya, Pending in Ghana / India	Hemoglobin A, S, C for normal, carrier and SCD
SickleScan	Lateral flow monoclonal	<i>No data</i>	>99% ²	>99% ²	Human eye	5 minutes	None	CE Mark, with Registration in several African countries, FDA pre-submission	Hemoglobin A, S, C for normal, carrier and SCD
Hemex HemeChip	Electrophoresis	\$2 / test	89% ³	86% ³	Digital	8 minutes	Battery-powered	<i>US clinical trials</i>	


1. Across all hemoglobin phenotypes (Steele et al. field study in Ghana, Martinique, USA), 2. Biomedomics pamphlet- Sickle Cell Introduction 3. Laboratory pilot (Noted in McGann et al.) Source: Hemex HemeChip: McGann PT, Hoppe C. The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies. *Blood Cells Mol Dis.* 2017;67:104–113. doi:10.1016/j.bcmd.2017.08.010, Hemex website, HemotypeSC: Nankanja et al., "HemotypeSC demonstrates >99% Field Accuracy in a Sickle Cell Disease Screening Initiative in Children of Southeastern Uganda." *American Journal of Hematology*, 11 March 2019; Steele C. et al., "Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test" in *Am J Hematol.* 2019 Jan;94(1):39–45. SickleScan: Segbena AY, Guindo A, Buono R, et al. Diagnostic accuracy in field conditions of the sickle SCAN® rapid test for sickle cell disease among children and adults in two West African settings: the DREPATEST study. *BMC Hematol.* 2018;18:26. Published 2018 Sep 17. doi:10.1186/s12878-018-0120-5, McGann PT, Schaefer BA, Paniagua M, Howard TA, Ware RE. Characteristics of a rapid, point-of-care lateral flow immunoassay for the diagnosis of sickle cell disease. *Am J Hematol.* 2016;91(2):205–210. doi:10.1002/ajh.24232, Sickle Scan brochure, introduction, and package insert

INITIAL PERSPECTIVES ON SELECT IMMUNOASSAYS FOR SCD

HemotypeSC Performance. Strong performance characteristics; >99% sensitivity, >99% specificity Regulatory. CE-mark Endorsement. Test is currently endorsed by NHLBI, in discussions with WHO on EDL, other NGOs; registered/available in several African countries Target end-user. Validated on newborns and older people; Fetal hemoglobin does not affect diagnostic results Pricing. Pricing is low at \$1-2 per test, driven down with scale. Interest in incorporating a reader, though impact on price could be prohibitive Distribution. Compact product, 500,000 tests fit in 1.5 m²; could be pairing with drone shipments of Rx Manufacturing. Manufactured in accordance with ISO standards.

SickleSCAN Performance. Strong performance characteristics; >99% sensitivity, >99% specificity Regulatory. CE-mark; FDA pre-submission Endorsement. Test is currently endorsed by USAID and other NGOs; strong NIH SBIR support; available in several African countries Target end-user. Test is pre-submission stage for submission to FDA for age >2+ years; test will require validation and expanded labeling for newborns, infants, young children Pricing. Pricing remains high, but likely driven by the volume and high-income markets. Possibility of reducing price for LMICs by changing design to remove cartridge Manufacturing. Manufactured in accordance with ISO standards.

CLOSED-LOOP SYSTEM FOR TEST-TO-TREATMENT FOR SCD



From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 1 Aug 2019 13:42:27 +0000
To: Mike McCune
Cc: Colleen Silcox; Gary Feldman; Patterson, Amy (NIH/NHLBI) [E]; Adam Jiang; Timothy Attoye; Emily Turner
Subject: RE: Materials for Steering Committee Meeting
Attachments: NIH BMGF Collaboration SCD DX Implementation Plan Overview FINAL 080119.pptx

Great. Here are some additional slides for those who will be calling in to follow along.

From: Mike McCune <(b)(6)>
Sent: Thursday, August 1, 2019 9:15 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman <(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Adam Jiang <Adam_Jiang@mckinsey.com>; Timothy Attoye <(b)(6)>
Subject: Re: Materials for Steering Committee Meeting

Hi Jessica,

Here is the slide deck that I will be showing.

See you soon!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Wednesday, July 31, 2019 10:47 PM

To: Mike McCune <(b)(6)>; Emily Turner

<(b)(6)>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: Materials for Steering Committee Meeting

Thanks for the discussion earlier today, Mike and Emily,

Apologies for the delay, but please find materials for the meeting tomorrow, attached.

Since I have not been in direct contact with those dialing in from BMGF, I won't pass this along to them directly, but please do share with them.

As you know, the dial-in for those calling in remotely from the West Coast is as follows:

Dial: <(b)(4); (b)(6)> Passcode: <(b)(4); (b)(6)>

I will have folders with copies for everyone in the room.

I look forward to the discussion tomorrow!

Best,

Jessica

From: Mike McCune <(b)(6)>

Sent: Tuesday, July 30, 2019 3:47 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner

<(b)(6)>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

My 3:30 meeting Wed afternoon is by phone, so meeting somewhere on the NIH campus would be fine.

I am also copying my colleague, Emily Turner, in hopes that she can join in person or by phone.

Just let us know the place (and, if need be, dial-in numbers).

Looking forward to it!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 12:05 PM

To: Mike McCune (b)(6)

Cc: Colleen Silcox (b)(6); Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: RE: Update for Steering Committee Meeting

Thanks, Mike,

No problem- I know you are at HIV reservoirs today (me too!). Amy is available at 2 PM tomorrow- should we try to meet then? Let me look into a good location- where is your 3:30 meeting?

Thanks,

Jessica

From: Mike McCune <(b)(6)>
Sent: Tuesday, July 30, 2019 12:01 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman <(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

Apologies for not getting back in touch more quickly.

We'll get materials to you for the SC meeting as soon as possible.

It would also be great to meet with you and Amy beforehand. I am in meetings until tomorrow at noon. Might we try to meet sometime between 12:30-3:30 (when I have another meeting scheduled)?

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V + (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 6:40 AM

To: Mike McCune <(b)(6)>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Friday, July 26, 2019 7:03 AM

To: Mike McCune (b)(6)

Cc: Colleen Silcox

Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6)
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 710 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 711 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 712 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 713 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 714 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 715 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 716 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 717 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 718 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 719 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 720 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Thu, 1 Aug 2019 13:15:26 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Colleen Silcox; Gary Feldman; Patterson, Amy (NIH/NHLBI) [E]; Adam Jiang; Timothy Attoye; Emily Turner
Subject: Re: Materials for Steering Committee Meeting
Attachments: BMGF Frontiers.NIH collaboration slide deck.080119.pptx

Hi Jessica,
Here is the slide deck that I will be showing.
See you soon!
Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers
Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, July 31, 2019 10:47 PM
To: Mike McCune (b)(6); Emily Turner (b)(6)
Cc: Colleen Silcox (b)(6); Gary Feldman (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Materials for Steering Committee Meeting

Thanks for the discussion earlier today, Mike and Emily,

Apologies for the delay, but please find materials for the meeting tomorrow, attached.

Since I have not been in direct contact with those dialing in from BMGF, I won't pass this along to them directly, but please do share with them.

As you know, the dial-in for those calling in remotely from the West Coast is as follows:

Dial: (b)(4); (b)(6) Passcode (b)(4); (b)(6)

I will have folders with copies for everyone in the room.

I look forward to the discussion tomorrow!

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, July 30, 2019 3:47 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6)
Cc: Colleen Silcox (b)(6); Gary Feldman (b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

My 3:30 meeting Wed afternoon is by phone, so meeting somewhere on the NIH campus would be fine.

I am also copying my colleague, Emily Turner, in hopes that she can join in person or by phone.

Just let us know the place (and, if need be, dial-in numbers).

Looking forward to it!

Mike

Joseph (Mike) McCune, MD, PhD
Head, HIV Frontiers
Global Health Innovative Technology Solutions
V (b)(6)
E (b)(6)

Senior Program Assistant: Gary Feldman
V (b)(6)
E (b)(6)

Bill & Melinda Gates *foundation*
www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 30, 2019 12:05 PM
To: Mike McCune (b)(6)

Cc: Colleen Silcox (b)(6); Gary Feldman
(b)(6); Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>
Subject: RE: Update for Steering Committee Meeting

Thanks, Mike,

No problem- I know you are at HIV reservoirs today (me too!). Amy is available at 2 PM tomorrow- should we try to meet then? Let me look into a good location- where is your 3:30 meeting?

Thanks,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, July 30, 2019 12:01 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6); Gary Feldman
(b)(6); Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

Apologies for not getting back in touch more quickly.

We'll get materials to you for the SC meeting as soon as possible.

It would also be great to meet with you and Amy beforehand. I am in meetings until tomorrow at noon. Might we try to meet sometime between 12:30-3:30 (when I have another meeting scheduled)?

Mike

Joseph (Mike) McCune, MD, PhD
Head, HIV Frontiers
Global Health Innovative Technology Solutions
V (b)(6)
E (b)(6)

Senior Program Assistant: Gary Feldman
V (b)(6)
E (b)(6)

Bill & Melinda Gates *foundation*
www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 30, 2019 6:40 AM
To: Mike McCune <(b)(6)>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman <(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Friday, July 26, 2019 7:03 AM
To: Mike McCune (b)(6)
Cc: Colleen Silcox
Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Thursday, July 25, 2019 1:00 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD
Head, HIV Frontiers
Global Health Innovative Technology Solutions
V (b)(6)
E (b)(6)

Senior Program Assistant: Gary Feldman
V (b)(6)
E (b)(6)

Bill & Melinda Gates *foundation*
www.gatesfoundation.org

Page 727 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 728 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 729 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 730 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 731 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 732 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 733 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 734 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 735 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 736 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 737 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 738 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 739 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 740 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 1 Aug 2019 02:47:04 +0000
To: Mike McCune;Emily Turner
Cc: Colleen Silcox;Gary Feldman;Patterson, Amy (NIH/NHLBI) [E]
Subject: Materials for Steering Committee Meeting
Attachments: APPENDIX A- NIH BMGF Steering Committee Meeting_agenda v073119_clean_final.docx, APPENDIX B-NIH BMGF PUSH Cures _Roster_DRAFT_073119_clean_5 PM.docx, APPENDIX C-PUSH Cures Goals Summary_073119_clean_5 PM.docx, APPENDIX D- NIH BMGF EC SC Charge _clean_073119_5 PM.docx, APPENDIX E- NIH BMGF Collaboration SCD overview FINAL 062419_073119.pptx, APPENDIX F-Precis Narrative and Project Plan DRAFT 06192019_073119.docx, APPENDIX G-NIH BMGF In Vivo Gene Tx DRAFT 06192019_073119.docx, APPENDIX H-HIV Cure NIH BMGF collaboration slides 062419_073119.pptx, APPENDIX I-NIHBMGF HIV WorkPlan 061419_073119.docx

Thanks for the discussion earlier today, Mike and Emily,

Apologies for the delay, but please find materials for the meeting tomorrow, attached.

Since I have not been in direct contact with those dialing in from BMGF, I won't pass this along to them directly, but please do share with them.

As you know, the dial-in for those calling in remotely from the West Coast is as follows:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

I will have folders with copies for everyone in the room.

I look forward to the discussion tomorrow!

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Tuesday, July 30, 2019 3:47 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6) >
Cc: Colleen Silcox (b)(6) >; Gary Feldman (b)(6) >; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

My 3:30 meeting Wed afternoon is by phone, so meeting somewhere on the NIH campus would be fine.

I am also copying my colleague, Emily Turner, in hopes that she can join in person or by phone.

Just let us know the place (and, if need be, dial-in numbers).

Looking forward to it!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 12:05 PM

To: Mike McCune <(b)(6)>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Update for Steering Committee Meeting

Thanks, Mike,

No problem- I know you are at HIV reservoirs today (me too!). Amy is available at 2 PM tomorrow- should we try to meet then? Let me look into a good location- where is your 3:30 meeting?

Thanks,

Jessica

From: Mike McCune <(b)(6)>
Sent: Tuesday, July 30, 2019 12:01 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman <(b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

Apologies for not getting back in touch more quickly.

We'll get materials to you for the SC meeting as soon as possible.

It would also be great to meet with you and Amy beforehand. I am in meetings until tomorrow at noon. Might we try to meet sometime between 12:30-3:30 (when I have another meeting scheduled)?

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V <(b)(6)>

E <(b)(6)>

Senior Program Assistant: Gary Feldman

V <(b)(6)>

E <(b)(6)>

Bill & Melinda Gates *foundation*

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 30, 2019 6:40 AM
To: Mike McCune <(b)(6)>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman
<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>
Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Friday, July 26, 2019 7:03 AM
To: Mike McCune (b)(6)
Cc: Colleen Silcox (b)(6)
Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune <(b)(6)>
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox (b)(6) >
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 747 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 748 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 749 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 750 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 751 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 752 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 753 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 754 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 755 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 756 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 757 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 758 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 759 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 760 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 761 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 762 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 763 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 764 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 765 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 766 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 767 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 768 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 769 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 770 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 771 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 772 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 773 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 774 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 775 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 776 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Gary Feldman
Sent: Wed, 31 Jul 2019 11:28:10 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Colleen Silcox
Subject: Re: Update for Steering Committee Meeting

No problem at all Jessica. (b)(6) is not that HIV Frontiers person but is a Program Coordinator on our team working closely with Mike on the work. She is happy to remain off the call if it causes any issue but will try to dial in she is able.

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, July 31, 2019 3:08 AM
To: Gary Feldman (b)(6); Colleen Silcox
(b)(6); >
Cc: Mike McCune (b)(6)
Subject: RE: Update for Steering Committee Meeting

Thanks, Gary and Colleen,

I'm just trying to make sure that I have the right list of steering committee members, based on the information that has been provided.

Originally, the steering committee members were listed as follows:

Mike McCune, Chair
Nina Russell
Kedest Tesfagiorgis
Emily Turner
HIV Frontiers FTE (To be hired)

I know that Adam and Timothy are observers. Is (b)(6)

Many thanks,

Jessica

From: Gary Feldman (b)(6)
Sent: Tuesday, July 30, 2019 10:48 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6)
Subject: RE: Update for Steering Committee Meeting

Hi Jessica thanks again, here's the rundown for the Gates Foundation:

In person around the table: Mike McCune and Emily Turner
In person observing but not participating: Adam Jiang and Timothy Attoye
Dialing in from Seattle: (b)(6)

Potentially dialing in: Kedest Tesfagiorgis, Chris Karp and Nina Russell (b)(6)

(b)(6)

If you need any additional info just let me know happy to provide.

Thanks,
Gary

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates foundation

Seattle Office

Tel + (b)(6)

Email (b)(6)

Web www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 30, 2019 9:40 AM
To: Mike McCune <(b)(6)>
Cc: Colleen Silcox <(b)(6)>; Gary Feldman
<(b)(6)>; Patterson, Amy (NIH/NHLBI) [E]
<amy.patterson@nih.gov>
Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan

had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Friday, July 26, 2019 7:03 AM

To: Mike McCune <(b)(6)>

Cc: Colleen Silcox <>

Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune <(b)(6)>
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD
Head, HIV Frontiers
Global Health Innovative Technology Solutions
V + (b)(6)
E n (b)(6)

Senior Program Assistant: Gary Feldman
V + (b)(6)
E g (b)(6)

Bill & Melinda Gates *foundation*
www.gatesfoundation.org

From: Gary Feldman on behalf of "Mike McCune"
(b)(6)
Sent: Tue, 30 Jul 2019 20:06:50 +0000
To: Emily Turner; Tucker, Jessica (NIH/OD) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: Mike/Emily/Jessica/Amy

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates *foundation*

Seattle Office

Tel + (b)(6)

Email (b)(6)

Web www.gatesfoundation.org

We have a room for our meeting -- Building 31, Room 5A48D on NIH Campus.

From: Mike McCune (b)(6) >
Sent: Tuesday, July 30, 2019 3:47 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner
(b)(6)
Cc: Colleen Silcox (b)(6); Gary Feldman
(b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

My 3:30 meeting Wed afternoon is by phone, so meeting somewhere on the NIH campus would be fine.

I am also copying my colleague, Emily Turner, in hopes that she can join in person or by phone.

Just let us know the place (and, if need be, dial-in numbers).

Looking forward to it!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 12:05 PM

To: Mike McCune (b)(6)

Cc: Colleen Silcox (b)(6); Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Update for Steering Committee Meeting

Thanks, Mike,

No problem- I know you are at HIV reservoirs today (me too!). Amy is available at 2 PM tomorrow- should we try to meet then? Let me look into a good location- where is your 3:30 meeting?

Thanks,

Jessica

From: Mike McCune (b)(6) >

Sent: Tuesday, July 30, 2019 12:01 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Cc: Colleen Silcox (b)(6); Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

Apologies for not getting back in touch more quickly.

We'll get materials to you for the SC meeting as soon as possible.

It would also be great to meet with you and Amy beforehand. I am in meetings until tomorrow at noon. Might we try to meet sometime between 12:30-3:30 (when I have another meeting scheduled)?

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 6:40 AM

To: Mike McCune (b)(6) >

Cc: Colleen Silcox (b)(6) >; Gary Feldman

(b)(6) >; Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Friday, July 26, 2019 7:03 AM

To: Mike McCune (b)(6)

Cc: Colleen Silcox

Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune <(b)(6)>
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Patterson, Amy (NIH/NHLBI) [E]
Sent: Tue, 30 Jul 2019 19:52:59 +0000
To: Mike McCune;Tucker, Jessica (NIH/OD) [E];Emily Turner
Cc: Colleen Silcox;Gary Feldman
Subject: RE: Update for Steering Committee Meeting

We have a room for our meeting -- Building 31, Room 5A48D on NIH Campus.

From: Mike McCune (b)(6)
Sent: Tuesday, July 30, 2019 3:47 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Emily Turner (b)(6)
Cc: Colleen Silcox (b)(6)>; Gary Feldman (b)(6)>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

My 3:30 meeting Wed afternoon is by phone, so meeting somewhere on the NIH campus would be fine.

I am also copying my colleague, Emily Turner, in hopes that she can join in person or by phone.

Just let us know the place (and, if need be, dial-in numbers).

Looking forward to it!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 12:05 PM

To: Mike McCune <(b)(6)>

Cc: Colleen Silcox <(b)(6)>, Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>

Subject: RE: Update for Steering Committee Meeting

Thanks, Mike,

No problem- I know you are at HIV reservoirs today (me too!). Amy is available at 2 PM tomorrow- should we try to meet then? Let me look into a good location- where is your 3:30 meeting?

Thanks,

Jessica

From: Mike McCune <(b)(6)>

Sent: Tuesday, July 30, 2019 12:01 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Cc: Colleen Silcox <(b)(6)>; Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Re: Update for Steering Committee Meeting

Hi Jessica,

Apologies for not getting back in touch more quickly.

We'll get materials to you for the SC meeting as soon as possible.

It would also be great to meet with you and Amy beforehand. I am in meetings until tomorrow at noon. Might we try to meet sometime between 12:30-3:30 (when I have another meeting scheduled)?

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Tuesday, July 30, 2019 6:40 AM

To: Mike McCune (b)(6)

Cc: Colleen Silcox (b)(6); Gary Feldman

(b)(6); Patterson, Amy (NIH/NHLBI) [E]

<amy.patterson@nih.gov>

Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling

in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: [REDACTED] Passcode: [REDACTED]

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Friday, July 26, 2019 7:03 AM

To: Mike McCune [REDACTED]

Cc: Colleen Silcox

Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune <(b)(6)>
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Colleen Silcox
Sent: Tue, 30 Jul 2019 15:34:51 +0000
To: Tucker, Jessica (NIH/OD) [E];Mike McCune
Cc: Gary Feldman;Patterson, Amy (NIH/NHLBI) [E];Alli Steiner
Subject: RE: Update for Steering Committee Meeting
Attachments: NIH BMGF PUSH Cures Steering Exec Committee Membership_DRAFT_072919_clean.docx, NIH BMGF Steering Committee Meeting_agenda v073019_clean.docx

Jessica,

Many thanks for the comprehensive update.

As I know Gary is working onsite with the current convening, I've added Alli from our team who may be able to assist getting an invite out to our foundation participants with the call-in information you've provided below and the meeting materials

Also appreciate the confirmation regarding observers at the meeting, we will let Timothy Attoye and Adam Jiang know they can attend in this capacity.

For reference, contact information is:

- Emily Turner (b)(6) - attending in person
- Nina Russell (b)(6) - dialing in
- Kedest Tesfagiorgis (b)(6) - TBD membership not confirm, would be dialing in
- Adam Jiang (McKinsey Secondment) (b)(6) - observer attendee
- Timothy Attoye (b)(6) - observer attendee

Many thanks,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 30, 2019 6:40 AM
To: Mike McCune (b)(6) >
Cc: Colleen Silcox (b)(6); Gary Feldman (b)(6) Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Update for Steering Committee Meeting

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also

ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: Passcode:

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Friday, July 26, 2019 7:03 AM

To: Mike McCune

Cc: Colleen Silcox

Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune <(b)(6)>
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Colleen Silcox <(b)(6)>
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V +1 (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 797 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 798 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 30 Jul 2019 13:40:02 +0000
To: Mike McCune
Cc: Colleen Silcox; Gary Feldman; Patterson, Amy (NIH/NHLBI) [E]
Subject: Update for Steering Committee Meeting
Attachments: NIH BMGF Steering Committee Meeting_agenda v073019_clean.docx, NIH BMGF PUSH Cures Steering Exec Committee Membership_DRAFT_072919_clean.docx

Mike, Colleen, and Gary,

I just wanted to follow up to ensure we are on track for the steering committee meeting on Thursday. I have attached the draft agenda and the roster of steering and executive committee members. I am also ccing Dr. Amy Patterson, who has graciously agreed to serve as the co-chair of the steering committee from NIH. We are very grateful to Amy, and I know she and Mike will make a great team in leading the steering committee.

I am waiting to hear from other NIH colleagues about any potential edits to additional meeting materials and will share those as they are available. I will also bring physical copies for those who will be attending in person. I don't have the contact information for those who are calling in from BMGF, so if you could either send me that contact information, or provide materials to them as they become available, I would be most appreciative. I have not placed the call-in information on the agenda, because I don't want local people to feel encouraged to call in! However, here is the information for those from BMGF who will be calling in:

Dial: Passcode

Mike, I also reached out to you separately to see if you, Amy, and me could find a time to chat before Thursday.

As some final additional updates, as noted, Francis was fine with a couple of additional observers from BMGF attending the steering committee meeting as non-members. Dan had previously mentioned the idea of involving FDA (specifically Peter Marks); Francis reached out to him, and he was enthusiastic, so perhaps we can discuss that at the meeting on Thursday. Finally, I understand we will hold off on a public announcement until the Grand Challenges meeting.

Looking forward to the meeting on Thursday, and I will be in touch as additional materials become available.

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Friday, July 26, 2019 7:03 AM
To: Mike McCune <

Cc: Colleen Silcox (b)(6)

Subject: RE: Materials shown at June 25 meeting

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune (b)(6)

Sent: Thursday, July 25, 2019 1:00 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Cc: Colleen Silcox (b)(6)

Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 802 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 803 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Teresa Poppink (Opus)
Sent: Mon, 29 Jul 2019 21:51:13 +0000
To: Undisclosed recipients:
Subject: US GO for Finding and Characterizing HIV Reservoirs - July 30-31, 2019

Hello,

Thank you for registering for the **Finding and Characterizing HIV Reservoirs** in **Bethesda, MD** on **July 30-July 31**. You have identified as a US Government Official for this event.

We have received final totals for meals served at the convening. Totals DO NOT exceed the \$95 per day the Gates Foundation is allowed to pay on your behalf. No action is needed.

Have a wonderful day!

Warmest Regards,
Teresa

Teresa Poppink
Opus Agency
Event Planner on assignment at Bill & Melinda Gates Foundation
+ (b)(6)
(b)(6)
Bill & Melinda Gates Foundation
www.gatesfoundation.org

From: Teresa Poppink (Opus) (b)(6)
Sent: Friday, July 12, 2019 7:03 AM
Subject: US GO for Finding and Characterizing HIV Reservoirs

Hello,

Thank you for registering for the **Finding and Characterizing HIV Reservoirs** in **Bethesda, MD** on **July 30-July 31**. You have identified as a US Government Official for this event.

As a reminder, please see the Government Officials policy regarding payments the Foundation can make to U.S. Government Officials:

Reimbursement of travel expenses for travel exclusively within the U.S., including the actual costs of transportation (airfare, taxis, etc.), plus meals and lodging up to 125% of the Federal "Per Diem Rates." These rates vary by city and in some cases, by season, and must be checked before any payment or reimbursement is made to a government official. These rates can be found at www.gsa.gov under "travel resources." Our conference planning and travel groups are both familiar with these requirements.

Food & Beverage Per Diem:

The current food and beverage per diem rate for Bethesda, MD is \$76 per day for meals. *The foundation can pay 125% of that amount during your stay, totaling \$95 each day.* We have received estimates

regarding catering costs and meals served at the convening will likely NOT EXCEED the \$95 per day we are allowed to pay on your behalf.

As we get closer to the event and catering orders are finalized, we will send an update should the totals exceed the allowable foundation spend amount per day.

Please don't hesitate to contact us if I can be of any additional assistance in the meantime. Thank you!

Warmest Regards,
Teresa

Teresa Poppink

Opus Agency

Event Planner on assignment at Bill & Melinda Gates Foundation

+1 (b)(6)

(b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E]
Sent: Fri, 26 Jul 2019 11:02:47 +0000
To: Mike McCune
Cc: Colleen Silcox
Subject: RE: Materials shown at June 25 meeting
Attachments: NIH BMGF Collaboration SCD overview FINAL 062419_v2.pptx, HIV Cure NIH BMGF collaboration slides 062419_v2.pptx, NIH BMGF In Vivo Gene Tx for SCD Precis and Project Plan with Table DRAFT 06192019_v2.docx, SCD DX Pilot Precis Narrative and Project Plan Table DRAFT 06192019_v2.docx, NIH BMGF HIV-SCD Charge to Exec and Steering Committees_clean_draft_072619.docx, MOU NIH_BMGF Collaborative Efforts on In Vivo Gene Editing for SCD and HIV signed 06252019.pdf, NIH BMGF Steering Committee Meeting_agenda v072619_clean.docx

Hi Mike,

Thanks for your message. Colleen, I am hoping the Comms folks have been in contact. As one additional update, I flagged for Francis the possibility of a couple additional observers from BMGF, and he has not raised any concerns.

Please find attached some of the relevant materials from the meeting at the end of June- these are projects plans that NIAID and NHLBI have developed, as well as high level overviews in the form of PowerPoint slides. These are draft, and NIH staff may make changes before the meeting next Thursday. We will share the updated/relevant materials for all steering committee members in advance of the meeting. Please let me know if BMGF is likely to present something similar, from your perspective.

I'm also attaching a rough draft outlining the roles of the Steering and Executive Committees (Colleen and Dan reviewed this earlier), and a signed copy of the MOU, for reference. The draft agenda for the steering committee meeting is also attached- feel free to share the draft agenda with the BMGF steering committee members (I don't have their contact information). I think the other materials may be preliminary to share at this time since there may be further edits before the meeting. A final piece I am pulling together is a short document that succinctly conveys the goals of the effort- it largely would be taken from existing materials, but I think it would be helpful to have as we try to map project plans to overarching goals, to see what gaps may exist.

Logistically, I will get a teleconference line and add that to the agenda for those who are calling in.

I will be in touch with more details as they become available, and please let me know if you have any questions. We look forward to our continued collaboration!

Best,

Jessica

From: Mike McCune (b)(6)
Sent: Thursday, July 25, 2019 1:00 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Cc: Colleen Silcox (b)(6)
Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others. This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V + (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 808 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 809 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 810 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 811 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 812 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 813 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 814 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 815 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 816 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 817 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 818 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 819 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 820 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 821 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 822 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 823 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 824 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 825 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 826 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 827 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 828 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 829 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 830 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 831 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 832 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 833 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 834 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Memorandum of Understanding

between

National Institutes of Health

and

Bill and Melinda Gates Foundation

for

Collaborative Efforts on *In Vivo* Gene Editing for Sickle Cell Disease and Human Immunodeficiency Virus

This Memorandum of Understanding (MOU) is between the National Institutes of Health (NIH), part of the U.S. Department of Health & Human Services, and the Bill and Melinda Gates Foundation (BMGF). NIH and BMGF are referred to herein individually as a Party and collectively as the Parties.

1. DESCRIPTION OF EACH PARTY AND ITS INTEREST

The NIH mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Under Section 402 of the Public Health Service Act, 42 U.S.C. § 282, the Director of NIH is responsible for the overall direction of the NIH and coordinates and oversees the operation of the national research institutes, national centers, and administrative entities within the NIH. The NIH is composed of various institutes, centers, and offices with unique research missions and capabilities that may contribute to the development of *in vivo* gene editing approaches for Sickle Cell Disease (SCD) and Human Immunodeficiency Virus (HIV) infection. Key NIH entities include:

- The National Institute of Allergy and Infectious Diseases (NIAID), which supports a global research portfolio on HIV/Acquired Immune Deficiency Syndrome (AIDS), its related co-infections, and co-morbidities;
- The National Heart, Lung, and Blood Institute (NHLBI), which provides global leadership in research, training, and education to prevent and treat heart, lung, blood, and sleep disorders; and
- The Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) within the Office of the NIH Director, which identifies emerging scientific opportunities, rising public health challenges, and scientific knowledge gaps that merit further research.

The HIV Frontiers Program at BMGF has as its vision to accelerate the decline of the global burden and incidence of HIV infection by ensuring development and use of impactful prevention and treatment interventions.

The Parties expect this non-binding agreement will help provide a structure for potential collaborative activities.

The Parties hereby agree as follows:

2. SCOPE AND PURPOSE OF COLLABORATION

The Parties agree that their mutual intention under this MOU is to collaborate to support studies to advance the development of *in vivo* gene editing and other relevant approaches to cure HIV infection and SCD.

For SCD, the ultimate goal is the availability in seven to ten years of a sustainable clinical trial platform that will provide the foundation for infant screening across high-risk geographic areas as well as for clinical trials evaluating an *in vivo* gene editing-based cure that would be readily available, scalable, and sustainable in low resource countries. The ultimate goal for HIV is the availability in seven to ten years of an affordable, one shot, *in vivo* gene editing product that results in reduction of virus to undetectable levels with no need for continuation of drug therapy, and with successful management of any recurrences.

3. ROLES AND PROPOSED CONTRIBUTIONS OF THE PARTIES

Subject to conclusion of an appropriate final binding agreement and the availability of resources, among other considerations, NIH is interested in supporting this collaborative effort, including providing anticipated financial support for the operational cost of the collaborative effort, and technical input to the development of such approaches. NIH may support research projects, in accordance with its mission and applicable laws, regulations, and policies, to further the goals of this collaborative effort.

Subject to conclusion of an appropriate final binding agreement and the availability of resources, among other considerations, BMGF is interested in supporting this collaborative effort, including providing anticipated financial support for the operational cost of the collaborative effort, and technical input to the development of such approaches. BMGF may support research projects, in accordance with its mission and applicable laws, regulations, and policies, to further the goals of this collaborative effort.

The intention of the collaboration between the Parties is to share costs in approximately a 1:1 ratio.

Additionally, the Parties have a shared intention to establish mechanisms to collaborate in this effort, which may include a Steering Committee and an Executive Committee, as described in Section 4 below.

4. ESTABLISHMENT OF STEERING AND EXECUTIVE COMMITTEES

Subject to final agreements, the Parties may establish a Steering Committee to guide implementation of the collaboration, allow for information sharing on progress of the collaborative efforts, and discuss which projects fit within the joint research plan for the collaboration. The Steering Committee will not provide recommendations regarding funding

decisions to either NIH or BMGF. The Steering Committee will convene as needed, but at least bimonthly to share information and assess progress on the research plan. The Steering Committee will be composed of representatives from NIH OD, NIAID, DPCPSI, NHLBI, and BMGF with appropriate content expertise and decision-making authority. The Steering Committee may form Working Groups and subcommittees made up of NIH and BMGF representatives as needed.

Subject to final agreements, the Parties will also establish an Executive Committee to assess overarching progress on the collaborative effort, consider any gaps that may exist, and discuss setting or adjusting priorities for the collaborative effort. The Executive Committee will not provide recommendations regarding funding decisions to either NIH or BMGF. The Executive Committee, if established, will convene as needed but no less than two (2) times per year and will be informed by input from the Steering Committee. The Executive Committee will be composed of NIH and BMGF leadership.

5. LIMITATIONS

This MOU is intended as an expression of mutual goodwill and of shared interest. Any statements of intent made under this MOU shall be subject to the Parties entering into a final, binding agreement related to the collaborative effort, the availability of sufficient resources to support the collaborative effort, and applicable laws, regulations, internal rules, policies, administrative procedures and practices, among other considerations.

This MOU imposes no funding obligations on the Parties. Nothing in this MOU authorizes or is intended to obligate the Parties to expend, exchange, or reimburse funds, services, or supplies, or transfer or receive anything of value, or to enter into any contract, assistance agreement, interagency agreement, or other financial obligation. Any financial arrangements between the Parties shall be subject to a separate agreement. This MOU is not intended to create any contractual rights between the Parties. This MOU in no way restricts the Parties from participating in any activity with other public or private agencies, organizations, or individuals.

6. PROPRIETARY INFORMATION AND CONFIDENTIALITY

It is acknowledged that each Party may possess confidential information, which may be required to be shared for the performance of joint work under this MOU. Any such information shall only be shared between the Parties under a separate confidential disclosure agreement, specifically covering such information. Each Party retains its intellectual property rights over its pre-existing information and know-how, including information related to the subject of the research projects covered by this MOU but not directly arising from the work conducted jointly under this MOU. Such information and know-how may be disclosed and used by the other Parties, subject to the above obligations of confidentiality and only for the purposes of the work to be carried out under this MOU.

No Party claims by virtue of this MOU any legal right, title, interest, or license in the other Party's intellectual property, including patent, copyright, trademark, or trade secret, of the other Party or in any intellectual property that might result from the other Parties' activities.

7. LIABILITY

Each Party shall be solely responsible for the manner in which it carries out its part of the collaborative activities under this MOU, except that the NIH, as an agency of the U.S. Government, may be liable only to the extent as provided under the Federal Tort Claims Act (28 U.S.C. Chapter 171). Thus, no Party shall be responsible for any loss, accident, damage or injury suffered or caused by any other Party, or any other Party's staff, grantees, or contractors, in connection with, or as a result of, the collaboration under this MOU.

8. USE OF THE PARTIES' NAMES

Each Party may refer to this MOU and the relationship with the other Party in communications, provided that such Party provides the other Party with an opportunity to review the drafts of communications at least seven (7) days prior to public availability or dissemination. Except as explicitly provided for in this MOU, no Party shall, in any written communication, statement or material of a promotional nature, use any other Party's name, acronym and/or logo without the prior written consent of that other Party.

9. RELATIONSHIP BETWEEN THE PARTIES

For the purposes of this MOU, each Party is an independent entity and not the joint venturer, agent or employee of any other Party. No Party shall have authority to make any statements, representations, or commitments of any kind, or to take any action which shall be binding on any other Party, except as may be authorized in writing by the other Party.

10. DURATION AND TERMINATION

This MOU becomes effective on the date of its last signature and shall continue for a period of 4 years, unless modified or terminated. Either Party may terminate its participation in this MOU at any time. Notwithstanding the foregoing, it is agreed that any termination of participation in this MOU by any Party shall be without prejudice to: (i) the orderly completion of any ongoing collaborative activity; and (ii) any other rights and obligations of the Parties accrued prior to the date of termination of this MOU.

11. AMENDMENTS

The Parties may revise, extend or modify this MOU by written amendment, provided such revisions and/or modifications are mutually agreed upon, and that any such amendment is signed by each Party hereto.

12. ENTIRE AGREEMENT

This MOU constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior and/or contemporaneous agreements or understandings, written or oral, with respect to the subject matter of this MOU.

13. SEVERABILITY

Any terms of this MOU found to be inconsistent with applicable laws, regulations, and/or policies of any of the Parties shall be invalid, but all the other terms shall remain in effect.

14. CONTACT INFORMATION OF THE PARTIES

NIH:

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health
U.S. Department of Health and Human Services
1 Center Drive
Bethesda, MD 20892

Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
U.S. Department of Health and Human Services
31 Center Dr.
Bethesda, MD 20892

Gary H. Gibbons, M.D.
Director
National Heart, Lung, and Blood Institute
National Institutes of Health
U.S. Department of Health and Human Services
31 Center Dr.
Bethesda, MD 20892

James M. Anderson, M.D., Ph.D.
Director
Division of Program Coordination, Planning, and Strategic Initiatives
National Institutes of Health
U.S. Department of Health and Human Services
1 Center Drive
Bethesda, MD 20892

BMGF:

Trevor Mundel, MD, PhD
President, Global Health Program
Bill & Melinda Gates Foundation
500 5th Avenue North
Seattle, WA 98109

Daniel J. Wattendorf, MD
Director, Global Health Program
Bill & Melinda Gates Foundation
500 5th Avenue North
Seattle, WA 98109

Joseph Mike McCune, MD, PhD
Senior Advisor, Global Health Program
Bill & Melinda Gates Foundation
500 5th Avenue North
Seattle, WA 98109

SIGNATURES

In witness whereof each Party has caused this MOU to be executed by its duly authorized representative, as of the dates set forth below.

(b)(6)

(Signature)

6/25/2019

(Date)

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health

(b)(6)

(Signature)

6/25/2019

(Date)

Bill Gates
Co-Chair
Bill & Melinda Gates Foundation

Page 841 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Thu, 25 Jul 2019 22:51:40 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Colleen Silcox
Subject: Re: Materials shown at June 25 meeting

Thanks, Jessica!

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V + (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Thursday, July 25, 2019 3:15 PM
To: Mike McCune (b)(6)
Cc: Colleen Silcox (b)(6)
Subject: Re: Materials shown at June 25 meeting

Hi Mike,

It has been a hectic day but I will get back to you as soon as I can tonight or early tomorrow.

Sorry for the delay.

Best,

Jessica

----- Original Message -----

From: Mike McCune (b)(6)

Date: Thu, Jul 25, 2019, 1:01 PM

To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>

CC: Colleen Silcox (b)(6)

Subject: Materials shown at June 25 meeting

Hi Jessica,

You mentioned the other day that materials (ppt shows?) had been distributed in advance of (and possibly also shown at?) the June 25 meeting with Francis, Bill, Trevor, Tony, and others.

This is the one that took place when I was in the Middle East and dialed in.

I cannot locate those materials now. Would you be able to re-send them to me, or let me know who I might otherwise contact?

Thanks!

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Samia Saad
Sent: Thu, 25 Jul 2019 11:19:46 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Automatic reply: NIH | BMGF Communications Update for HIV/SCD Partnership

I am out of the office on 25th July. If urgent please contact (b)(6)

Best regards,
Samia

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 25 Jul 2019 11:19:40 +0000
To: Colleen Silcox
Cc: Bryan Callahan; Samia Saad; Dan Wattendorf; Mike McCune
Subject: RE: NIH | BMGF Communications Update for HIV/SCD Partnership

Hi Colleen,

Many thanks to all of you for your work in developing this document. Our communications staff will be in touch with you soon for further discussions about the public messaging strategy.

We really appreciate working with you on this important effort.

Best,

Jessica

From: Colleen Silcox <(b)(6)>
Sent: Thursday, July 25, 2019 1:53 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Bryan Callahan <(b)(6)>; Samia Saad <(b)(6)>; Dan Wattendorf <(b)(6)>; Mike McCune <(b)(6)>
Subject: NIH | BMGF Communications Update for HIV/SCD Partnership

Hi Jessica,

Thanks for your patience as our internal teams worked to pull together a communications approach that we hope will be amenable to both NIH and BMGF.

I've attached the outline of this approach, as well as copied two of our key communications team members who can work with NIH on next steps -- Bryan Callahan and Samia Saad.

We look forward to hearing your comments on the attached. Let us know if it would be helpful to get on the phone, and we're happy to quickly make that happen.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager
Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Colleen Silcox
Sent: Thu, 25 Jul 2019 05:52:46 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Bryan Callahan;Samia Saad;Dan Wattendorf;Mike McCune
Subject: NIH | BMGF Communications Update for HIV/SCD Partnership
Attachments: 072419 Outline of HIV-SCD Announcement Strategy.docx

Hi Jessica,

Thanks for your patience as our internal teams worked to pull together a communications approach that we hope will be amenable to both NIH and BMGF.

I've attached the outline of this approach, as well as copied two of our key communications team members who can work with NIH on next steps -- Bryan Callahan and Samia Saad.

We look forward to hearing your comments on the attached. Let us know if it would be helpful to get on the phone, and we're happy to quickly make that happen.

All the best,

Colleen

Colleen Silcox, MPA

Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Page 848 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

Page 849 of 977

Withheld pursuant to exemption

(b)(4)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 25 Jul 2019 00:01:46 +0000
To: Gary Feldman
Subject: Re: Checking in / Updates

Hi Gary,

Thanks. That information will be forthcoming but I don't have it right now. Per a prior discussion with Colleen, she indicated I could send out information centrally to all participants, but if I should send through you or her instead, please let me know. Of course, I will then need everyone's email addresses when the time is right.

Many thanks,

Jessica

----- Original Message -----

From: Gary Feldman (b)(6)
Date: Wed, Jul 24, 2019, 7:57 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
Subject: RE: Checking in / Updates

Thanks so much for everything Jessica. I believe Mike is having one colleague dial in, is there a conf.line or number I can provide them to call in for? Or if that's being sent out in the invite I can wait for that.

Best Regards,
Gary

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director
Mike McCune, Senior Advisor
Colleen Silcox, Senior Program Manager
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates foundation

Seattle Office

Tel: (b)(6)
Email: (b)(6)
Web: www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, July 24, 2019 3:29 PM
To: Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Gary Feldman
(b)(6)
Subject: Re: Checking in / Updates

Hi Colleen and Mike,

Hope you are well. I've locked in the 10-12:30 ET time for the meeting on Aug 1 with Francis (for the short time he will be there to say hello) and the NIH Steering Committee members.

Any word on the comms one pager? Francis has been very eager to know the status of thinking on a public announcement next week, so any updates would be appreciated.

Thanks much,

Jessica

----- Original Message -----

From: Colleen Silcox (b)(6)
Date: Tue, Jul 23, 2019, 9:55 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
CC: Mike McCune (b)(6), Gary Feldman (b)(6)
Subject: RE: Checking in / Updates

Hi Jessica,

Thanks for the quick response!

Great, I'd say go ahead with the 7AM-9:30AM PT/10AM-12:30PM ET time slot as we have confirmation from Mike, Nina, and Emily.

Appreciate you checking on observers. They'll be there in person for the reservoir meeting, should they be able to join the SC as well.

Much appreciated, as always!

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 23, 2019 6:47 PM
To: Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6); Gary Feldman (b)(6)
Subject: RE: Checking in / Updates

Colleen,

Thanks so much for the update.

Regarding BMGF member confirmations, that is great- can I proceed with the Aug 1 date, from 10 AM-12:30 PM? I'd like to confirm the final times with Francis' scheduler and with the NIH (and BMGF, when appropriate) Steering Committee members as soon as possible.

I don't think having observers will be a problem at all, but I will double check.

Thanks to Gary for offering to stay to help with this. I don't think this last day will be very formal/complicated that will require any support (just print outs and IT, which we can handle here within NIH), but as I said, I think it is fine for you stay.

We look forward to hearing more about the communications plan tomorrow.

It's great working with you, and thanks again.

Best,

Jessica

From: Colleen Silcox (b)(6) >
Sent: Tuesday, July 23, 2019 9:34 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune (b)(6); Gary Feldman
(b)(6) <rg>
Subject: Checking in / Updates

Hi Jessica,

Thanks for the time today. Still awaiting an update on communications planning, hope to share that soon. A few quick updates below:

Member Confirmations

We have affirmative responses for two of our members, 1 of whom will be able to join in person (Emily Turner) and another who will likely be able to join via phone (Nina Russel). Waiting on Kedest.

Logistics Planning

We can initiate logistics messaging with Emily and Nina at any time. I'd also like to check on any on-site foundation support. Gary Feldman, our team's Senior Program Assistant will be there working with the onsite event team and has kindly offered to stay the extra day to assist as required.

Question: Observer Members

We have two team members who are working very closely with Mike and the team on HIV Frontiers at BMGF. While we have not proposed them to join the Steering Committee we would like to request their attendance as observers. Would this be possible?

Many thanks,

Colleen

Colleen Silcox, MPA

Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Tucker, Jessica (NIH/OD) [E]
Sent: Wed, 24 Jul 2019 23:59:13 +0000
To: Mike McCune; Colleen Silcox
Cc: Gary Feldman
Subject: Re: Checking in / Updates

Hi Mike,

Thanks. I don't have a final answer on observers but I really don't think it should be a problem. I will let you know as soon as I can.

Have a good evening.

Best,

Jessica

----- Original Message -----

From: Mike McCune (b)(6)
Date: Wed, Jul 24, 2019, 7:54 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>, Colleen Silcox (b)(6) rg>
CC: Gary Feldman (b)(6) >
Subject: Re: Checking in / Updates

Hi Jessica,

Colleen will hopefully have additional information about the one pager.

I wonder: did you learn whether or not Adam Jiang and Timothy Attoye would be able to join the SC meeting next Thurs as observers? I think it would be very helpful for me if they could do so.

Thanks!

M

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers
Global Health Innovative Technology Solutions

V (b)(6)

(b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, July 24, 2019 3:28 PM
To: Colleen Silcox (b)(6) >
Cc: Mike McCune (b)(6) >; Gary Feldman (b)(6)
Subject: Re: Checking in / Updates

Hi Colleen and Mike,
Hope you are well. I've locked in the 10-12:30 ET time for the meeting on Aug 1 with Francis (for the short time he will be there to say hello) and the NIH Steering Committee members. Any word on the comms one pager? Francis has been very eager to know the status of thinking on a public announcement next week, so any updates would be appreciated.
Thanks much,
Jessica

----- Original Message -----

From: Colleen Silcox (b)(6)
Date: Tue, Jul 23, 2019, 9:55 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
CC: Mike McCune (b)(6), Gary Feldman
(b)(6) g>
Subject: RE: Checking in / Updates
Hi Jessica,

Thanks for the quick response!

Great, I'd say go ahead with the 7AM-9:30AM PT/10AM-12:30PM ET time slot as we have confirmation from Mike, Nina, and Emily.

Appreciate you checking on observers. They'll be there in person for the reservoir meeting, should they be able to join the SC as well.

Much appreciated, as always!

Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 23, 2019 6:47 PM
To: Colleen Silcox (b)(6)
Cc: Mike McCune (b)(6), Gary Feldman
(b)(6)
Subject: RE: Checking in / Updates

Colleen,

Thanks so much for the update.

Regarding BMGF member confirmations, that is great- can I proceed with the Aug 1 date, from 10 AM-12:30 PM? I'd like to confirm the final times with Francis' scheduler and with the NIH (and BMGF, when appropriate) Steering Committee members as soon as possible.

I don't think having observers will be a problem at all, but I will double check.

Thanks to Gary for offering to stay to help with this. I don't think this last day will be very formal/complicated that will require any support (just print outs and IT, which we can handle here within NIH), but as I said, I think it is fine for you stay.

We look forward to hearing more about the communications plan tomorrow.

It's great working with you, and thanks again.

Best,

Jessica

From: Colleen Silcox <(b)(6)>
Sent: Tuesday, July 23, 2019 9:34 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune <(b)(6)>; Gary Feldman <(b)(6)>
Subject: Checking in / Updates

Hi Jessica,

Thanks for the time today. Still awaiting an update on communications planning, hope to share that soon. A few quick updates below:

Member Confirmations

We have affirmative responses for two of our members, 1 of whom will be able to join in person (Emily Turner) and another who will likely be able to join via phone (Nina Russel). Waiting on Kedest.

Logistics Planning

We can initiate logistics messaging with Emily and Nina at any time. I'd also like to check on any on-site foundation support. Gary Feldman, our team's Senior Program Assistant will be there working with the onsite event team and has kindly offered to stay the extra day to assist as required.

Question: Observer Members

We have two team members who are working very closely with Mike and the team on HIV Frontiers at BMGF. While we have not proposed them to join the Steering Committee we would like to request their attendance as observers. Would this be possible?

Many thanks,

Colleen

Colleen Silcox, MPA

Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V

(b)(6)

E (b)(6)

From: Mike McCune
Sent: Wed, 24 Jul 2019 01:59:03 +0000
To: Tucker, Jessica (NIH/OD) [E]; Colleen Silcox
Cc: Gary Feldman
Subject: Re: Checking in / Updates

Thanks, Jessica - great working with you, too!

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 23, 2019 6:47 PM
To: Colleen Silcox <(b)(6)>
Cc: Mike McCune <(b)(6)>; Gary Feldman
<(b)(6)>
Subject: RE: Checking in / Updates

Colleen,

Thanks so much for the update.

Regarding BMGF member confirmations, that is great- can I proceed with the Aug 1 date, from 10 AM-12:30 PM? I'd like to confirm the final times with Francis' scheduler and with the NIH (and BMGF, when appropriate) Steering Committee members as soon as possible.

I don't think having observers will be a problem at all, but I will double check.

Thanks to Gary for offering to stay to help with this. I don't think this last day will be very formal/complicated that will require any support (just print outs and IT, which we can handle here within NIH), but as I said, I think it is fine for you stay.

We look forward to hearing more about the communications plan tomorrow.

It's great working with you, and thanks again.

Best,

Jessica

From: Colleen Silcox (b)(6)
Sent: Tuesday, July 23, 2019 9:34 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Mike McCune <(b)(6)>; Gary Feldman
(b)(6)
Subject: Checking in / Updates

Hi Jessica,

Thanks for the time today. Still awaiting an update on communications planning, hope to share that soon. A few quick updates below:

Member Confirmations

We have affirmative responses for two of our members, 1 of whom will be able to join in person (Emily Turner) and another who will likely be able to join via phone (Nina Russel). Waiting on Kedest.

Logistics Planning

We can initiate logistics messaging with Emily and Nina at any time. I'd also like to check on any on-site foundation support. Gary Feldman, our team's Senior Program Assistant will be there working with the onsite event team and has kindly offered to stay the extra day to assist as required.

Question: Observer Members

We have two team members who are working very closely with Mike and the team on HIV Frontiers at BMGF. While we have not proposed them to join the Steering Committee we would like to request their attendance as observers. Would this be possible?

Many thanks,

Colleen

Colleen Silcox, MPA

Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 23 Jul 2019 16:04:32 +0000
To: Mike McCune; Colleen Silcox
Subject: RE: BMGF/NIH Catch Up

No problem! Thanks!

From: Mike McCune (b)(6)
Sent: Tuesday, July 23, 2019 12:03 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox (b)(6)
Subject: Re: BMGF/NIH Catch Up

Hi,

I (and maybe also Colleen) are tied up in a call now and will dial in asap!

Apologies,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V + (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tuesday, July 23, 2019 8:41 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox (b)(6); Mike McCune (b)(6)

Subject: BMGF/NIH Catch Up

When: Tuesday, July 23, 2019 9:00 AM-9:30 AM.

Where: Dial: (b)(4); (b)(6)

From: Mike McCune
Sent: Tue, 23 Jul 2019 15:57:14 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Accepted: BMGF/NIH Catch Up

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 23 Jul 2019 15:41:49 +0000
To: Colleen Silcox;Mike McCune
Subject: BMGF/NIH Catch Up

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 23 Jul 2019 15:27:51 +0000
To: Colleen Silcox
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Yes, I can talk then (in ~30 mins). I will send a conference line shortly.

From: Colleen Silcox (b)(6)
Sent: Tuesday, July 23, 2019 10:00 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Great, Mike and I could join a call at 9 am PT, does that still work for you?

Much appreciated,
Colleen

Sent from my iPhone

On Jul 22, 2019, at 8:58 PM, Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov> wrote:

Hi Colleen,

Thanks. I would be happy to speak tomorrow. Is there any chance sometime in the window of 11:30- 1 ET (8:30- 10 PT) will work for you? It may be a little late for you to confirm that today, I know. If not, please let me know and I can try to rearrange some other meetings. 1-2 ET (10-11 PT) is also possible for me. I do think it would be great if we could talk tomorrow, if possible.

Many thanks,

Jessica

From: Colleen Silcox (b)(6)
Sent: Monday, July 22, 2019 5:44 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Great!

Will work on the first point of contact and confirming when / how to step in around logistics ASAP. In that regard, a quick call + Mike M. might be helpful. What's your availability tomorrow, or Wednesday?

We have an internal comms call tomorrow morning, I can give an update immediately after that. There's still some churn internally on the timing, and I'm sensing it may be efficient for our representatives to talk this through as a next step.

Does that work?

Many thanks,
Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, July 22, 2019 2:19 PM

To: Colleen Silcox (b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks so much!

As noted, we will proceed with ensuring NIH parity on the Executive Committee, if required/requested by OGC.

We will assume an Aug 1 morning Steering Committee meeting and start planning accordingly. Please let me know if/when I should reach out to the BMGF steering committee members re logistics, or if you will be the one reaching out to them directly. (I realize you need to touch base with them first, anyway, but after that has happened, I would be happy to be in communication with them directly, always ccing you and Dan, accordingly, if appropriate).

I have also just been pinged by our Comms staff, as Francis is eager to know the status of the public announcement. Is there a POC at BMGF Comms they should contact, or will they be contacting our Comms staff soon?

Many thanks,

Jessica

From: Colleen Silcox (b)(6)

Sent: Monday, July 22, 2019 4:35 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Great, everything is coming together!

- Just heard from Mike, Aug. 1 will work for an initial date with as many SC members as we can gather together

- Here's the draft of our members, I've received leadership sign off on these but we have not extended invitations yet / confirmed directly with the individuals so there's still time to revise if necessary. (Apologies this isn't in the format desired, running between meetings so optimizing for speed, can adjust later.)

NIH Members

Francis Collins

BMGF

Bill Gates

(b)(5)

Many thanks,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, July 22, 2019 1:09 PM

To: Colleen Silcox (b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Colleen,

Thanks much. Yes, if we could confirm Aug 1, that would be great. Please let me know when you hear from Mike.

Do you think you will be able to share the BMGF proposed steering committee members with me today? For legal reasons, we may need to supplement the Exec Comm numbers on our side to reach parity within that committee. I hope that is OK, on your end. I will double check that with OGC. I think that could be done easily, but I did not want you to be caught off guard if it goes in that direction.

Please let me know if that sounds OK.

Many thanks,

Jessica

From: Colleen Silcox (b)(6)
Sent: Monday, July 22, 2019 3:52 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica -- great. Aug. 1 sounds reasonable. Let me just confirm quickly with Mike -- should be able to confirm within the next hour or so.

I think we've reached alignment on a set of attendees that maps well to what you proposed originally. So, no need to propose the alternate model to Francis unless you think necessary.

We are at 5 (+ Bill G.) for Executive Committee and 5 for Steering Committee making our overall ratio between NIH and BMGF relatively even, but off within the two committees.

Much appreciated,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Monday, July 22, 2019 11:52 AM
To: Colleen Silcox (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks, Colleen,

I will hold off on getting Francis's feedback until later today on the Executive Committee membership.

I am also getting questions from Francis' schedulers about releasing some time on his calendar, since we have not selected a final time for the steering committee to meet and had placed holds on his calendar so he could attend at least part of the meeting. Do you think we can tentatively decide that the steering committee will convene with whomever is available the morning of Aug 1? I realize this is less than ideal, but given that one of the dates (7/29) is a week away, we will need to select a time very soon.

Many thanks,

Jessica

From: Colleen Silcox (b)(6)
Sent: Monday, July 22, 2019 2:35 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Understood. Let's see what else I hear today before taking this up to Francis, appreciate you offering do so.

Very best,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, July 22, 2019 11:25 AM

To: Colleen Silcox (b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Colleen,

Thanks for looping back. I'm not totally sure, since we may then need to consider putting some of the people on the Executive Committee (Tony Fauci, etc.) on the Steering Committee instead. I don't think it is likely those folks will be able to participate in every Steering Committee meeting... but I will just have to run this idea by Francis and get back to you, which I am happy to do. Would be happy to discuss over the phone, if that is easier so we make sure we are speaking the same language about what the concerns/issues might be.

I look forward to receiving your further thoughts/input soon.

Thanks again,

Jessica

From: Colleen Silcox (b)(6)

Sent: Monday, July 22, 2019 2:05 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Hope you enjoyed the weekend! Quickly wanted to close the loop on the suggested about reducing the EC to Francis and Bill, is that a feasible option from NIH perspective?

Hoping to confirm SC members today. More soon.

Many thanks,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v + (b)(6) 37

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Friday, July 19, 2019 6:04 PM
To: Colleen Silcox (b)(6); Dan Wattendorf
(b)(6)
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Happy to align on a core set of members for the steering committee- Francis approved the list I provided earlier of NIH members. If needed, we/you could likely add on later. So, sharing your core BMGF members may make good sense, so we can find the right time for the 1st meeting for at least some individuals.

I'm happy to have a call next week.

Thanks for the update, and have a good weekend!

Jessica

----- Original Message -----

From: Colleen Silcox (b)(6)
Date: Fri, Jul 19, 2019, 8:56 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>, Dan Wattendorf
(b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Still some back and forth internally on venue and date for announcement going into the weekend. It may be best to set up a call next week on this.

If we're focusing on the steering committee for July, that helps some. In the interest of accelerating the planning, what if we were able to align on a core set of members first and leave open the possibility for additions. Or, is that unnecessarily complex?

Apologies for the lag here -- we'll keep bouncing this around over the weekend.

Many thanks,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v(b)(6)

From: Colleen Silcox
Sent: Friday, July 19, 2019 2:01 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Dan Wattendorf

(b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Dan has been checking with Francis on the comms questions, but not committees to my knowledge.

Right now, we're looking at ~5 possible additions to the Steering Committee. Some trouble narrowing the Director-level.

Thank you!

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v + (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Friday, July 19, 2019 1:43 PM

To: Colleen Silcox (b)(6); Dan Wattendorf

(b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

I completely understand. Thanks for the update. Just checking- has Francis been involved in these discussions?

Really my primary focus is on optimizing the number of people who might be able to participate in the steering committee meeting, but we will make it work with whoever can participate.

Many thanks, and have a great weekend!

Best,

Jessica

From: Colleen Silcox (b)(6)

Sent: Friday, July 19, 2019 4:35 PM

To: Dan Wattendorf (b)(6); Tucker, Jessica (NIH/OD) [E]
<jessica.tucker@nih.gov>

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks for checking in Jessica, appreciate the patience. This has generated a lot of interest, and more back and forth than expected.

It was suggested to reduce the EC to Bill and Francis. I'm not sure that's realistic as the charters are currently envisioned, but sharing the idea.

More shortly.

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Dan Wattendorf (b)(6)
Sent: Friday, July 19, 2019 1:17 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox
(b)(6)
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Ok,

We will make the connection shortly. There has been some internal discussions in both sides about the timing and venue of the announcement. We are trying to have the near finalized before activating both teams. The other docs should be forthcoming.

Dan

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Friday, July 19, 2019 1:14:47 PM
To: Dan Wattendorf (b)(6); Colleen Silcox
(b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

John leads all of NIH communications- you can feel free to cc him, but I think Amanda will be the staff person working on this; I would suggest including all three, as I believe Renate is Amanda's boss. John is John BurklowJ@OD.NIH.GOV.

From: Dan Wattendorf (b)(6)
Sent: Friday, July 19, 2019 4:10 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox
(b)(6)
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

I'll let Colleen respond too; however, Francis mentioned John Burklow as the comms lead. Should we connect our comms team to all three?

Dan

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Friday, July 19, 2019 1:06:08 PM
To: Dan Wattendorf (b)(6) Colleen Silcox
(b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Dan and Colleen,

Just checking in before the weekend. I was wondering when you expect to be able to share further information about the steering/executive committee members from BMGF? Once we have those names, we can work to identify a time that works for the most people for the first meeting. I am working on identifying a woman who could serve on the Executive Committee from NIH and have an idea to float by Francis.

Also, our Comms folks are ready and eager to start talking about the public announcement, and they have asked for a Comms POC at BMGF to start those discussions. On our end, the people to loop in are Amanda Fine (amanda.fine@nih.gov) and Renate Myles (mylesr@mail.nih.gov).

Many thanks, and have a great weekend!

Best,

Jessica

From: Dan Wattendorf <(b)(6)>
Sent: Thursday, July 18, 2019 3:30 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox <(b)(6)>
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Ok

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Thursday, July 18, 2019 12:29:41 PM
To: Dan Wattendorf <(b)(6)>; Colleen Silcox <(b)(6)>
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

It seems fine to me- I don't know of anything that would preclude that.

From: Dan Wattendorf <(b)(6)>
Sent: Thursday, July 18, 2019 3:27 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox <(b)(6)>
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

If possible, I would put Mike M as our chair of steering committee, but then have him also on executive committee too—would that work?

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Thursday, July 18, 2019 12:25:50 PM
To: Dan Wattendorf (b)(6); Colleen Silcox
(b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks, Dan,

As far as I know, that has not been decided. Of the individuals listed, I may propose Amy Patterson or Carl Dieffenbach for Dr. Collins' consideration.

Thanks much,

Jessica

From: Dan Wattendorf (b)(6)
Sent: Thursday, July 18, 2019 3:22 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox
(b)(6)
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Who would be the NIH chair of steering committee?

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Thursday, July 18, 2019 6:22:51 AM
To: Colleen Silcox (b)(6)
Cc: Dan Wattendorf (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks, Colleen. I sent Francis a brief update last night.

We look forward to receiving your additional BMGF steering committee members. Hopefully, we can find a time where most people can at least call in to a discussion- whether in tandem with the workshop or beforehand. Also, if you have ideas for a co-chair for the steering committee from BMGF, please let me know.

As for the public announcement next steps, I will try to check on that and get back to you soon.

Great working with you, and thanks again.

Best,

Jessica

From: Colleen Silcox (b)(6)
Sent: Thursday, July 18, 2019 1:18 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Dan Wattendorf (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Quick note to say we're hoping to get one more piece of input before sending back the materials your way.

No comments from us on the committee charges or agenda for initial meeting -- these make sense and understand they will evolve.

We have recommendations on additional attendees from the foundation, I will get this to you first thing tomorrow.

For the public announcement, we're working on narrowing on our internal communications points of contact. Once we've done that, how would you recommend advancing discussions with NIH and BMGF?

All the best,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v + (b)(6)

From: Colleen Silcox
Sent: Wednesday, July 17, 2019 9:31 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Dan Wattendorf (b)(6)
Cc: Gary Feldman (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks Jessica, we'll review quickly and get comments back your way soon.

Many thanks,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v + (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, July 17, 2019 9:10 AM
To: Dan Wattendorf (b)(6); Colleen Silcox (b)(6)

Cc: Gary Feldman (b)(6)

Subject: Follow-Up: NIH/BMGF Collaboration Materials

Hi Dan and Colleen,

Thanks for the productive discussion this morning, bright and early on the West coast.

Per our discussion, I'd like to get an update to Francis today (likely tonight), along with any relevant materials that are ready for his review and questions for him. These are all very DRAFT (and edited quickly after our call, so please forgive any errors), but I would appreciate any feedback/additions you may have to the following:

- Steering Committee and Executive Committee Membership- this is still draft, but articulates our tentative membership. If you could populate with BMGF members, that would be great.
- Draft Agenda for first SC Meeting- Per our discussion, this MAY be divided up into two separate meetings, depending on the timing of a public announcement. This is practically identical to what I sent Dan earlier.
- Draft charges to the Steering and Executive Committees- Very similar to the document distributed at the June meeting in DC. This document is likely to evolve over time but may be useful to provide so members know their role.

I have also added comments and some highlighting to the documents to flag where decisions or additions are needed.

Please let me know your thoughts, and thanks again for working with us on this! We are all really looking forward to it.

Best,

Jessica

Jessica Tucker, Ph.D.
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy
Office of Science Policy
National Institutes of Health
301-451-4431

<image001.png>

OSP Blog: [Under the Poliscope](#)
Twitter: @CWolinetzNIH

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 18 Jul 2019 20:08:29 +0000
To: Colleen Silcox
Cc: Dan Wattendorf
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Colleen,

Thanks for flagging that very important issue. I will raise it with Francis.

I really appreciate your work on this.

Best,

Jessica

From: Colleen Silcox (b)(6)
Sent: Thursday, July 18, 2019 3:49 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Dan Wattendorf (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Thanks for your patience. We're still circling around a few options. One comment to note, it was suggested each of our organizations identify a woman to serve on the EC.

Many thanks,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Dan Wattendorf
Sent: Thursday, July 18, 2019 12:30 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox (b)(6)>
Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Ok

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Thursday, July 18, 2019 12:29:41 PM
To: Dan Wattendorf (b)(6); Colleen Silcox

(b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

It seems fine to me- I don't know of anything that would preclude that.

From: Dan Wattendorf (b)(6)

Sent: Thursday, July 18, 2019 3:27 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox

(b)(6)

Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

If possible, I would put Mike M as our chair of steering committee, but then have him also on executive committee too—would that work?

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Thursday, July 18, 2019 12:25:50 PM

To: Dan Wattendorf (b)(6); Colleen Silcox

(b)(6) g>

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks, Dan,

As far as I know, that has not been decided. Of the individuals listed, I may propose (b)(5)

(b)(6) for Dr. Collins' consideration.

Thanks much,

Jessica

From: Dan Wattendorf (b)(6)

Sent: Thursday, July 18, 2019 3:22 PM

To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Colleen Silcox

(b)(6)

Subject: Re: Follow-Up: NIH/BMGF Collaboration Materials

Who would be the NIH chair of steering committee?

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Thursday, July 18, 2019 6:22:51 AM

To: Colleen Silcox (b)(6)

Cc: Dan Wattendorf (b)(6)

Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks, Colleen. I sent Francis a brief update last night.

We look forward to receiving your additional BMGF steering committee members. Hopefully, we can find a time where most people can at least call in to a discussion- whether in tandem with the workshop or beforehand. Also, if you have ideas for a co-chair for the steering committee from BMGF, please let me know.

As for the public announcement next steps, I will try to check on that and get back to you soon.

Great working with you, and thanks again.

Best,

Jessica

From: Colleen Silcox (b)(6)
Sent: Thursday, July 18, 2019 1:18 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Cc: Dan Wattendorf (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Hi Jessica,

Quick note to say we're hoping to get one more piece of input before sending back the materials your way.

No comments from us on the committee charges or agenda for initial meeting -- these make sense and understand they will evolve.

We have recommendations on additional attendees from the foundation, I will get this to you first thing tomorrow.

For the public announcement, we're working on narrowing on our internal communications points of contact. Once we've done that, how would you recommend advancing discussions with NIH and BMGF?

All the best,

Colleen

Colleen Silcox

Innovative Technology Solutions, Global Health

v (b)(6)

From: Colleen Silcox
Sent: Wednesday, July 17, 2019 9:31 AM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Dan Wattendorf
(b)(6)

Cc: Gary Feldman (b)(6)
Subject: RE: Follow-Up: NIH/BMGF Collaboration Materials

Thanks Jessica, we'll review quickly and get comments back your way soon.

Many thanks,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Wednesday, July 17, 2019 9:10 AM
To: Dan Wattendorf (b)(6); Colleen Silcox
(b)(6)
Cc: Gary Feldman (b)(6)
Subject: Follow-Up: NIH/BMGF Collaboration Materials

Hi Dan and Colleen,

Thanks for the productive discussion this morning, bright and early on the West coast.

Per our discussion, I'd like to get an update to Francis today (likely tonight), along with any relevant materials that are ready for his review and questions for him. These are all very DRAFT (and edited quickly after our call, so please forgive any errors), but I would appreciate any feedback/additions you may have to the following:

- Steering Committee and Executive Committee Membership- this is still draft, but articulates our tentative membership. If you could populate with BMGF members, that would be great.
- Draft Agenda for first SC Meeting- Per our discussion, this MAY be divided up into two separate meetings, depending on the timing of a public announcement. This is practically identical to what I sent Dan earlier.
- Draft charges to the Steering and Executive Committees- Very similar to the document distributed at the June meeting in DC. This document is likely to evolve over time but may be useful to provide so members know their role.

I have also added comments and some highlighting to the documents to flag where decisions or additions are needed.

Please let me know your thoughts, and thanks again for working with us on this! We are all really looking forward to it.

Best,

Jessica

Jessica Tucker, Ph.D.

Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy
Office of Science Policy
National Institutes of Health
301-451-4431



OSP Blog: [Under the Poliscopes](#)
Twitter: @CWolinetzNIH

From: Bill & Melinda Gates Foundation Events Team
Sent: Wed, 17 Jul 2019 16:17:42 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Registration Confirmed - Finding and Characterizing HIV Reservoirs

BILL & MELINDA
GATES *foundation*

Dear Jessica,

Your registration has been confirmed for the upcoming **Finding and Characterizing HIV Reservoirs** in Bethesda, MD. Please save this email for future reference.

Dates

8:30 am Tuesday, July 30, 2019 to 12:00 pm Wednesday, July 31, 2019

Should you have any changes to your registration, questions, or need to cancel your participation, please contact Events Registration by email at EventsRegistration@gatesfoundation.org.

If you have updates to your original travel request, please email our Travel Team directly at BMGFgroups@cwt-me.com.

Hotel

Upon receipt of your registration, a hotel sleeping room will be reserved for you, if requested. A formal hotel confirmation will be emailed to you one week prior to the convening. Your submitted information is below.

Hotel Name:

Hotel check in date:

Hotel check out date:

Special Notes: I am local.

Expenses

Bill & Melinda Gates Foundation will cover your expenses for this trip. Your flight, hotel (room & tax only) and ground transfers will be charged directly to the foundation. Travel must be booked through our travel department - BMGFgroups@cwt-me.com - who will contact you within four business days of your registration to coordinate your arrangements.

Any flights booked through an outside vendor will not be reimbursed without prior approval from our travel team. Any hotel booked through an outside vendor will not be reimbursed.

Reimbursement

Please review the foundation's [Travel & Expense Policy](#) for information on which out-of-pocket expenses are eligible for reimbursement. You will receive instructions for how to submit your claim after the meeting. You will have 60 days from the date of the meeting to submit your claim. *Please note that per diems will not be provided on-site.*

For questions about reimbursement, please contact
Gary.Feldman@gatesfoundation.org.

Transportation

Transportation to the hotel and back to the airport will be booked by travel along with your flights.

Thank you for registering. We look forward to your participation.

Warm regards,
Events Registration
Bill & Melinda Gates Foundation

© 2019 Bill & Melinda Gates Foundation All Rights Reserved
500 5th Ave. N, Seattle, WA 98109

[Privacy & Cookies Notice](#)

If you no longer want to receive emails from Bill & Melinda Gates Foundation Events Team, please [Opt-Out](#).

powered by
cvent

From: Tucker, Jessica (NIH/OD) [E]
Sent: Wed, 17 Jul 2019 16:10:21 +0000
To: Dan Wattendorf; Colleen Silcox
Cc: Gary Feldman
Subject: Follow-Up: NIH/BMGF Collaboration Materials
Attachments: NIH BMGF PUSH Cures Steering Exec Committee Membership_DRAFT_071719.docx, NIH BMGF Steering Committee Meeting_agenda v071719_clean.docx, NIH BMGF HIV-SCD Charge to Exec and Steering Committees_clean_draft_071719.docx

Hi Dan and Colleen,

Thanks for the productive discussion this morning, bright and early on the West coast.

Per our discussion, I'd like to get an update to Francis today (likely tonight), along with any relevant materials that are ready for his review and questions for him. These are all very DRAFT (and edited quickly after our call, so please forgive any errors), but I would appreciate any feedback/additions you may have to the following:

- Steering Committee and Executive Committee Membership- this is still draft, but articulates our tentative membership. If you could populate with BMGF members, that would be great.
- Draft Agenda for first SC Meeting- Per our discussion, this MAY be divided up into two separate meetings, depending on the timing of a public announcement. This is practically identical to what I sent Dan earlier.
- Draft charges to the Steering and Executive Committees- Very similar to the document distributed at the June meeting in DC. This document is likely to evolve over time but may be useful to provide so members know their role.

I have also added comments and some highlighting to the documents to flag where decisions or additions are needed.

Please let me know your thoughts, and thanks again for working with us on this! We are all really looking forward to it.

Best,

Jessica

Jessica Tucker, Ph.D.
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy
Office of Science Policy
National Institutes of Health
301-451-4431



OSP Blog: [Under the Poliscopes](#)

Twitter: @CWolinetzNIH

Page 885 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 886 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 887 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 888 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Colleen Silcox
Sent: Tue, 16 Jul 2019 21:24:50 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Accepted: NIH/BMGF HIV SCD Collaboration

From: Dan Wattendorf
Sent: Tue, 16 Jul 2019 21:06:44 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Accepted: NIH/BMGF HIV SCD Collaboration

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 16 Jul 2019 20:59:52 +0000
To: Dan Wattendorf; Colleen Silcox; Gary Feldman
Subject: NIH/BMGF HIV SCD Collaboration

Dan and Colleen,

While I'm sure this will not take an hour, I reserved a line for us to chat and wanted to ensure we have ample time. I hope the time zones come across correctly on Outlook- but this will be at 11 AM ET and 8 AM PT.

I look forward to talking tomorrow, and thanks again for making some time.

Best,

Jessica

From: Gary Feldman
Sent: Tue, 16 Jul 2019 20:41:24 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Sure that is great thanks 😊 Please feel free to send to (b)(6) and (b)(6)

Thanks again,
Gary

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director
Mike McCune, Senior Advisor
Innovative Technology Solutions (ITS)
Global Health (GH)

Bill & Melinda Gates foundation

Seattle Office

Tel +1 (b)(6)
Email (b)(6)
Web www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 16, 2019 1:10 PM
To: Gary Feldman (b)(6)
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Gary,

Unfortunately, my IT point of contact has left for the day, so I'm not able to confirm if that will work. Would it be possible for me to send you a conference call number instead?

Thanks,

Jessica

From: Gary Feldman (b)(6)
Sent: Tuesday, July 16, 2019 3:49 PM
To: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Great thanks. If I send through a Skype for Business link would that work as well as both Dan and Colleen would be connecting at different locations.

Gary

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 16, 2019 12:37:24 PM
To: Gary Feldman <(b)(6)>
Subject: Re: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

That works. Thank you! I can be reached at (b)(6)

----- Original Message -----

From: Gary Feldman <(b)(6)>
Date: Tue, Jul 16, 2019, 3:31 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Jessica, would 8:00 am PT work tomorrow morning for a call?

Gary Feldman

Senior Program Assistant to:

Dan Wattendorf, Director

Mike McCune, Senior Advisor

Innovative Technology Solutions (ITS)

Global Health (GH)

Bill & Melinda Gates foundation

Seattle Office

Tel: (b)(6)

Email: (b)(6)

Web www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 16, 2019 11:33 AM
To: Colleen Silcox <(b)(6)>
Cc: Gary Feldman <(b)(6)> Beckham, Shayla (NIH/OD) [E] <shayla.beckham@nih.gov>
Subject: Re: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Sure. Please let me know some options and I am sure we can make something work.

Best,

Jessica

----- Original Message -----

From: Colleen Silcox <(b)(6)>
Date: Tue, Jul 16, 2019, 2:25 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>

CC: Gary Feldman <(b)(6)>
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Jessica,

Hope you're doing well.

I'm following up on behalf of Dan regarding next steps for the NIH/BMGF Steering Committee. Would it be possible to have a quick call later today or tomorrow, before you need to follow up with Francis?

Gary, copied here will follow up with a couple options for us to connect.

Very best,

Colleen

Colleen Silcox, MPA

Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org



Facebook



Twitter



Impatient Optimists

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, July 15, 2019 8:40:39 AM

To: Dan Wattendorf <(b)(6)>

Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Dan,

I hope you had a great weekend.

Just to follow up on my note below, please find attached a rough first draft of an agenda for the first steering committee meeting. I'd certainly appreciate any feedback you may have, as I plan to share this with Dr. Collins for his feedback by the end of the day on Wed, July 17.

As noted below, if any dates work best for the BMGF attendees (afternoon of July 29, afternoon of July 31, or morning of August 1) for the first steering committee meeting, please let me know. While we have a preference for the morning of August 1, if possible, we certainly want to find a time that would work well for the BMGF attendees, especially since you will be traveling here.

We all really look forward to working on this. Please let me know what you think about date/time options and the draft agenda. And please let me know if there is any additional information I can provide. Thanks again!

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thursday, July 11, 2019 3:21 PM
To: Dan Wattendorf (b)(6)
Subject: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Dan,

I hope you are doing well. To follow up on the connection below, I wanted to check in regarding an idea that was floated after the meeting in June in DC, to have the 1st meeting of this collaboration's Steering Committee happen in tandem with the HIV reservoir workshop. Apologies if further discussions about that idea have already transpired. Dr. Collins is out of the office this week, so I just thought it would be useful for me to get the ball rolling on what dates and times might work best for everyone.

As you likely know, the HIV reservoir workshop (agenda attached, though I'm sure you have it) is scheduled for July 30-31 at NIH, to end around 12 PM on the 31st. So, some options for the steering committee meeting might be the afternoon of July 29 (prior to the start of the workshop), the afternoon of July 31 (after the workshop ends), or the morning of August 1. I am not sure whether you have identified the BMGF steering committee members yet and, if so, whether they plan to attend the HIV reservoir workshop. We may have a slight preference for August 1 (just in terms of individuals' availability), but we realize that BMGF steering committee members may not want to stay that long after the workshop ends, if they will be attending it. So, I wanted to reach out to see what might work best for you.

In addition to working together on identifying the committee members from BMGF and NIH and finding a good time for the meeting, it would be great to start to flesh out a draft agenda for the meeting. I am already working on that here and would be happy to share it with you to get your thoughts, in a couple of days.

Of course, please also let me know if there is someone else at BMGF that I should be working with on this- I just wanted to reach out to you first, especially given Lyric's high praise and great comments about working with you!

Please let me know what you think, and I would also be happy to set up a time to talk, if that is easier.

Best,

Jessica

From: Dan Wattendorf (b)(6)
Sent: Monday, July 1, 2019 8:46 PM
To: Jennifer Weisman (b)(6); Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Connections!

Great to hear from you again Lyric. I am happy to hear you are still keeping NIH on track...
:)

Get [Outlook for iOS](#)

From: Jennifer Weisman
Sent: Monday, July 1, 2019 5:45:02 PM
To: Jorgenson, Lyric (NIH/OD) [E]; Dan Wattendorf; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Connections!

Lyric, thanks for reaching out! Sue's EA is the best person to direct this invitation to ensure that it gets to Sue, here is her email: (b)(6)

Jessica, delighted to e-meet you and it would be great to meet in person the next time I'm in the DC area.

Best,
Jenni

From: Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>
Sent: Thursday, June 27, 2019 11:03 AM
To: Dan Wattendorf (b)(6); Jennifer Weisman (b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Connections!

Hi Dan (long time no talk!) and Jenni –

I wanted to introduce you to my colleague Jessica Tucker who has been working closely with Francis on the collaboration with BMGF and NIH. As we all know, it is always good to know the people who can pull the strings instead of always having to go all the way to Bill and Francis, so I thought I'd make the e-introductions.

Jessica – I used to work with Dan when he was at DARPA, and he and Kathy Hudson were changing the world. We built Tissue Chip at NCATS which, as you know, is now in SPACE! Dan is officially a guy that WILL MAKE THINGS HAPPEN. Jenni worked here at

NIH with Larry and basically will cut through any bulls*&t at anytime so she is a person YOU NEED TO KNOW.

Speaking of – Francis would like to invite Susan Desmond-Hellman to join our newest, hot ticket emerging tech board. I think I can guess her email address based on the very cryptic format your email addresses have, but if you all wouldn't mind providing it, that would be great.

Congrats on the MOU guys. This is amazing!

Best,

Lyric

Lyric Jorgenson, PhD
Deputy Director, Office of Science Policy
National Institutes of Health
jorgensonla@od.nih.gov
301.496.6837



From: Colleen Silcox
Sent: Tue, 16 Jul 2019 20:29:37 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Gary Feldman; Beckham, Shayla (NIH/NCI) [E]
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Great, thanks Jessica -- looking forward to it. Gary will be able to provide some times that will work for Dan.

Many thanks,
Colleen
Colleen Silcox
Innovative Technology Solutions, Global Health
v (b)(6)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Sent: Tuesday, July 16, 2019 11:33 AM
To: Colleen Silcox (b)(6)
Cc: Gary Feldman (b)(6); Beckham, Shayla (NIH/OD) [E] <shayla.beckham@nih.gov>
Subject: Re: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Sure. Please let me know some options and I am sure we can make something work.

Best,

Jessica

----- Original Message -----

From: Colleen Silcox (b)(6)
Date: Tue, Jul 16, 2019, 2:25 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>
CC: Gary Feldman (b)(6)
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Jessica,

Hope you're doing well.

I'm following up on behalf of Dan regarding next steps for the NIH/BMGF Steering Committee. Would it be possible to have a quick call later today or tomorrow, before you need to follow up with Francis?

Gary, copied here will follow up with a couple options for us to connect.

Very best,

Colleen

Colleen Silcox, MPA

Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org



Facebook



Twitter



Impatient Optimists

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, July 15, 2019 8:40:39 AM

To: Dan Wattendorf (b)(6) >

Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Dan,

I hope you had a great weekend.

Just to follow up on my note below, please find attached a rough first draft of an agenda for the first steering committee meeting. I'd certainly appreciate any feedback you may have, as I plan to share this with Dr. Collins for his feedback by the end of the day on Wed, July 17.

As noted below, if any dates work best for the BMGF attendees (afternoon of July 29, afternoon of July 31, or morning of August 1) for the first steering committee meeting, please let me know. While we have a preference for the morning of August 1, if possible, we certainly want to find a time that would work well for the BMGF attendees, especially since you will be traveling here.

We all really look forward to working on this. Please let me know what you think about date/time options and the draft agenda. And please let me know if there is any additional information I can provide. Thanks again!

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]

Sent: Thursday, July 11, 2019 3:21 PM

To: Dan Wattendorf (b)(6)

Subject: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Dan,

I hope you are doing well. To follow up on the connection below, I wanted to check in regarding an idea that was floated after the meeting in June in DC, to have the 1st meeting of this collaboration's Steering

Committee happen in tandem with the HIV reservoir workshop. Apologies if further discussions about that idea have already transpired. Dr. Collins is out of the office this week, so I just thought it would be useful for me to get the ball rolling on what dates and times might work best for everyone.

As you likely know, the HIV reservoir workshop (agenda attached, though I'm sure you have it) is scheduled for July 30-31 at NIH, to end around 12 PM on the 31st. So, some options for the steering committee meeting might be the afternoon of July 29 (prior to the start of the workshop), the afternoon of July 31 (after the workshop ends), or the morning of August 1. I am not sure whether you have identified the BMGF steering committee members yet and, if so, whether they plan to attend the HIV reservoir workshop. We may have a slight preference for August 1 (just in terms of individuals' availability), but we realize that BMGF steering committee members may not want to stay that long after the workshop ends, if they will be attending it. So, I wanted to reach out to see what might work best for you.

In addition to working together on identifying the committee members from BMGF and NIH and finding a good time for the meeting, it would be great to start to flesh out a draft agenda for the meeting. I am already working on that here and would be happy to share it with you to get your thoughts, in a couple of days.

Of course, please also let me know if there is someone else at BMGF that I should be working with on this- I just wanted to reach out to you first, especially given Lyric's high praise and great comments about working with you!

Please let me know what you think, and I would also be happy to set up a time to talk, if that is easier.

Best,

Jessica

From: Dan Wattendorf (b)(6)
Sent: Monday, July 1, 2019 8:46 PM
To: Jennifer Weisman (b)(6); Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Connections!

Great to hear from you again Lyric. I am happy to hear you are still keeping NIH on track...
:)

Get [Outlook for iOS](#)

From: Jennifer Weisman
Sent: Monday, July 1, 2019 5:45:02 PM
To: Jorgenson, Lyric (NIH/OD) [E]; Dan Wattendorf; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Connections!

Lyric, thanks for reaching out! Sue's EA is the best person to direct this invitation to ensure that it gets to Sue, here is her email: (b)(6)

Jessica, delighted to e-meet you and it would be great to meet in person the next time I'm in the DC area.

Best,
Jenni

From: Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>
Sent: Thursday, June 27, 2019 11:03 AM
To: Dan Wattendorf (b)(6); Jennifer Weisman
(b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Connections!

Hi Dan (long time no talk!) and Jenni –

I wanted to introduce you to my colleague Jessica Tucker who has been working closely with Francis on the collaboration with BMGF and NIH. As we all know, it is always good to know the people who can pull the strings instead of always having to go all the way to Bill and Francis, so I thought I'd make the e-introductions.

Jessica – I used to work with Dan when he was at DARPA, and he and Kathy Hudson were changing the world. We built Tissue Chip at NCATS which, as you know, is now in SPACE! Dan is officially a guy that WILL MAKE THINGS HAPPEN. Jenni worked here at NIH with Larry and basically will cut through any bulls*&t at anytime so she is a person YOU NEED TO KNOW.

Speaking of – Francis would like to invite Susan Desmond-Hellman to join our newest, hot ticket emerging tech board. I think I can guess her email address based on the very cryptic format your email addresses have, but if you all wouldn't mind providing it, that would be great.

Congrats on the MOU guys. This is amazing!

Best,

Lyric

Lyric Jorgenson, PhD
Deputy Director, Office of Science Policy
National Institutes of Health
jorgensonla@od.nih.gov
301.496.6837



From: Mike McCune
Sent: Mon, 15 Jul 2019 18:54:23 +0000
To: Tucker, Jessica (NIH/OD) [E];Patterson, Amy (NIH/NHLBI) [E]
Cc: Finzi, Diana (NIH/NIAID) [E]
Subject: Re: NIH BMGF collaboration meeting

Very good, Jessica!

I will confer with Dan and we'll get back to you shortly.

Cheers,

M

Get [Outlook for iOS](#)

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, July 15, 2019 11:44 AM

To: Mike McCune; Patterson, Amy (NIH/NHLBI) [E]

Cc: Finzi, Diana (NIH/NIAID) [E]

Subject: RE: NIH BMGF collaboration meeting

Hi Mike,

Thanks for your message. It's great to hear from you.

I recently reached out to Dan Wattendorf via e-mail to discuss next steps for planning the steering committee meeting, including possible dates/times. I haven't heard back yet, but I initially reached out to him on Thursday, so it has just been a couple of days. Right now, the morning of Aug 1 works best for those of us here at NIH, but obviously, since BMGF staff will be traveling, we certainly want to find a time that works well for you. All current options include the afternoon of July 29, the afternoon of July 31, or the morning of Aug 1.

I hope that helps. We look forward to continuing to work with you!

Best,

Jessica

Jessica Tucker, Ph.D.

Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy

Office of Science Policy

National Institutes of Health

301-451-4431



OSP Blog: [Under the Poliscope](#)

Twitter: @CWolinetzNIH

From: Mike McCune (b)(6)

Sent: Monday, July 15, 2019 2:32 PM

To: Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Cc: Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>

Subject: Fw: NIH BMGF collaboration meeting

Greetings Amy and Jessica,

It's been a pleasure to work with you by e-mail!

Diana (b)(6) has referred me your way with a question she thought you might be able to answer:

I understand that, before or after or during the July 30-31 NIH-BMGF "reservoirs meeting," there might be a side meeting to discuss the newly-blessed collaboration on targeting and editing between us. So that I can make sure to keep my schedule open, I wonder: do you know if this meeting will happen then and, if so, when?

Thanks for any thoughts you have.

I look forward to working with you later.

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E (b)(6)

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

From: Tucker, Jessica (NIH/OD) [E]
Sent: Mon, 15 Jul 2019 15:40:39 +0000
To: Dan Wattendorf
Subject: RE: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD
Attachments: NIH BMGF Steering Committee Meeting_agenda v071519_clean.docx

Hi Dan,

I hope you had a great weekend.

Just to follow up on my note below, please find attached a rough first draft of an agenda for the first steering committee meeting. I'd certainly appreciate any feedback you may have, as I plan to share this with Dr. Collins for his feedback by the end of the day on Wed, July 17.

As noted below, if any dates work best for the BMGF attendees (afternoon of July 29, afternoon of July 31, or morning of August 1) for the first steering committee meeting, please let me know. While we have a preference for the morning of August 1, if possible, we certainly want to find a time that would work well for the BMGF attendees, especially since you will be traveling here.

We all really look forward to working on this. Please let me know what you think about date/time options and the draft agenda. And please let me know if there is any additional information I can provide. Thanks again!

Best,

Jessica

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thursday, July 11, 2019 3:21 PM
To: Dan Wattendorf (b)(6)
Subject: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD

Hi Dan,

I hope you are doing well. To follow up on the connection below, I wanted to check in regarding an idea that was floated after the meeting in June in DC, to have the 1st meeting of this collaboration's Steering Committee happen in tandem with the HIV reservoir workshop. Apologies if further discussions about that idea have already transpired. Dr. Collins is out of the office this week, so I just thought it would be useful for me to get the ball rolling on what dates and times might work best for everyone.

As you likely know, the HIV reservoir workshop (agenda attached, though I'm sure you have it) is scheduled for July 30-31 at NIH, to end around 12 PM on the 31st. So, some options for the steering committee meeting might be the afternoon of July 29 (prior to the start of the workshop), the afternoon of July 31 (after the workshop ends), or the morning of August 1. I am not sure whether you have identified the BMGF steering committee members yet and, if so, whether they plan to attend the HIV reservoir workshop. We may have a slight preference for August 1 (just in terms of individuals'

availability), but we realize that BMGF steering committee members may not want to stay that long after the workshop ends, if they will be attending it. So, I wanted to reach out to see what might work best for you.

In addition to working together on identifying the committee members from BMGF and NIH and finding a good time for the meeting, it would be great to start to flesh out a draft agenda for the meeting. I am already working on that here and would be happy to share it with you to get your thoughts, in a couple of days.

Of course, please also let me know if there is someone else at BMGF that I should be working with on this- I just wanted to reach out to you first, especially given Lyric's high praise and great comments about working with you!

Please let me know what you think, and I would also be happy to set up a time to talk, if that is easier.

Best,

Jessica

From: Dan Wattendorf <(b)(6)>
Sent: Monday, July 1, 2019 8:46 PM
To: Jennifer Weisman <(b)(6)>; Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Connections!

Great to hear from you again Lyric. I am happy to hear you are still keeping NIH on track...
:)

Get [Outlook for iOS](#)

From: Jennifer Weisman
Sent: Monday, July 1, 2019 5:45:02 PM
To: Jorgenson, Lyric (NIH/OD) [E]; Dan Wattendorf; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Connections!

Lyric, thanks for reaching out! Sue's EA is the best person to direct this invitation to ensure that it gets to Sue, here is her email: <(b)(6)>

Jessica, delighted to e-meet you and it would be great to meet in person the next time I'm in the DC area.

Best,
Jenni

From: Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>
Sent: Thursday, June 27, 2019 11:03 AM
To: Dan Wattendorf <(b)(6)>; Jennifer Weisman

(b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Subject: Connections!

Hi Dan (long time no talk!) and Jenni –

I wanted to introduce you to my colleague Jessica Tucker who has been working closely with Francis on the collaboration with BMGF and NIH. As we all know, it is always good to know the people who can pull the strings instead of always having to go all the way to Bill and Francis, so I thought I'd make the e-introductions.

Jessica – I used to work with Dan when he was at DARPA, and he and Kathy Hudson were changing the world. We built Tissue Chip at NCATS which, as you know, is now in SPACE! Dan is officially a guy that WILL MAKE THINGS HAPPEN. Jenni worked here at NIH with Larry and basically will cut through any bulls*&t at anytime so she is a person YOU NEED TO KNOW.

Speaking of – Francis would like to invite Susan Desmond-Hellman to join our newest, hot ticket emerging tech board. I think I can guess her email address based on the very cryptic format your email addresses have, but if you all wouldn't mind providing it, that would be great.

Congrats on the MOU guys. This is amazing!

Best,

Lyric

Lyric Jorgenson, PhD
Deputy Director, Office of Science Policy
National Institutes of Health
jorgensonla@od.nih.gov
301.496.6837



Page 909 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Thu, 11 Jul 2019 19:21:06 +0000
To: Dan Wattendorf
Subject: Follow Up- Next Steps for NIH/BMGF Steering Committee on HIV/SCD
Attachments: BMGF-NIH Reservoirs Workshop.Agenda.060519.docx

Hi Dan,

I hope you are doing well. To follow up on the connection below, I wanted to check in regarding an idea that was floated after the meeting in June in DC, to have the 1st meeting of this collaboration's Steering Committee happen in tandem with the HIV reservoir workshop. Apologies if further discussions about that idea have already transpired. Dr. Collins is out of the office this week, so I just thought it would be useful for me to get the ball rolling on what dates and times might work best for everyone.

As you likely know, the HIV reservoir workshop (agenda attached, though I'm sure you have it) is scheduled for July 30-31 at NIH, to end around 12 PM on the 31st. So, some options for the steering committee meeting might be the afternoon of July 29 (prior to the start of the workshop), the afternoon of July 31 (after the workshop ends), or the morning of August 1. I am not sure whether you have identified the BMGF steering committee members yet and, if so, whether they plan to attend the HIV reservoir workshop. We may have a slight preference for August 1 (just in terms of individuals' availability), but we realize that BMGF steering committee members may not want to stay that long after the workshop ends, if they will be attending it. So, I wanted to reach out to see what might work best for you.

In addition to working together on identifying the committee members from BMGF and NIH and finding a good time for the meeting, it would be great to start to flesh out a draft agenda for the meeting. I am already working on that here and would be happy to share it with you to get your thoughts, in a couple of days.

Of course, please also let me know if there is someone else at BMGF that I should be working with on this- I just wanted to reach out to you first, especially given Lyric's high praise and great comments about working with you!

Please let me know what you think, and I would also be happy to set up a time to talk, if that is easier.

Best,

Jessica

From: Dan Wattendorf (b)(6)
Sent: Monday, July 1, 2019 8:46 PM
To: Jennifer Weisman (b)(6); Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Connections!

Great to hear from you again Lyric. I am happy to hear you are still keeping NIH on track...

:)

Get [Outlook for iOS](#)

From: Jennifer Weisman
Sent: Monday, July 1, 2019 5:45:02 PM
To: Jorgenson, Lyric (NIH/OD) [E]; Dan Wattendorf; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Connections!

Lyric, thanks for reaching out! Sue's EA is the best person to direct this invitation to ensure that it gets to Sue, here is her email (b)(6)

Jessica, delighted to e-meet you and it would be great to meet in person the next time I'm in the DC area.

Best,
Jenni

From: Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>
Sent: Thursday, June 27, 2019 11:03 AM
To: Dan Wattendorf (b)(6); Jennifer Weisman
(b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Connections!

Hi Dan (long time no talk!) and Jenni –

I wanted to introduce you to my colleague Jessica Tucker who has been working closely with Francis on the collaboration with BMGF and NIH. As we all know, it is always good to know the people who can pull the strings instead of always having to go all the way to Bill and Francis, so I thought I'd make the e-introductions.

Jessica – I used to work with Dan when he was at DARPA, and he and Kathy Hudson were changing the world. We built Tissue Chip at NCATS which, as you know, is now in SPACE! Dan is officially a guy that WILL MAKE THINGS HAPPEN. Jenni worked here at NIH with Larry and basically will cut through any bulls*&t at anytime so she is a person YOU NEED TO KNOW.

Speaking of – Francis would like to invite Susan Desmond-Hellman to join our newest, hot ticket emerging tech board. I think I can guess her email address based on the very cryptic format your email addresses have, but if you all wouldn't mind providing it, that would be great.

Congrats on the MOU guys. This is amazing!

Best,

Lyric

Lyric Jorgenson, PhD

Deputy Director, Office of Science Policy
National Institutes of Health
jorgensonla@od.nih.gov
301.496.6837



Page 913 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 914 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 915 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 916 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Thu, 11 Jul 2019 01:27:35 +0000
To: Tucker, Jessica (NIH/OD) [E]
Cc: Finzi, Diana (NIH/NIAID) [E]
Subject: Re: Registration for the workshop on HIV reservoirs at NIH, July 30-31
Attachments: BMGF-NIH Reservoirs Workshop.Agenda.060519.docx

Dear Dr. Tucker,

We look forward to your participation at the upcoming BMGF-NIH workshop on "Finding and Characterizing HIV Reservoirs" (see attached agenda).

The following website has been set up to register you and to detail additional logistics about the meeting:

<http://events.gatesfoundation.org/d/dyq7k5?ct=b04f1db7-ca77-4e09-80e9-6db53cdb6b6b>

So that we can have a fix on attendance, it would be great if you could register by 7/15 (noting that, in order to do so, you will have to use the same email address used on this email). Please just ignore the portions about travel and accommodation.

If you have any questions, let me know.

I look forward to seeing you there!

All my best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V [REDACTED]

E [REDACTED]

Senior Program Assistant: Gary Feldman

V [REDACTED]

E [REDACTED]

Bill & Melinda Gates *foundation*

www.gatesfoundation.org

Page 918 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 919 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 920 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 921 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Mike McCune
Sent: Wed, 3 Jul 2019 15:02:31 +0000
To: Collins, Francis (NIH/OD) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Dan Wattendorf; Tucker, Jessica (NIH/OD) [E]
Cc: Wolinetz, Carrie (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Tisdale, John (NIH/NHLBI) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: Re: Gene editing and HIV in humanized mice


Hi Francis (and all),

Dan, Trevor, and I have been in touch already with Carl and Tony about this paper, and are making plans to repeat and extend the experiments.

To put everyone on the same page, re: critiques and next steps that have been discussed...

Here are some thoughts I shared with Trevor and Dan yesterday:

(b)(4); (b)(5)



comparative experiment:

Carl quickly wrote back to say:

In reading the Dash paper, I think the one critical fact we can all agree on is that this work needs to be replicated. From the NIH/NIAID perspective, we find great value in having other investigator teams, as well as the original team, attempt to repeat findings.

The how-to-do-this needs some planning and discussion and the devil is completely in the details. I suggest we take a measured approach. Between now and the July meeting at NIH, I propose we get our groups, along with others at the NIH that are supporting this work together to map out a stepwise plan to replicate this experiment.

Looking forward to discussing more!

Best,

Mike

Joseph (Mike) McCune, MD, PhD

Head, HIV Frontiers

Global Health Innovative Technology Solutions

V (b)(6)

E mike.mccune@gatesfoundation.org

Senior Program Assistant: Gary Feldman

V (b)(6)

E (b)(6)

Bill & Melinda Gates foundation

www.gatesfoundation.org

From: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>

Sent: Wednesday, July 3, 2019 6:43 AM

To: Dieffenbach, Carl (NIH/NIAID) [E]; Finzi, Diana (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Dan Wattendorf; Mike McCune; Tucker, Jessica (NIH/OD) [E]

Cc: Wolinetz, Carrie (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Tisdale, John (NIH/NHLBI) [E]; Patterson, Amy (NIH/NHLBI) [E]

Subject: Gene editing and HIV in humanized mice

Hi all,

In case you haven't seen this already, check out the attached article.

I know, it's humanized mice – but still looks pretty encouraging. Critique?

Francis

From: Dan Wattendorf
Sent: Tue, 2 Jul 2019 16:29:19 +0000
To: Tucker, Jessica (NIH/OD) [E]
Subject: Automatic reply: Connections!

Please note I am out of the office this week traveling and will have limited email access, so my response might be delayed. While I am still available, if your matter is critical and you require assistance, please contact my assistant Gary Feldman (b)(6)

Thank you,
Dan

From: Tucker, Jessica (NIH/OD) [E]
Sent: Tue, 2 Jul 2019 16:28:59 +0000
To: Dan Wattendorf;Jennifer Weisman;Jorgenson, Lyric (NIH/OD) [E]
Subject: RE: Connections!

Hello all,

Lyric, thanks for the connection. Dan, it was great to see you in DC last week, and Jenni, I look forward to hopefully having an opportunity to work with you and meet you.

Thanks for the information about Sue's EA. The invitations did go out yesterday (someone here gave us Sue's direct e-mail address), but when I follow up, I will definitely include Amissa in future communications. Always good to know who to reach out to!

Best,

Jessica

Jessica Tucker, Ph.D.
Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy
Office of Science Policy
National Institutes of Health
301-451-4431



OSP Blog: [Under the Poliscope](#)
Twitter: @CWolinetzNIH

From: Dan Wattendorf (b)(6)
Sent: Monday, July 1, 2019 8:46 PM
To: Jennifer Weisman (b)(6); Jorgenson, Lyric (NIH/OD) [E]
<lyric.jorgenson@nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Re: Connections!

Great to hear from you again Lyric. I am happy to hear you are still keeping NIH on track...
:)

Get [Outlook for iOS](#)

From: Jennifer Weisman
Sent: Monday, July 1, 2019 5:45:02 PM
To: Jorgenson, Lyric (NIH/OD) [E]; Dan Wattendorf; Tucker, Jessica (NIH/OD) [E]
Subject: RE: Connections!

Lyric, thanks for reaching out! Sue's EA is the best person to direct this invitation to ensure that it gets to Sue, here is her email (b)(6)

Jessica, delighted to e-meet you and it would be great to meet in person the next time I'm in the DC area.

Best,
Jenni

From: Jorgenson, Lyric (NIH/OD) [E] <lyric.jorgenson@nih.gov>
Sent: Thursday, June 27, 2019 11:03 AM
To: Dan Wattendorf (b)(6); Jennifer Weisman
(b)(6); Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>
Subject: Connections!

Hi Dan (long time no talk!) and Jenni –

I wanted to introduce you to my colleague Jessica Tucker who has been working closely with Francis on the collaboration with BMGF and NIH. As we all know, it is always good to know the people who can pull the strings instead of always having to go all the way to Bill and Francis, so I thought I'd make the e-introductions.

Jessica – I used to work with Dan when he was at DARPA, and he and Kathy Hudson were changing the world. We built Tissue Chip at NCATS which, as you know, is now in SPACE! Dan is officially a guy that WILL MAKE THINGS HAPPEN. Jenni worked here at NIH with Larry and basically will cut through any bulls*&t at anytime so she is a person YOU NEED TO KNOW.

Speaking of – Francis would like to invite Susan Desmond-Hellman to join our newest, hot ticket emerging tech board. I think I can guess her email address based on the very cryptic format your email addresses have, but if you all wouldn't mind providing it, that would be great.

Congrats on the MOU guys. This is amazing!

Best,

Lyric

Lyric Jorgenson, PhD
Deputy Director, Office of Science Policy
National Institutes of Health
jorgensonla@od.nih.gov
301.496.6837

From: Trevor Mundel
Sent: Tue, 25 Jun 2019 00:54:43 +0000
To: Colleen Silcox
Cc: Tucker, Jessica (NIH/OD) [E]; Josie Ekberg; Gary Feldman; Dan Wattendorf; Mike McCune
Subject: Re: Draft MOU NIH-BMGF In Vivo Gene Editing for HIV and SCD

Thanks Colleen, will see our group live or on audio bright and early tomorrow. Trevor

Trevor Mundel, MD, PhD

President, Global Health Program

V (b)(6)

F

E (b)(6)

Christa Bowles

Executive Assistant

Office of the President, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org

From: Colleen Silcox

Sent: Monday, June 24, 2019 8:23:09 PM

To: Trevor Mundel

Cc: Tucker, Jessica (NIH/OD) [E]; Josie Ekberg; Gary Feldman; Dan Wattendorf; Mike McCune

Subject: Draft MOU NIH-BMGF In Vivo Gene Editing for HIV and SCD

Trevor,

Draft MOU between NIH and BMGF for *In Vivo* Gene Editing for SCD and HIV is attached.

I understand this has been reviewed by Mark.

We've added a term of 4 years (Section 10) to match the HIV Frontiers program timeline.

Many thanks,

Colleen

Colleen Silcox, MPA

Interim Senior Program Manager

Innovative Technology Solutions, Global Health

V (b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org



[Facebook](#)



[Twitter](#)



[Impatient Optimists](#)

From: Colleen Silcox
Sent: Tue, 25 Jun 2019 00:23:09 +0000
To: Trevor Mundel
Cc: Tucker, Jessica (NIH/OD) [E];Josie Ekberg;Gary Feldman;Dan Wattendorf;Mike McCune
Subject: Draft MOU NIH-BMGF In Vivo Gene Editing for HIV and SCD
Attachments: NIH-BMGF HIV-SCD MOU_clean_draft_061919.docx

Trevor,

Draft MOU between NIH and BMGF for *In Vivo* Gene Editing for SCD and HIV is attached.

I understand this has been reviewed by Mark.

We've added a term of 4 years (Section 10) to match the HIV Frontiers program timeline.

Many thanks,

Colleen

Colleen Silcox, MPA

Interim Senior Program Manager

Innovative Technology Solutions, Global Health

V

(b)(6)

M

E (b)(6)

Bill & Melinda Gates Foundation

www.gatesfoundation.org



Facebook



Twitter



Impatient Optimists

Page 931 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 932 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 933 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 934 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 935 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 936 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Tucker, Jessica (NIH/OD) [E]
Sent: Mon, 24 Jun 2019 20:34:50 +0000
To: Mike McCune;McManus, Ayanna (NIH/OD) [E];Finzi, Diana (NIH/NIAID) [E]
Cc: Dan Wattendorf;Wood, Gretchen (NIH/OD) [E];Josie Ekberg;Gary Feldman
Subject: Re: Tuesday meeting

If arrangements have been made with the hotel, please use that route.

Thanks,

Jessica

----- Original Message -----

From: Mike McCune <(b)(6)>
Date: Mon, Jun 24, 2019, 4:29 PM
To: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>,"McManus, Ayanna (NIH/OD) [E]" <ayanna.mcmanus@nih.gov>,"Finzi, Diana (NIH/NIAID) [E]" <dfinzi@niaid.nih.gov>
CC: Dan Wattendorf <(b)(6)>"Wood, Gretchen (NIH/OD) [E]" <woodgs@od.nih.gov>,"Josie Ekberg <(b)(6)>,"Gary Feldman <(b)(6)>
Subject: Re: Tuesday meeting

Thanks, Jessica.

I also have a note from my colleague, Josie Ekberg, that "the hotel will call me" at (b)(6) at 8:25 am ET on Tuesday.

Please advise which route is best.

Thanks.

Mike

PS I believe that Dan Wattenberg will be there in person.

Get Outlook for iOS

From: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Sent: Monday, June 24, 2019 7:47 PM

To: McManus, Ayanna (NIH/OD) [E]; Finzi, Diana (NIH/NIAID) [E]

Cc: Dan Wattendorf; Mike McCune; Wood, Gretchen (NIH/OD) [E]

Subject: RE: Tuesday meeting

All,

Thanks for looping me in. The latest information I have is that the meeting will be from 8:45- 10:15 AM tomorrow.

We have not been involved in setting up the room or phone line at the Hay-Adams, but if it is useful, this teleconference line can be used to dial in to the meeting:

Dial: (b)(4); (b)(6) Passcode: (b)(4); (b)(6)

We will plan to use this line, unless we hear otherwise.

I hope that helps.

Best,

Jessica

From: McManus, Ayanna (NIH/OD) [E] <ayanna.mcmanus@nih.gov>

Sent: Sunday, June 23, 2019 4:40 PM

To: Finzi, Diana (NIH/NIAID) [E] <dfinzi@niaid.nih.gov>; Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>

Cc: Dan Wattendorf (b)(6); Mike McCune

(b)(6)

Subject: RE: Tuesday meeting

Hi Diana,

Apologies, I do not have the logistics, nevertheless, I've looped in Jessica Tucker who will be able to assist.

Thank you,
Ayanna

From: Finzi, Diana (NIH/NIAID) [E]
Sent: Sunday, June 23, 2019 4:36 PM
To: McManus, Ayanna (NIH/OD) [E] <ayanna.mcmanus@nih.gov>
Cc: Dan Wattendorf <(b)(6)> Mike McCune
<(b)(6)>
Subject: Re: Tuesday meeting

Hi Ayanna,
Do you have a phone number for Mike and Dan to call into the Bill Gates- NIH meeting at the Hay Adams on Tuesday morning?
Thank you,
Diana

On Jun 23, 2019, at 4:26 PM, Mike McCune <(b)(6)> wrote:

Greetings, Diana.
I will be calling into the meeting on Tuesday, as may Dan.
Do you know who we should contact to figure out the right time and number to join the meeting?
Thanks!
M

Get [Outlook for iOS](#)

From: McCune, Mike
Sent: Fri, 21 Jun 2019 20:41:59 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tucker, Jessica (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Chris Karp; Anderson, James (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Dan Wattendorf; Dieffenbach, Carl (NIH/NIAID) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: Re: Materials for June 25 meeting

Agreed, Francis – I think it's great the way things are shaping up, and I very much look forward to the conversation next week and to many continued interactions in the future. I will be calling in from abroad (currently on a long-planned trip with (b)(6)) and hope to have as clear as line as possible. Should that not be the case, Dan will be there - and we are walking in unison with our enthusiasm about this collaboration.

All my best,

Mike

From: Dan Wattendorf (b)(6)
Date: Friday, June 21, 2019 at 6:09 PM
To: "Collins, Francis (NIH/OD) [E]" <collinsf@od.nih.gov>, Chris Karp (b)(6), Mike McCune <Mike.McCune@ucsf.edu>
Cc: "Tucker, Jessica (NIH/OD) [E]" <jessica.tucker@nih.gov>, Tony Fauci <afauci@niaid.nih.gov>, "Gibbons, Gary (NIH/NHLBI) [E]" <gary.gibbons@nih.gov>, "Anderson, James (NIH/OD) [E]" <james.anderson2@nih.gov>, "Tabak, Lawrence (NIH/OD) [E]" <lawrence.tabak@nih.gov>, "Wolinetz, Carrie (NIH/OD) [E]" <carrie.wolinetz@nih.gov>, Carl Dieffenbach <cdieffenba@niaid.nih.gov>, "Patterson, Amy (NIH/NHLBI) [E]" <amy.patterson@nih.gov>
Subject: Re: Materials for June 25 meeting

Hi Francis,
We have reviewed. I don't think this is an issue with the content. Just a question of completing all the applicable information to have the MOU ready to sign at the meeting or a bit later. Bill would not need to be involved in the MOU anyway, but a high level discussion of any of the approaches, milestones, or goals is good.
Dan

Get [Outlook for iOS](#)

From: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
Sent: Friday, June 21, 2019 8:03:42 AM
To: Chris Karp; Dan Wattendorf; Mike.McCune@ucsf.edu
Cc: Tucker, Jessica (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Anderson, James (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: RE: Materials for June 25 meeting

Hi Chris, Dan, and Mike,

Just checking in to see if you've had a chance to review these materials. We are really looking forward to the meeting on Tuesday!

Best, Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Wednesday, June 19, 2019 6:07 AM
To: chris.karp(b)(6); Dan.Wattendorf(b)(6); Mike.McCune@ucsf.edu
Cc: Tucker, Jessica (NIH/OD) [E] <jessica.tucker@nih.gov>; Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Gibbons, Gary (NIH/NHLBI) [E] <Gary.Gibbons@nih.gov>; Anderson, James (NIH/OD) [E] <james.anderson2@nih.gov>; Tabak, Lawrence (NIH/OD) [E] <Lawrence.Tabak@nih.gov>; Wolinetz, Carrie (NIH/OD) [E] <carrie.wolinetz@nih.gov>; Dieffenbach, Carl (NIH/NIAID) [E] <CDieffenba@niaid.nih.gov>; Patterson, Amy (NIH/NHLBI) [E] <amy.patterson@nih.gov>
Subject: Materials for June 25 meeting

Hi Chris, Dan, and Mike,

We are looking forward to the meeting next Tuesday to further discuss the HIV/SCD in vivo gene editing collaboration, as well as hearing from Dina Katabi on some interesting work in AI.

To make the best use of our time next week, we have compiled some information for your review prior to the meeting. Please find attached a draft MOU and a draft charge to an Executive and Steering Committee that could help to guide this effort (1st two attachments). We welcome any feedback or edits to these documents that you may have. Ideally, it would be great to sign off on the high-level MOU at the meeting on Tuesday.

I've also attached the draft agenda for Tuesday's meeting, and the draft project plans that NIH could pursue as part of this effort. I think we can spend much of our time on Tuesday mapping out a general work plan, including what NIH and BMGF could each undertake as part of this collaboration.

We are extremely excited at the prospect of working with you on this important effort. Please let me know what you think, and I look forward to the discussion.

ATTACHMENTS:

1- MOU

2- Charge to Executive and Steering Committee

3- Agenda

4- Pilot project- Burden of SCD and DX

5- In vivo gene editing for SCD

6- HIV Project Plan

From: McCune, Mike
Sent: Wed, 19 Jun 2019 20:19:49 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: chris.karp@gatesfoundation.org; Dan.Wattendorf@gatesfoundation.org; Tucker, Jessica (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Anderson, James (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: Re: Materials for June 25 meeting

Thanks, Francis.
This is all very helpful and we very much look forward to talking.
All my best,
Mike

On Jun 19, 2019, at 1:10 PM, Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov> wrote:

Hi Chris, Dan, and Mike,

We are looking forward to the meeting next Tuesday to further discuss the HIV/SCD in vivo gene editing collaboration, as well as hearing from Dina Katabi on some interesting work in AI.

To make the best use of our time next week, we have compiled some information for your review prior to the meeting. Please find attached a draft MOU and a draft charge to an Executive and Steering Committee that could help to guide this effort (1st two attachments). We welcome any feedback or edits to these documents that you may have. Ideally, it would be great to sign off on the high-level MOU at the meeting on Tuesday.

I've also attached the draft agenda for Tuesday's meeting, and the draft project plans that NIH could pursue as part of this effort. I think we can spend much of our time on Tuesday mapping out a general work plan, including what NIH and BMGF could each undertake as part of this collaboration.

We are extremely excited at the prospect of working with you on this important effort. Please let me know what you think, and I look forward to the discussion.

ATTACHMENTS:

- 1- MOU
- 2- Charge to Executive and Steering Committee
- 3- Agenda
- 4- Pilot project- Burden of SCD and DX
- 5- In vivo gene editing for SCD
- 6- HIV Project Plan

<1-NIH-BMGF HIV-SCD MOU_clean_draft_061919.docx>
<2-NIH BMGF HIV-SCD Charge to Exec and Steering Committees_clean_draft_061919.docx>
<3-NIH BMGF 062519 Meeting_draft agenda v061819.docx>
<4-SCD DX Pilot Precis Narrative and Project Plan Table DRAFT 06192019.docx>
<5-NIH BMGF In Vivo Gene Tx for SCD Precis and Project Plan with Table DRAFT
06192019.docx>
<6-NIHBMGF HIV WorkPlan 061419.docx>

From: Collins, Francis (NIH/OD) [E]
Sent: Wed, 19 Jun 2019 10:07:08 +0000
To: chris.karp(b)(6); an.Wattendorf(b)(6); Mike.McCune@ucsf.edu
Cc: Tucker, Jessica (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Anderson, James (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Patterson, Amy (NIH/NHLBI) [E]
Subject: Materials for June 25 meeting
Attachments: 1-NIH-BMGF HIV-SCD MOU_clean_draft_061919.docx, 2-NIH BMGF HIV-SCD Charge to Exec and Steering Committees_clean_draft_061919.docx, 3-NIH BMGF 062519 Meeting_draft agenda v061819.docx, 4-SCD DX Pilot Precis Narrative and Project Plan Table DRAFT 06192019.docx, 5-NIH BMGF In Vivo Gene Tx for SCD Precis and Project Plan with Table DRAFT 06192019.docx, 6-NIHBMGF HIV WorkPlan 061419.docx

Hi Chris, Dan, and Mike,

We are looking forward to the meeting next Tuesday to further discuss the HIV/SCD in vivo gene editing collaboration, as well as hearing from Dina Katabi on some interesting work in AI.

To make the best use of our time next week, we have compiled some information for your review prior to the meeting. Please find attached a draft MOU and a draft charge to an Executive and Steering Committee that could help to guide this effort (1st two attachments). We welcome any feedback or edits to these documents that you may have. Ideally, it would be great to sign off on the high-level MOU at the meeting on Tuesday.

I've also attached the draft agenda for Tuesday's meeting, and the draft project plans that NIH could pursue as part of this effort. I think we can spend much of our time on Tuesday mapping out a general work plan, including what NIH and BMGF could each undertake as part of this collaboration.

We are extremely excited at the prospect of working with you on this important effort. Please let me know what you think, and I look forward to the discussion.

ATTACHMENTS:

1- MOU

2- Charge to Executive and Steering Committee

3- Agenda

4- Pilot project- Burden of SCD and DX

5- In vivo gene editing for SCD

6- HIV Project Plan

Page 947 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 948 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 949 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 950 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 951 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 952 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 953 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 954 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 955 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 956 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 957 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 958 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 959 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 960 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 961 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 962 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 963 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 964 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 965 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 966 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 967 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: McCune, Mike
Sent: Wed, 20 Feb 2019 06:10:46 +0000
To: Collins, Francis (NIH/OD) [E]; Dan Wattendorf; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Anderson, James (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Patterson, Amy (NIH/NHLBI) [E]; Cook, Nakela (NIH/NHLBI) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Wilder, Elizabeth (NIH/OD) [E]; Glass, Roger (NIH/FIC) [E]; Eiss, Robert (NIH/FIC) [E]; Finzi, Diana (NIH/NIAID) [E]; Tisdale, John (NIH/NHLBI) [E]; Read, Sarah (NIH/NIAID) [E]; McManus, Ayanna (NIH/OD) [E]; Wood, Gretchen (NIH/OD) [E]; Schwetz, Tara (NIH/OD) [E]
Cc: Trevor Mundel
Subject: Re: BMGF/NIH Meeting Summary and Next Steps- HIV and SCD
Attachments: BMGF NIH DRAFT Meeting Summary_021919[1].docx, Addendum- BMGF Summary of Next Steps.docx

Dear Francis and NIH colleagues (also including Trevor here),

My thanks, too, for the time that all of you have devoted to this, for the fun and very productive meeting, and for preparing this excellent summary!

I concur with the points within it and also with those raised by Dan, and have two comments:

(b)(6)

It will be great to have the opportunity to work with all of you on this.

Best regards,

Mike

On 2/19/19, 1:23 PM, "Collins, Francis (NIH/OD) [E]" <collinsf@od.nih.gov> wrote:

Dear Dan, Mike, and NIH colleagues,

Thanks to our friends from BMGF for joining us in a very productive discussion last Tuesday about a possible scientific partnership on in vivo gene editing for sickle cell disease and HIV cures. I really appreciated the opportunity to have a candid discussion about these bold ideas.

In an effort to capture this robust discussion, please find attached a draft meeting summary prepared by Jessica Tucker, with a focus on the concrete next steps we mentioned. Of course, please let me know if you have any edits

to these attached notes, to ensure they accurately convey what was discussed. I've also attached some very helpful and provocative thoughts that Dan was kind enough to share after the meeting, emphasizing some of his key take-home messages.

To keep the ball moving on this, we will work to get a teleconference scheduled about a month from now to discuss next steps (like, for example, a potential joint workshop on the use of rapid autopsy and advanced detection methods to identify the latent HIV reservoir).

I look forward to continued dialogue and collaboration on these important issues.

Best, Francis

Page 970 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 971 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 972 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 973 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 974 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

Page 975 of 977

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

From: Dan Wattendorf
Sent: Sat, 9 Feb 2019 18:21:23 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: McCune, Mike; Fauci, Anthony (NIH/NIAID) [E]; Gibbons, Gary (NIH/NHLBI) [E]; Anderson, James (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Tucker, Jessica (NIH/OD) [E]; Patterson, Amy (NIH/NHLBI) [E]; Cook, Nakela (NIH/NHLBI) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Wilder, Elizabeth (NIH/OD) [E]; Glass, Roger (NIH/FIC) [E]; Eiss, Robert (NIH/FIC) [E]; Finzi, Diana (NIH/NIAID) [E]; Tisdale, John (NIH/NHLBI) [E]; Read, Sarah (NIH/NIAID) [E]; McManus, Ayanna (NIH/OD) [E]; Wood, Gretchen (NIH/OD) [E]; Schwetz, Tara (NIH/OD) [E]
Subject: Re: Materials for NIH-BMGF meeting

Thanks Francis,
We look forward to this meeting and planning the next steps with all of you.
Dan

Sent from my iPhone

> On Feb 9, 2019, at 10:14 AM, Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov> wrote:
>
> Hi Dan and Mike,
>
> All of us are looking forward to the morning meeting on Tuesday, February 12, where we will discuss a possible scientific partnership on in vivo gene editing for sickle cell disease and HIV cure. With thanks to Amy Patterson, I attach a possible agenda, together with some background material on current NIH programs that are of relevance. I am also re-attaching Dan's note from last week, and the white paper from Mike on HIV cure, so that everyone on this e-mail will have all of the materials in one place. Please let me know if this agenda looks right to you.
>
> This potential joint effort certainly fits the definition of high risk high reward research! To design a realistic path forward, with appropriate attention to intermediate milestones, we will need to employ a heavy dose of the kind of scientific vision and fearlessness that BMGF and NIH are famous for. Looking forward to it!
>
> Best, Francis
>
> P.S. to NIH colleagues -- if I have left off any addressees that should see these materials in advance of Tuesday, please forward.
> <NIH-BMGF Meeting Feb 12 2019.pdf>
> <NIH-BMGF New opportunities for SCD and HIV>
> <120418 Opportunities in HIV Cure Memo[1].docx>

From: Dan Wattendorf
Sent: Sat, 9 Feb 2019 00:48:49 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tucker, Jessica (NIH/OD) [E]
Subject: Re: BMGF meeting

Terrific, thanks.
Dan

Sent from my iPhone

> On Feb 8, 2019, at 10:41 AM, Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov> wrote:
>
> Hi Dan,
>
> Working on our part of the agenda right now. Pulling in pieces from NHLBI, NIAID, and Common Fund.
>
> I'm hoping to send you and Mike something by Saturday.
>
> Looking forward to the meeting!
>
> Francis
>
> P.S. I'm looping in Jessica Tucker, who is staffing me on this effort.
>
> -----Original Message-----
> From: Dan Wattendorf <(b)(4); (b)(5)>
> Sent: Friday, February 08, 2019 10:56 AM
> To: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>
> Subject: BMGF meeting
>
> Francis,
> Just checking on status of meeting. Dan
>
> Sent from my iPhone